<i>K-ras</i>Mutations and Benefit from Cetuximab in A

New England Journal of Medicine 359, 1757-1765 DOI: 10.1056/nejmoa0804385

Citation Report

#	Article	IF	CITATIONS
1	ecancermedicalscience. Ecancermedicalscience, 2014, 8, 441.	1.1	30
2	Gastrointestinal stromal tumors – A model for understanding solid tumor biology and development of targeted therapies, or just another lowâ€hanging fruit?. Asia-Pacific Journal of Clinical Oncology, 2008, 4, 185-187.	1.1	0
4	Sequential or combination chemotherapy for a patient with mCRC?. Cancer Treatment Reviews, 2008, 34, S12-S16.	7.7	0
5	Voting opens for paper of the year 2008. Lancet, The, 2008, 372, 2096-2097.	13.7	2
6	Targeting EGFR in Colorectal Cancer. New England Journal of Medicine, 2008, 359, 1834-1836.	27.0	123
8	Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients. OncoTargets and Therapy, 2008, , 17.	2.0	0
9	Molecular biomarkers to individualise treatment: assessing the evidence. Medical Journal of Australia, 2009, 190, 631-636.	1.7	23
10	Large Intestine (Colon). , 2009, , 755-836.		2
11	Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck. OncoTargets and Therapy, 2009, 2, 243.	2.0	5
12	Evolving role of cetuximab in the treatment of colorectal cancer. Cancer Management and Research, 2009, Volume 1, 79-88.	1.9	6
13	Divide and Conquer: Progress in the Molecular Stratification of Cancer. Yonsei Medical Journal, 2009, 50, 464.	2.2	4
16	Recent Advances Relating to the Clinical Application of Naked Monoclonal Antibodies in Solid Tumors. Molecular Medicine, 2009, 15, 183-191.	4.4	15
18	Vascular Endothelial Growth Factor Plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?. Journal of Oncology, 2009, 2009, 1-9.	1.3	11
20	Concordance ofKRAS/BRAFMutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy. Journal of Oncology, 2009, 2009, 1-9.	1.3	21
21	Update in Antiepidermal Growth Factor Receptor Therapy in the Management of Metastatic Colorectal Cancer. Journal of Oncology, 2009, 2009, 1-6.	1.3	6
22	Update on Anti-EGFR Targeted Therapy. Journal of Oncology, 2009, 2009, 1-2.	1.3	2
23	Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer. PLoS ONE, 2009, 4, e7287.	2.5	241
24	Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics. PLoS ONE, 2009, 4, e7746.	2.5	73

#	Article	IF	CITATIONS
25	Population Pharmacokinetic Analysis of Panitumumab in Patients With Advanced Solid Tumors. Journal of Clinical Pharmacology, 2009, 49, 1142-1156.	2.0	77
26	Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives. Expert Opinion on Pharmacotherapy, 2009, 10, 1095-1108.	1.8	10
27	Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations. Journal of the National Cancer Institute, 2009, 101, 1284-1285.	6.3	79
28	Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance. Clinical Cancer Research, 2009, 15, 6570-6581.	7.0	33
29	Predictive Biomarkers: Identification and Verification. Journal of Clinical Oncology, 2009, 27, 2743-2744.	1.6	12
30	Review: Medical treatment of advanced colorectal cancer in 2009. Therapeutic Advances in Medical Oncology, 2009, 1, 55-68.	3.2	7
31	Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 167-181.	3.2	7
32	PIK3CA Mutation Associates with Improved Outcome in Breast Cancer. Clinical Cancer Research, 2009, 15, 5049-5059.	7.0	338
33	Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. Expert Opinion on Pharmacotherapy, 2009, 10, 2467-2478.	1.8	6
34	Hyperphosphorylation and Aggregation of Tau in Laforin-deficient Mice, an Animal Model for Lafora Disease. Journal of Biological Chemistry, 2009, 284, 22657-22663.	3.4	52
35	Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. British Journal of Cancer, 2009, 100, 1379-1384.	6.4	47
36	Do we need biopsies of metastases for colorectal cancer patients?. British Journal of Cancer, 2009, 101, 374-375.	6.4	2
37	Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array. British Journal of Cancer, 2009, 101, 357-362.	6.4	34
38	TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. British Journal of Cancer, 2009, 100, 1330-1335.	6.4	86
39	Anti–Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?. Oncologist, 2009, 14, 29-39.	3.7	69
40	Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab – an Antibody against Epidermal Growth Factor Receptor: Systemic Review and Meta-Analysis. Oncology, 2009, 77, 124-133.	1.9	61
41	Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Molecular Cancer Therapeutics, 2009, 8, 821-833.	4.1	64
42	Clinical and economic value of screening for <i>Kras</i> mutations as predictors of response to epidermal growth factor receptor inhibitors. American Journal of Health-System Pharmacy, 2009, 66, 2105-2112.	1.0	24

#	Article	IF	CITATIONS
43	Health-Related Quality of Life in Patients With Advanced Colorectal Cancer Treated With Cetuximab: Overall and <i>KRAS</i> -Specific Results of the NCIC CTG and AGITG CO.17 Trial. Journal of Clinical Oncology, 2009, 27, 1822-1828.	1.6	106
44	Moyamoya Disease and Moyamoya Syndrome. New England Journal of Medicine, 2009, 361, 97-98.	27.0	13
45	Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas. Clinical Cancer Research, 2009, 15, 6790-6799.	7.0	176
46	The Role of <i>KRAS</i> Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients. Oncology, 2009, 77, 224-230.	1.9	27
47	Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2009, 15, 7492-7501.	7.0	45
48	Sensitivity and resistance to EGF-R inhibitors. MAbs, 2009, 1, 590-599.	5.2	5
49	Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction. Science Signaling, 2009, 2, ra80.	3.6	84
50	Targeted Therapy for Advanced Colorectal Cancer — More Is Not Always Better. New England Journal of Medicine, 2009, 360, 623-625.	27.0	85
51	<i>K-ras</i> Mutations and Cetuximab in Colorectal Cancer. New England Journal of Medicine, 2009, 360, 833-836.	27.0	21
52	Cetuximab for Metastatic Colorectal Cancer. New England Journal of Medicine, 2009, 361, 95-97.	27.0	9
53	The overexpression of ERCC-1 is involved in the resistance of lung cancer cells to cetuximab combined with DDP. Cancer Biology and Therapy, 2009, 8, 1914-1921.	3.4	12
54	Current situation of zalutumumab. Expert Opinion on Biological Therapy, 2009, 9, 667-674.	3.1	15
55	Conference Scene: DGVS Spring Conference 2009. Biomarkers in Medicine, 2009, 3, 573-575.	1.4	0
56	Bevacizumab: current indications and future development for management of solid tumors. Expert Opinion on Biological Therapy, 2009, 9, 507-517.	3.1	61
57	KRASmutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue. Expert Opinion on Biological Therapy, 2009, 9, 565-577.	3.1	10
58	New trends in epidermal growth factor receptor-directed monoclonal antibodies. Immunotherapy, 2009, 1, 965-982.	2.0	10
59	Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium. Journal of Clinical Oncology, 2009, 27, 5102-5108.	1.6	42

~		<u> </u>	
		IV F D(DDT
\sim	IIAI	IVE F	

#	Article	IF	CITATIONS
61	K- <i>RAS</i> mutation in the screening, prognosis and treatment of cancer. Biomarkers in Medicine, 2009, 3, 757-769.	1.4	34
62	The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway. Oncology, 2009, 77, 57-68.	1.9	49
63	<i>KRAS</i> Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803. Clinical Cancer Research, 2009, 15, 7322-7329.	7.0	187
64	Cancer Research and Privacy: The Problem With Being Joined at the Hip. Journal of Clinical Oncology, 2009, 27, 3879-3880.	1.6	2
65	Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3. Journal of Clinical Oncology, 2009, 27, 3117-3125.	1.6	437
66	Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug Approval. Journal of Clinical Oncology, 2009, 27, 5868-5873.	1.6	88
67	Aspirin as Adjuvant Therapy for Colorectal Cancer. JAMA - Journal of the American Medical Association, 2009, 302, 688.	7.4	10
68	A Phase 2 Clinical Trial of Panitumumab Monotherapy in Japanese Patients with Metastatic Colorectal Cancer. Japanese Journal of Clinical Oncology, 2009, 39, 321-326.	1.3	54
69	Parallel Paths to Predictive Biomarkers in Oncology: Uncoupling of Emergent Biomarker Development and Phase III Trial Execution. Science Translational Medicine, 2009, 1, 10ps11.	12.4	9
70	Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. Journal of the National Cancer Institute, 2009, 101, 1446-1452.	6.3	899
71	ASCO Provisional Clinical Opinion: <i>KRAS</i> , Cetuximab, and Panitumumab—Clinical Implications in Colorectal Cancer. Journal of Oncology Practice, 2009, 5, 71-72.	2.5	19
72	KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer, 2009, 9, 111.	2.6	80
73	Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer, 2009, 9, 112.	2.6	42
74	A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC Cancer, 2009, 9, 145.	2.6	26
75	Fast simultaneous detection of K-RASmutations in colorectal cancer. BMC Cancer, 2009, 9, 179.	2.6	38
76	Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer, 2009, 9, 246.	2.6	31
78	High sensitivity of both sequencing and realâ€ŧime PCR analysis of <i>KRAS</i> mutations in colorectal cancer tissue. Journal of Cellular and Molecular Medicine, 2010, 14, 2122-2131.	3.6	73
80	Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology, 2009, 625, 6-22.	3.5	22

		CITATION RE	EPORT	
#	Article		IF	Citations
81	Lack of KRAS and BRAF Mutation in Renal Cell Carcinoma. European Urology, 2009, 55,	1490-1491.	1.9	31
82	Novel multiple, monoallelic <i>KRAS</i> mutations at codon 12 and 13. International Jc Cancer, 2009, 125, 2744-2745.	urnal of	5.1	4
83	Assessment of Kâ€∢i>ras mutation. Cancer, 2009, 115, 3609-3617.		4.1	69
84	Prognosis and prediction in a Facebook world. Cancer, 2009, 115, 5368-5370.		4.1	5
85	Gastrointestinal stromal tumor: a bridge between bench and bedside. Gastric Cancer, 2	009, 12, 175-188.	5.3	19
86	La recherche clinique en cancérologie digestive: de la cible à la véritable personnali traitement?. Oncologie, 2009, 11, 325-330.	sation du	0.7	0
88	Pharmacogenomics in chemotherapy for GI tract cancer. Journal of Gastroenterology, 2 1016-1025.	009, 44,	5.1	12
90	Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. Cli Translational Oncology, 2009, 11, 737-747.	nical and	2.4	9
91	The importance of KRAS status in managing metastatic colorectal cancer. Current Colo Reports, 2009, 5, 129-134.	rectal Cancer	0.5	0
92	Incidence of KRAS status in ongoing adjuvant trials in colon cancer. Current Colorectal Reports, 2009, 5, 171-178.	Cancer	0.5	2
93	Drug development in advanced colorectal cancer: Challenges and opportunities. Curren Reports, 2009, 11, 175-185.	t Oncology	4.0	4
94	Implications of KRAS mutation status for the treatment of metastatic colorectal cancer Oncology, 2009, 4, 311-322.	. Targeted	3.6	3
95	Medical Product Development, Innovation, andÂLife-Cycle Regulation: The Challenges for Statistics in Biosciences, 2009, 1, 1-9.	orÂBiostatistics.	1.2	1
96	Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemot metastatic colorectal patients: a multicenter phase II study. Cancer Chemotherapy and 2009, 64, 657-663.	nerapy in Pharmacology,	2.3	69
97	Tumor biology and cancer therapy $\hat{a} \in$ " an evolving relationship. Cell Communication an 2009, 7, 19.	d Signaling,	6.5	11
98	High quality copy number and genotype data from FFPE samples using Molecular Invers microarrays. BMC Medical Genomics, 2009, 2, 8.	ion Probe (MIP)	1.5	83
99	Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clinica Experimental Immunology, 2009, 158, 1-9.	l and	2.6	271
100	Novel Clinical Trial Designs for Innovative Therapies. Clinical Pharmacology and Therape 85, 212-216.	utics, 2009,	4.7	3

#	Article	IF	CITATIONS
101	Predictive Biomarkers in the Development of Oncology Drugs: A Therapeutic Industry Perspective. Clinical Pharmacology and Therapeutics, 2009, 85, 535-538.	4.7	17
102	Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Modern Pathology, 2009, 22, 1023-1031.	5.5	112
103	Genetic prognostic and predictive markers in colorectal cancer. Nature Reviews Cancer, 2009, 9, 489-499.	28.4	602
104	More is less—combining targeted therapies in metastatic colorectal cancer. Nature Reviews Clinical Oncology, 2009, 6, 731-733.	27.6	70
105	Biomarkers of response and resistance to antiangiogenic therapy. Nature Reviews Clinical Oncology, 2009, 6, 327-338.	27.6	541
106	Predictive value of KRAS mutations in chemoresistant CRC. Nature Reviews Clinical Oncology, 2009, 6, 306-307.	27.6	32
107	Treatment in advanced colorectal cancer: what, when and how?. British Journal of Cancer, 2009, 100, 1704-1719.	6.4	89
108	Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. British Journal of Cancer, 2009, 101, 465-472.	6.4	283
109	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. British Journal of Cancer, 2009, 101, 715-721.	6.4	509
110	UK Third National Colorectal Cancer Consensus Meeting 2008. Clinical Oncology, 2009, 21, 306-310.	1.4	3
111	Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions. Current Problems in Cancer, 2009, 33, 245-294.	2.0	9
112	Insulin-like growth factor receptor type I as a target for cancer therapy. Immunotherapy, 2009, 1, 265-279.	2.0	26
113	Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial. Journal of the National Cancer Institute, 2009, 101, 1182-1192.	6.3	119
114	Challenges and Opportunities for Use of Cost-Effectiveness Analysis. Journal of the National Cancer Institute, 2009, 101, 1161-1163.	6.3	13
115	Are RAS mutations predictive markers of resistance to standard chemotherapy?. Nature Reviews Clinical Oncology, 2009, 6, 528-534.	27.6	79
116	Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer. New England Journal of Medicine, 2009, 360, 563-572.	27.0	1,243
117	<i>BRAF</i> Mutation in Metastatic Colorectal Cancer. New England Journal of Medicine, 2009, 361, 98-99.	27.0	489
118	Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 663-671.	1.6	1,524

#	Article	IF	CITATIONS
119	Targeted therapy for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 423-432.	17.8	106
120	A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 672-680.	1.6	828
121	American Society of Clinical Oncology Provisional Clinical Opinion: Testing for <i>KRAS</i> Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy. Journal of Clinical Oncology, 2009, 27, 2091-2096.	1.6	1,138
122	Molecular markers of chemotherapy in advanced colorectal cancer: Back to square one. European Journal of Cancer, 2009, 45, 1902-1903.	2.8	1
123	Targeted therapies in the treatment of advanced/metastatic NSCLC. European Journal of Cancer, 2009, 45, 2473-2487.	2.8	68
124	KRAS et cancer colorectalÂ: un pas de géant vers la médecine personnalisée. Immuno-Analyse Et Biologie Specialisee, 2009, 24, 196-209.	0.0	0
125	The Effects of Epidermal Growth Factor Receptor Activation and Attenuation of the TGFβ Pathway in an Orthotopic Model of Colon Cancer. Journal of Surgical Research, 2009, 156, 250-256.	1.6	12
126	Molecular Basis of Colorectal Cancer. New England Journal of Medicine, 2009, 361, 2449-2460.	27.0	1,581
127	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nature Reviews Clinical Oncology, 2009, 6, 519-527.	27.6	391
128	Can phenotypic pathway signatures improve the prediction of response to PI3K pathway inhibitors?. Drug Discovery Today: Therapeutic Strategies, 2009, 6, 57-62.	0.5	3
129	Molecular Detection of Circulating Tumor Cells in Colorectal Cancer Patients: From Laboratory Investigation to Clinical Implication. Fooyin Journal of Health Sciences, 2009, 1, 2-10.	0.2	4
130	Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. New England Journal of Medicine, 2009, 360, 1408-1417.	27.0	3,543
131	Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab. Journal of Clinical Oncology, 2009, 27, 5068-5074.	1.6	325
132	Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. British Journal of Cancer, 2009, 101, 998-1004.	6.4	84
133	<i>KRAS</i> and <i>BRAF</i> Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial. Journal of Clinical Oncology, 2009, 27, 5931-5937.	1.6	517
134	The Dark Side of the Moon: The PI3K/PTEN/AKT Pathway in Colorectal Carcinoma. Oncology, 2009, 77, 69-74.	1.9	16
135	KRAS Testing in Metastatic Colorectal Cancer: Implications on the Use of Biologic Agents. Clinical Colorectal Cancer, 2009, 8, 135-140.	2.3	4
136		2.6	23

#	Article	IF	CITATIONS
137	The Role of Cetuximab in the Management of Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2009, 10, 230-238.	2.6	11
139	Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. Journal of Hematology and Oncology, 2009, 2, 18.	17.0	50
140	Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opinion on Biological Therapy, 2009, 9, 1199-1206.	3.1	86
141	Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. Journal of Clinical Pathology, 2009, 62, 886-891.	2.0	46
142	Targeting targeted agents: open issues for clinical trial design. Journal of Experimental and Clinical Cancer Research, 2009, 28, 66.	8.6	18
143	Genomic advances and their impact on clinical trial design. Genome Medicine, 2009, 1, 69.	8.2	16
144	Textbook of Personalized Medicine. , 2009, , .		74
145	Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut, 2009, 58, 357-365.	12.1	289
146	Antiangiogenic drugs in ovarian cancer. Expert Opinion on Pharmacotherapy, 2009, 10, 2269-2277.	1.8	10
147	PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 2622-2629.	1.6	402
148	Clinical Biomarkers in Oncology. Molecular Diagnosis and Therapy, 2009, 13, 103-114.	3.8	44
149	Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Review of Anticancer Therapy, 2009, 9, 1421-1428.	2.4	99
150	Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2009, 101, 1308-1324.	6.3	486
151	Current management of colorectal hepatic metastasis. Expert Review of Gastroenterology and Hepatology, 2009, 3, 131-144.	3.0	79
153	Pharmacogenetics and biomarkers in colorectal cancer. Pharmacogenomics Journal, 2009, 9, 147-160.	2.0	26
154	Should we be surprised at the paucity of response to EGFR inhibitors?. Lancet Oncology, The, 2009, 10, 522-527.	10.7	45
155	Retrospective subset analyses in early breast cancer revisited. Lancet Oncology, The, 2009, 10, 1136-1137.	10.7	0
156	How to integrate biologicals in the continuum of care. European Journal of Cancer, 2009, 45, 57-69.	2.8	0

#	Article	IF	CITATIONS
157	Impact of molecular markers on treatment selection in advanced colorectal cancer. European Journal of Cancer, 2009, 45, 70-78.	2.8	10
158	EGFR Signaling and Drug Discovery. Oncology, 2009, 77, 400-410.	1.9	387
159	Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges. Journal of Clinical Oncology, 2009, 27, 4027-4034.	1.6	364
160	Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anti-Cancer Drugs, 2009, 20, 634-638.	1.4	41
161	Role of molecular markers and gene profiling in head and neck cancers. Current Opinion in Oncology, 2009, 21, 206-211.	2.4	36
163	KRAS Mutation Testing in Colorectal Cancer. Advances in Anatomic Pathology, 2009, 16, 196-203.	4.3	98
164	KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2009, 15, 110-113.	2.0	32
165	New targeted therapies for non-small-cell lung cancer. Therapy: Open Access in Clinical Medicine, 2009, 6, 335-350.	0.2	4
166	Clinical implications of microsatellite instability in sporadic colon cancers. Current Opinion in Oncology, 2009, 21, 369-373.	2.4	80
167	Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anti-Cancer Drugs, 2009, 20, 616-624.	1.4	102
168	Targeted therapeutics-oriented tumor classification: a paradigm shift. Personalized Medicine, 2009, 6, 465-468.	1.5	7
169	Rectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 838-881.	4.9	289
170	Colon Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 778-831.	4.9	409
173	A Correction to the Research Article Titled: "Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction" by A. Bertotti, M. F. Burbridge, S. Gastaldi, F. Galimi, D. Torti, E. Medico, S. Giordano, S. Corso, G. Rolland-Valognes, B. P. Lockhart, J. A. Hickman, P. M. Comoglio, L. Trusolino. Science Signaling, 2009. 2, er11	3.6	23
174	Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodies. Personalized Medicine, 2009, 6, 145-157.	1.5	2
176	Evaluation and Validation of Diagnostic Tests for Guiding Therapeutic Decisions. Therapie, 2009, 64, 195-201.	1.0	7
178	The â€~timely' development of Rexin-G: First targeted injectable gene vector (Review). International Journal of Oncology, 2009, , .	3.3	6
179	KRAS Mutational Status as a Predictor of Epidermal Growth Factor Receptor Inhibitor Efficacy in Colorectal Cancer. American Journal of Therapeutics, 2009, 16, 554-561.	0.9	24

#	Article	IF	CITATIONS
181	Anti-Egfr Therapy in Colorectal Cancer: How to Choose The Right Patient. Current Drug Targets, 2009, 10, 1033-1040.	2.1	14
182	Molecular Targeted Therapy in Prevalent Tumors: Learning from the Past and Future Perspectives. Current Clinical Pharmacology, 2010, 5, 166-177.	0.6	8
183	Integration of Anti-Epidermal Growth Factor Receptor Therapies With Cytotoxic Chemotherapy. Cancer Journal (Sudbury, Mass), 2010, 16, 226-234.	2.0	5
184	Pharmacodynamic (Phase 0) Study Using Etaracizumab in Advanced Melanoma. Journal of Immunotherapy, 2010, 33, 316-325.	2.4	22
185	Monoclonal Antibodies in Solid Tumours. Current Clinical Pharmacology, 2010, 5, 160-165.	0.6	3
187	Molecular Targeted Therapy of Biliary Tract Cancer – Results of the First Clinical Studies. Current Drug Targets, 2010, 11, 834-850.	2.1	36
188	KRAS Mutation Analysis Prior to EGFR-Directed Therapy for Metastatic Colorectal Cancer: A Review and Cost Analysis. Current Cancer Therapy Reviews, 2010, 6, 256-261.	0.3	3
189	Artificial Intelligence Techniques for Colorectal Cancer Drug Metabolism: Ontologies and Complex Networks. Current Drug Metabolism, 2010, 11, 347-368.	1.2	59
190	Biomarkers for Colorectal Cancer: Identification Through Proteomics. Current Proteomics, 2010, 7, 212-221.	0.3	9
191	Is it prime time for personalized medicine in cancer treatment?. Personalized Medicine, 2010, 7, 387-397.	1.5	1
191 192	Is it prime time for personalized medicine in cancer treatment?. Personalized Medicine, 2010, 7, 387-397. Targeted therapy in advanced colorectal cancer: more data, more questions. Anti-Cancer Drugs, 2010, 21, 737-748.	1.5 1.4	1
191 192 193	Is it prime time for personalized medicine in cancer treatment?. Personalized Medicine, 2010, 7, 387-397. Targeted therapy in advanced colorectal cancer: more data, more questions. Anti-Cancer Drugs, 2010, 21, 737-748. HPV in Head and Neck Cancers Among 5-Year Survivors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 425-426.	1.5 1.4 1.3	1 14 0
191 192 193 194	Is it prime time for personalized medicine in cancer treatment?. Personalized Medicine, 2010, 7, 387-397. Targeted therapy in advanced colorectal cancer: more data, more questions. Anti-Cancer Drugs, 2010, 21, 737-748. HPV in Head and Neck Cancers Among 5-Year Survivors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 425-426. When More is Worse in Clinical Research and Clinical Practice. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 424.	1.5 1.4 1.3 1.3	1 14 0 0
191 192 193 194	Is it prime time for personalized medicine in cancer treatment?. Personalized Medicine, 2010, 7, 387-397. Targeted therapy in advanced colorectal cancer: more data, more questions. Anti-Cancer Drugs, 2010, 21, 737-748. HPV in Head and Neck Cancers Among 5-Year Survivors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 425-426. When More is Worse in Clinical Research and Clinical Practice. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 424. A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 609-613.	1.5 1.4 1.3 1.3	1 14 0 0
 191 192 193 194 195 196 	Is it prime time for personalized medicine in cancer treatment?. Personalized Medicine, 2010, 7, 387-397. Targeted therapy in advanced colorectal cancer: more data, more questions. Anti-Cancer Drugs, 2010, 21, 737-748. HPV in Head and Neck Cancers Among 5-Year Survivors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 425-426. When More is Worse in Clinical Research and Clinical Practice. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 424. A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 609-613. Detection of Occult Metastases in Sentinel Lymph Nodes From Colon Cancer Patients by K-ras Mutation Peptide Nucleic Acid Clamp PCR. Annals of Surgery, 2010, 251, 1087-1091.	1.5 1.4 1.3 1.3 1.3 4.2	1 14 0 0 61 10
 191 192 193 194 194 195 196 197 	Is it prime time for personalized medicine in cancer treatment?. Personalized Medicine, 2010, 7, 387-397. Targeted therapy in advanced colorectal cancer: more data, more questions. Anti-Cancer Drugs, 2010, 21, 737-748. HPV in Head and Neck Cancers Among 5-Year Survivors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 425-426. When More is Worse in Clinical Research and Clinical Practice. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 424. A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 609-613. Detection of Occult Metastases in Sentinel Lymph Nodes From Colon Cancer Patients by K-ras Mutation Peptide Nucleic Acid Clamp PCR. Annals of Surgery, 2010, 251, 1087-1091. Novel Agents in the Treatment of Metastatic Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2010, 16, 273-282.	1.5 1.4 1.3 1.3 4.2 2.0	1 14 0 0 0 61 10 6
 191 192 193 194 194 195 196 197 198 	Is it prime time for personalized medicine in cancer treatment?. Personalized Medicine, 2010, 7, 387-397. Targeted therapy in advanced colorectal cancer: more data, more questions. Anti-Cancer Drugs, 2010, 21, 737-748. HPV in Head and Neck Cancers Among 5-Year Survivors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 425-426. When More is Worse in Clinical Research and Clinical Practice. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 424. A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 609-613. Detection of Occult Metastases in Sentinel Lymph Nodes From Colon Cancer Patients by K-ras Mutation Peptide Nucleic Acid Clamp PCR. Annals of Surgery, 2010, 251, 1087-1091. Novel Agents in the Treatment of Metastatic Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2010, 16, 273-282. Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6. Oncology Letters, 2010, 1, 253-259.	1.5 1.4 1.3 1.3 4.2 2.0 1.8	1 14 0 0 0 10 6 19

#	Article	IF	CITATIONS
200	Inhibition of MLK3 Decreases Proliferation and Increases Antiproliferative Activity of Epidermal Growth Factor Receptor (EGFR) Inhibitor in pancreatic cancer cell Lines. Cancer Growth and Metastasis, 2010, 3, CGM.S2824.	3.5	4
201	Translational Research in Surgical Disease. Archives of Surgery, 2010, 145, 187.	2.2	3
202	Increased Expression of Annexin A1 Is Correlated with K-Ras Mutation in Colorectal Cancer. Tohoku Journal of Experimental Medicine, 2010, 222, 243-250.	1.2	24
203	Current Progress in Targeted Therapy for Colorectal Cancer. Cancer Control, 2010, 17, 7-15.	1.8	57
204	KRAS Mutation Testing in Human Cancers: The Pathologist's Role in the Era of Personalized Medicine. Advances in Anatomic Pathology, 2010, 17, 23-32.	4.3	80
205	Mutation analysis of K-ras protooncogene in colorectal adenocarcinomas and polyps in Russian patients. Russian Journal of Genetics, 2010, 46, 617-624.	0.6	1
206	KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy. Annals of Surgical Oncology, 2010, 17, 1168-1176.	1.5	112
207	Profiling the Cancer Genome. Annual Review of Genomics and Human Genetics, 2010, 11, 133-159.	6.2	43
208	lgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Human Antibodies, 2010, 19, 89-99.	1.5	73
209	Clinical trials for predictive medicine: new challenges and paradigms. Clinical Trials, 2010, 7, 516-524.	1.6	64
210	Predictive biomarker validation in practice: lessons from real trials. Clinical Trials, 2010, 7, 567-573.	1.6	83
211	Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials. Cancer Chemotherapy and Pharmacology, 2010, 65, 849-861.	2.3	23
214	Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations. International Journal of Colorectal Disease, 2010, 25, 713-721.	2.2	25
216	Cancer colorectal: stratégies thérapeutiques en situation métastatique. Oncologie, 2010, 12, 593-600.	0.7	0
218	Palliative endoscopic and chemotherapeutic treatment. European Surgery - Acta Chirurgica Austriaca, 2010, 42, 287-298.	0.7	0
220	Moving from correlative science to predictive oncology. EPMA Journal, 2010, 1, 377-387.	6.1	4
222	Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Targeted Oncology, 2010, 5, 19-28.	3.6	27
223	A Case Report of Gemcitabine Treatment for Duodenal Cancer: The Good (A Sustained Response) and The Bad (Life Threatening Refractory Thrombotic Thrombocytopenic Purpura). Journal of Gastrointestinal Cancer, 2010, 41, 71-74.	1.3	4

#	Article	IF	CITATIONS
224	MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. Medical Oncology, 2010, 27, 1066-1072.	2.5	15
225	Biomarkers in colorectal cancer. Clinical and Translational Oncology, 2010, 12, 261-270.	2.4	3
226	Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clinical and Translational Oncology, 2010, 12, 533-542.	2.4	51
227	Multidisciplinary management in rectal cancer. Clinical and Translational Oncology, 2010, 12, 805-818.	2.4	1
228	PrÃ d iktive und prognostische genetische Biomarker. Wiener Klinische Wochenschrift Education, 2010, 5, 49-71.	0.0	0
229	Molecular Markers of Chemotherapy Response in Colorectal Cancer. Current Colorectal Cancer Reports, 2010, 6, 118-125.	0.5	0
230	Management Strategies for Patients with KRAS Mutations. Current Colorectal Cancer Reports, 2010, 6, 199-205.	0.5	0
231	The Biology of K-Ras and B-Raf Mutations in Colorectal Cancer. Current Colorectal Cancer Reports, 2010, 6, 206-211.	0.5	0
232	B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma. Current Oncology Reports, 2010, 12, 146-152.	4.0	49
233	KRAS Testing and Its Importance in Colorectal Cancer. Current Oncology Reports, 2010, 12, 160-167.	4.0	12
234	Current and Emerging Treatment Strategies for Anal Cancer. Current Oncology Reports, 2010, 12, 168-174.	4.0	10
235	Cetuximab in combination therapy: from bench to clinic. Cancer and Metastasis Reviews, 2010, 29, 171-180.	5.9	27
236	Gene expression profiling of primary and metastatic colon cancers identifies a reduced proliferative rate in metastatic tumors. Clinical and Experimental Metastasis, 2010, 27, 1-9.	3.3	23
237	Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience. Investigational New Drugs, 2010, 28, 353-360.	2.6	28
238	Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents. , 2010, 128, 82-90.		10
239	Radiation, chemotherapy and biological therapy in the curative treatment of locally advanced rectal cancer. Colorectal Disease, 2010, 12, 2-24.	1.4	11
240	The Emerging Role of Biomarkers in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2010, 11, 149-159.	2.6	20
241	Use of Cetuximab After Failure of Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2010, 11, 257-263.	2.6	8

#	Article	IF	CITATIONS
242	Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer, 2010, 10, 136.	2.6	59
243	Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer, 2010, 10, 302.	2.6	43
244	Allelotyping identification of genomic alterations in rectal chromosomally unstable tumors without preoperative treatment. BMC Cancer, 2010, 10, 561.	2.6	1
245	KRAS analysis in colorectal carcinoma: Analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer, 2010, 10, 660.	2.6	66
246	Quantitative methodology using CT for predicting survival in patients with metastatic colorectal carcinoma: a pilot study. Clinical Imaging, 2010, 34, 196-202.	1.5	2
247	Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review. Clinical Therapeutics, 2010, 32, 437-453.	2.5	164
248	Therapeutic modulation of k-ras signaling in colorectal cancer. Drug Discovery Today, 2010, 15, 502-516.	6.4	38
249	Mechanisms of resistance to HER family targeting antibodies. Experimental Cell Research, 2010, 316, 1083-1100.	2.6	136
250	Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy. Journal of Cellular and Molecular Medicine, 2010, 14, 805-817.	3.6	3
251	Individualized medicine 2010. Journal of Cellular and Molecular Medicine, 2010, 14, 2257-2263.	3.6	2
252	Oncomutations as biomarkers of cancer risk. Environmental and Molecular Mutagenesis, 2010, 51, 836-850.	2.2	28
253	Mutated <i>KRAS</i> results in overexpression of <i>DUSP4</i> , a MAPâ€kinase phosphatase, and <i>SMYD3</i> , a histone methyltransferase, in rectal carcinomas. Genes Chromosomes and Cancer, 2010, 49, 1024-1034.	2.8	169
254	Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin. Cancer, 2010, 116, 316-322.	4.1	109
255	The role of targeted agents in preoperative chemoradiation for rectal cancer. Cancer, 2010, 116, 3537-3548.	4.1	28
256	Translating research into evidenceâ€based practice. Cancer, 2010, 116, 4440-4449.	4.1	79
257	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. Cancer, 2010, 116, 5599-5607.	4.1	143
258	Expression of p16 ^{INK4A} but not hypoxia markers or poly adenosine diphosphateâ€ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. Cancer, 2010, 116, 5179-5187.	4.1	16
259	Sorafenib: Where do we go from here?. Hepatology, 2010, 52, 360-369.	7.3	92

#	Article	IF	CITATIONS
260	Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to antiâ€EGFR antibodies in colorectal cancer. International Journal of Cancer, 2010, 127, 1321-1331.	5.1	45
261	Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: The role of antiâ€VEGF and antiâ€EGFR antibodies. Journal of Surgical Oncology, 2010, 102, 937-945.	1.7	8
262	Proteomics of colorectal cancer: Overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. Journal of Proteomics, 2010, 73, 1873-1895.	2.4	101
263	Detection of N-, H-, and KRAS codons 12, 13, and 61 mutations with universal RAS primer multiplex PCR and N-, H-, and KRAS-specific primer extension. Clinical Biochemistry, 2010, 43, 296-301.	1.9	28
264	UK Fourth National Colorectal Cancer Consensus Meeting 2009. Clinical Oncology, 2010, 22, 533-537.	1.4	2
265	Integration of panitumumab into the treatment of colorectal cancer. Critical Reviews in Oncology/Hematology, 2010, 74, 16-26.	4.4	24
266	Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab. Critical Reviews in Oncology/Hematology, 2010, 74, 193-202.	4.4	24
267	Optimizing the management of metastatic colorectal cancer. Critical Reviews in Oncology/Hematology, 2010, 75, 15-26.	4.4	5
268	Colon cancer. Critical Reviews in Oncology/Hematology, 2010, 74, 106-133.	4.4	285
269	ACR Appropriateness Criteria®: Rectal Cancer—Metastatic Disease at Presentation. Current Problems in Cancer, 2010, 34, 201-210.	2.0	11
270	COLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma. BMC Clinical Pathology, 2010, 10, 6.	1.8	26
271	A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Medical Genomics, 2010, 3, 26.	1.5	124
272	Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics. Journal of Ovarian Research, 2010, 3, 7.	3.0	46
273	Epidermal growth factor receptor in relation to tumor development: EGFRâ€ŧargeted anticancer therapy. FEBS Journal, 2010, 277, 309-315.	4.7	71
274	Mitomycin , 5â€fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. Asia-Pacific Journal of Clinical Oncology, 2010, 6, 286-291.	1.1	7
275	Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. Cancer Science, 2010, 101, 793-799.	3.9	24
276	Fcâ€engineered EGFâ€R antibodies mediate improved antibodyâ€dependent cellular cytotoxicity (ADCC) against <i>KRAS</i> â€mutated tumor cells. Cancer Science, 2010, 101, 1080-1088.	3.9	42
277	Biomarkers in bladder cancer. Histopathology, 2010, 57, 1-13.	2.9	74

#	Article	IF	CITATIONS
278	Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. Histopathology, 2010, 57, 418-426.	2.9	30
279	Comparative analysis of pyrosequencing and QMCâ€PCR in conjunction with high resolution melting for <i>KRAS/BRAF</i> mutation detection. International Journal of Experimental Pathology, 2010, 91, 500-505.	1.3	31
280	Oncogenic mutations as predictive factors in colorectal cancer. Oncogene, 2010, 29, 3033-3043.	5.9	98
281	Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients. British Journal of Cancer, 2010, 102, 151-161.	6.4	49
282	Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). British Journal of Cancer, 2010, 102, 500-505.	6.4	163
283	KRAS status analysis and anti-ECFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?. British Journal of Cancer, 2010, 102, 1074-1075.	6.4	6
284	Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. British Journal of Cancer, 2010, 102, 1137-1144.	6.4	24
285	Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. British Journal of Cancer, 2010, 103, 1407-1414.	6.4	155
286	Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. British Journal of Cancer, 2010, 103, 1765-1772.	6.4	70
287	Assessing the Clinical Utility of Diagnostics Used in Drug Therapy. Clinical Pharmacology and Therapeutics, 2010, 88, 765-773.	4.7	78
288	Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor. Gene Therapy, 2010, 17, 1000-1010.	4.5	17
289	Translating cancer research into targeted therapeutics. Nature, 2010, 467, 543-549.	27.8	310
290	Targeting the cancer kinome through polypharmacology. Nature Reviews Cancer, 2010, 10, 130-137.	28.4	618
291	Personalized medicine in oncology: the future is now. Nature Reviews Drug Discovery, 2010, 9, 363-366.	46.4	265
292	Targeted cancer therapies. Nature Reviews Drug Discovery, 2010, 9, 427-428.	46.4	160
293	Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU International, 2010, 105, 317-321.	2.5	99
294	Epidermal Growth Factor Receptor Targeted Therapy in Stages III and IV Head and Neck Cancer. Current Oncology, 2010, 17, 37-48.	2.2	88
295	Circulating Tumor Cells, Enumeration and Beyond. Cancers, 2010, 2, 1236-1250.	3.7	42

#	Article	IF	CITATIONS
296	Biological and clinical markers in colorectal cancer state of the art. Frontiers in Bioscience - Scholar, 2010, S2, 422-431.	2.1	16
297	Eastern Canadian Colorectal Cancer Consensus Conference: Setting the Limits of Resectable Disease. Current Oncology, 2010, 17, 70-77.	2.2	43
298	Consensus Recommendations for the Use of Anti-EGFR Therapies in Metastatic Colorectal Cancer. Current Oncology, 2010, 17, 39-45.	2.2	8
299	Mutation Analysis of Braf Exon 15 and Kras Codons 12 and 13 in Moroccan Patients with Colorectal Cancer. International Journal of Biological Markers, 2010, 25, 179-184.	1.8	12
300	The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biologics: Targets and Therapy, 2010, 4, 289.	3.2	30
301	KRAS Mutation Testing in the Treatment of Metastatic Colorectal Cancer with Anti-EGFR Therapies. Current Oncology, 2010, 17, 31-40.	2.2	54
302	Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2010, 36, 273-282.	1.5	8
303	Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. JAMA - Journal of the American Medical Association, 2010, 304, 1812.	7.4	663
304	Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K- <i>ras</i> –Mutated Colorectal Cancer. Molecular Cancer Therapeutics, 2010, 9, 3351-3362.	4.1	71
305	Epidermal Growth Factor Receptor Biomarkers in Non–Small-Cell Lung Cancer: A Riddle, Wrapped in a Mystery, Inside an Enigma. Journal of Clinical Oncology, 2010, 28, 903-905.	1.6	28
306	A Review of the Most Promising Biomarkers in Colorectal Cancer: One Step Closer to Targeted Therapy. Oncologist, 2010, 15, 699-731.	3.7	137
307	EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. Expert Opinion on Emerging Drugs, 2010, 15, 185-201.	2.4	32
308	Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 4240-4246.	1.6	129
309	New Strategies in Colorectal Cancer: Biomarkers of Response to Epidermal Growth Factor Receptor Monoclonal Antibodies and Potential Therapeutic Targets in Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Pathways. Clinical Cancer Research, 2010, 16, 3811-3818.	7.0	41
311	Randomized Clinical Trials With Biomarkers: Design Issues. Journal of the National Cancer Institute, 2010, 102, 152-160.	6.3	325
312	Three DNA Methylation Epigenotypes in Human Colorectal Cancer. Clinical Cancer Research, 2010, 16, 21-33.	7.0	207
313	Reply to D.J. Stewart. Journal of Clinical Oncology, 2010, 28, e652-e653.	1.6	3
314	Integration of Epidermal Growth Factor Receptor Inhibitors with Preoperative Chemoradiation. Clinical Cancer Research, 2010, 16, 2709-2714.	7.0	29

#	Article	IF	CITATIONS
315	Gene Array and Fluorescence In situ Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer. Clinical Cancer Research, 2010, 16, 4165-4177.	7.0	41
316	VRK2 Inhibits Mitogen-Activated Protein Kinase Signaling and Inversely Correlates with ErbB2 in Human Breast Cancer. Molecular and Cellular Biology, 2010, 30, 4687-4697.	2.3	37
317	New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer. Clinical Cancer Research, 2010, 16, 2921-2926.	7.0	70
318	Refocusing the War on Cancer: The Critical Role of Personalized Treatment. Science Translational Medicine, 2010, 2, 28cm13.	12.4	33
319	Patient With Colorectal Cancer With Heterogeneous <i>KRAS</i> Molecular Status Responding to Cetuximab-Based Chemotherapy. Journal of Clinical Oncology, 2010, 28, e756-e758.	1.6	14
320	EGFR Antibodies in Colorectal Cancer: Where Do They Belong?. Journal of Clinical Oncology, 2010, 28, 4668-4670.	1.6	41
321	Raising the Bar of Efficacy for Drug Approval Requires an Understanding of Patient Diversity. Journal of Clinical Oncology, 2010, 28, e343-e344.	1.6	6
322	Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?. Clinical Cancer Research, 2010, 16, 5972-5980.	7.0	105
323	Phase II Study of Combination Chemotherapy with Biweekly Cetuximab and Irinotecan for Pre-treated Metastatic Colorectal Cancer Harboring Wild-type KRAS. Japanese Journal of Clinical Oncology, 2010, 40, 699-701.	1.3	3
324	The Evolving Role of Monoclonal Antibodies in Colorectal Cancer: Early Presumptions and Impact on Clinical Trial Development. Oncologist, 2010, 15, 73-84.	3.7	42
325	Establishment of the Australian In Situ Hybridization Program for the Assessment of HER2 Amplification in Breast Cancer. Diagnostic Molecular Pathology, 2010, 19, 187-193.	2.1	11
326	Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. Journal of Clinical Oncology, 2010, 28, 3191-3198.	1.6	370
327	High Sensitivity of Reverse-hybridization Methodology in the Detection of KRAS Mutations from Formalin-fixed Paraffin-embedded Colorectal Cancer Samples. Diagnostic Molecular Pathology, 2010, 19, 201-208.	2.1	8
328	miR-192/miR-215 Influence 5-Fluorouracil Resistance through Cell Cycle-Mediated Mechanisms Complementary to Its Post-transcriptional Thymidilate Synthase Regulation. Molecular Cancer Therapeutics, 2010, 9, 2265-2275.	4.1	154
329	Ethics of Mandatory Research Biopsy for Correlative End Points Within Clinical Trials in Oncology. Journal of Clinical Oncology, 2010, 28, 2635-2640.	1.6	76
330	The Scientific Basis of Urology. , 0, , .		18
331	Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination. Molecular Cancer Therapeutics, 2010, 9, 358-368.	4.1	44
332	PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. Neuro-Oncology, 2010, 12, 967-975.	1.2	31

#	Article	IF	CITATIONS
333	Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocrine-Related Cancer, 2010, 17, 623-636.	3.1	59
334	A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in <i>KRAS</i> gene from both serum and tissue samples. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1103-1106.	2.3	23
335	Predicting Response to EGFR Inhibitors in Metastatic Colorectal Cancer: Current Practice and Future Directions. Oncologist, 2010, 15, 157-167.	3.7	28
336	Palliative treatment of unresectable metastatic colorectal cancer. Expert Opinion on Pharmacotherapy, 2010, 11, 63-77.	1.8	18
337	Novel biomarkers of metastatic cancer. Expert Review of Molecular Diagnostics, 2010, 10, 581-590.	3.1	17
338	Understanding resistance to EGFR inhibitors—impact on future treatment strategies. Nature Reviews Clinical Oncology, 2010, 7, 493-507.	27.6	593
339	Activating K-Ras mutations outwith â€~hotspot' codons in sporadic colorectal tumours – implications for personalised cancer medicine. British Journal of Cancer, 2010, 102, 693-703.	6.4	156
340	Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2010, 10, 1589-1599.	2.4	8
341	Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2010, 10, 499-505.	2.4	20
342	Evolution of systemic therapy for advanced pancreatic cancer. Expert Review of Anticancer Therapy, 2010, 10, 529-540.	2.4	37
343	Redefining disease. Clinical Medicine, 2010, 10, 584-594.	1.9	13
344	On Target? Off Target? Why We Really Do Not Know. Journal of Clinical Oncology, 2010, 28, 2937-2938.	1.6	0
345	Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study. Journal of Clinical Oncology, 2010, 28, 3491-3497.	1.6	246
346	T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12605-12610.	7.1	140
348	From combinatorial peptide selection to drug prototype (II): Targeting the epidermal growth factor receptor pathway. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5118-5123.	7.1	52
349	Reply to D.J. Stewart. Journal of Clinical Oncology, 2010, 28, e651-e651.	1.6	2
350	Proteomics as a guiding tool for more effective personalized therapy. Annals of Oncology, 2010, 21, vii205-vii210.	1.2	35
351	Genotype-Based Risk and Pharmacogenetic Sampling in Clinical Trials. Journal of Biopharmaceutical Statistics, 2010, 20, 315-333.	0.8	19

#	Article	IF	CITATIONS
352	Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer—an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Annals of Oncology, 2010, 21, 1579-1584.	1.2	58
353	Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Annals of Oncology, 2010, 21, v93-v97.	1.2	384
354	What Constitutes Reasonable Evidence of Efficacy and Effectiveness to Guide Oncology Treatment Decisions?. Oncologist, 2010, 15, 19-23.	3.7	31
355	Optical molecular imaging and its emerging role in colorectal cancer. American Journal of Physiology - Renal Physiology, 2010, 299, G807-G820.	3.4	18
357	Case 19-2010. New England Journal of Medicine, 2010, 362, 2411-2419.	27.0	0
358	Epigenetic Biomarkers. Current Topics in Microbiology and Immunology, 2010, 355, 189-216.	1.1	16
359	Systemic therapy for metastatic pancreatic adenocarcinoma. Therapeutic Advances in Medical Oncology, 2010, 2, 85-106.	3.2	5
360	Incorporating New Data on Colorectal Cancer Into Nursing Practice. Clinical Journal of Oncology Nursing, 2010, 14, 92-100.	0.6	4
361	Treatment of Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma. Oncologist, 2010, 15, 1320-1328.	3.7	109
362	Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 358-365.	2.5	61
363	A growing family: Adding mutated Erbb4 as a novel cancer target. Cell Cycle, 2010, 9, 1487-1503.	2.6	34
364	NF-Ä,B and Bcl-3 Activation Are Prognostic in Metastatic Colorectal Cancer. Oncology, 2010, 78, 181-188.	1.9	76
365	High Plasma TIMP-1 and Serum CEA Levels during Combination Chemotherapy for Metastatic Colorectal Cancer Are Significantly Associated with Poor Outcome. Oncology, 2010, 79, 144-149.	1.9	24
366	Recent Advances in Combined Modality Therapy. Oncologist, 2010, 15, 372-381.	3.7	37
367	Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2010, 5, 142-151.	1.6	3
368	Synthetic Lethality through Combined Notch–Epidermal Growth Factor Receptor Pathway Inhibition in Basal-Like Breast Cancer. Cancer Research, 2010, 70, 5465-5474.	0.9	64
369	Challenges of drug resistance in the management of pancreatic cancer. Expert Review of Anticancer Therapy, 2010, 10, 1647-1661.	2.4	47
373	Predictive Genomic Biomarkers. Current Topics in Microbiology and Immunology, 2010, 355, 173-188.	1.1	1

#	Article	IF	CITATIONS
374	Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway. Current Cancer Drug Targets, 2010, 10, 824-833.	1.6	28
376	Colorectal cancer: cetuximab, <i>KRAS</i> , <i>BRAF</i> , <i>PIK3CA</i> mutations and beyond. Expert Review of Gastroenterology and Hepatology, 2010, 4, 525-529.	3.0	18
378	Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies. Current Cancer Drug Targets, 2010, 10, 799-812.	1.6	28
379	Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2010, 11, 2363-2389.	1.8	19
380	Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery. Oncologist, 2010, 15, 390-404.	3.7	155
381	Targeting Heart Failure Therapeutics: A Historical Perspective. Heart Failure Clinics, 2010, 6, 11-23.	2.1	6
382	Oncogenic KRAS Desensitizes Colorectal Tumor Cells to Epidermal Growth Factor Receptor Inhibition and Activation. Neoplasia, 2010, 12, 443-IN2.	5.3	42
383	Targeted Therapeutic Agents for Colorectal Cancer. Gastroenterology Clinics of North America, 2010, 39, 601-613.	2.2	22
384	Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Personalized Medicine, 2010, 7, 33-47.	1.5	155
385	Three-dimensionally Specific Inhibition of DNA Repair-Related Genes by Activated KRAS in Colon Crypt Model. Neoplasia, 2010, 12, 397-IN5.	5.3	32
386	Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. Expert Opinion on Pharmacotherapy, 2010, 11, 2187-2198.	1.8	12
387	Treatment of Colorectal Cancer. Cancer Metastasis - Biology and Treatment, 2010, , 359-388.	0.1	0
388	Biomarkers and surrogate end points—the challenge of statistical validation. Nature Reviews Clinical Oncology, 2010, 7, 309-317.	27.6	283
389	The Long and Winding Road to Warfarin Pharmacogenetic Testing. Journal of the American College of Cardiology, 2010, 55, 2813-2815.	2.8	40
390	New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer, 2010, 69, 1-12.	2.0	59
391	Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer. Translational Research, 2010, 156, 98-105.	5.0	27
392	Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2010, 9, 274-281.	2.3	63
393	Personalized therapies in the cancer "omics" era. Molecular Cancer, 2010, 9, 202.	19.2	52

#	Article	IF	CITATIONS
394	Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab. Journal of Translational Medicine, 2010, 8, 36.	4.4	16
395	Management of Patients with Advanced Non-Small Cell Lung Cancer. Drugs, 2010, 70, 167-179.	10.9	18
396	Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. Clinical Colorectal Cancer, 2010, 9, 8-14.	2.3	7
397	Is Tailored Adjuvant Treatment for Colon Cancer Possible?. Clinical Colorectal Cancer, 2010, 9, 15-21.	2.3	1
398	KRAS Mutation Screening in Colorectal Cancer: From Paper to Practice. Clinical Colorectal Cancer, 2010, 9, 22-30.	2.3	22
399	Cetuximab Plus Irinotecan in Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: The LABEL Study. Clinical Colorectal Cancer, 2010, 9, 282-289.	2.3	9
400	Cetuximab is Associated With Excessive Toxicity When Combined With Bevacizumab Plus mFOLFOX6 in Metastatic Colorectal Carcinoma. Clinical Colorectal Cancer, 2010, 9, 290-296.	2.3	8
401	Integrating Biomarkers Into Clinical Decision Making for Colorectal Cancer. Clinical Colorectal Cancer, 2010, 9, S16-S27.	2.3	7
402	Treatment Paradigms With Epidermal Growth Factor Receptor–Targeted Therapies in Colorectal Cancer. Clinical Colorectal Cancer, 2010, 9, S44-S50.	2.3	2
403	Phase II Study of Cetuximab, Docetaxel, and Gemcitabine in Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2010, 11, 198-203.	2.6	9
404	Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer. Gastroenterology, 2010, 138, 2163-2176.	1.3	85
405	KRAS Genotyping of Paraffin-Embedded Colorectal Cancer Tissue in Routine Diagnostics. Journal of Molecular Diagnostics, 2010, 12, 35-42.	2.8	94
407	Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. Journal of Clinical Oncology, 2010, 28, 4697-4705.	1.6	1,644
408	Testing the Homogeneity of Two Survival Functions Against a Mixture Alternative Based on Censored Data. Communications in Statistics Part B: Simulation and Computation, 2010, 39, 767-776.	1.2	0
409	Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study. Journal of Clinical Oncology, 2010, 28, 1181-1189.	1.6	113
410	Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 1254-1261.	1.6	668
411	The molecular therapy of colorectal cancer. Molecular Aspects of Medicine, 2010, 31, 171-178.	6.4	52
412	High sensitive mutation analysis on KRAS gene using LNA/DNA chimeras as PCR amplification blockers of wild-type alleles. Molecular and Cellular Probes, 2010, 24, 376-380.	2.1	20

#	Article	IF	CITATIONS
413	Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance. Biomedicine and Pharmacotherapy, 2010, 64, 550-558.	5.6	13
414	Molecular predictive and prognostic markers in colon cancer. Cancer Treatment Reviews, 2010, 36, 550-556.	7.7	57
415	Predictive biomarkers for personalised anti-cancer drug use: Discovery to clinical implementation. European Journal of Cancer, 2010, 46, 869-879.	2.8	49
416	Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). European Journal of Cancer, 2010, 46, 1703-1711.	2.8	58
417	Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. European Journal of Cancer, 2010, 46, 1829-1834.	2.8	75
418	Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. European Journal of Cancer, 2010, 46, 1997-2009.	2.8	193
419	Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies. European Journal of Cancer, 2010, 46, 2781-2787.	2.8	80
420	Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. European Journal of Cancer, 2010, 46, 2746-2752.	2.8	41
421	The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: A comparison between direct sequencing and real-time PCR. Biochemical and Biophysical Research Communications, 2010, 395, 158-162.	2.1	45
422	NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome. Cell, 2010, 142, 218-229.	28.9	190
423	Targeted Molecular Therapy in Melanoma. Seminars in Cutaneous Medicine and Surgery, 2010, 29, 196-201.	1.6	45
424	Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy. Annual Review of Medicine, 2010, 61, 317-328.	12.2	229
425	The molecular pathology of cancer. Nature Reviews Clinical Oncology, 2010, 7, 251-265.	27.6	224
426	A Commercial Real-Time PCR Kit Provides Greater Sensitivity than Direct Sequencing to Detect KRAS Mutations. Journal of Molecular Diagnostics, 2010, 12, 292-299.	2.8	95
427	Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. European Journal of Oncology Nursing, 2010, 14, 337-349.	2.1	34
428	KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiotherapy and Oncology, 2010, 94, 76-81.	0.6	90
429	Colorectal cancer. Lancet, The, 2010, 375, 1030-1047.	13.7	1,318
430	The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer. Cancer Treatment Reviews, 2010, 36, S1-S10.	7.7	23

		EPORT	
#	ARTICLE Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type	IF	CITATIONS
431	status required for anti-EGFR therapy?. Cancer Treatment Reviews, 2010, 36, S56-S61.	1.1	103
432	36 DETECTION OF KRAS MUTATIONS IN COLORECTAL CARCINOMA PATIENTS WITH AN INTEGRATED PCR/SEQUENCING AND REAL TIME PCR APPROACH. Cancer Treatment Reviews, 2010, 36, S105.	7.7	1
433	Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer. Chemotherapy, 2010, 56, 142-146.	1.6	20
434	Molecular markers to individualize adjuvant therapy for colon cancer. Nature Reviews Clinical Oncology, 2010, 7, 318-325.	27.6	79
435	Chemotherapy: Metastatic Disease. , 2010, , 189-222.		0
436	Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 918-927.	1.6	263
437	Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncology, The, 2010, 11, 845-852.	10.7	234
438	Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?. Lancet Oncology, The, 2010, 11, 1020-1021.	10.7	2
439	Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncology, The, 2010, 11, 1142-1148.	10.7	220
441	Targeted Therapies for Cancer. , 2010, , 532-547.		1
442	Detection ofKRASmutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics, 2010, 11, 1169-1179.	1.3	41
443	An Update on Randomized Clinical Trials in Advanced and Metastatic Colorectal Carcinoma. Surgical Oncology Clinics of North America, 2010, 19, 163-181.	1.5	7
444	Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations. Journal of Molecular Diagnostics, 2010, 12, 425-432.	2.8	422
445	Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. Biomarkers in Medicine, 2010, 4, 535-541.	1.4	16
448	Epidermal Growth Factor Receptor Signaling in Nonsmall Cell Lung Cancer. Cancer Investigation, 2010, 28, 515-525.	1.3	20
449	Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 119-128.	1.4	83
450	Cost-Effectiveness Analysis of KRAS Testing and Cetuximab as Last-Line Therapy for Colorectal Cancer. Molecular Diagnosis and Therapy, 2010, 14, 375-384.	3.8	43
451	Drug-Diagnostic Co-Development in Cancer. Pharmaceutical Medicine, 2010, 24, 363-375.	1.9	10

#	Article	IF	CITATIONS
452	Targeted treatments in colorectal cancer: state of the art and future perspectives. Gut, 2010, 59, 838-858.	12.1	45
453	Genotype–phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Review of Molecular Diagnostics, 2010, 10, 541-545.	3.1	78
454	EGFR and KRAS in Colorectal Cancer. Advances in Clinical Chemistry, 2010, 51, 71-119.	3.7	103
455	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Annals of Oncology, 2011, 22, 1535-1546.	1.2	696
456	Melanoma vaccines: developments over the past 10 years. Expert Review of Vaccines, 2011, 10, 853-873.	4.4	27
457	Predicting tumor-suppressing genes in cancer via clustering the developmental stage gene expression profile. , 2011, , .		1
458	Cetuximab in the treatment of patients with colorectal cancer. Expert Opinion on Biological Therapy, 2011, 11, 937-949.	3.1	48
459	Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer. Expert Opinion on Biological Therapy, 2011, 11, 519-531.	3.1	3
460	Integrating biomarkers in clinical trials. Expert Review of Molecular Diagnostics, 2011, 11, 171-182.	3.1	124
461	Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction. Journal of Clinical Oncology, 2011, 29, 610-618.	1.6	864
462	Impact of <i>KRAS</i> and <i>BRAF</i> Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. Journal of Clinical Oncology, 2011, 29, 2675-2682.	1.6	198
463	Probabilistic Methods in Cancer Biology. European Journal of Control, 2011, 17, 483-511.	2.6	9
464	SNaPshot and StripAssay as Valuable Alternatives to Direct Sequencing for KRAS Mutation Detection in Colon Cancer Routine Diagnostics. Journal of Molecular Diagnostics, 2011, 13, 199-205.	2.8	41
465	Personalized cancer medicine—advances and socio-economic challenges. Nature Reviews Clinical Oncology, 2011, 8, 735-741.	27.6	23
466	Sensitive Quantification of Somatic Mutations Using Molecular Inversion Probes. Analytical Chemistry, 2011, 83, 8215-8221.	6.5	6
467	Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in <i>K</i> - <i>Ras</i> Mutant Colorectal and Pancreatic Cancers. Clinical Cancer Research, 2011, 17, 6531-6541.	7.0	47
468	Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status. Journal of Clinical Oncology, 2011, 29, 2011-2019.	1.6	1,713
469	Genetic-based biomarkers and next-generation sequencing: the future of personalized care in colorectal cancer. Personalized Medicine, 2011, 8, 331-345.	1.5	21

#	Article	IF	CITATIONS
470	Increased Detection Sensitivity for <i>KRAS</i> Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer. Clinical Cancer Research, 2011, 17, 4901-4914.	7.0	150
471	<i>KRAS</i> Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer. Clinical Cancer Research, 2011, 17, 1122-1130.	7.0	193
472	Detection of KRAS and BRAF Mutations in Colorectal Carcinoma. Journal of Molecular Diagnostics, 2011, 13, 64-73.	2.8	134
473	Epidermal growth factor receptor as a biomarker for cervical cancer. Annals of Oncology, 2011, 22, 2166-2178.	1.2	94
474	A Multiplex SNaPshot Assay as a Rapid Method for Detecting KRAS and BRAF Mutations in Advanced Colorectal Cancers. Journal of Molecular Diagnostics, 2011, 13, 485-492.	2.8	47
475	KRAS, NRAS, PIK3CA Exon 20, and BRAF Genotypes in Synchronous and Metachronous Primary Colorectal Cancers. Journal of Molecular Diagnostics, 2011, 13, 436-445.	2.8	39
476	Individualizing therapy of monoclonal antibodies and fusion proteins: emerging potential in the age of personalized medicine. Therapeutic Delivery, 2011, 2, 369-381.	2.2	3
477	Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Expert Opinion on Biological Therapy, 2011, 11, 1223-1231.	3.1	28
478	Targeting the human EGFR family in esophagogastric cancer. Nature Reviews Clinical Oncology, 2011, 8, 492-503.	27.6	132
479	Targeted biotherapy in metastatic colorectal carcinoma: Current practice. Journal of Visceral Surgery, 2011, 148, 12-18.	0.8	13
479 480	Targeted biotherapy in metastatic colorectal carcinoma: Current practice. Journal of Visceral Surgery, 2011, 148, 12-18. A phase I study of nimotuzumab in combination with radiotherapy in stages IIB–IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer, 2011, 71, 55-59.	0.8	13 42
479 480 481	 Targeted biotherapy in metastatic colorectal carcinoma: Current practice. Journal of Visceral Surgery, 2011, 148, 12-18. A phase I study of nimotuzumab in combination with radiotherapy in stages IIB–IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer, 2011, 71, 55-59. ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478. Lung Cancer, 2011, 73, 274-282. 	0.8 2.0 2.0	13 42 9
479 480 481 483	Targeted biotherapy in metastatic colorectal carcinoma: Current practice. Journal of Visceral Surgery, 2011, 148, 12-18. A phase I study of nimotuzumab in combination with radiotherapy in stages IIB–IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer, 2011, 71, 55-59. ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478. Lung Cancer, 2011, 73, 274-282. A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatientsâ€) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer. Cancer Discovery, 2011, 1, 508-523.	0.8 2.0 2.0 9.4	13 42 9 818
479 480 481 483 483	Targeted biotherapy in metastatic colorectal carcinoma: Current practice. Journal of Visceral Surgery, 2011, 148, 12-18. A phase I study of nimotuzumab in combination with radiotherapy in stages IIB–IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer, 2011, 71, 55-59. ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478. Lung Cancer, 2011, 73, 274-282. A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatientsâ€) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer. Cancer Discovery, 2011, 1, 508-523. Adjuvant Therapy for Early Colon Cancer. Drugs, 2011, 71, 2257-2275.	0.8 2.0 2.0 9.4 10.9	13 42 9 818 21
479 480 481 483 483 485	Targeted biotherapy in metastatic colorectal carcinoma: Current practice. Journal of Visceral Surgery, 2011, 148, 12-18. A phase I study of nimotuzumab in combination with radiotherapy in stages IIB–IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer, 2011, 71, 55-59. ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478. Lung Cancer, 2011, 73, 274-282. A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatientsâ€) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer. Cancer Discovery, 2011, 1, 508-523. Adjuvant Therapy for Early Colon Cancer. Drugs, 2011, 71, 2257-2275. Effect of KRAS Mutational Status in Advanced Colorectal Cancer on the Outcomes of Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: A Systematic Review and Meta-analysis. Clinical Colorectal Cancer, 2011, 10, 63-69.	0.8 2.0 2.0 9.4 10.9 2.3	 13 42 9 818 21 36
479 480 481 483 485 485 486	Targeted biotherapy in metastatic colorectal carcinoma: Current practice. Journal of Visceral Surgery, 2011, 148, 12-18. A phase I study of nimotuzumab in combination with radiotherapy in stages IIB–IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer, 2011, 71, 55-59. ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478. Lung Cancer, 2011, 73, 274-282. A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatientsâ€) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer. Cancer Discovery, 2011, 1, 508-523. Adjuvant Therapy for Early Colon Cancer. Drugs, 2011, 71, 2257-2275. Effect of KRAS Mutational Status in Advanced Colorectal Cancer on the Outcomes of Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: A Systematic Review and Meta-analysis. Clinical Colorectal Cancer, 2011, 10, 63-69. Mutations in K-ras and Epidermal Growth Factor Receptor Expression in Korean Patients With Stages III and IV Colorectal Cancer. International Journal of Surgical Pathology, 2011, 19, 145-151.	0.8 2.0 2.0 9.4 10.9 2.3 0.8	 13 42 9 818 21 36 14
479 480 481 483 483 485 486 487 488	Targeted biotherapy in metastatic colorectal carcinoma: Current practice. Journal of Visceral Surgery, 2011, 148, 12-18. A phase I study of nimotuzumab in combination with radiotherapy in stages IIB–IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer, 2011, 71, 55-59. ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478. Lung Cancer, 2011, 73, 274-282. A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatientsâ€) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer. Cancer Discovery, 2011, 1, 508-523. Adjuvant Therapy for Early Colon Cancer. Drugs, 2011, 71, 2257-2275. Effect of KRAS Mutational Status in Advanced Colorectal Cancer on the Outcomes of Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: A Systematic Review and Meta-analysis. Clinical Colorectal Cancer, 2011, 10, 63-69. Mutations in K-ras and Epidermal Growth Factor Receptor Expression in Korean Patients With Stages III and IV Colorectal Cancer. International Journal of Surgical Pathology, 2011, 140, 1410-1426.	0.8 2.0 2.0 9.4 10.9 2.3 0.8 1.3	 13 42 9 818 21 36 14 408

#	Article	IF	CITATIONS
490	KRAS mutation detection in Tunisian sporadic coloractal cancer patients with direct sequencing, high resolution melting and denaturating high performance liquid chromatography. Cancer Biomarkers, 2011, 8, 331-340.	1.7	9
491	Advances in personalized cancer management. , 2011, , .		0
492	Tumeurs digestives : cÃ1on — rectum. , 2011, , 359-386.		0
494	Cancer Immunotherapy. Cancer Biotherapy and Radiopharmaceuticals, 2011, 26, 1-64.	1.0	120
495	Prospective Molecular Marker Analyses of <i>EGFR</i> and <i>KRAS</i> From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 4113-4120.	1.6	280
496	A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue. Clinical Chemistry and Laboratory Medicine, 2011, 49, 191-5.	2.3	17
497	The landscape of <i>EGFR</i> pathways and personalized management of non-small-cell lung cancer. Future Oncology, 2011, 7, 519-541.	2.4	47
498	Systemic Therapy for Colon Cancer. , 2011, , 167-183.		0
499	Gastrointestinal Oncology. , 2011, , .		2
500	Optimized Allele-Specific Real-Time PCR Assays for the Detection of Common Mutations in KRAS and BRAF. Journal of Molecular Diagnostics, 2011, 13, 23-28.	2.8	91
501	Differential detection of KRAS mutations in codons 12 and 13 with a modified loop-hybrid (LH) mobility shift assay using an insert-type LH-generator. Clinica Chimica Acta, 2011, 412, 1874-1878.	1.1	3
502	Prognostic and Predictive Markers in Stage II Colon Cancer: Is There a Role for Gene Expression Profiling?. Clinical Colorectal Cancer, 2011, 10, 73-80.	2.3	72
503	Development of Molecular Biomarkers in Individualized Treatment of Colorectal Cancer. Clinical Colorectal Cancer, 2011, 10, 279-289.	2.3	24
504	Integration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2011, 10, 245-257.	2.3	20
505	Development of Novel Targeted Agents in the Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2011, 10, 266-278.	2.3	6
506	All about KRAS for clinical oncology practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treatment Reviews, 2011, 37, 221-233.	7.7	45
507	Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?. Cancer Treatment Reviews, 2011, 37, 533-542.	7.7	31
508	KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomedicine and Pharmacotherapy, 2011, 65, 22-26.	5.6	52

#	Article	IF	CITATIONS
509	The Ras signaling pathway mediates cetuximab resistance in nasopharyngeal carcinoma. Biomedicine and Pharmacotherapy, 2011, 65, 168-174.	5.6	10
510	Correlation of polypoid colorectal adenocarcinoma with pre-existing adenomatous polyps and KRAS mutation. Cancer Genetics, 2011, 204, 245-251.	0.4	5
511	Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor–targeted therapy with cetuximab and gefitinib. Cancer Letters, 2011, 306, 85-91.	7.2	10
512	Cutaneous Toxicity Associated With Cetuximab Treatment in Metastatic Colorectal Cancer. Farmacia Hospitalaria (English Edition), 2011, 35, 114-120.	0.0	1
513	A novel hybrid peptide targeting EGFR-expressing cancers. European Journal of Cancer, 2011, 47, 773-783.	2.8	69
514	Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance. European Journal of Cancer, 2011, 47, 1231-1243.	2.8	127
515	Differential gene expression signatures between colorectal cancers with and without KRAS mutations: Crosstalk between the KRAS pathway and other signalling pathways. European Journal of Cancer, 2011, 47, 1946-1954.	2.8	51
516	A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. European Journal of Cancer, 2011, 47, 1343-1354.	2.8	60
517	Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 2011, 47, 1826-1836.	2.8	17
518	Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer. European Journal of Cancer, 2011, 47, 2673-2680.	2.8	1
519	A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity. Biochemical and Biophysical Research Communications, 2011, 407, 383-388.	2.1	32
520	Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel <i>In Vivo</i> Model of Acquired Cetuximab Resistance. Clinical Cancer Research, 2011, 17, 5935-5944.	7.0	87
521	Effector Cell Recruitment by Bispecific Antibodies. , 2011, , 217-241.		1
522	Thérapies ciblées dans le traitement des cancers colorectaux métastatiquesÂ: place actuelle. Journal De Chirurgie Viscérale, 2011, 148, 12-19.	0.0	0
523	Coamplification at lower denaturation temperature polymerase chain reaction enables selective identification of K-Ras mutations in formalin-fixed, paraffin-embedded tumor tissues without tumor-cell enrichment. Human Pathology, 2011, 42, 1312-1318.	2.0	2
524	Syndecan-1 and -4 differentially regulate oncogenic K-ras dependent cell invasion into collagen through α2β1 integrin and MT1-MMP. Matrix Biology, 2011, 30, 207-217.	3.6	41
525	Proteomics and biomarkers in clinical trials for drug development. Journal of Proteomics, 2011, 74, 2632-2641.	2.4	72
526	A Model of Primary Culture of Colorectal Cancer and Liver Metastasis to Predict Chemosensitivity. Journal of Surgical Research, 2011, 166, 247-254.	1.6	11

#	Article	IF	CITATIONS
527	Neoadjuvant chemotherapy for non-/resectable metastases. European Journal of Cancer, 2011, 47, S52-S60.	2.8	6
528	The treatment of patients with low tumour burden and/or slow growing disease. European Journal of Cancer, 2011, 47, S67-S75.	2.8	2
529	Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncology, The, 2011, 12, 795-805.	10.7	199
530	Laboratory methods for <i>KRAS</i> mutation analysis. Expert Review of Molecular Diagnostics, 2011, 11, 635-642.	3.1	50
531	Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine. Expert Review of Molecular Diagnostics, 2011, 11, 567-577.	3.1	6
532	Unraveling the Genetics of Cancer: Genome Sequencing and Beyond. Annual Review of Genomics and Human Genetics, 2011, 12, 407-430.	6.2	85
533	Optimal integration of EGFR inhibitors in advanced colorectal cancer. Community Oncology, 2011, 8, 155-162.	0.2	0
534	Recent developments in therapy for gastrointestinal cancers. Community Oncology, 2011, 8, 4-8.	0.2	0
535	Is There a Role for IGF1R and c-MET Pathways in Resistance to Cetuximab in Metastatic Colorectal Cancer?. Clinical Colorectal Cancer, 2011, 10, 325-332.	2.3	78
536	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet, The, 2011, 377, 2103-2114.	13.7	876
537	A strategic revolution in HIV and global health. Lancet, The, 2011, 378, 226.	13.7	8
538	Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer. Frontiers in Bioscience - Landmark, 2011, 16, 116.	3.0	8
539	Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study. World Journal of Gastroenterology, 2011, 17, 1879.	3.3	19
540	Critical Stages in the Development of the First Targeted, Injectable Molecular-Genetic Medicine for Cancer. , 0, , .		2
541	Optimal chemotherapy treatment for patients with advanced colorectal cancer. Wspolczesna Onkologia, 2011, 1, 31-39.	1.4	1
542	A phase II study of mitomycin-C and S-1 as third-line chemotherapy in patients with advanced colorectal cancer. Oncology Letters, 2011, 2, 1253-1256.	1.8	2
543	KRAS and BRAF Mutation Status in Patients with Sporadic Colorectal Cancer: Data from Two Different Mediterranean Countries. International Journal of Biological Markers, 2011, 26, 276-277.	1.8	1
544	Trastuzumab-Resistance and Breast Cancer. , 2011, , .		3

#	Article	IF	CITATIONS
545	Impact of KRAS Mutations on Management of Colorectal Carcinoma. Pathology Research International, 2011, 2011, 1-11.	1.4	18
546	Targeted therapies in cancer - challenges and chances offered by newly developed techniques for protein analysis in clinical tissues. Journal of Cancer, 2011, 2, 26-35.	2.5	21
547	Canadian Expert Group Consensus Recommendations: KRAS Testing in Colorectal Cancer. Current Oncology, 2011, 18, 180-184.	2.2	23
548	KRAS Codons 12 and 13 Mutation Analysis: A Comparative Study between Direct Sequencing and a New Sensitive Real-Time PCR Assay. Sequencing, 2011, 2011, 1-7.	0.5	3
549	EGFR Signaling in Colorectal Carcinoma. Pathology Research International, 2011, 2011, 1-6.	1.4	118
550	Management of stage IV rectal cancer: Palliative options. World Journal of Gastroenterology, 2011, 17, 835.	3.3	53
551	The Role of Genetics. Oncology Issues, 2011, 26, 38-43.	0.1	0
552	Novel Oncology Drug Development Strategies in the Era of Personalised Medicine. , 0, , .		0
553	Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients. PLoS ONE, 2011, 6, e15980.	2.5	114
554	Economic evaluation of targeted cancer interventions: Critical review and recommendations. Genetics in Medicine, 2011, 13, 853-860.	2.4	19
556	Personalized Medicine and Oncology Practice Guidelines: A Case Study of Contemporary Biomarkers in Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 13-25.	4.9	31
557	Heterogeneity of KRAS Status May Explain the Subset of Discordant KRAS Status Between Primary and Metastatic Colorectal Cancer. Diseases of the Colon and Rectum, 2011, 54, 1170-1178.	1.3	71
558	Mechanism of Cell Adaptation. Cancer Journal (Sudbury, Mass), 2011, 17, 89-95.	2.0	162
559	Pharmacogenomic Contribution to Drug Response. Cancer Journal (Sudbury, Mass), 2011, 17, 80-88.	2.0	16
560	Molecular Tumor Profiling for Prediction of Response to Anticancer Therapies. Cancer Journal (Sudbury, Mass), 2011, 17, 71-79.	2.0	22
561	Molecular Predictors of Response to Chemotherapy in Colorectal Cancer. Cancer Journal (Sudbury,) Tj ETQq1 1 C	.784314 r 2.0	$gBT_{40}/Overloc$
562	High Aromatase Activity and Overexpression of Epidermal Growth Factor Receptor in Fibrolamellar Hepatocellular Carcinoma in a Child. Journal of Pediatric Hematology/Oncology, 2011, 33, e195-e197.	0.6	19
563	Editorial [Hot Topic: Molecular Targeted Therapy of Gastrointestinal Cancer (Guest Editor: Marcus W.) Tj ETQq1	1 0.78431 1.6	4 rgBT /Overi

		CITATION RE	EPORT	
#	Article		IF	CITATIONS
564	Biomarkers in Colorectal Cancer. Proceedings of Singapore Healthcare, 2011, 20, 26-3	1.	0.6	0
565	Clinical characterization of patients with metastatic colorectal cancer depending on th Anti-Cancer Drugs, 2011, 22, 913-918.	e KRAS status.	1.4	44
566	Anti-VEGF and Anti-EGFR Monoclonal Antibodies in the First-line Therapy for Metastati Cancer - A Meta-Analysis. Current Cancer Therapy Reviews, 2011, 7, 282-289.	c Colorectal	0.3	0
567	Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modif by <i>KRAS</i> Mutations in Advanced Colorectal Cancer. Annals of Internal Medicine, I	cation 2011, 154, 37.	3.9	155
568	Metastatic colorectal cancer in the elderly: An overview of the systemic treatment mod (Review). Oncology Letters, 2011, 2, 3-11.	Jalities	1.8	13
569	Design and Endpoints of Clinical and Translational Trials in Advanced Colorectal Cance from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD). Reviews on Re Trials, 2011, 6, 158-170.	r. A Proposal cent Clinical	0.8	2
570	The Potential of Statins for Individualized Colorectal Cancer Chemoprevention. Curren Targets, 2011, 12, 1903-1908.	t Drug	2.1	11
571	Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cet (ErbituxÂ ⁻ ¿½) efficacy in KRAS wild-type squamous carcinomas: A pathway-based at human-genome microarray data from cetuximab-adapted tumor cell-line models. Intern of Oncology, 2011, 39, 1455-79.	uximab halysis of whole hational Journal	3.3	15
572	18F-Fluorothymidine PET/CT as an early predictor of tumor response to treatment with human lung cancer xenografts. Oncology Reports, 2011, 26, 725-30.	ı cetuximab in	2.6	10
573	Measuring the Performance of Markers for Guiding Treatment Decisions. Annals of Inte 2011, 154, 253.	ernal Medicine,	3.9	120
574	Biomarker Use in Colorectal Cancer Therapy. Journal of the National Comprehensive Ca JNCCN, 2011, 9, 1293-1302.	ancer Network:	4.9	29
575	NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology. National Comprehensive Cancer Network: JNCCN, 2011, 9, S-1-S-32.	Journal of the	4.9	227
576	On target? Strategies and progress in the development of therapies for colorectal can against WNT signalling. Colorectal Disease, 2011, 13, 360-369.	er targeted	1.4	4
577	Molecular detection of epidermal growth factor receptor in colorectal cancer: does it s sense?. Colorectal Disease, 2011, 13, 542-548.	till make	1.4	3
578	Clinicopathological staging of colorectal cancer: Evolution and consensus—an Austra perspective. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 58-64.	alian	2.8	7
579	Future role of gastroenterologists in digestive oncology in the Asia Pacific region: Pani Memorial Lecture, Asian Pacific Digestive Week 2010. Journal of Gastroenterology and (Australia), 2011, 26, 432-436.	r Chelvam Hepatology	2.8	4
580	How pharmacogenomics of biological response modifiers will influence clinical response toxicity in dermatology. International Journal of Dermatology, 2011, 50, 114-118.	se and	1.0	1
581	KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological sp metastatic colorectal carcinoma. Cytopathology, 2011, 22, 358-364.	becimens of	0.7	28

	CITATION RI	EPORT	
#	Article	IF	CITATIONS
582	Is step section necessary for determination of complete pathological response in rectal cancer patients treated with preoperative chemoradiotherapy?. Histopathology, 2011, 59, 650-659.	2.9	16
583	Update on monoclonal antibodies for the treatment of cancer. Asia-Pacific Journal of Clinical Oncology, 2011, 7, 20-25.	1.1	0
584	Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nature Medicine, 2011, 17, 304-312.	30.7	94
585	Strategies to improve radiotherapy with targeted drugs. Nature Reviews Cancer, 2011, 11, 239-253.	28.4	889
586	Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene, 2011, 30, 561-574.	5.9	118
587	Towards novel paradigms for cancer therapy. Oncogene, 2011, 30, 1-20.	5.9	112
588	Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. British Journal of Cancer, 2011, 104, 488-495.	6.4	93
589	Rapid detection of low-abundance K-ras mutation in stools of colorectal cancer patients using chip-based temperature gradient capillary electrophoresis. Laboratory Investigation, 2011, 91, 788-798.	3.7	12
590	Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer. British Journal of Cancer, 2011, 104, 1619-1627.	6.4	90
591	BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. British Journal of Cancer, 2011, 104, 856-862.	6.4	347
592	KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. British Journal of Cancer, 2011, 104, 1020-1026.	6.4	262
593	Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. British Journal of Cancer, 2011, 104, 1038-1048.	6.4	67
594	Systemic chemotherapy and its implications for resection of colorectal liver metastasis. Surgical Oncology, 2011, 20, 57-72.	1.6	27
595	Antibodies in oncology. New Biotechnology, 2011, 28, 518-529.	4.4	62
596	Perspectives on Current Tumor-Node-Metastasis (TNM) Staging of Cancers of the Colon and Rectum. Seminars in Oncology, 2011, 38, 500-510.	2.2	46
597	Predictive Molecular Classifiers in Colorectal Cancer. Seminars in Oncology, 2011, 38, 576-587.	2.2	23
598	EGFR-targeted therapy. Experimental Cell Research, 2011, 317, 2765-2771.	2.6	94
599	Pharmacogenomics in the Assessment of Therapeutic Risks versus Benefits: Inside the United States Food and Drug Administration. Pharmacotherapy, 2011, 31, 729-735.	2.6	38

#	Article	IF	CITATIONS
600	Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome. Critical Reviews in Oncology/Hematology, 2011, 80, 264-277.	4.4	11
602	Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors. Cancer Cell, 2011, 20, 400-413.	16.8	231
604	Colorectal Cancer: Epidemiology, Etiology, and Molecular Basis. , 2011, , 669-690.		1
605	Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2011, 29, 3783-3790.	1.6	76
606	Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nature Reviews Clinical Oncology, 2011, 8, 587-596.	27.6	259
607	Epidermal growth factor receptor-targeted treatment strategies in advanced pancreatic cancer: Is K-RAS mutational testing ready for prime time?. Memo - Magazine of European Medical Oncology, 2011, 4, 257-259.	0.5	0
608	Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients. Surgery Today, 2011, 41, 1067-1074.	1.5	18
609	Inflammation and Gastrointestinal Cancers. Recent Results in Cancer Research, 2011, , .	1.8	10
610	Re: Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations. Journal of the National Cancer Institute, 2011, 103, 1278-1278.	6.3	2
611	Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. European Respiratory Journal, 2011, 37, 183-193.	6.7	37
612	A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. Investigational New Drugs, 2011, 29, 167-174.	2.6	30
613	Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS. Investigational New Drugs, 2011, 29, 688-693.	2.6	12
614	Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 487-493.	2.8	20
615	Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1379-1396.	2.5	27
616	Somatic variation and cancer: therapies lost in the mix. Human Genetics, 2011, 130, 79-91.	3.8	40
617	Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. International Journal of Colorectal Disease, 2011, 26, 143-151.	2.2	70
618	Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. International Journal of Colorectal Disease, 2011, 26, 173-181.	2.2	35
619	Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. International Journal of Colorectal Disease, 2011, 26, 823-833.	2.2	63

#	Article	IF	CITATIONS
620	Overall and KRAS-specific results of combined cetuximab treatment and chemotherapy for metastatic colorectal cancer: a meta-analysis. International Journal of Colorectal Disease, 2011, 26, 1025-1033.	2.2	14
621	Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy. International Journal of Colorectal Disease, 2011, 26, 1271-1277.	2.2	39
622	Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports. International Journal of Colorectal Disease, 2011, 26, 1241-1248.	2.2	31
625	Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer, 2011, 14, 219-225.	5.3	21
627	Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX. Cancer Chemotherapy and Pharmacology, 2011, 68, 317-323.	2.3	8
628	Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan. Cancer Chemotherapy and Pharmacology, 2011, 68, 871-878.	2.3	25
629	Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemotherapy and Pharmacology, 2011, 68, 1207-1213.	2.3	67
630	ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology, 2011, 53, 291-302.	2.2	90
631	Treatment recommendations for metastatic colorectal cancer. Clinical and Translational Oncology, 2011, 13, 162-178.	2.4	24
632	SEOM clinical guidelines for using molecular markers in clinical practice. Clinical and Translational Oncology, 2011, 13, 587-591.	2.4	0
633	Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. Tumor Biology, 2011, 32, 417-424.	1.8	13
635	Predictive and prognostic biomarkers in colorectal cancer. Frontiers in Biology, 2011, 6, 482-489.	0.7	0
636	Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Targeted Oncology, 2011, 6, 133-145.	3.6	46
637	Prognostic Markers and Staging Systems for Patients with Colorectal Liver Metastases. Journal of Gastrointestinal Surgery, 2011, 15, 406-409.	1.7	0
638	Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2011, 23, 271-275.	2.2	13
639	Molecular Prognostic and Predictive Markers in Colorectal Cancer: Current Status. Current Colorectal Cancer Reports, 2011, 7, 136-144.	0.5	15
640	Biological Markers in Patients with Early-Stage Colon Cancer: Consensus and Controversies. Current Colorectal Cancer Reports, 2011, 7, 227-240.	0.5	0
641	Future Solutions for Patients with Metastatic Colorectal Cancer Positive for K-RAS Mutations. Current Colorectal Cancer Reports, 2011, 7, 275-280.	0.5	0

	Сіта	tion Report	
#	Article	IF	CITATIONS
642	Predictive and Prognostic Markers in Colorectal Cancer. Current Oncology Reports, 2011, 13, 206-215.	4.0	48
643	Update on Treatment Advances in Combined-Modality Therapy for Anal and Rectal Carcinomas. Current Oncology Reports, 2011, 13, 177-185.	4.0	9
644	The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain. BMC Medical Genetics, 2011, 12, 144.	2.1	41
645	Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer, 2011, 11, 177.	2.6	25
646	Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer, 2011, 11, 496.	2.6	45
647	The breast cancer genome - a key for better oncology. BMC Cancer, 2011, 11, 501.	2.6	9
648	KRAS and BRAF: drug targets and predictive biomarkers. Journal of Pathology, 2011, 223, 220-230.	4.5	133
649	The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. Journal of Pathology, 2011, 223, 336-346.	4.5	102
650	Subgroup identification based on differential effect search—A recursive partitioning method for establishing response to treatment in patient subpopulations. Statistics in Medicine, 2011, 30, 2601-26	21. ^{1.6}	218
651	The status of EGFRâ€associated genes could predict the outcome and tumor response of chemoâ€refractory metastatic colorectal patients using cetuximab and chemotherapy. Journal of Surgical Oncology, 2011, 104, 661-666.	1.7	14
652	The inhibitory effects of 5â€hydroxyâ€3,6,7,8,3′,4′â€hexamethoxyflavone on human colon cancer Molecular Nutrition and Food Research, 2011, 55, 1523-1532.	cells. 3.3	31
653	Epidermal growth factor receptor mutations in patients with oral cavity cancer in a betel nut chewing–prevalent area. Head and Neck, 2011, 33, 1758-1764.	2.0	19
654	Identification of EGFR mutations in lung sarcomatoid carcinoma. International Journal of Cancer, 2011, 128, 732-735.	5.1	37
655	Prognostic but not predictive role of plateletâ€derived growth factor receptors in patients with recurrent glioblastoma. International Journal of Cancer, 2011, 128, 1981-1988.	5.1	44
656	Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF ^{<i>V600E</i>} mutation. International Journal of Cancer, 2011, 128, 2075-2084.	5.1	200
657	Increased epidermal growth factor receptor expression at the invasive margin is a negative prognostic factor in colorectal cancer. International Journal of Cancer, 2011, 128, 2031-2037.	5.1	28
658	Multi-biomarker pattern for tumor identification and prognosis. Journal of Cellular Biochemistry, 2011, 112, 2703-2715.	2.6	25
659	Detection of DNA mutations by fluorescence resonance energy transfer-based preferential homoduplex formation assay. Analytical Biochemistry, 2011, 408, 197-205.	2.4	7

#	Article	IF	CITATIONS
660	Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status. Critical Reviews in Oncology/Hematology, 2011, 78, 243-251.	4.4	31
661	Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Critical Reviews in Oncology/Hematology, 2011, 79, 224-250.	4.4	38
662	Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases. Pathology Research and Practice, 2011, 207, 399-402.	2.3	5
663	"Un-Slugging―Resistance to Epidermal Growth Factor Receptor Inhibition. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 970-972.	5.6	1
664	Analysis of protein biomarkers in human clinical tumor samples: critical aspects to success from tissue acquisition to analysis. Biomarkers in Medicine, 2011, 5, 227-248.	1.4	4
665	Design of clinical trials for biomarker research in oncology. Clinical Investigation, 2011, 1, 1627-1636.	0.0	21
666	Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Annals of Oncology, 2011, 22, 118-126.	1.2	41
667	Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biology and Therapy, 2011, 11, 777-792.	3.4	209
668	Colorectal cancer molecular biology moves into clinical practice. Gut, 2011, 60, 116-129.	12.1	280
669	Interlaboratory Comparison of K-ras Testing by Real-time PCR and RFLP in Colorectal Cancer Samples. Diagnostic Molecular Pathology, 2011, 20, 90-93.	2.1	4
670	Pharmacogenomics. Circulation, 2011, 123, 1661-1670.	1.6	162
671	Some essential considerations in the design and conduct of non-inferiority trials. Clinical Trials, 2011, 8, 432-439.	1.6	63
672	KRAS Detection in Colonic Tumors by DNA Extraction From FTA Paper. Diagnostic Molecular Pathology, 2011, 20, 189-193.	2.1	10
673	Concordance of Predictive Markers for ECFR Inhibitors in Primary Tumors and Metastases in Colorectal Cancer: A Review. Oncologist, 2011, 16, 1239-1249.	3.7	85
674	Wobble-enhanced ARMS Method for Detection of KRAS and BRAF Mutations. Diagnostic Molecular Pathology, 2011, 20, 158-165.	2.1	27
675	Survival Benefit From Up-Front Fluorouracil, Leucovorin, and Irinotecan/Cetuximab in Metastatic Colorectal Cancer: Is It Just a Now-or-Never Result?. Journal of Clinical Oncology, 2011, 29, 4207-4207.	1.6	2
676	A Multicenter Phase-II Study of 5-FU, Leucovorin and Oxaliplatin (FOLFOX6) in Patients with Pretreated Metastatic Colorectal Cancer. Japanese Journal of Clinical Oncology, 2011, 41, 63-68.	1.3	7
677	Feasibility and Robustness of Amplification Refractory Mutation System (ARMS)-based KRAS Testing Using Clinically Available Formalin-fixed, Paraffin-embedded Samples of Colorectal Cancers. Japanese Journal of Clinical Oncology, 2011, 41, 52-56.	1.3	13
	CITATION	CITATION REPORT	
-----	--	-----------------	-----------
#	Article	IF	CITATIONS
678	Gastrointestinal and liver diseases: genetic and epigenetic markers. Gut, 2011, 60, 1630-1634.	12.1	2
679	Making sense of anti-EGFR plus oxaliplatin-based therapy in the first-line treatment of metastatic colorectal cancer. Future Oncology, 2011, 7, 223-226.	2.4	0
680	CT Findings of Chemotherapy-induced Toxicity: What Radiologists Need to Know about the Clinical and Radiologic Manifestations of Chemotherapy Toxicity. Radiology, 2011, 258, 41-56.	7.3	180
681	A new frontier in personalized cancer therapy: mapping molecular changes. Future Oncology, 2011, 7, 873-894.	2.4	12
682	HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation. Clinical Cancer Research, 2011, 17, 472-482.	7.0	160
683	The Akt signaling pathway. Cancer Biology and Therapy, 2011, 12, 1032-1049.	3.4	77
684	SWOG Cooperative Group Biorepository Resource: Access for Scientific Research Studies. Clinical Cancer Research, 2011, 17, 5239-5246.	7.0	2
685	Liver Metastasis: Biology and Clinical Management. Cancer Metastasis - Biology and Treatment, 2011, , .	0.1	6
686	Pushing an Old Issue Towards a New Front Line. Japanese Journal of Clinical Oncology, 2011, 41, 935-936.	1.3	0
687	Reply to D. Santini et al. Journal of Clinical Oncology, 2011, 29, e208-e209.	1.6	4
688	Kinase Suppressor of Ras 1 (KSR1) Regulates PGC1α and Estrogen-Related Receptor α To Promote Oncogenic Ras-Dependent Anchorage-Independent Growth. Molecular and Cellular Biology, 2011, 31, 2453-2461.	2.3	41
689	The Importance of Evaluation of DNA Amplificability in KRAS Mutation Testing with Dideoxy Sequencing using Formalin-fixed and Paraffin-embedded Colorectal Cancer Tissues. Japanese Journal of Clinical Oncology, 2011, 41, 165-171.	1.3	19
690	Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations. Journal of the National Cancer Institute, 2011, 103, 674-688.	6.3	87
691	Next Generation Radiologic-Pathologic Correlation in Oncology: Rad-Path 2.0. American Journal of Roentgenology, 2011, 197, 990-997.	2.2	29
692	Review of Histopathological and Molecular Prognostic Features in Colorectal Cancer. Cancers, 2011, 3, 2767-2810.	3.7	84
693	Balancing the efficacy and toxicity of chemotherapy in colorectal cancer. Therapeutic Advances in Medical Oncology, 2011, 3, 43-52.	3.2	90
694	Impact of New Drugs and Biologics on Colorectal Cancer Treatment and Costs. Journal of Oncology Practice, 2011, 7, e30s-e37s.	2.5	22
695	Part 1: Background, Methodology, and Clinical Adoption of Pharmacogenetics. Oncologist, 2011, 16, 811-819.	3.7	32

#	Article	IF	CITATIONS
696	Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects. Oncologist, 2011, 16, 1006-1020.	3.7	13
697	<i>KRAS</i> and Colorectal Cancer: Ethical and Pragmatic Issues in Effecting Real-Time Change in Oncology Clinical Trials and Practice. Oncologist, 2011, 16, 1061-1068.	3.7	16
698	Proteomic and Functional Genomic Landscape of Receptor Tyrosine Kinase and Ras to Extracellular Signal–Regulated Kinase Signaling. Science Signaling, 2011, 4, rs10.	3.6	87
699	Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab. Science Translational Medicine, 2011, 3, 99ra86.	12.4	543
700	Tumor KRAS Status Predicts Responsiveness to Panitumumab in Japanese Patients with Metastatic Colorectal Cancer. Japanese Journal of Clinical Oncology, 2011, 41, 210-216.	1.3	10
701	Reply to M. Buyse et al. Journal of Clinical Oncology, 2011, 29, e453-e453.	1.6	2
702	Where now for anti-EGF receptor therapies in colorectal cancer?. Expert Review of Anticancer Therapy, 2011, 11, 1543-1553.	2.4	2
703	Genetics Primer for the General Cardiologist. Circulation, 2011, 123, 467-467.	1.6	3
704	A fully integrated, automated and rapid detection system for KRAS mutations. Oncology Reports, 2011, 26, 609-13.	2.6	5
705	Prolonged Survival of Patients with Metastatic Colorectal Cancer following First-Line Oxaliplatin-Based Chemotherapy with Molecular Targeting Agents and Curative Surgery. Oncology, 2011, 81, 167-174.	1.9	3
706	Clinical and Economic Aspects of KRAS Mutational Status as Predictor for Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer Patients. Oncology, 2011, 81, 359-364.	1.9	12
707	KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations. Genes and Cancer, 2011, 2, 335-343.	1.9	28
708	The cetuximab experience: developing predictive biomarkers in oncology. Personalized Medicine, 2011, 8, 149-159.	1.5	1
709	Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: A GEMCAD study. Cancer Biology and Therapy, 2011, 11, 177-183.	3.4	8
710	An in vitro chemoresponse assay defines a subset of colorectal and lung carcinomas responsive to cetuximab. Cancer Biology and Therapy, 2011, 11, 196-203.	3.4	4
711	Chemotherapy for downstaging unresectable liver metastases from colorectal cancer. The Cochrane Library, 0, , .	2.8	0
712	Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate. Cancer Biology and Therapy, 2011, 11, 368-370.	3.4	2
713	Genetic Alterations in the K-Ras Gene Influence the Prognosis in Patients With Cervical Cancer Treated by Radiotherapy. International Journal of Gynecological Cancer, 2011, 21, 86-91.	2.5	25

#	Article	IF	CITATIONS
714	The Efficacy of IGF-I Receptor Monoclonal Antibody against Human Gastrointestinal Carcinomas is Independent of k-ras Mutation Status. Clinical Cancer Research, 2011, 17, 5048-5059.	7.0	23
715	Reply to M.J. Rother. Journal of Clinical Oncology, 2011, 29, 4207-4208.	1.6	0
716	Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy. Oncologist, 2011, 16, 228-238.	3.7	94
717	Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs. Journal of Clinical Oncology, 2011, 29, 2543-2549.	1.6	64
718	Drug approval challenges in the age of personalized cancer treatment. Personalized Medicine, 2011, 8, 633-640.	1.5	4
719	Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apcmin/+ mouse. British Journal of Cancer, 2011, 105, 649-657.	6.4	9
720	Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. British Journal of Cancer, 2011, 105, 44-52.	6.4	31
721	Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment. British Journal of Cancer, 2011, 105, 1495-1502.	6.4	51
722	Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. British Journal of Cancer, 2011, 105, 246-254.	6.4	23
723	KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab. British Journal of Cancer, 2011, 105, 403-406.	6.4	42
724	Detection of KRAS and BRAF mutations in advanced colorectal cancer by allele-specific single-base primer extension. Expert Review of Molecular Diagnostics, 2011, 11, 799-802.	3.1	5
725	A let-7 microRNA-binding site polymorphism in 3â€2-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Annals of Oncology, 2011, 22, 104-109.	1.2	114
726	Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy. Cancer Research, 2011, 71, 5670-5677.	0.9	369
727	Models of partnership between the pharmaceutical and diagnostics industries around companion diagnostics for cancer and beyond. Expert Opinion on Medical Diagnostics, 2011, 5, 91-94.	1.6	0
728	Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. Annals of Oncology, 2011, 22, 1717-1725.	1.2	49
729	The Ras Inhibitors Caveolin-1 and Docking Protein 1 Activate Peroxisome Proliferator-Activated Receptor Î ³ through Spatial Relocalization at Helix 7 of Its Ligand-Binding Domain. Molecular and Cellular Biology, 2011, 31, 3497-3510.	2.3	39
730	Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer. Acta Oncológica, 2011, 50, 574-577.	1.8	12
731	Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer. Journal of Clinical Oncology, 2011, 29, 4611-4619.	1.6	341

#	Article	IF	CITATIONS
732	Impact of KRAS and BRAF Gene Mutations on Targeted Therapies in Colorectal Cancer. Journal of Clinical Oncology, 2011, 29, 2728-2729.	1.6	7
733	Prospective–retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group. Pharmacogenomics, 2011, 12, 939-951.	1.3	45
734	Use of a Mouse Model of Pancreatic Neuroendocrine Tumors to Find Pericyte Biomarkers of Resistance to Anti-angiogenic Therapy. Hormone and Metabolic Research, 2011, 43, 884-889.	1.5	35
735	Prognostic Value of Colorectal Cancer Biomarkers. Cancers, 2011, 3, 2080-2105.	3.7	5
736	The Role of Colorectal Cancer Stem Cells in Metastatic Disease and Therapeutic Response. Cancers, 2011, 3, 319-339.	3.7	65
737	MEK1/2 Inhibitors AS703026 and AZD6244 May Be Potential Therapies for <i>KRAS</i> Mutated Colorectal Cancer That Is Resistant to EGFR Monoclonal Antibody Therapy. Cancer Research, 2011, 71, 445-453.	0.9	85
738	Biased Discordance of KRAS Mutation Detection in Archived Colorectal Cancer Specimens Between the ARMS-Scorpion Method and Direct Sequencing. Japanese Journal of Clinical Oncology, 2011, 41, 239-244.	1.3	20
739	<i>KRAS</i> and <i>BRAF</i> Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective. Clinical Cancer Research, 2011, 17, 6338-6346.	7.0	74
740	Treatment of Pancreatic Cancer: What Can We Really Predict Today?. Cancers, 2011, 3, 675-699.	3.7	8
741	Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR. International Journal of Oncology, 2011, 40, 378-84.	3.3	16
742	Predictive and Prognostic Factors in Colorectal Cancer: A Personalized Approach. Cancers, 2011, 3, 1622-1638.	3.7	31
743	Epidermal Growth Factor Receptor in Pancreatic Cancer. Cancers, 2011, 3, 1513-1526.	3.7	114
744	Biomarkers in Advanced Colorectal Cancer: Challenges in Translating Clinical Research into Practice. Cancers, 2011, 3, 1844-1860.	3.7	1
745	The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. Annals of Oncology, 2011, 22, 2366-2374.	1.2	24
746	Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study. Journal of Clinical Oncology, 2012, 30, 2861-2868.	1.6	117
747	Proposal for a Novel Methodology to Screen And Score Cost Versus Survival for Anticancer Drugs in Metastatic Disease: Could Cost Weigh in Evaluation?. Journal of Oncology Practice, 2012, 8, 224-230.	2.5	6
748	Resistancethe true face of biological defiance. Rheumatology, 2012, 51, 413-422.	1.9	3
749	Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas. Journal of Clinical Oncology, 2012, 30, 2956-2962.	1.6	254

#	Article	IF	CITATIONS
750	Mucinous tumours of the ovary. Journal of Clinical Pathology, 2012, 65, 580-584.	2.0	26
751	Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity. International Journal of Molecular Sciences, 2012, 13, 12000-12016.	4.1	21
752	How Many Diseases Are Colorectal Cancer?. Gastroenterology Research and Practice, 2012, 2012, 1-12.	1.5	22
753	Clinical Outcome of Japanese Metastatic Colorectal Cancer Patients Harbouring the KRAS p.G13D Mutation Treated with Cetuximab + Irinotecan. Japanese Journal of Clinical Oncology, 2012, 42, 1146-1151.	1.3	16
754	The Role of Molecular Pathology in Non-Small-Cell Lung Carcinoma—Now and in the Future. Current Oncology, 2012, 19, 24-32.	2.2	25
755	The frequency and spectrum of K-ras mutations among Iraqi patients with sporadic colorectal carcinoma. Indian Journal of Cancer, 2012, 49, 163.	0.2	15
756	Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points. Annals of Oncology, 2012, 23, 1646-1651.	1.2	54
757	KRAS Wild-Type Lung Cancer: A Moving Target in an Era of Genotype Migration. Journal of Clinical Oncology, 2012, 30, 3322-3324.	1.6	9
758	KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment. Modern Pathology, 2012, 25, 731-739.	5.5	33
759	Development of a Novel, Fully-Automated Genotyping System: Principle and Applications. Sensors, 2012, 12, 16614-16627.	3.8	26
760	Clinical Implementation of KRAS Testing in Metastatic Colorectal Carcinoma: The Pathologist's Perspective. Archives of Pathology and Laboratory Medicine, 2012, 136, 1298-1307.	2.5	19
761	Detection of Tumor <i>PIK3CA</i> Status in Metastatic Breast Cancer Using Peripheral Blood. Clinical Cancer Research, 2012, 18, 3462-3469.	7.0	296
762	Effective therapy of epidermal growth factor receptor inhibitor-associated dermatologic side effects in a patient with metastatic colorectal cancer: a and review of literature. Advances in Dermatology and Allergology, 2012, 4, 324-329.	1.0	2
763	The proteasomal subunit Rpn6 is a molecular clamp holding the core and regulatory subcomplexes together. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 149-154.	7.1	136
764	Attitudes of Patients With Cancer About Personalized Medicine and Somatic Genetic Testing. Journal of Oncology Practice, 2012, 8, 329-335.	2.5	104
765	Explaining the Unexplainable: EGFR Antibodies in Colorectal Cancer. Journal of Clinical Oncology, 2012, 30, 1735-1737.	1.6	53
766	Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients. Expert Opinion on Biological Therapy, 2012, 12, 1505-1515.	3.1	14
767	Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies. Clinical Cancer Research, 2012, 18, 6436-6445.	7.0	217

#	Article	IF	CITATIONS
768	Comparison of a PNA Clamp PCR and an ARMS/Scorpion PCR Assay for the Detection of K-ras Mutations. Diagnostic Molecular Pathology, 2012, 21, 9-13.	2.1	18
769	Clinical development of new formulations of cytotoxics in solid tumors. Current Opinion in Oncology, 2012, 24, 325-331.	2.4	10
770	KRAS Mutation Testing in Colorectal Cancer. Diagnostic Molecular Pathology, 2012, 21, 14-23.	2.1	14
771	Viewing Metastatic Colorectal Cancer as a Curable Chronic Disease. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 77-80.	1.3	35
772	KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach. Polish Journal of Pathology, 2012, 3, 145-164.	0.3	29
774	KRAS Testing: A Tool for the Implementation of Personalized Medicine. Genes and Cancer, 2012, 3, 459-466.	1.9	45
775	Validation of a Radiosensitivity Molecular Signature in Breast Cancer. Clinical Cancer Research, 2012, 18, 5134-5143.	7.0	174
776	Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2012, 104, 1785-1795.	6.3	88
777	Therapeutic Kinase Inhibitors. Current Topics in Microbiology and Immunology, 2012, , .	1.1	1
778	Personalized medicine in colorectal cancer: the evidence so far. Clinical Investigation, 2012, 2, 1013-1021.	0.0	0
779	<i><i>K-Ras</i></i> gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy. Cancer Biology and Therapy, 2012, 13, 1235-1243.	3.4	10
780	Tumor Infiltration by T Lymphocytes Expressing Chemokine Receptor 7 (CCR7) Is Predictive of Favorable Outcome in Patients with Advanced Colorectal Carcinoma. Clinical Cancer Research, 2012, 18, 850-857.	7.0	72
781	Relationship between 18F-Fluorodeoxyglucose Accumulation and <i>KRAS</i> / <i>BRAF</i> Mutations in Colorectal Cancer. Clinical Cancer Research, 2012, 18, 1696-1703.	7.0	91
782	A molecular assay of tumor radiosensitivity: a roadmap towards biology-based personalized radiation therapy. Personalized Medicine, 2012, 9, 547-557.	1.5	71
783	Analysis of the Concordance in the EGFR Pathway Status Between Primary Tumors and Related Metastases of Colorectal Cancer Patients:Implications for Cancer Therapy. Current Cancer Drug Targets, 2012, 12, 124-131.	1.6	38
784	Validation of KRAS Testing for Anti-EGFR Therapeutic Decisions for Patients With Metastatic Colorectal Carcinoma. Archives of Pathology and Laboratory Medicine, 2012, 136, 26-32.	2.5	26
785	Emerging Role of Cetuximab in the Treatment of Colorectal Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2012, 7, 233-247.	1.6	9
786	Integration of radioembolisation into multimodal treatment of liver-dominant metastatic colorectal cancer. Expert Opinion on Therapeutic Targets, 2012, 16, S11-S16.	3.4	7

ARTICLE IF CITATIONS Gene of the month: BRAF. Journal of Clinical Pathology, 2012, 65, 986-988. 787 2.0 12 Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid,) Tj ETQq1 1 0.784314 rgBT /C 788 49 6.4 unresectable/metastatic colorectal cancer (mCRC). British Journal of Cancer, 2012, 106, 453-459. 789 Bringing on the BRAF. Science-Business EXchange, 2012, 5, 140-140. 0.0 0 KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. 790 6.4 British Journal of Cancer, 2012, 107, 340-344. Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy 791 6.4 38 in patients with metastatic colorectal cancer. British Journal of Cancer, 2012, 106, 748-755. Reply: KRAS mutation in colorectal cancer metastases after adjuvant folfox for the primary. British Journal of Cancer, 2012, 107, 1444-1444. 792 6.4 Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and 793 Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: 1.6 482 The NORDIC-VII Study. Journal of Clinical Oncology, 2012, 30, 1755-1762. Delineation of the infrequent mosaicism of <i>KRAS </i> 794 2.0 14 adenocarcinomas. Journal of Clinical Pathology, 2012, 65, 466-469. Methodology for Comparative Effectiveness Research: Potential and Limitations. Journal of Clinical 795 39 1.6 Oncology, 2012, 30, 4185-4187. Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of 796 242 Genome Instability and Oncogenesis. Cancer Research, 2012, 72, 4383-4393. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 797 7.1 51 2012, 109, E353-9. Inhibition of TGF-Î² Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy. 798 4.1 Molecular Cancer Therapeutics, 2012, 11, 2429-2439. Association of <i>KRAS</i> G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab. Journal of 799 1.6 324 Clinical Oncology, 2012, 30, 3570-3577. Correlation between Gene Expression of IGF-1R Pathway Markers and Cetuximab Benefit in Metastatic Colorectal Cancer. Clinical Cancer Research, 2012, 18, 1156-1166. Freedom to Innovate: The Perils of Centralized Medical Researchâ€"Reply. Archives of Internal Medicine, 801 3.8 0 2012, 172, 1692. Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer., 2012, 2012, 1-11. Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the 803 Treatment of Colorectal Cancer: A Systematic Review. Chemotherapy Research and Practice, 2012, 2012, 1.6 14 1-11. The Current State of Targeted Agents in Rectal Cancer. International Journal of Surgical Oncology, 804 2012, 2012, 1-14.

#	Article	IF	CITATIONS
805	Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?. Chemotherapy Research and Practice, 2012, 2012, 1-8.	1.6	3
806	Preferences for cancer treatments: an overview of methods and applications in oncology. Annals of Oncology, 2012, 23, 1104-1110.	1.2	87
807	Freedom to Innovate: The Perils of Centralized Medical Research. Archives of Internal Medicine, 2012, 172, 1692.	3.8	0
808	Folliculitis Induced by EGFR Inhibitors, Preventive and Curative Efficacy of Tetracyclines in the Management and Incidence Rates According to the Type of EGFR Inhibitor Administered: A Systematic Literature Review. Oncologist, 2012, 17, 555-568.	3.7	44
809	Randomized Phase II Trial Designs With Biomarkers. Journal of Clinical Oncology, 2012, 30, 3304-3309.	1.6	86
810	Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. Journal of Chemotherapy, 2012, 24, 207-211.	1.5	5
811	Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer. Clinical Cancer Research, 2012, 18, 6023-6031.	7.0	81
812	A Japanese Post-marketing Surveillance of Cetuximab (Erbitux(R)) in Patients with Metastatic Colorectal Cancer. Japanese Journal of Clinical Oncology, 2012, 42, 287-294.	1.3	47
813	Pharmacogenetics of the Antiplatelet Effect of Aspirin. Current Pharmaceutical Design, 2012, 18, 5294-5308.	1.9	37
814	Patient-Tailored Treatments with Anti-EGFR Monoclonal Antibodies in Advanced Colorectal Cancer: KRAS and Beyond. Current Cancer Drug Targets, 2012, 12, 316-328.	1.6	25
815	Healthcare reform: it is getting personal. Personalized Medicine, 2012, 9, 405-412.	1.5	4
816	Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. International Journal of Biological Markers, 2012, 27, 27-33.	1.8	21
817	Multidisciplinary Management of Early-Stage Rectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1577-1585.	4.9	4
818	Antiepidermal growth factor receptor monoclonal antibody improves survival outcomes in the treatment of patients with metastatic colorectal cancer. Anti-Cancer Drugs, 2012, 23, 155-160.	1.4	5
819	Resistance to EGF receptor-targeted monoclonal antibodies in the management of advanced colorectal cancer. Colorectal Cancer, 2012, 1, 137-148.	0.8	1
820	Immune-modulating Effects of the Newest Cetuximab-based Chemoimmunotherapy Regimen in Advanced Colorectal Cancer Patients. Journal of Immunotherapy, 2012, 35, 440-447.	2.4	34
821	Role of Oncogenic Pathways and KRAS/BRAF Mutations in the Behavior of Colon Adenocarcinoma in Renal Transplant Patients. Transplantation, 2012, 93, 509-517.	1.0	7
822	Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer. Anti-Cancer Drugs, 2012, 23, 666-673.	1.4	14

#	Article	IF	CITATIONS
823	EGFR and KRAS Mutational Analysis and Their Correlation to Survival in Pancreatic and Periampullary Cancer. Pancreas, 2012, 41, 428-434.	1.1	45
824	The newly discovered variant enhancer loci: providing new epigenetic clues for biomarker discovery in colon cancer?. Personalized Medicine, 2012, 9, 671-673.	1.5	0
825	BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon. American Journal of Surgical Pathology, 2012, 36, 744-752.	3.7	161
826	Pharmacogenetic screening for drug therapy: From single gene markers to decision making in the next generation sequencing era. Pathology, 2012, 44, 166-180.	0.6	23
827	The prognostic value of KRAS mutations in patients with colorectal cancer. Oncology Reports, 2012, 28, 1579-1584.	2.6	23
828	KRAS mutations and subtyping in colorectal cancer in Jordanian patients. Oncology Letters, 2012, 4, 705-710.	1.8	16
830	Mechanisms of acquired resistance to anti-EGF receptor treatment in colorectal cancer. Colorectal Cancer, 2012, 1, 491-502.	0.8	1
831	Recent advances in treatment of metastatic colorectal cancer. Clinical Investigation, 2012, 2, 1109-1122.	0.0	0
832	UHRF1 expression is upregulated and associated with cellular proliferation in colorectal cancer. Oncology Reports, 2012, 28, 1997-2002.	2.6	43
833	Optimizing first-line chemotherapy for metastatic colorectal cancer. Colorectal Cancer, 2012, 1, 241-253.	0.8	0
834	Towards the biomarker-guided rational use of antiangiogenic agents in the treatment of metastatic colorectal cancer. Colorectal Cancer, 2012, 1, 149-161.	0.8	7
835	Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations. Oncology Reports, 2012, 27, 1336-40.	2.6	23
836	mTOR Signaling Pathway and mTOR Inhibitors in Cancer Therapy. Hematology/Oncology Clinics of North America, 2012, 26, 483-505.	2.2	97
837	Comment on â€~A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens'. British Journal of Cancer, 2012, 107, 1791-1792.	6.4	1
838	The paradigm of personalized therapy in oncology. Expert Opinion on Therapeutic Targets, 2012, 16, S7-S16.	3.4	17
839	Clinical Trial Design in the Age of Molecular Profiling. Methods in Molecular Biology, 2012, 823, 19-34.	0.9	2
840	miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?. Pharmacogenomics, 2012, 13, 1635-1650.	1.3	24
841	Clinical Pharmacogenetics. , 2012, , 195-215.		0

		CITATION RE	PORT	
#	Article		IF	Citations
842	Genetic heterogeneity and cancer drug resistance. Lancet Oncology, The, 2012, 13, e178-	2185.	10.7	386
843	Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocelli carcinoma. Hepatology, 2012, 56, 2416-2419.	ular	7.3	16
844	Personalized medicine using DNA biomarkers: a review. Human Genetics, 2012, 131, 1627	-1638.	3.8	169
845	Acneiform rash due to epidermal growth factor receptor inhibitors: high-level laser therapy innovative approach. Lasers in Medical Science, 2012, 27, 1085-1090.	as an	2.1	18
846	EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocar Cancer Cell, 2012, 22, 318-330.	cinoma.	16.8	339
847	MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-Î ² Rece Signaling. Cell, 2012, 151, 937-950.	eptor	28.9	371
848	Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic cancer patients. Tumor Biology, 2012, 33, 1829-1835.	colorectal	1.8	9
849	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A p approach to clinical decision making. Annals of Oncology, 2012, 23, 2479-2516.	ersonalized	1.2	1,233
850	A Virtual Pyrogram Generator to Resolve Complex Pyrosequencing Results. Journal of Mole Diagnostics, 2012, 14, 149-159.	cular	2.8	21
851	Genetic and Epigenetic Biomarkers of Colorectal Cancer. Clinical Gastroenterology and He 2012, 10, 9-15.	patology,	4.4	37
852	Identifying patient subgroups who benefit most from a treatment: using administrative cla uncover treatment heterogeneity. Journal of Medical Economics, 2012, 15, 1078-1087.	ims data to	2.1	7
853	Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targete and advances in the treatment of colorectal cancer. Therapeutic Advances in Gastroentero 5, 319-337.	ed therapies logy, 2012,	3.2	24
854	Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinica Future Oncology, 2012, 8, 1193-1197.	l practice.	2.4	4
855	PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclona in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncology, 2012, 23, 1518-1525.	l antibodies als of	1.2	161
856	RAS signalling in the colorectum in health and disease. Cell Communication and Adhesion,	2012, 19, 1-9.	1.0	21
857	Surgical systems biology and personalized longitudinal phenotyping in critical care. Person Medicine, 2012, 9, 593-608.	alized	1.5	6
858	K-ras Mutation is Strongly Associated with Perineural Invasion and Represents an Independ Prognostic Factor of Intrahepatic Cholangiocarcinoma after Hepatectomy. Annals of Surgio Oncology, 2012, 19, 675-681.	lent cal	1.5	41
859	Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials. Scandinavian Journal of Gastroenterology, 2012, 47, 356-362.		1.5	15

#	Article	IF	CITATIONS
860	Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer. Journal of Clinical Oncology, 2012, 30, 1505-1512.	1.6	95
861	The vaccine adverse event reporting system and vaccine safety research in the genomics era. Vaccine, 2012, 30, 1162-1164.	3.8	2
862	Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut, 2012, 61, 1291-1298.	12.1	74
863	Hotspot oncomutations: implications for personalized cancer treatment. Expert Review of Molecular Diagnostics, 2012, 12, 603-620.	3.1	13
864	Recent approaches to identifying biomarkers for high-risk stage II colon cancer. Surgery Today, 2012, 42, 1037-1045.	1.5	29
865	Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nature Medicine, 2012, 18, 221-223.	30.7	434
866	Biosignatures: Comparative effectiveness research in biomarker clinical studies. Journal of the Formosan Medical Association, 2012, 111, 300-304.	1.7	0
867	The Desmoid Tumor: Still an Enigma. Journal of Surgical Research, 2012, 173, 46-48.	1.6	5
870	BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition. Biochemical and Biophysical Research Communications, 2012, 425, 328-332.	2.1	41
871	Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models. Cancer Letters, 2012, 324, 98-108.	7.2	41
872	Biologic therapies in the metastatic colorectal cancer treatment continuum – Applying current evidence to clinical practice. Cancer Treatment Reviews, 2012, 38, 397-406.	7.7	72
873	Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review. Cancer Treatment Reviews, 2012, 38, 505-514.	7.7	53
874	Panitumumab in Combination With Cytotoxic Chemotherapy for the Treatment of Metastatic Colorectal Carcinoma. Clinical Colorectal Cancer, 2012, 11, 14-23.	2.3	19
875	PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2012, 11, 143-150.	2.3	87
876	Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma. European Journal of Cancer, 2012, 48, 1108-1115.	2.8	27
877	A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. British Journal of Cancer, 2012, 107, 345-351.	6.4	77
878	A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial. BMC Cancer, 2012, 12, 108.	2.6	5
879	Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer, 2012, 12, 292.	2.6	60

#	Article	IF	CITATIONS
880	Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer, 2012, 12, 347.	2.6	121
881	Copy Number Amplification of the PIK3CA Gene Is Associated with Poor Prognosis in Non-lymph node metastatic Head and Neck Squamous Cell Carcinoma. BMC Cancer, 2012, 12, 416.	2.6	58
882	Let-7 miRNA-binding site polymorphism in the KRAS 3′UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/â^ cetuximab. BMC Cancer, 2012, 12, 534.	2.6	42
883	Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study. Journal of Translational Medicine, 2012, 10, 87.	4.4	37
884	Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis. Diagnostic Pathology, 2012, 7, 56.	2.0	23
885	Overcoming implementation challenges of personalized cancer therapy. Nature Reviews Clinical Oncology, 2012, 9, 542-548.	27.6	115
886	Impact of the Specific Mutation in <i>KRAS</i> Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials. Oncology, 2012, 83, 241-247.	1.9	24
889	Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab. Oncologist, 2012, 17, 14-e34.	3.7	74
890	Clinical Benefit of High-Sensitivity KRAS Mutation Testing in Metastatic Colorectal Cancer Treated with Anti-EGFR Antibody Therapy. Oncology, 2012, 82, 298-304.	1.9	20
891	Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study. International Journal of Colorectal Disease, 2012, 27, 1325-1332.	2.2	29
892	Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C). Journal of Clinical Oncology, 2012, 30, 1620-1627.	1.6	357
893	Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice. Journal of Zhejiang University: Science B, 2012, 13, 663-675.	2.8	19
894	Genomic biomarkers for patient selection and stratification: the cancer paradigm. Bioanalysis, 2012, 4, 2499-2511.	1.5	8
895	Predictors of EGF receptor monoclonal antibody activity in metastatic colorectal cancer: current status. Colorectal Cancer, 2012, 1, 423-432.	0.8	0
896	Antiâ€EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab. Journal of Clinical Pharmacology, 2012, 52, 128-155.	2.0	46
897	No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis. PLoS ONE, 2012, 7, e50925.	2.5	30
898	EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?. British Journal of Cancer, 2012, 107, 1864-1868.	6.4	56
899	Molecular Testing in Colorectal Cancer. American Journal of Clinical Pathology, 2012, 137, 847-859.	0.7	39

#	Article	IF	CITATIONS
900	Progress in the management of chemorefractory colorectal cancer. European Journal of Cancer, Supplement, 2012, 10, 7-9.	2.2	0
901	TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncology, The, 2012, 13, 993-1001.	10.7	267
902	Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncology, The, 2012, 13, 1152-1160.	10.7	377
903	Cost-Minimization Analysis of the Treatment of Patients With Metastatic Colorectal Cancer in Greece. Clinical Therapeutics, 2012, 34, 2132-2142.	2.5	7
904	Looking ahead to rational combinatorial therapy. Community Oncology, 2012, 9, 40-41.	0.2	0
905	Biologics against cancer-specific receptors – challenges to personalised medicine from early trial results. Current Opinion in Pharmacology, 2012, 12, 392-397.	3.5	2
906	Discrepancies between primary tumor and metastasis: A literature review on clinically established biomarkers. Critical Reviews in Oncology/Hematology, 2012, 84, 301-313.	4.4	76
907	Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treatment Reviews, 2012, 38, 618-625.	7.7	101
908	Biomarkers in the development of anti-angiogenic therapies for ovarian cancer. Cancer Treatment Reviews, 2012, 38, 662-672.	7.7	18
909	The interaction of EGFR and repair of DNA damage following chemotherapy and radiation. Drug Discovery Today: Disease Models, 2012, 9, e69-e73.	1.2	1
910	TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in lipid rafts antagonises TRAIL-induced apoptosis in gastric cancer cells. European Journal of Cancer, 2012, 48, 3288-3299.	2.8	56
911	Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development. Trends in Pharmacological Sciences, 2012, 33, 449-455.	8.7	36
913	Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon. Revista Espanola De Patologia, 2012, 45, 76-85.	0.2	6
914	Molecular typing of colorectal cancer: applications in diagnosis and treatment. Diagnostic Histopathology, 2012, 18, 70-80.	0.4	7
915	Predictive markers in early research and companion diagnostic developments in oncology. New Biotechnology, 2012, 29, 651-655.	4.4	11
916	Some Research Directions. Springer Briefs in Electrical and Computer Engineering, 2012, , 69-80.	0.5	Ο
917	Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. British Journal of Cancer, 2012, 106, 1826-1832.	6.4	83
918	Early Patient Stratification and Predictive Biomarkers in Drug Discovery and Development. Advances in Experimental Medicine and Biology, 2012, 736, 645-653.	1.6	20

	Ст	ation Report	
#	Article	IF	Citations
919	Targeted therapies: how personal should we go?. Nature Reviews Clinical Oncology, 2012, 9, 87-97.	27.6	94
920	EGFR/HER-targeted therapeutics in ovarian cancer. Future Medicinal Chemistry, 2012, 4, 447-469.	2.3	46
921	Overview of Personalized Medicine in GI Cancers. Journal of Gastrointestinal Surgery, 2012, 16, 1641-1644.	1.7	4
922	Potential Role of KRAS and Other Mutations in the Adjuvant Therapy of Colorectal Cancer. Current Colorectal Cancer Reports, 2012, 8, 192-203.	0.5	0
923	Treatment Options for Patients With Unresectable Colorectal Cancer With Wild-Type KRAS. Current Colorectal Cancer Reports, 2012, 8, 170-176.	0.5	1
924	Pharmacogenetic Concerns in Metastatic Colorectal Cancer Therapy. Current Colorectal Cancer Reports, 2012, 8, 263-271.	0.5	1
925	Clinical Implications of Circulating Tumor Cells in Advanced Colorectal Cancer. Current Colorectal Cancer Reports, 2012, 8, 233-242.	0.5	0
926	The Role of the Insulin-like Growth Factor-1 Receptor (IGF-1R), Phosphatase and Tensin Homolog (PTEN c-Met, and the PI3-Kinase Pathway in Colorectal Cancer. Current Colorectal Cancer Reports, 2012, 8, 243-253.	N), 0.5	0
927	Is Codon 13 KRAS Mutation Biologically Different from Codon 12 Mutation?. Current Colorectal Cancer Reports, 2012, 8, 272-276.	0.5	1
928	Expression of EGFR, HER2, Phosphorylated ERK and Phosphorylated MEK in Colonic Neoplasms of Familial Adenomatous Polyposis Patients. Journal of Gastrointestinal Cancer, 2012, 43, 444-455.	1.3	9
929	A Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab with or Without Bevacizumab as Frontling Therapy for Metastatic Colorectal Cancer. A Fox Chase Extramural Research Study. Journal of Gastrointestinal Cancer, 2012, 43, 562-569.	e 1.3	24
930	Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study). Medical Oncology, 2012, 29, 2842-2848	2.5 8.	15
931	Three different KRAS statuses in three synchronous colorectal cancers. Medical Oncology, 2012, 29, 2864-2865.	2.5	1
932	Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer. Medical Oncology, 2012, 29, 3119-3124.	2.5	12
933	Study of KRAS new predictive marker in a clinical laboratory. Clinical and Translational Oncology, 2012, 14, 937-942.	2.4	4
934	In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption. Neoplasia, 2012, 14, 121-130.	5.3	66
936	Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. European Child and Adolescent Psychiatry, 2012, 21, 477-492.	4.7	114
937	Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer. International Journal of Molecular Sciences, 2012, 13, 12153-12168.	4.1	171

		LPORT	
#	Article	IF	Citations
938	The road to resistance: EGFR mutation and cetuximab. Nature Medicine, 2012, 18, 199-200.	30.7	56
939	Dual Blockade of Epidermal Growth Factor Receptor–Induced Pathways: A New Avenue to Treat Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2012, 30, 1550-1552.	1.6	8
940	Metastatic colorectal cancer: Current treatment and future options for improved survivalMedical approach – present status. Scandinavian Journal of Gastroenterology, 2012, 47, 296-314.	1.5	53
941	Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review. Cancer Investigation, 2012, 30, 741-747.	1.3	63
942	Designs for Clinical Trials. , 2012, , .		4
943	Implementation of Formalin-Fixed, Paraffin-Embedded Cell Line Pellets as High-Quality Process Controls in Quality Assessment Programs for KRAS Mutation Analysis. Journal of Molecular Diagnostics, 2012, 14, 187-191.	2.8	13
944	A New Model for Raf Kinase Inhibitory Protein Induced Chemotherapeutic Resistance. PLoS ONE, 2012, 7, e29532.	2.5	41
945	Allele Specific Locked Nucleic Acid Quantitative PCR (ASLNAqPCR): An Accurate and Cost-Effective Assay to Diagnose and Quantify KRAS and BRAF Mutation. PLoS ONE, 2012, 7, e36084.	2.5	55
946	A Network-Based Gene Expression Signature Informs Prognosis and Treatment for Colorectal Cancer Patients. PLoS ONE, 2012, 7, e41292.	2.5	35
947	Increasing the Clinical Efficacy of NK and Antibody-Mediated Cancer Immunotherapy: Potential Predictors of Successful Clinical Outcome Based on Observations in High-Risk Neuroblastoma. Frontiers in Pharmacology, 2012, 3, 91.	3.5	31
948	The Management of Skin Toxicity during Cetuximab Treatment in Advanced Colorectal Cancer: How much does it Cost? A Retrospecive Economic Assessment from a Single-Center Experience. Tumori, 2012, 98, 408-412.	1.1	8
949	Role of Pharmacogenetics in Gastrointestinal Cancer. , 2012, , .		1
950	Cancer classification by genome-wide and quantitative DNA methylation analyses. , 0, , 293-305.		0
951	Promoter CpG island methylation in colorectal cancer. , 0, , 306-322.		0
952	Pharmacogenetics: transforming clinical medicine. Journal of the Royal College of Physicians of Edinburgh, The, 2012, 42, 244-247.	0.6	2
953	Therapeutic Targeting of the Epidermal Growth Factor Receptor in Human Cancer. Critical Reviews in Oncogenesis, 2012, 17, 31-50.	0.4	59
954	Biology of Rectal Cancerâ^'The Rationale for Targeted Therapy. Critical Reviews in Oncogenesis, 2012, 17, 383-392.	0.4	3
955	Application of alternative fixatives to formalin in diagnostic pathology. European Journal of Histochemistry, 2012, 56, 12.	1.5	33

# 956	ARTICLE Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 163-171.	IF 1.7	CITATIONS
957	Low Percentage of KRAS Mutations Revealed by Locked Nucleic Acid Polymerase Chain Reaction: Implications for Treatment of Metastatic Colorectal Cancer. Molecular Medicine, 2012, 18, 1519-1526.	4.4	24
958	Detection of point mutations in KRAS oncogene by real-time PCR-based genotyping assay in GIT diseases. Bratislava Medical Journal, 2012, 113, 73-79.	0.8	2
959	Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma. Neoplasma, 2012, 60, 83-91.	1.6	4
960	Adjuvant Therapy for Elderly Patients with Breast, Colon, and Lung Cancer. , 2012, , 79-88.		1
961	Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab. Clinical Medicine Insights Ear, Nose and Throat, 2012, 5, CMENT.S5129.	1.5	17
962	A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers. Journal of Cancer, 2012, 3, 231-240.	2.5	50
963	Biomarkers and surrogate endpoints in clinical trials. Statistics in Medicine, 2012, 31, 2973-2984.	1.6	387
964	On Bayesian methods of exploring qualitative interactions for targeted treatment. Statistics in Medicine, 2012, 31, 3693-3707.	1.6	14
965	Cetuximab in metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2012, 12, 555-565.	2.4	32
966	Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology, 2012, 25, 347-369.	5.5	215
967	Translating cancer â€~omics' to improved outcomes: Figure 1 Genome Research, 2012, 22, 188-195.	5.5	107
968	Cancer Genomics: Technology, Discovery, and Translation. Journal of Clinical Oncology, 2012, 30, 647-660.	1.6	173
969	Circulating CD133: A Promising Biomarker, but What Are We Measuring?. Annals of Surgical Oncology, 2012, 19, 351-352.	1.5	1
970	Nanofluidic Digital PCR for KRAS Mutation Detection and Quantification in Gastrointestinal Cancer. Clinical Chemistry, 2012, 58, 1332-1341.	3.2	52
971	Combination Agents Versus Multi-Targeted Agents – Pros and Cons. RSC Drug Discovery Series, 2012, , 155-180.	0.3	5
972	Tumour molecular profiling for deciding therapy—the French initiative. Nature Reviews Clinical Oncology, 2012, 9, 479-486.	27.6	81
973	Lentiviral vector followed by protein immunisation breaks tolerance against the selfâ€antigen Her1 and results in lung cancer immunotherapy. Journal of Gene Medicine, 2012, 14, 151-157.	2.8	5

#	Article	IF	CITATIONS
974	Pharmacokinetic parameters from 3â€Tesla DCEâ€MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. International Journal of Cancer, 2012, 130, 2359-2365.	5.1	59
975	Costâ€effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. International Journal of Cancer, 2012, 131, 438-445.	5.1	60
976	The influence of <i>KRAS</i> and <i>BRAF</i> mutations on the efficacy of cetuximabâ€based firstâ€line therapy of metastatic colorectal cancer: An analysis of the AIO KRKâ€0104â€trial. International Journal of Cancer, 2012, 131, 980-986.	5.1	43
977	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature, 2012, 483, 100-103.	27.8	1,769
978	Personalized medicine: hope or hype?. European Heart Journal, 2012, 33, 1564-1570.	2.2	59
979	Modified PNA-PCR method. Cancer Biology and Therapy, 2012, 13, 314-320.	3.4	11
980	Personalized Treatment of Colorectal Cancer. Onkologie, 2012, 35, 42-48.	0.8	9
981	How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Review of Molecular Diagnostics, 2012, 12, 621-628.	3.1	143
982	Exploring biomarkers in head and neck cancer. Cancer, 2012, 118, 3882-3892.	4.1	56
983	Influence of <i>KRAS</i> mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. Cancer, 2012, 118, 6243-6252.	4.1	20
984	Antibody therapy of cancer. Nature Reviews Cancer, 2012, 12, 278-287.	28.4	1,861
985	Emergence of KRAS mutations and acquired resistance to anti-ECFR therapy in colorectal cancer. Nature, 2012, 486, 532-536.	27.8	1,605
986	The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature, 2012, 486, 537-540.	27.8	1,506
987	Targeting the VEGF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 5-13.	3.4	57
988	Metastatic malignant liver tumors. , 2012, , 1290-1304.e4.		1
989	Systemic chemotherapy for hepatic colorectal cancer. , 2012, , 1434-1443.e3.		0
990	Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Investigational New Drugs, 2012, 30, 1607-1613.	2.6	24
992	Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases. International Journal of Colorectal Disease, 2012, 27, 635-645.	2.2	13

#	Article	IF	CITATIONS
993	Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 141-149.	2.8	53
994	In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype. Gastric Cancer, 2012, 15, 252-264.	5.3	30
996	A systematic review of treatment guidelines for metastatic colorectal cancer. Colorectal Disease, 2012, 14, e31-47.	1.4	91
997	Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. Journal of Internal Medicine, 2012, 271, 111-121.	6.0	179
998	Stratified medicine for cancer therapy. Drug Discovery Today, 2012, 17, 261-268.	6.4	5
999	Assessing Treatment‣election Markers using a Potential Outcomes Framework. Biometrics, 2012, 68, 687-696.	1.4	46
1000	Antiâ€angiogenic Therapy: Concept to Clinic. Microcirculation, 2012, 19, 115-125.	1.8	30
1001	Kâ€ras mutations are correlated to lymph node metastasis and tumor stage, but not to the growth pattern of colon carcinoma. Apmis, 2012, 120, 459-468.	2.0	20
1002	Principles of cancer treatment by immunotherapy. Surgery, 2012, 30, 198-202.	0.3	1
1003	Improving the clinical risk score: An analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. Surgery, 2012, 151, 162-170.	1.9	30
1004	MicroRNA profiling differentiates colorectal cancer according to <i>KRAS</i> status. Genes Chromosomes and Cancer, 2012, 51, 1-9.	2.8	96
1005	Cetuximab ± chemotherapy enhances dendritic cellâ€mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigenâ€specific cytotoxic Tâ€cell response <i>in vitro</i> . International Journal of Cancer, 2012, 130, 1577-1589.	5.1	67
1006	Clinical Implications and Quality Assurance of Molecular Testing for EGFR-Targeting Agents in Colorectal Cancer. Current Colorectal Cancer Reports, 2012, 8, 42-50.	0.5	4
1007	The "Virtual Patient―system: modeling cancer using deep sequencing technologies for personalized cancer treatment. Journal Fur Verbraucherschutz Und Lebensmittelsicherheit, 2012, 7, 55-62.	1.4	8
1008	Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. Investigational New Drugs, 2012, 30, 846-852.	2.6	11
1009	Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Investigational New Drugs, 2012, 30, 787-793.	2.6	16
1010	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. International Journal of Clinical Oncology, 2012, 17, 1-29.	2.2	658
1012	Next generation sequencing and a new era of medicine. Gut, 2013, 62, 920-932.	12.1	24

#	Article	IF	CITATIONS
1013	Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment. Head and Neck, 2013, 35, 294-306.	2.0	32
1014	Prognostic value of cetuximabâ€related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group. International Journal of Cancer, 2013. 132. 236-245.	5.1	68
1015	EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines. Journal of Oral Pathology and Medicine, 2013, 42, 26-36.	2.7	48
1016	Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials, 2013, 34, 8690-8707.	11.4	408
1017	KRAS gene amplification in colorectal cancer and impact on response to EGFRâ€ŧargeted therapy. International Journal of Cancer, 2013, 133, 1259-1265.	5.1	154
1018	EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1391-1396.	2.5	3
1019	Cancer Genomics. , 2013, , .		4
1020	The growing complexity of HIF-1α's role in tumorigenesis: DNA repair and beyond. Oncogene, 2013, 32, 3569-3576.	5.9	72
1021	Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer. British Journal of Cancer, 2013, 109, 408-415.	6.4	43
1022	<i><scp>KRAS</scp></i> and <i><scp>BRAF</scp></i> mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. International Journal of Cancer, 2013, 133, 130-141.	5.1	128
1023	Cell mates: paracrine and stromal targets for prostate cancer therapy. Nature Reviews Urology, 2013, 10, 441-451.	3.8	32
1024	Resistance to Immunotherapeutic Antibodies in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2013, , .	0.1	2
1025	KRAS gene mutations in correlation with clinicopathological features of colorectal carcinomas in Indian patient cohort. Medical Oncology, 2013, 30, 617.	2.5	13
1026	Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer, 2013, 13, 193.	2.6	42
1027	High resolution melting analysis of KRAS, BRAF and PIK3CA in KRASexon 2 wild-type metastatic colorectal cancer. BMC Cancer, 2013, 13, 169.	2.6	44
1028	Decreased expression of DUSP4 is associated with liver and lung metastases in colorectal cancer. Medical Oncology, 2013, 30, 620.	2.5	38
1029	KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2013, 139, 953-961.	2.5	16
1030	A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. Journal of Cancer Research and Clinical Oncology, 2013, 139, 367-378.	2.5	27

#	Article	IF	CITATIONS
1031	Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. Journal of Gastroenterology, 2013, 48, 640-646.	5.1	93
1032	The Continuum of Care in Chemotherapy Approach to Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 230-241.	0.5	2
1033	Treatment Strategy for Elderly Patients with Metastatic Colorectal Cancer: A Review of the Systemic Chemotherapy Options. Current Colorectal Cancer Reports, 2013, 9, 213-222.	0.5	1
1034	Newer Agents in Colon Cancer: What's Next?. Current Colorectal Cancer Reports, 2013, 9, 74-84.	0.5	0
1035	Cetuximab enhances TRAIL-induced gastric cancer cell apoptosis by promoting DISC formation in lipid rafts. Biochemical and Biophysical Research Communications, 2013, 439, 285-290.	2.1	27
1036	Targeting the ERBB family in cancer: couples therapy. Nature Reviews Cancer, 2013, 13, 663-673.	28.4	379
1037	Cetuximab therapy in the treatment of metastatic colorectal cancer: The future frontier?. International Journal of Surgery, 2013, 11, 507-513.	2.7	14
1038	An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer. Targeted Oncology, 2013, 8, 127-136.	3.6	28
1039	Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 397-403.	2.3	15
1040	Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography. Cancer Chemotherapy and Pharmacology, 2013, 72, 209-215.	2.3	7
1041	Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. Cancer Chemotherapy and Pharmacology, 2013, 72, 223-230.	2.3	34
1042	Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors. Cancer Chemotherapy and Pharmacology, 2013, 71, 1473-1483.	2.3	15
1043	Hepatic arterial infusion but not systemic application of cetuximab in combination with oxaliplatin significantly reduces growth of CC531 colorectal rat liver metastases. International Journal of Colorectal Disease, 2013, 28, 555-562.	2.2	5
1044	Multiplex detection of KRAS and BRAF mutations using cationic conjugated polymers. Science Bulletin, 2013, 58, 873-878.	1.7	2
1045	Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy. Drug Safety, 2013, 36, 413-426.	3.2	122
1046	Immunohistochemistry using the <scp>BRAF</scp> V600E mutationâ€specific monoclonal antibody <scp>VE</scp> 1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology, 2013, 63, 187-193.	2.9	74
1047	Contributions of molecular analysis to the diagnosis and treatment of gastrointestinal neoplasms. Seminars in Diagnostic Pathology, 2013, 30, 329-361.	1.5	13
1048	Genetically engineered mouse models of pancreatic adenocarcinoma. Molecular Oncology, 2013, 7, 232-247.	4.6	140

#	Article	IF	CITATIONS
1049	Ephrin B2 Receptor and Microsatellite Status in Lymph Node-Positive Colon Cancer Survival. Translational Oncology, 2013, 6, 520-527.	3.7	10
1050	Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. European Journal of Cancer, 2013, 49, 439-448.	2.8	58
1051	The quest to overcome resistance to EGFR-targeted therapies in cancer. Nature Medicine, 2013, 19, 1389-1400.	30.7	883
1052	EGFR Inhibition Promotes an Aggressive Invasion Pattern Mediated by Mesenchymal-like Tumor Cells within Squamous Cell Carcinomas. Molecular Cancer Therapeutics, 2013, 12, 2176-2186.	4.1	23
1053	Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer. Clinical Biochemistry, 2013, 46, 1453-1461.	1.9	48
1054	Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers. Clinical Trials, 2013, 10, 647-652.	1.6	26
1055	Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathologie Et Biologie, 2013, 61, 273-276.	2.2	20
1056	The Prognostic Role of Ephrin A2 and Endothelial Growth Factor Receptor Pathway Mediators in Patients With Advanced Colorectal Cancer Treated With Cetuximab. Clinical Colorectal Cancer, 2013, 12, 267-274.e2.	2.3	23
1057	Clinical Utility of KRAS and BRAF Mutations in a Cohort of Patients With Colorectal Neoplasms Submitted for Microsatellite Instability Testing. Clinical Colorectal Cancer, 2013, 12, 168-178.	2.3	35
1058	Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation. Human Pathology, 2013, 44, 2636-2642.	2.0	41
1059	Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Annals of Oncology, 2013, 24, 1267-1273.	1.2	96
1060	Circulating tumor cells in colorectal cancer patients. Cancer Treatment Reviews, 2013, 39, 759-772.	7.7	49
1061	Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation analysis. Experimental and Molecular Pathology, 2013, 94, 121-125.	2.1	64
1062	Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer. Journal of Clinical Oncology, 2013, 31, 3133-3140.	1.6	282
1063	Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer. European Journal of Cancer, 2013, 49, 3344-3352.	2.8	7
1065	Resistance to targeted therapies: a role for microRNAs?. Trends in Molecular Medicine, 2013, 19, 633-642.	6.7	31
1066	Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer, 2013, 119, 4137-4144.	4.1	161
1067	Network quantification of EGFR signaling unveils potential for targeted combination therapy. Molecular Systems Biology, 2013, 9, 673.	7.2	158

IF

CITATIONS

Designing Genomics-Based Clinical Studies., 2013, , 237-246. 0 1068 KRAS Mutations in Lung Cancer. Clinical Lung Cancer, 2013, 14, 205-214. 1069 2.6 182 Association of candidate single nucleotide polymorphisms with somatic mutation of the epidermal 1070 1.5 8 growth factor receptor pathway. BMC Medical Genomics, 2013, 6, 43. Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CAin a single reaction by multiplex assay kit. BMC Cancer, 2013, 13, 405. Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in 1073 4.1 29 colorectal cancer: a cohort study. Biology of Sex Differences, 2013, 4, 17. Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor 1074 monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with 2.3 advanced colorectal cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 643-652. Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and 1075 2.6 12 ras-transformed epithelial cells. Investigational New Drugs, 2013, 31, 525-534. Influence of Pharmacogenomic Profiling Prior to Pharmaceutical Treatment in Metastatic Colorectal 3.3 29 Cancer on Cost Effectiveness. Pharmacoeconomics, 2013, 31, 215-228. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine. Cancer 1077 5.9 30 and Metastasis Reviews, 2013, 33, 161-71. The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or 2.6 metachronous metastatic colorectal cancer. BMC Cancer, 2013, 13, 599. Efficacy and Safety of Aflibercept and Its Role in the Treatment of Metastatic Colorectal Cancer. Rare 1079 2 0.2 Cancers and Therapy, 2013, 1, 3-19. Rechallenge therapy and treatment holiday: different strategies in management of metastatic 8.6 colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2013, 32, 92. 1081 Integration of cancer genomics with treatment selection. Cancer, 2013, 119, 3914-3928. 4.1 15 Biomarkers in Oncology., 2013, , . Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. 1083 1.5 52 Bioanalysis, 2013, 5, 369-391. Molecular biomarkers in esophageal, gastric, and colorectal adenocarcinoma., 2013, 140, 133-147. 1084 Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline. Clinical Therapeutics, 2013, 35, 1085 2.581 1282-1303. How Do We Make Choices in Salvage Therapy: Panitumumab, Cetuximab, or Regorafenib?. Current

Colorectal Cancer Reports, 2013, 9, 326-330.

ARTICLE

#	Article	IF	CITATIONS
1087	Immunohistochemical analysis of K-RAS expression in curatively treated colorectal cancer patients: Correlations of clinicopathological features with clinical outcome. Hellenike Cheirourgike Acta Chirurgica Hellenica, 2013, 85, 165-174.	0.1	1
1090	Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Annals of Oncology, 2013, 24, 718-725.	1.2	81
1091	Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer. Clinical Cancer Research, 2013, 19, 1902-1912.	7.0	214
1092	Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy. Investigational New Drugs, 2013, 31, 183-191.	2.6	11
1093	Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Annals of Oncology, 2013, 24, 412-419.	1.2	76
1094	Clinical significance of KRAS gene mutation and epidermal growth factor receptor expression in Japanese patients with squamous cell carcinoma of the larynx, oropharynx and hypopharynx. International Journal of Clinical Oncology, 2013, 18, 454-463.	2.2	18
1095	Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opinion on Biological Therapy, 2013, 13, 241-255.	3.1	50
1096	Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. Hpb, 2013, 15, 106-115.	0.3	44
1097	Heterogeneity of Epidermal Growth Factor Receptor Status and Mutations of KRAS/PIK3CA in Circulating Tumor Cells of Patients with Colorectal Cancer. Clinical Chemistry, 2013, 59, 252-260.	3.2	215
1098	KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 39-46.	2.8	26
1099	<i>MLH1</i> â€silenced and nonâ€silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. Journal of Pathology, 2013, 229, 99-110.	4.5	67
1100	Impact of STAT3 Phosphorylation on the Clinical Effectiveness of Anti-EGFR–Based Therapy in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2013, 12, 28-36.	2.3	35
1101	Functional Role and Therapeutic Potential of the Pim-1 Kinase in Colon Carcinoma. Neoplasia, 2013, 15, 773-IN27.	5.3	19
1102	Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 211-218.	1.6	22
1103	A framework for the analysis of heterogeneity of treatment effect inÂpatient-centered outcomes research. Journal of Clinical Epidemiology, 2013, 66, 818-825.	5.0	101
1104	Magnetic Resonance Imaging as an Early Indicator of Clinical Outcome in Patients With Metastatic Colorectal Carcinoma Treated With Cetuximab or Panitumumab. Clinical Colorectal Cancer, 2013, 12, 45-53.	2.3	13
1105	Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer. Value in Health, 2013, 16, 288-296.	0.3	36
1106	Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology. Experimental and Molecular Pathology, 2013, 95, 74-82.	2.1	14

#	Article	IF	CITATIONS
1107	Comparison of KRAS Genotype: Therascreen Assay vs. LNA-Mediated qPCR Clamping Assay. Clinical Colorectal Cancer, 2013, 12, 195-203.e2.	2.3	5
1108	Cancer Concepts and Principles: Primer for the Interventional Oncologist—Part II. Journal of Vascular and Interventional Radiology, 2013, 24, 1167-1188.	0.5	26
1110	Regorafenib for metastatic colorectal cancer. Lancet, The, 2013, 381, 1537-1538.	13.7	3
1111	Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells. Radiotherapy and Oncology, 2013, 108, 473-478.	0.6	41
1112	Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer. Medical Oncology, 2013, 30, 428.	2.5	3
1113	Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nature Reviews Drug Discovery, 2013, 12, 103-115.	46.4	66
1114	Comparison of COBAS 4800 KRAS, TaqMan PCR and High Resolution Melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 329-335.	2.8	32
1115	The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology, 2013, 62, 367-386.	2.9	377
1116	Treatment with unfunded drugs in oncology: the impact of access programmes and clinical trials. Internal Medicine Journal, 2013, 43, 23-31.	0.8	5
1117	A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. Journal of Hematology and Oncology, 2013, 6, 1.	17.0	301
1118	Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer. Cancer, 2013, 119, 1941-1950.	4.1	16
1119	Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. International Journal of Clinical Oncology, 2013, 18, 670-677.	2.2	32
1120	Management of advanced colorectal cancer, part 2. American Journal of Health-System Pharmacy, 2013, 70, 491-506.	1.0	17
1121	The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: A status report in France in 2011. European Journal of Cancer, 2013, 49, 2126-2133.	2.8	18
1122	Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics, 2013, 14, 315-324.	1.3	88
1123	Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. Journal of Cancer Research and Clinical Oncology, 2013, 139, 595-603.	2.5	5
1124	Individualized therapy for metastatic colorectal cancer. Journal of Internal Medicine, 2013, 274, 1-24.	6.0	25
1125	BRAF, KRAS, and Phosphatidylinositol 3-Kinase in the Management of Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 57-67.	0.5	1

#	Article	IF	CITATIONS
1126	Targeting mechanisms of resistance to anti-EGF receptor therapy inKRASwild-type colorectal cancer: the path to more personalized medicine. Future Oncology, 2013, 9, 551-560.	2.4	9
1127	Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Therapy, 2013, 20, 211-221.	4.6	58
1129	Predictive and Prognostic Biomarkers for Colorectal Cancer. , 2013, , 131-162.		2
1130	Molecular mapping the presence of druggable targets in preinvasive and precursor breast lesions: A comprehensive review of biomarkers related to therapeutic interventions. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1835, 230-242.	7.4	6
1132	Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunology, Immunotherapy, 2013, 62, 1293-1301.	4.2	76
1134	Expression and prognostic significance of GATA-binding protein 2 in colorectal cancer. Medical Oncology, 2013, 30, 498.	2.5	17
1135	Role of targeted agents in metastatic colorectal cancer. Targeted Oncology, 2013, 8, 83-96.	3.6	58
1136	Incorporating Pharmacogenomics in Drug Development. , 2013, , 343-366.		0
1137	Pharmacogenomics in Cancer Therapeutics. , 2013, , 89-116.		0
1138	Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Modern Pathology, 2013, 26, 825-834.	5.5	126
1139	Monoclonal antibodies in oncology therapeutics: present and future indications. Expert Opinion on Biological Therapy, 2013, 13, 269-282.	3.1	22
1140	Strategies for optimizing the response of cancer and normal tissues to radiation. Nature Reviews Drug Discovery, 2013, 12, 526-542.	46.4	335
1141	Panitumumab in metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2013, 13, 781-793.	2.4	5
1142	Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma. NeuroMolecular Medicine, 2013, 15, 420-434.	3.4	34
1143	Companion Diagnostic Testing for Targeted Cancer Therapies: An Overview. Genetic Testing and Molecular Biomarkers, 2013, 17, 515-523.	0.7	14
1144	Current opinion on optimal treatment for colorectal cancer. Expert Review of Anticancer Therapy, 2013, 13, 597-611.	2.4	30
1145	Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade. Oncogene, 2013, 32, 2873-2881.	5.9	32
1146	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncology, The, 2013, 14, 749-759.	10.7	333

#	Article	IF	CITATIONS
1147	New Developments in the Second-Line Treatment of Metastatic Colorectal Cancer: Potential Place in Therapy. Drugs, 2013, 73, 883-891.	10.9	22
1148	Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations. Critical Reviews in Oncology/Hematology, 2013, 85, 45-81.	4.4	90
1149	Ethics for end-of-life treatments: Metastatic colorectal cancer is one example. Health Policy, 2013, 109, 97-103.	3.0	6
1150	Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World Journal of Surgical Oncology, 2013, 11, 306.	1.9	59
1151	Personalizing health care: feasibility and future implications. BMC Medicine, 2013, 11, 179.	5.5	81
1152	Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells. Clinical Cancer Research, 2013, 19, 6751-6765.	7.0	130
1153	Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Investigational New Drugs, 2013, 31, 345-354.	2.6	17
1154	Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. Cancer Discovery, 2013, 3, 658-673.	9.4	585
1155	Sorafenib Overcomes Irinotecan Resistance in Colorectal Cancer by Inhibiting the ABCG2 Drug-Efflux Pump. Molecular Cancer Therapeutics, 2013, 12, 2121-2134.	4.1	48
1156	Tumour heterogeneity in the clinic. Nature, 2013, 501, 355-364.	27.8	993
1156 1157	Tumour heterogeneity in the clinic. Nature, 2013, 501, 355-364. Panitumumab and irinotecan every 3Âweeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. Clinical and Translational Oncology, 2013, 15, 705-711.	27.8 2.4	993 7
1156 1157 1158	Tumour heterogeneity in the clinic. Nature, 2013, 501, 355-364. Panitumumab and irinotecan every 3Âweeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. Clinical and Translational Oncology, 2013, 15, 705-711. Personalised cancer management: closer, but not here yet. Annals of Oncology, 2013, 24, 1951-1955.	27.8 2.4 1.2	993 7 5
1156 1157 1158 1159	Tumour heterogeneity in the clinic. Nature, 2013, 501, 355-364.Panitumumab and irinotecan every 3Âweeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. Clinical and Translational Oncology, 2013, 15, 705-711.Personalised cancer management: closer, but not here yet. Annals of Oncology, 2013, 24, 1951-1955.Building a Personalized Medicine Infrastructure at a Major Cancer Center. Journal of Clinical Oncology, 2013, 31, 1849-1857.	27.8 2.4 1.2 1.6	993 7 5 101
1156 1157 1158 1159	Tumour heterogeneity in the clinic. Nature, 2013, 501, 355-364.Panitumumab and irinotecan every 3Âweeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. Clinical and Translational Oncology, 2013, 15, 705-711.Personalised cancer management: closer, but not here yet. Annals of Oncology, 2013, 24, 1951-1955.Building a Personalized Medicine Infrastructure at a Major Cancer Center. Journal of Clinical Oncology, 2013, 31, 1849-1857.Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells. Cancer Chemotherapy and Pharmacology, 2013, 72, 767-775.	27.8 2.4 1.2 1.6 2.3	 993 7 5 101 15
1156 1157 1158 1159 1160	Tumour heterogeneity in the clinic. Nature, 2013, 501, 355-364. Panitumumab and irinotecan every 3Âweeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. Clinical and Translational Oncology, 2013, 15, 705-711. Personalised cancer management: closer, but not here yet. Annals of Oncology, 2013, 24, 1951-1955. Building a Personalized Medicine Infrastructure at a Major Cancer Center. Journal of Clinical Oncology, 2013, 31, 1849-1857. Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells. Cancer Chemotherapy and Pharmacology, 2013, 72, 767-775. <i>>KRAS <i>>KRAS <i>>RARAS <i>> <i>> <i>></i></i></i></i></i></i>	27.8 2.4 1.2 1.6 2.3 4.1	 993 7 5 101 15 86
1156 1157 1158 1159 1160 1162	Tumour heterogeneity in the clinic. Nature, 2013, 501, 355-364. Panitumumab and irinotecan every 3Âweeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. Clinical and Translational Oncology, 2013, 15, 705-711. Personalised cancer management: closer, but not here yet. Annals of Oncology, 2013, 24, 1951-1955. Building a Personalized Medicine Infrastructure at a Major Cancer Center. Journal of Clinical Oncology, 2013, 31, 1849-1857. Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells. Cancer Chemotherapy and Pharmacology, 2013, 72, 767-775. <i>kRAS</i> p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer. Cancer, 2013, 119, 714-721. Assessing Personalized Medicines in Australia. Medical Decision Making, 2013, 33, 333-342.	27.8 2.4 1.2 1.6 2.3 4.1	 993 7 5 101 15 86 48
1156 1157 1158 1159 1160 1162 1163	Tumour heterogeneity in the clinic. Nature, 2013, 501, 355-364. Panitumumab and irinotecan every 3Âweeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. Clinical and Translational Oncology, 2013, 15, 705-711. Personalised cancer management: closer, but not here yet. Annals of Oncology, 2013, 24, 1951-1955. Building a Personalized Medicine Infrastructure at a Major Cancer Center. Journal of Clinical Oncology, 2013, 31, 1849-1857. Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells. Cancer Chemotherapy and Pharmacology, 2013, 72, 767-775. <i>kRRAS</i> p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer. Cancer, 2013, 119, 714-721. Assessing Personalized Medicines in Australia. Medical Decision Making, 2013, 33, 333-342. Indications et prise en charge des effets secondaires des biothÃ@rapies anti-EGFR., 2013, 143-158.	27.8 2.4 1.2 1.6 2.3 4.1 2.4	 993 7 5 101 15 86 48 0

#	Article	IF	CITATIONS
1166	Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?. Genetics in Medicine, 2013, 15, 517-527.	2.4	64
1167	Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Annals of Oncology, 2013, 24, 2342-2349.	1.2	89
1168	The Role of p53 in Combination Radioimmunotherapy with 64Cu-DOTA-Cetuximab and Cisplatin in a Mouse Model of Colorectal Cancer. Journal of Nuclear Medicine, 2013, 54, 1621-1629.	5.0	29
1169	Treatment of Metastatic Colorectal Cancer with Cetuximab: Influence on the Quality of Life Zeitschrift Fur Gastroenterologie, 2013, 51, 733-739.	0.5	11
1170	<i>RAS</i> mutations: impact on treatment outcome. Colorectal Cancer, 2013, 2, 525-534.	0.8	0
1171	Colorectal Cancer: Basic and Translational Research. Gastrointestinal Tumors, 2013, 1, 18-24.	0.7	0
1172	Early Prediction of Treatment Response to Sorafenib with Elastosonography in a Mice Xenograft Model of Hepatocellular Carcinoma: A Proof-of-Concept Study. Ultraschall in Der Medizin, 2013, 34, 541-549.	1.5	8
1173	How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?. Future Oncology, 2013, 9, 825-829.	2.4	2
1174	Bone Marrow Biopsy: RNA Isolation with Expression Profiling in Men with Metastatic Castration-resistant Prostate Cancer—Factors Affecting Diagnostic Success. Radiology, 2013, 269, 816-823.	7.3	54
1175	Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones. Cell Research, 2013, 23, 13-14.	12.0	5
1176	Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Annals of Oncology, 2013, 24, 2554-2559.	1.2	83
1177	Prevalence of K-RAS Codons 12 and 13 Mutations in Locally Advanced Head and Neck Squamous Cell Carcinoma and Impact on Clinical Outcomes. International Journal of Otolaryngology, 2013, 2013, 1-6.	0.9	21
1178	An evolutionary perspective on anti-tumor immunity. Frontiers in Oncology, 2012, 2, 202.	2.8	15
1179	Panitumumab Monotherapy Compared with Cetuximab and Irinotecan Combination Therapy in Patients with Previously Treated KRAS Wild-Type Metastatic Colorectal Cancer. Current Oncology, 2013, 20, 326-332.	2.2	11
1180	The Homeobox Only Protein Homeobox (HOPX) and Colorectal Cancer. International Journal of Molecular Sciences, 2013, 14, 23231-23243.	4.1	37
1181	A Real-Life Experience Using Panitumumab in Chemo-Refractory Metastatic Colorectal Cancer Patients: A Retrospective Analysis at the Jewish General Hospital, 2009–2012. Current Oncology, 2013, 20, 107-112.	2.2	2
1182	Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers. Clinical Science, 2013, 124, 567-579.	4.3	73
1183	Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial. Acta Oncol³gica, 2013, 52, 956-962.	1.8	58

#	Article	IF	CITATIONS
1184	Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer. Cancer Biomarkers, 2013, 13, 89-97.	1.7	17
1185	Role of cMET in the Development and Progression of Colorectal Cancer. International Journal of Molecular Sciences, 2013, 14, 18056-18077.	4.1	47
1186	Validation of Companion Diagnostic for Detection of Mutations in Codons 12 and 13 of the <i>KRAS</i> Gene in Patients with Metastatic Colorectal Cancer: Analysis of the NCIC CTG CO.17 Trial. Archives of Pathology and Laboratory Medicine, 2013, 137, 820-827.	2.5	27
1187	Genomic stratification for the treatment of lymphomas. Hematology American Society of Hematology Education Program, 2013, 2013, 331-334.	2.5	2
1188	Erlotinib Prolongs Survival in Pancreatic Cancer by Blocking Gemcitabine-Induced MAPK Signals. Cancer Research, 2013, 73, 2221-2234.	0.9	47
1189	Development of a Computerized Morphometry Application for Assessment of the Tumor Fraction in Colon Carcinoma Tissue Samples. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 54-58.	1.2	6
1190	Molecular Markers for Novel Therapeutic Strategies in Pancreatic Endocrine Tumors. Pancreas, 2013, 42, 411-421.	1.1	38
1191	Pathways of Colorectal Carcinogenesis. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 97-102.	1.2	100
1192	N-Glycoprotein SRMAtlas. Molecular and Cellular Proteomics, 2013, 12, 1005-1016.	3.8	48
1193	Learning subgroup-specific regulatory interactions and regulator independence with PARADIGM. Bioinformatics, 2013, 29, i62-i70.	4.1	27
1194	Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients With <i>KRAS</i> Wild-Type Unresectable Colorectal Liver-Limited Metastases. Journal of Clinical Oncology, 2013, 31, 1931-1938.	1.6	362
1195	On being "actionableâ€ı clinical sequencing and the emerging contours of a regime of genomic medicine in oncology. New Genetics and Society, 2013, 32, 405-428.	1.2	51
1196	FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study. Annals of Oncology, 2013, 24, 1769-1777.	1.2	52
1197	KRAS Mutational Status in Japanese Patients with Colorectal Cancer: Results from a Nationwide, Multicenter, Cross-sectional Study. Japanese Journal of Clinical Oncology, 2013, 43, 706-712.	1.3	39
1198	A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Annals of Oncology, 2013, 24, 1777-1785.	1.2	84
1199	Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations. PLoS ONE, 2013, 8, e55793.	2.5	59
1200	Advanced gastric cancer: is chemotherapy needed after surgery?. Expert Review of Gastroenterology and Hepatology, 2013, 7, 673-675.	3.0	4
1201	American Society of Clinical Oncology 2013 Top Five List in Oncology. Journal of Clinical Oncology, 2013, 31, 4362-4370.	1.6	126

#	Article	IF	CITATIONS
1202	Are Companion Diagnostics Useful?. Clinical Chemistry, 2013, 59, 198-201.	3.2	11
1203	Controversies and challenges regarding the impact of radiation therapy on survival. Annals of Oncology, 2013, 24, 38-46.	1.2	39
1204	Ziv-aflibercept in metastatic colorectal cancer. Biologics: Targets and Therapy, 2013, 8, 13.	3.2	30
1205	Scientific Challenges and Implementation Barriers to Translation of Pharmacogenomics in Clinical Practice. ISRN Pharmacology, 2013, 2013, 1-17.	1.6	50
1206	Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens. Cancer Biology and Therapy, 2013, 14, 1098-1103.	3.4	27
1207	Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer. Cancer Biomarkers, 2013, 13, 359-366.	1.7	31
1208	Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Annals of Oncology, 2013, 24, 953-960.	1.2	44
1209	Human tissue in systems medicine. FEBS Journal, 2013, 280, 5949-5956.	4.7	10
1210	Which is false: Oxaliplatin or fluoropyrimidine? An analysis of patients with <scp>KRAS</scp> wildâ€type metastatic colorectal cancer treated with firstâ€line epidermal growth factor receptor monoclonal antibody. Cancer Science, 2013, 104, 1330-1338.	3.9	11
1211	Adaptive clinical trial designs to detect interaction between treatment and a dichotomous biomarker. Canadian Journal of Statistics, 2013, 41, 525-539.	0.9	11
1212	Secondâ€line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wildâ€ŧype <i><scp>KRAS</scp></i> . Cancer Science, 2013, 104, 473-480.	3.9	6
1213	Optimization of routine <scp><i>KRAS</i></scp> mutation <scp>PCR</scp> â€based testing procedure for rational individualized firstâ€lineâ€targeted therapy selection in metastatic colorectal cancer. Cancer Medicine, 2013, 2, 11-20.	2.8	18
1214	Preparation of <scp>DNA</scp> from cytological material. Cancer Cytopathology, 2013, 121, 344-353.	2.4	98
1215	Prognostic impact and the relevance of <scp>PTEN</scp> copy number alterations in patients with advanced colorectal cancer (<scp>CRC</scp>) receiving bevacizumab. Cancer Medicine, 2013, 2, 277-285.	2.8	33
1216	Feasibility and safety of sequential researchâ€related tumor core biopsies in clinical trials. Cancer, 2013, 119, 1357-1364.	4.1	24
1217	Coâ€funded expanded access programmes for new oncology drugs: creating a twoâ€tier system for <scp>A</scp> ustralian cancer patients?. Internal Medicine Journal, 2013, 43, 843-844.	0.8	5
1218	Somatic Mutations in H-RAS in Sporadic Pheochromocytoma and Paraganglioma Identified by Exome Sequencing. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1266-E1271.	3.6	118
1220	Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type <i>K-RAS</i> Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial. Journal of Clinical Oncology, 2013, 31, 2477-2484.	1.6	122

#	Article	IF	CITATIONS
1221	The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therapeutic Advances in Gastroenterology, 2013, 6, 381-395.	3.2	33
1222	Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. MAbs, 2013, 5, 34-46.	5.2	46
1223	Mechanisms of resistance to EGFR targeted therapies. Cancer Biology and Therapy, 2013, 14, 304-314.	3.4	56
1224	Innovative estimation of survival using log-normal survival modelling on ACCENT database. British Journal of Cancer, 2013, 108, 784-790.	6.4	17
1225	KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients. British Journal of Cancer, 2013, 108, 115-120.	6.4	30
1226	Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges. Journal of Clinical Oncology, 2013, 31, 1874-1884.	1.6	101
1227	Utility of Covariate-Adjusted Response-Adaptive Randomization in Survival Trials. Statistics in Biopharmaceutical Research, 2013, 5, 38-53.	0.8	20
1228	Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab. Clinical Cancer Research, 2013, 19, 4104-4113.	7.0	95
1229	From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development. Journal of the National Cancer Institute, 2013, 105, 1441-1456.	6.3	51
1231	A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma. Internal Medicine, 2013, 52, 1589-1592.	0.7	12
1232	Predictive Biomarkers for Epidermal Growth Factor Receptor Agents in Non-Small Cell Lung Cancer. , 2013, , 155-182.		0
1233	Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer. , 2013, , 183-232.		0
1234	KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 530-542.	1.1	104
1235	Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer. Oncology Letters, 2013, 5, 1295-1300.	1.8	10
1236	Multigene Assays in Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, S-9-S-17.	4.9	11
1237	Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity. Oncology Letters, 2013, 5, 1741-1743.	1.8	10
1238	Regorafenib: carving a niche in the crowded therapeutic landscape. Expert Review of Anticancer Therapy, 2013, 13, 385-393.	2.4	4
1239	Emerging Treatments in Recurrent and Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, S-18-S-27.	4.9	9

#	Article	IF	CITATIONS
1240	Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways. Current Pharmaceutical Design, 2013, 19, 841-863.	1.9	12
1242	Personalized medicine for radiation therapy. Personalized Medicine, 2013, 10, 107-110.	1.5	0
1243	Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer. Annals of Surgery, 2013, 257, 800-806.	4.2	288
1244	A Postmarketing Surveillance Study on Erbitux (Cetuximab) in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-Containing Treatment. Journal of Investigative Medicine, 2013, 61, 1108-1114.	1.6	4
1245	Analysis of the anatomic subsites, gender and age in unresectable advanced colorectal carcinomas in Tochigi, Japan suggests a shift in location towards the right side colon in elderly patients treated with cetuximab. Molecular and Clinical Oncology, 2013, 1, 291-296.	1.0	2
1246	Significance of HPV Infection and Genic Mutation of APC and K-ras in Patients with Rectal Cancer. Asian Pacific Journal of Cancer Prevention, 2013, 14, 121-126.	1.2	8
1247	Analgesic-antitumor peptide induces apoptosis and inhibits the proliferation of SW480 human colon cancer cells. Oncology Letters, 2013, 5, 483-488.	1.8	31
1248	Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications. Oncology Letters, 2013, 5, 249-254.	1.8	13
1249	A modified Phenol-chloroform extraction method for isolating circulating cell free DNA of tumor patients. Journal of Nucleic Acids Investigation, 2013, 4, 1.	0.8	24
1250	Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Management and Research, 2013, 5, 387.	1.9	17
1252	Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. OncoTargets and Therapy, 2013, 6, 1761.	2.0	7
1253	Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer. OncoTargets and Therapy, 2013, 6, 485.	2.0	5
1254	A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab. Case Reports in Oncology, 2013, 6, 382-386.	0.7	2
1255	A Novel Fully Automated Molecular Diagnostic System (AMDS) for Colorectal Cancer Mutation Detection. PLoS ONE, 2013, 8, e62989.	2.5	7
1256	Can K-ras Gene Mutation Be Utilized as Prognostic Biomarker for Colorectal Cancer Patients Receiving Chemotherapy? A Meta-Analysis and Systematic Review. PLoS ONE, 2013, 8, e77901.	2.5	14
1257	Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized Medicine. PLoS ONE, 2013, 8, e81628.	2.5	86
1258	Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer Cells. PLoS ONE, 2013, 8, e66302.	2.5	26
1259	Systemic cancer therapy: achievements and challenges that lie ahead. Frontiers in Pharmacology, 2013, 4, 57.	3.5	165

#	Article	IF	CITATIONS
1260	Research on molecular mechanism of platelet granule secretion that contributed to development of a screening method of diagnosis of familial hemophagocytic syndrome. Tenri Medical Bulletin, 2013, 16, 59-69.	0.1	0
1261	Molecular profiling and therapeutic decision-making: the promise of personalized medicine. , 0, , 929-935.		0
1263	Adenocarcinoma of the lung. , 2013, , 1043-1092.		1
1264	A PNA-Mediated Clamping PCR for Routine Detection of KRAS Mutations in Colorectal Carcinoma. International Journal of Biological Markers, 2014, 29, e55-e61.	1.8	1
1265	Biomarkers in mood disorders research: developing new and improved therapeutics. Revista De Psiquiatria Clinica, 2014, 41, 131-134.	0.6	11
1266	Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype. International Journal of Oncology, 2014, 44, 17-26.	3.3	10
1267	Effective Therapeutic Approach for Head and Neck Cancer by an Engineered Minibody Targeting the EGFR Receptor. PLoS ONE, 2014, 9, e113442.	2.5	12
1268	Clinico-pathological Study of K-ras Mutations in Colorectal Tumors in Saudi Arabia. Tumori, 2014, 100, 75-79.	1.1	11
1269	Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status. PLoS ONE, 2014, 9, e92147.	2.5	18
1270	Analysis and Comparison of Somatic Mutations in Paired Primary and Recurrent Epithelial Ovarian Cancer Samples. PLoS ONE, 2014, 9, e99451.	2.5	15
1271	miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan. PLoS ONE, 2014, 9, e99886.	2.5	68
1272	PCR-Based Assays versus Direct Sequencing for Evaluating the Effect of KRAS Status on Anti-EGFR Treatment Response in Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e107926.	2.5	6
1273	c-Met Targeting Enhances the Effect of Irradiation and Chemical Agents against Malignant Colon Cells Harboring a KRAS Mutation. PLoS ONE, 2014, 9, e113186.	2.5	15
1275	Colorectal cancer in Chinese patients: current and emerging treatment options. OncoTargets and Therapy, 2014, 7, 1817.	2.0	29
1276	From Genotype to Functional Phenotype: Unraveling the Metabolomic Features of Colorectal Cancer. Genes, 2014, 5, 536-560.	2.4	39
1277	Pharmacogenomics in oncology care. Frontiers in Genetics, 2014, 5, 73.	2.3	34
1278	Systematic review/Meta-analysis Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients. Archives of Medical Science, 2014, 1, 1-9.	0.9	31
1279	EGF and EGFR genetic polymorphisms predict prognosis in locally advanced pharyngolaryngeal squamous cell carcinoma patients receiving postoperative concurrent chemoradiotherapy. OncoTargets and Therapy, 2014, 7, 2197.	2.0	12

#	Article	IF	CITATIONS
1280	Controversies in the pathological assessment of colorectal cancer. World Journal of Gastroenterology, 2014, 20, 9850.	3.3	69
1281	Assessing the role of the ECF receptor in the development and progression of pancreatic cancer. Gastrointestinal Cancer: Targets and Therapy, 2014, , 23.	5.5	3
1282	Advantages and Disadvantages of Targeting the C-erbB Family of Receptors in Cancer Treatment: A Review. Biology and Medicine (Aligarh), 2014, 06, .	0.3	1
1283	Potential Role of MEK Inhibition in Treating Patients with Colorectal Cancer. Current Cancer Therapy Reviews, 2014, 10, 34-38.	0.3	0
1284	Review Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer. Wspolczesna Onkologia, 2014, 1, 7-16.	1.4	10
1285	Management of locally advanced and metastatic colon cancer in elderly patients. World Journal of Gastroenterology, 2014, 20, 1910.	3.3	17
1286	Prognostic and predictive response factors in colorectal cancer patients: Between hope and reality. World Journal of Gastroenterology, 2014, 20, 15049.	3.3	74
1287	Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World Journal of Gastroenterology, 2014, 20, 943.	3.3	205
1288	Tumor Biomarkers: Clinical Utility, Promises and Problems. Applied Clinical Research Clinical Trials and Regulatory Affairs, 2014, 1, 51-55.	0.4	0
1289	KRAS <i>and</i> PIK3CA <i>Mutation Frequencies in Patient-derived Xenograft Models of Pancreatic and Colorectal Cancer Are Reflective of Patient Tumors and Stable Across Passages</i> . American Surgeon, 2014, 80, 873-877.	0.8	27
1290	Adjuvant Treatment in Colorectal Cancer. , 2014, , .		5
1291	Mechanisms of resistance to EGFR inhibitors in colorectal cancers. Colorectal Cancer, 2014, 3, 511-520.	0.8	0
1292	Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test. Future Oncology, 2014, 10, 2133-2140.	2.4	14
1293	Molecular profiling in colorectal cancer: current state of play and future directions. Colorectal Cancer, 2014, 3, 41-56.	0.8	1
1294	Personalized Cancer Therapy. , 2014, , 671-824.		1
1295	Panitumumab: leading to better overall survival in metastatic colorectal cancer?. Expert Opinion on Biological Therapy, 2014, 14, 535-548.	3.1	1
1296	Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity. Cancer Biology and Therapy, 2014, 15, 623-632.	3.4	27
1297	CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. MAbs, 2014, 6, 1571-1584.	5.2	75

#	Article	IF	CITATIONS
1298	Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future Perspectives. Current Colorectal Cancer Reports, 2014, 10, 380-394.	0.5	1
1299	Chemotherapy and Targeted Therapy in Advanced Biliary Tract Carcinoma: A Pooled Analysis of Clinical Trials. Chemotherapy, 2014, 60, 13-23.	1.6	40
1300	Association Study of the let-7 miRNA-Complementary Site Variant in the 3′ Untranslated Region of the <i>KRAS</i> Gene in Stage III Colon Cancer (NCCTG N0147 Clinical Trial). Clinical Cancer Research, 2014, 20, 3319-3327.	7.0	40
1301	Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 661-672.	2.8	61
1302	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24.	12.4	3,665
1303	Response to comment on †Interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review'. British Journal of Cancer, 2014, 111, 2378-2379.	6.4	1
1304	Fucosylated TGF-β receptors transduces a signal for epithelial–mesenchymal transition in colorectal cancer cells. British Journal of Cancer, 2014, 110, 156-163.	6.4	69
1305	Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. British Journal of Cancer, 2014, 110, 1221-1227.	6.4	25
1306	Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study. British Journal of Cancer, 2014, 111, 843-850.	6.4	21
1307	Regulation of ¹⁸ F-FDG Accumulation in Colorectal Cancer Cells with Mutated <i>KRAS</i> . Journal of Nuclear Medicine, 2014, 55, 2038-2044.	5.0	65
1309	Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. British Journal of Cancer, 2014, 110, 648-655.	6.4	71
1310	Role of aflibercept in the treatment of advanced colorectal cancer. Colorectal Cancer, 2014, 3, 27-40.	0.8	0
1311	Comment on â€~KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'. British Journal of Cancer, 2014, 111, 2379-2380.	6.4	3
1312	Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer. Journal of Medical Economics, 2014, 17, 99-110.	2.1	5
1313	Resistance to dual blockade of the kinases PI3K and mTOR in <i>KRAS</i> -mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. Science Signaling, 2014, 7, ra107.	3.6	30
1314	Immunotherapy for Gastrointestinal Malignancies. Journal of Cancer Therapy, 2014, 05, 622-646.	0.4	0
1315	Acta Oncologica and a new generation of scientists in oncology. Acta OncolÃ ³ gica, 2014, 53, 849-851.	1.8	3
1316	Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing. PLoS Genetics, 2014, 10, e1004271.	3.5	157

#	Article	IF	CITATIONS
1317	Cetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells. International Journal of Molecular Sciences, 2014, 15, 5838-5851.	4.1	34
1318	Predictive biomarkers of response to anti-EGF receptor monoclonal antibody therapies. Colorectal Cancer, 2014, 3, 223-232.	0.8	1
1319	Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer. Hepatic Oncology, 2014, 1, 331-345.	4.2	0
1320	RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells. Cell Reports, 2014, 8, 1475-1483.	6.4	103
1321	Clinical relevance of the K-ras oncogene in colorectal cancer: Experience in a Mexican population. Revista De GastroenterologÃa De México (English Edition), 2014, 79, 166-170.	0.2	1
1322	Analysis of <i>KRAS</i> Mutations in Cases of Metastatic Colorectal Cancer at a Single Institution in Tochigi, Japan. Pathobiology, 2014, 81, 133-137.	3.8	4
1323	Impact of cetuximab in current treatment of metastatic colorectal cancer. Expert Opinion on Biological Therapy, 2014, 14, 387-399.	3.1	7
1325	Biologic agents in the treatment of colorectal cancer: an update. Colorectal Cancer, 2014, 3, 363-374.	0.8	1
1326	Mutation-Specific RAS Oncogenicity Explains NRAS Codon 61 Selection in Melanoma. Cancer Discovery, 2014, 4, 1418-1429.	9.4	174
1327	Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer. Thoracic Cancer, 2014, 5, 398-404.	1.9	6
1328	Expression of DIAPH1 is upâ€regulated in colorectal cancer and its downâ€regulation strongly reduces the metastatic capacity of colon carcinoma cells. International Journal of Cancer, 2014, 134, 1571-1582.	5.1	33
1329	DNA synthesis inhibitors for the treatment of gastrointestinal cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 2361-2372.	1.8	4
1330	<i>ALK</i> Molecular Phenotype in Non–Small Cell Lung Cancer: CT Radiogenomic Characterization. Radiology, 2014, 272, 568-576.	7.3	140
1331	Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand. Thrombosis Research, 2014, 134, 1278-1284.	1.7	14
1332	FOLFIRI with cetuximab or bevacizumab: FIRE-3. Lancet Oncology, The, 2014, 15, e581-e582.	10.7	2
1333	High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma. Clinical Biochemistry, 2014, 47, 340-343.	1.9	9
1334	CT versus FDGâ€PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab. Cancer Medicine, 2014, 3, 1294-1301.	2.8	20
1335	Coevolutionary Dynamics of Automotive Competition: Product Innovation, Change, and Marketplace Survival. Journal of Product Innovation Management, 2014, 31, 61-78.	9.5	35

#	Article	IF	CITATIONS
1336	Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. Pharmacogenomics Journal, 2014, 14, 322-327.	2.0	11
1337	Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Annals of Oncology, 2014, 25, 2378-2385.	1.2	93
1338	Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials. Tumor Biology, 2014, 35, 11741-11750.	1.8	18
1339	Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. British Journal of Cancer, 2014, 110, 1148-1154.	6.4	49
1340	Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer. Therapeutic Advances in Gastroenterology, 2014, 7, 20-37.	3.2	28
1341	Personalized medicine and genome-based treatments: Why personalized medicine â‰â€‰individualized treatments. Clinical Ethics, 2014, 9, 135-144.	0.7	11
1342	Biomarkers in Metastatic Colorectal Cancer. , 2014, , 1-25.		0
1343	The promise of methylation on beads for cancer detection and treatment. Expert Review of Molecular Diagnostics, 2014, 14, 845-852.	3.1	14
1344	Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Expert Review of Anticancer Therapy, 2014, 14, 1477-1493.	2.4	12
1345	Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clinical Cancer Research, 2014, 20, 4210-4217.	7.0	56
1346	KRAS and BRAF mutational status in colon cancer from Albanian patients. Diagnostic Pathology, 2014, 9, 187.	2.0	11
1347	Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3. Journal of Ovarian Research, 2014, 7, 103.	3.0	6
1348	Suppression of TET1-Dependent DNA Demethylation Is Essential for KRAS-Mediated Transformation. Cell Reports, 2014, 9, 1827-1840.	6.4	55
1349	Investigational therapies targeting the ErbB family in oesophagogastric cancer. Expert Opinion on Investigational Drugs, 2014, 23, 1349-1363.	4.1	3
1350	Molecular Predictive and Prognostic Markers of Colorectal Carcinoma. , 2014, 19, 252-255.		0
1351	Automated Objective Determination of Percentage of Malignant Nuclei for Mutation Testing. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 363-371.	1.2	16
1352	Emerging combination therapies to overcome resistance in EGFR-driven tumors. Anti-Cancer Drugs, 2014, 25, 127-139.	1.4	15
1353	Targeting the epidermal growth factor receptor in solid tumors: focus on safety. Expert Opinion on Drug Safety, 2014, 13, 535-549.	2.4	30
#	Article	IF	CITATIONS
------	--	----------------	-------------------------
1354	BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer. Pathology, 2014, 46, 311-315.	0.6	10
1355	ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition. Cancer Biology and Therapy, 2014, 15, 317-328.	3.4	48
1356	Characterization of rare transforming <i>KRAS</i> mutations in sporadic colorectal cancer. Cancer Biology and Therapy, 2014, 15, 768-776.	3.4	61
1357	Gemcitabine, Oxaliplatin, Levofolinate, 5-Fluorouracil, Granulocyte-Macrophage Colony-Stimulating Factor, and Interleukin-2 (GOLFIG) Versus FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients. Journal of Immunotherapy, 2014, 37, 26-35.	2.4	41
1358	Optimal duration of systemic treatment in metastatic colorectal cancer. Current Opinion in Oncology, 2014, 26, 448-453.	2.4	9
1359	Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs.) Tj ETQq1 I	0.78431 1.4	4 ₄ gBT /Ove
1360	Ras in digestive oncology. Current Opinion in Oncology, 2014, 26, 454-461.	2.4	11
1361	Performance Evaluation Comparison of 3 Commercially Available PCR-based KRAS Mutation Testing Platforms. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 231-235.	1.2	10
1362	Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non–Small Cell Lung Cancer. Clinical Cancer Research, 2014, 20, 4478-4487.	7.0	18
1363	Receptor Tyrosine Kinases in Osteosarcoma: Not Just the Usual Suspects. Advances in Experimental Medicine and Biology, 2014, 804, 47-66.	1.6	26
1365	KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment. Molecular and Clinical Oncology, 2014, 2, 356-362.	1.0	5
1366	miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. Journal of Clinical Pathology, 2014, 67, 198-203.	2.0	85
1367	Effects of Fixation and Storage of Human Tissue Samples on Nucleic Acid Preservation. Korean Journal of Pathology, 2014, 48, 36.	1.3	38
1368	From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors. Tumor Biology, 2014, 35, 8471-8482.	1.8	3
1369	Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer. Neoplasia, 2014, 16, 751-756.	5.3	4
1371	Molecular Diagnostic Applications in Colorectal Cancer. Microarrays (Basel, Switzerland), 2014, 3, 168-179.	1.4	7
1372	Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy inKRASWild-Type Patients. BioMed Research International, 2014, 2014, 1-8.	1.9	10
1373	Targeting Mast Cells Tryptase in Tumor Microenvironment: A Potential Antiangiogenetic Strategy. BioMed Research International, 2014, 2014, 1-16.	1.9	52

#	Article	IF	CITATIONS
1374	Colorectal cancer and screening programs: not only analytical issues. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1087-90.	2.3	0
1375	Bespoke treatment: Drivers beware!. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 378-380.	1.1	1
1376	A Survey of Patients Who Were Referred to Our Palliative Care Division From Other Hospitals and Appeared to Have Obvious Indications for Cancer Chemotherapies. American Journal of Hospice and Palliative Medicine, 2014, 31, 804-807.	1.4	1
1377	GI-4000 in <i>KRAS</i> mutant cancers. Expert Opinion on Investigational Drugs, 2014, 23, 273-278.	4.1	4
1378	Oncologists' Response to New Data Regarding the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer. Journal of Oncology Practice, 2014, 10, 308-314.	2.5	5
1379	<i>FcγRlla</i> and <i>Fc<i>γ</i>Rllla</i> Polymorphisms and Cetuximab Benefit in the Microscopic Disease. Clinical Cancer Research, 2014, 20, 4511-4519.	7.0	7
1380	Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on <i>KRAS</i> Mutation Status (T-CORE0801). Oncology, 2014, 87, 7-20.	1.9	69
1381	Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement. Future Oncology, 2014, 10, 2643-2657.	2.4	6
1382	Correlation Between PET/CT Parameters and KRAS Expression in Colorectal Cancer. Clinical Nuclear Medicine, 2014, 39, 685-689.	1.3	42
1383	Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene, 2014, 33, 3894-3907.	5.9	89
1384	Biomarkers in Oncology and Nephrology. , 2014, , 21-38.		5
1385	Acquired resistance to EGFRâ€ŧargeted therapies inÂcolorectal cancer. Molecular Oncology, 2014, 8, 1084-1094.	4.6	121
1386	Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. European Journal of Cancer, 2014, 50, 1361-1369.	2.8	276
1387	MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies. Clinical Colorectal Cancer, 2014, 13, 37-45.e4.	2.3	46
1388	Omics-based nanomedicine: The future of personalized oncology. Cancer Letters, 2014, 352, 126-136.	7.2	75
1389	Application of Translational Science to Clinical Development. , 2014, , 1-21.		1
1390	Personalized Health Care (PHC) in Cancer. , 2014, , 23-49.		0
1391	Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. Targeted Oncology, 2014, 9, 155-162.	3.6	26

#	Article	IF	Citations
1392	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Targeted Oncology, 2014, 9, 205-214.	3.6	27
1393	Is biomarker research advancing in the era of personalized medicine for head and neck cancer?. International Journal of Clinical Oncology, 2014, 19, 211-219.	2.2	21
1394	Cell therapies and regenerative medicine. Hepatology International, 2014, 8, 158-165.	4.2	0
1395	A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. Journal of Cancer Research and Clinical Oncology, 2014, 140, 537-547.	2.5	85
1396	Estudio de minimización de costes de panitumumab frente a cetuximab en combinación con quimioterapia en primera lÃnea y segunda lÃnea en el cáncer colorrectal metastásico KRAS nativo en España. Pharmacoeconomics - Spanish Research Articles, 2014, 11, 135-145.	0.0	1
1397	Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nature Medicine, 2014, 20, 430-435.	30.7	582
1398	Human and Mouse <i>VEGFA</i> -Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment. Cancer Discovery, 2014, 4, 730-743.	9.4	165
1399	Harnessing system models of cell death signalling for cytotoxic chemotherapy: towards personalised medicine approaches?. Journal of Molecular Medicine, 2014, 92, 227-237.	3.9	11
1401	Current concepts in clinical radiation oncology. Radiation and Environmental Biophysics, 2014, 53, 1-29.	1.4	143
1402	Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS. Tumor Biology, 2014, 35, 1041-1049.	1.8	20
1403	Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer. Familial Cancer, 2014, 13, 109-119.	1.9	14
1404	High-sensitivity PCR method for detecting BRAF V600Emutations in metastatic colorectal cancer using LNA/DNA chimeras to block wild-type alleles. Analytical and Bioanalytical Chemistry, 2014, 406, 2477-2487.	3.7	17
1405	Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 367-378.	2.8	148
1407	Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review. Clinical and Translational Oncology, 2014, 16, 425-435.	2.4	17
1408	Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer. Clinical Cancer Research, 2014, 20, 1428-1444.	7.0	81
1409	KRAS mutations: Analytical considerations. Clinica Chimica Acta, 2014, 431, 211-220.	1.1	26
1410	DEVELOPING BIOMARKERS IN MOOD DISORDERS RESEARCH THROUGH THE USE OF RAPID-ACTING ANTIDEPRESSANTS. Depression and Anxiety, 2014, 31, 297-307.	4.1	43
1411	Principles and methods of integrative genomic analyses in cancer. Nature Reviews Cancer, 2014, 14, 299-313.	28.4	337

#	Article	IF	CITATIONS
1412	Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncology, The, 2014, 15, 569-579.	10.7	384
1413	Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy. Clinical Cancer Research, 2014, 20, 3338-3347.	7.0	98
1414	RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial. European Journal of Cancer, 2014, 50, 1430-1436.	2.8	29
1415	Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. Clinica Chimica Acta, 2014, 433, 284-289.	1.1	56
1416	Comparison of <scp>HER</scp> 2 expression between primary colorectal cancer and their corresponding metastases. Cancer Medicine, 2014, 3, 674-680.	2.8	42
1417	Pharmacogenomics and Personalized Medicines in Cancer Treatment. , 2014, , 55-90.		0
1418	<scp><i>KRAS</i></scp> mutation testing of metastatic colorectal cancer in <scp>A</scp> ustralia: Where are we at?. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 261-265.	1.1	6
1419	Update: The Status of Clinical Trials With Kinase Inhibitors in Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1543-1555.	3.6	30
1420	Comparison of Conjugation Strategies of Cross-Bridged Macrocyclic Chelators with Cetuximab for Copper-64 Radiolabeling and PET Imaging of EGFR in Colorectal Tumor-Bearing Mice. Molecular Pharmaceutics, 2014, 11, 3980-3987.	4.6	38
1421	Palliative Treatment of Metastatic Colorectal Cancer: What is the Optimal Approach?. Current Oncology Reports, 2014, 16, 363.	4.0	9
1422	KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. Journal of Clinical Pathology, 2014, 67, 1-9.	2.0	30
1423	Molecular Alterations and Biomarkers in Colorectal Cancer. Toxicologic Pathology, 2014, 42, 124-139.	1.8	80
1424	Tapping the treasure of intracellular oncotargets with immunotherapy. FEBS Letters, 2014, 588, 350-355.	2.8	23
1425	Methods of overcoming treatment resistance in colorectal cancer. Critical Reviews in Oncology/Hematology, 2014, 89, 217-230.	4.4	58
1426	Clinical relevance of KRAS mutations in codon 13: Where are we?. Cancer Letters, 2014, 343, 1-5.	7.2	31
1427	Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies. Pharmacogenomics Journal, 2014, 14, 1-5.	2.0	12
1428	Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA. Clinical Cancer Research, 2014, 20, 1698-1705.	7.0	717
1429	mTOR Inhibition Specifically Sensitizes Colorectal Cancers with <i>KRAS</i> or <i>BRAF</i> Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1. Cancer Discovery, 2014, 4, 42-52.	9.4	116

#	Article	IF	CITATIONS
1430	Molecularly targeted cancer therapy: some lessons from the past decade. Trends in Pharmacological Sciences, 2014, 35, 41-50.	8.7	255
1431	Validation of a Next-Generation Sequencing Assay for Clinical Molecular Oncology. Journal of Molecular Diagnostics, 2014, 16, 89-105.	2.8	168
1433	KRAS mutation confers resistance to antibodyâ€dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells. International Journal of Cancer, 2014, 134, 2146-2155.	5.1	39
1434	Ganetespib, a Novel Hsp90 Inhibitor in Patients With KRAS Mutated and Wild Type, Refractory Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 207-212.	2.3	37
1435	Selection of DNA aptamers against epidermal growth factor receptor with high affinity and specificity. Biochemical and Biophysical Research Communications, 2014, 453, 681-685.	2.1	57
1436	PPARβ/Î′ promotes HRAS-induced senescence and tumor suppression by potentiating p-ERK and repressing p-AKT signaling. Oncogene, 2014, 33, 5348-5359.	5.9	39
1437	Optimization of Anti-EGFR Treatment of Advanced Colorectal Cancer. Current Colorectal Cancer Reports, 2014, 10, 263-271.	0.5	1
1438	Prognostic Impact of Deficient DNA Mismatch Repair and KRAS and BRAF V600E Mutations in Patients with Lymph-Node-Positive Colon Cancer. Current Colorectal Cancer Reports, 2014, 10, 346-353.	0.5	11
1439	Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer. Clinical Cancer Research, 2014, 20, 6346-6356.	7.0	24
1440	A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 2014, 50, 3136-3144.	2.8	17
1441	Incidence and Clinical Features of Drug-induced Lung Injury in Patients with Advanced Colorectal Cancer Receiving Cetuximab: Results of a Prospective Multicenter Registry. Japanese Journal of Clinical Oncology, 2014, 44, 1032-1039.	1.3	28
1442	Navigating later lines of treatment for advanced colorectal cancer – Optimizing targeted biological therapies to improve outcomes. Cancer Treatment Reviews, 2014, 40, 1171-1181.	7.7	18
1443	A Prospective Observational Study to Examine the Relationship between Quality of Life and Adverse Events of First-line Chemotherapy Plus Cetuximab in Patients with KRAS Wild-type Unresectable Metastatic Colorectal Cancer: QUACK Trial. Japanese Journal of Clinical Oncology, 2014, 44, 383-387.	1.3	7
1444	Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, iii1-iii9.	1.2	910
1445	A <i>let-7</i> microRNA-Binding Site Polymorphism in <i>KRAS</i> Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy. Clinical Cancer Research, 2014, 20, 4499-4510.	7.0	55
1446	The promise of circulating tumor cell analysis in cancer management. Genome Biology, 2014, 15, 448.	8.8	47
1447	Targeted Therapies in Metastatic Colorectal Cancer: A Systematic Review and Assessment of Currently Available Data. Oncologist, 2014, 19, 1156-1168.	3.7	90
1448	Letâ€7 micro RNA â€bindingâ€site polymorphism in the 3′ UTR of KRAS and colorectal cancer outcome: a systematic review and metaâ€analysis. Cancer Medicine, 2014, 3, 1385-1395.	2.8	18

#	Article	IF	CITATIONS
1449	Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel. Oncologist, 2014, 19, 616-622.	3.7	94
1450	A hazard ratio was estimated by a ratio of median survival times, but with considerable uncertainty. Journal of Clinical Epidemiology, 2014, 67, 1172-1177.	5.0	16
1451	Risk factors for stent-related adverse events in patients with obstructive colorectal cancer: Are we missing something?. Gastrointestinal Endoscopy, 2014, 80, 742-743.	1.0	1
1452	Personalized medicine in metastatic colorectal cancer treated with antiâ€epidermal growth factor receptor agents: A future opportunity?. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 2-10.	1.1	4
1453	The "pot-of-gold―sign: not always a lipoma. Gastrointestinal Endoscopy, 2014, 80, 743-744.	1.0	0
1454	Patterns of Use and Tolerance of Anti–Epidermal Growth Factor Receptor Antibodies in Older Adults With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 192-198.	2.3	8
1455	Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncology, The, 2014, 15, 894-904.	10.7	270
1456	YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer. Oral Oncology, 2014, 50, 832-839.	1.5	45
1457	Successes, toxicities and challenges in solid tumours. Nature Reviews Clinical Oncology, 2014, 11, 627-628.	27.6	23
1458	Highlights from the latest articles in lung cancer personalized medicine. Personalized Medicine, 2014, 11, 377-379.	1.5	0
1459	Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. Cancer Discovery, 2014, 4, 1269-1280.	9.4	415
1460	Apoptosis Induction by 13â€Acetoxyrolandrolide through the Mitochondrial Intrinsic Pathway. Phytotherapy Research, 2014, 28, 1045-1053.	5.8	8
1461	Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. BMC Cancer, 2014, 14, 521.	2.6	32
1462	Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Molecular Cancer, 2014, 13, 141.	19.2	24
1464	Integration of genomic information in the clinical management of HCC. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 831-842.	2.4	19
1465	Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. Journal of Molecular Medicine, 2014, 92, 709-722.	3.9	75
1466	Targeted therapies in cancer and mechanisms of resistance. Journal of Molecular Medicine, 2014, 92, 677-679.	3.9	6
1467	Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 447-455.	2.3	4

#	Article	IF	CITATIONS
1468	Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 575-581.	2.8	10
1469	The BRAF mutation is associated with the prognosis in colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1863-1871.	2.5	21
1470	Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1927-1936.	2.5	13
1471	Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan. Surgery Today, 2014, 44, 1457-1464.	1.5	4
1472	Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. Investigational New Drugs, 2014, 32, 535-541.	2.6	30
1473	A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. Investigational New Drugs, 2014, 32, 1197-1203.	2.6	22
1474	A new generation of companion diagnostics: cobasBRAF, KRASandEGFRmutation detection tests. Expert Review of Molecular Diagnostics, 2014, 14, 517-524.	3.1	22
1475	Circulating tumour cells and circulating free nucleic acid as prognostic and predictive biomarkers in colorectal cancer. Cancer Letters, 2014, 346, 24-33.	7.2	54
1476	Quality of life in patients with Kâ€≺i>RAS wildâ€ŧype colorectal cancer. Cancer, 2014, 120, 181-189.	4.1	18
1477	Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. Cancer Letters, 2014, 347, 204-211.	7.2	36
1478	Towards the introduction of the â€Immunoscore' in the classification of malignant tumours. Journal of Pathology, 2014, 232, 199-209.	4.5	1,151
1479	PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17. Clinical Cancer Research, 2014, 20, 744-753.	7.0	140
1480	A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC) Tj ETQqO Journal of Cancer, 2014, 110, 2178-2186.	0 0 rgBT /0 6.4	Overlock 10 27
1481	TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial. Journal of the National Cancer Institute, 2014, 106, .	6.3	46
1482	Can We Predict Response and/or Resistance to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer?. Current Colorectal Cancer Reports, 2014, 10, 164-172.	0.5	4
1483	The Evolving Use of Prognostic Factors After Resection of Colorectal Liver Metastases. Current Colorectal Cancer Reports, 2014, 10, 218-226.	0.5	0
1484	FcÎ ³ R and EGFR Polymorphisms as Predictive Markers of Cetuximab Efficacy in Metastatic Colorectal Cancer. Molecular Diagnosis and Therapy, 2014, 18, 541-548.	3.8	11
1485	KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients. BMC Gastroenterology, 2014, 14, 73.	2.0	31

	CHANC	N REPORT	
#	Article	IF	Citations
1486	Can we accurately report PTEN status in advanced colorectal cancer?. BMC Cancer, 2014, 14, 128.	2.6	10
1487	FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab. BMC Cancer, 2014, 14, 340.	2.6	34
1488	Detection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array. Journal of Translational Medicine, 2014, 12, 147.	4.4	6
1489	Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2014, 14, 1051-1061.	2.4	3
1490	Tumor Heterogeneity Revealed by <i>KRAS</i> , <i>BRAF</i> , and <i>PIK3CA</i> Pyrosequencing: <i>KRAS</i> and <i>PIK3CA</i> Intratumor Mutation Profile Differences and Their Therapeutic Implications. Human Mutation, 2014, 35, 329-340.	2.5	63
1491	NO147: The Giving Tree. Journal of the National Cancer Institute, 2014, 106, .	6.3	0
1492	<i>KRAS</i> mutations and <i>CDKN2A</i> promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. International Journal of Cancer, 2014, 134, 2820-2828.	5.1	44
1493	Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology. Biochemical Pharmacology, 2014, 91, 135-143.	4.4	153
1494	Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Annals of Oncology, 2014, 25, 2008-2014.	1.2	47
1495	Pilot Phase I/II Personalized Therapy Trial for Metastatic Colorectal Cancer: Evaluating the Feasibility of Protein Pathway Activation Mapping for Stratifying Patients to Therapy with Imatinib and Panitumumab. Journal of Proteome Research, 2014, 13, 2846-2855.	3.7	35
1496	The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. British Journal of Cancer, 2014, 111, 1122-1131.	6.4	28
1497	Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. International Journal of Cancer, 2014, 135, 731-741.	5.1	27
1498	Combined Assessment of Endothelial Growth Factor Receptor Dual Color In Situ Hybridization and Immunohistochemistry with Downstream Gene Mutations in Prediction of Response to the Anti-EGFR Therapy for Patients with Metastatic Colorectal Cancer. Archives of Medical Research, 2014, 45, 366-374.	3.3	7
1499	Targeting EGFR in colorectal cancer: beyond KRAS exon 2. Lancet Oncology, The, 2014, 15, 540-541.	10.7	2
1500	Options for metastatic colorectal cancer beyond the second line of treatment. Digestive and Liver Disease, 2014, 46, 105-112.	0.9	42
1501	Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: A retrospective multicentre study. Digestive and Liver Disease, 2014, 46, 561-567.	0.9	16
1502	Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy. European Journal of Cancer, 2014, 50, 1819-1828.	2.8	68
1503	Advances in individualized and regenerative medicine. Advances in Medical Sciences, 2014, 59, 7-12.	2.1	8

#	Article	IF	CITATIONS
1504	Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncology, The, 2014, 15, 631-639.	10.7	97
1505	Genomic Technologies and the New Era of Genomic Medicine. Journal of Molecular Diagnostics, 2014, 16, 7-10.	2.8	11
1506	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncology, The, 2014, 15, 601-611.	10.7	371
1507	A New Predictive Molecular Marker for Cetuximab Benefit in Rectal Cancer?. Journal of the National Cancer Institute, 2014, 106, .	6.3	0
1508	Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms. Oncogene, 2014, 33, 3129-3139.	5.9	31
1509	A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/â^ targeted therapy. Cancer Treatment Reviews, 2014, 40, 701-715.	7.7	64
1510	Current Advances in Osteosarcoma. Advances in Experimental Medicine and Biology, 2014, , .	1.6	14
1511	Relationships between KRAS mutation status and baseline radiographic distribution of disease in patients with stage IV colorectal cancer. Abdominal Imaging, 2014, 39, 1261-1266.	2.0	6
1512	Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay. Clinica Chimica Acta, 2014, 436, 169-175.	1.1	11
1513	Clinical application of pharmacogenomics through clinical exercises and online resources. Currents in Pharmacy Teaching and Learning, 2014, 6, 571-576.	1.0	5
1514	Drug resistance to targeted therapies: Déjà vu all over again. Molecular Oncology, 2014, 8, 1067-1083.	4.6	187
1515	A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. European Journal of Cancer, 2014, 50, 1909-1915.	2.8	31
1516	Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. European Journal of Cancer, 2014, 50, 496-505.	2.8	26
1517	Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene, 2014, 33, 1073-1081.	5.9	99
1518	Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World Journal of Gastroenterology, 2014, 20, 9732.	3.3	29
1519	Novel KRAS Gene Mutations in Sporadic Colorectal Cancer. PLoS ONE, 2014, 9, e113350.	2.5	11
1520	Safety and Efficacy of FOLFOX Followed by Cetuximab for Metastatic Colorectal Cancer With Severe Liver Dysfunction. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 155-160.	4.9	11
1521	Colon Cancer, Version 3.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1028-1059.	4.9	192

#	Article	IF	CITATIONS
1522	<i>KRAS</i> and extended <i>RAS</i> molecular profiling in metastatic colorectal cancer. Colorectal Cancer, 2014, 3, 491-499.	0.8	0
1523	The use of covariates and random effects in evaluating predictive biomarkers under a potential outcome framework. Annals of Applied Statistics, 2014, 8, 2336-2355.	1.1	13
1524	Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer. Oncology Reports, 2014, 32, 887-892.	2.6	16
1526	Tissue-Based Companion Diagnostics: Development of IHC Assays from an Industry Perspective. Methods in Pharmacology and Toxicology, 2014, , 281-304.	0.2	0
1527	Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer. Case Reports in Oncology, 2014, 7, 316-322.	0.7	8
1528	BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies. Cancer Control, 2014, 21, 221-230.	1.8	80
1529	Predictive Biomarkers for Anti-Epidermal Growth Factor Receptor Therapy: BeyondKRASTesting. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1433-1442.	4.9	6
1530	Evidence-based integration of selective internal radiation therapy in the management of colorectal liver metastases. Future Oncology, 2014, 10, 33-36.	2.4	0
1531	Patient navigation and cancer disparities in the era of personalized medicine. Colorectal Cancer, 2014, 3, 109-112.	0.8	0
1532	Conversion Therapy Using mFOLFOX6 With Panitumumab for Unresectable Liver Metastases From Multiple Colorectal Cancers With Familial Adenomatous Polyposis. International Surgery, 2014, 99, 795-801.	0.1	2
1533	Biomarker-driven Studies in Metastatic Colorectal Cancer (mCRC): Challenges and Opportunities. The Journal of Oncopathology, 2014, 2, 37-45.	0.1	0
1534	Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations. Oncology Reports, 2014, 32, 50-56.	2.6	31
1535	Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer. Medicine (United States), 2015, 94, e1698.	1.0	6
1536	Identification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer. Cancer Medicine, 2015, 4, 90-100.	2.8	26
1537	DNA methylation status as a biomarker of antiâ€epidermal growth factor receptor treatment for metastatic colorectal cancer. Cancer Science, 2015, 106, 1722-1729.	3.9	25
1538	Some Caveats for Outcome Adaptive Randomization in Clinical Trials. , 2015, , 305-324.		0
1540	Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer. Molecular Medicine Reports, 2015, 12, 1219-1224.	2.4	14
1541	Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype. Scientific Reports, 2015, 5, 13347.	3.3	13

#	Article	IF	CITATIONS
1542	Personalized medicine: challenges in biomarker-related clinical trial design. Clinical Investigation, 2015, 5, 175-188.	0.0	0
1546	Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients. Human Genome Variation, 2015, 2, 15009.	0.7	58
1547	Evidence used in model-based economic evaluations for evaluating pharmacogenetic and pharmacogenomic tests: a systematic review protocol. BMJ Open, 2015, 5, e008465-e008465.	1.9	4
1549	Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer. Oncology Letters, 2015, 10, 2519-2526.	1.8	14
1550	Prognostic and Predictive Significance of Stromal Fibroblasts and Macrophages in Colon Cancer. Biomarkers in Cancer, 2015, 7s1, BIC.S25247.	3.6	9
1551	An NGS Workflow Blueprint for DNA Sequencing Data and Its Application in Individualized Molecular Oncology. Cancer Informatics, 2015, 14s5, CIN.S30793.	1.9	10
1552	A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction. International Journal of Oncology, 2015, 47, 97-105.	3.3	5
1553	Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients. Anti-Cancer Drugs, 2015, 26, 872-877.	1.4	15
1555	Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. Journal of Translational Medicine, 2015, 13, 217.	4.4	36
1556	Cytokeratin 20 positive circulating tumor cells are a marker for response after neoadjuvant chemoradiation but not for prognosis in patients with rectal cancer. BMC Cancer, 2015, 15, 953.	2.6	29
1557	Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique. Diagnostic Pathology, 2015, 10, 132.	2.0	33
1558	Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine. EPMA Journal, 2015, 6, 19.	6.1	37
1559	Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments. Journal of Comparative Effectiveness Research, 2015, 4, 203-213.	1.4	2
1560	Antibody treatment. Drug Delivery System, 2015, 30, 16-24.	0.0	0
1561	KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers. Journal of Surgical Oncology, 2015, 111, 1059-1064.	1.7	14
1562	Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine. Proteomics - Clinical Applications, 2015, 9, 928-937.	1.6	32
1563	Biobanking and Privacy Laws in Australia. Journal of Law, Medicine and Ethics, 2015, 43, 703-713.	0.9	5
1564	Genetic Alterations in Colorectal Cancer Have Different Patterns on 18F-FDG PET/CT. Clinical Nuclear Medicine, 2015, 40, 621-626.	1.3	24

~		_
CITATI	ON	REDUBL
CILAI		KLI OKI

#	Article	IF	CITATIONS
1565	Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in <scp>A</scp> ustralia. Asia-Pacific Journal of Clinical Oncology, 2015, 11, 262-271.	1.1	6
1566	KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery. Medicine (United States), 2015, 94, e1284.	1.0	19
1567	Identification of somatic gene mutations in penile squamous cell carcinoma. Genes Chromosomes and Cancer, 2015, 54, 629-637.	2.8	17
1568	Prognostic and Predictive Values and Statistical Interactions in the Era of Targeted Treatment. Genetic Epidemiology, 2015, 39, 509-517.	1.3	8
1569	MiRâ€96â€5p influences cellular growth and is associated with poor survival in colorectal cancer patients. Molecular Carcinogenesis, 2015, 54, 1442-1450.	2.7	81
1570	Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer. American Journal of Surgical Pathology, 2015, 39, 1140-1147.	3.7	35
1571	Systemic Treatment: Maintenance Compared with Holiday. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 85-90.	3.8	3
1572	Improving Clinical Trial Efficiency: Thinking outside the Box. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e141-e147.	3.8	57
1573	Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. OncoTargets and Therapy, 2016, 9, 75.	2.0	5
1574	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget, 2015, 6, 40360-40369.	1.8	85
1575	Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Oncotarget, 2015, 6, 20785-20800.	1.8	112
1576	Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Design, Development and Therapy, 2015, 9, 3099.	4.3	45
1577	Anticoagulant therapy of cancer patients: Will patient selection increase overall survival?. Thrombosis and Haemostasis, 2015, 114, 530-536.	3.4	17
1578	Biologic Therapies in Colorectal Cancer: Indications and Contraindications. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e197-e206.	3.8	7
1579	K-Ras, Intestinal Homeostasis and Colon Cancer. Current Clinical Pharmacology, 2015, 10, 73-81.	0.6	33
1580	Expression of anti-VECF antibody together with anti-ECFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy. Molecular Therapy - Oncolytics, 2015, 2, 15003.	4.4	23
1581	Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations. PLoS ONE, 2015, 10, e0128202.	2.5	8
1582	EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells. PLoS ONE, 2015, 10, e0130543.	2.5	9

#	Article	IF	Citations
1583	Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. PLoS ONE, 2015, 10, e0135599.	2.5	22
1584	Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review. PLoS ONE, 2015, 10, e0140717.	2.5	9
1585	Single-Tubed Wild-Type Blocking Quantitative PCR Detection Assay for the Sensitive Detection of Codon 12 and 13 KRAS Mutations. PLoS ONE, 2015, 10, e0145698.	2.5	8
1586	Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. Frontiers in Pharmacology, 2015, 6, 120.	3.5	21
1587	Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. OncoTargets and Therapy, 2015, 8, 2949.	2.0	7
1588	Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms. BioMed Research International, 2015, 2015, 1-6.	1.9	12
1589	A Case of Six Synchronous Primary Colorectal Cancers Showing Multiple Oncogenic Mechanisms at the Same Time. Nihon Daicho Komonbyo Gakkai Zasshi, 2015, 68, 544-551.	0.0	0
1591	Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity. Oncotarget, 2015, 6, 18224-18237.	1.8	71
1592	Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e149-e156.	3.8	53
1593	Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer. Oncotarget, 2015, 6, 34288-34299.	1.8	52
1594	Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget, 2015, 6, 12035-12047.	1.8	60
1595	MiR-21/RASA1 axis affects malignancy of colon cancer cells <i>via</i> RAS pathways. World Journal of Gastroenterology, 2015, 21, 1488.	3.3	52
1596	MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. Oncotarget, 2015, 6, 38695-38704.	1.8	67
1597	FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. New England Journal of Medicine, 2015, 372, 290-292.	27.0	11
1598	Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. Drug Resistance Updates, 2015, 20, 39-70.	14.4	83
1599	CCR 20th Anniversary Commentary: In Search of Cetuximab's First Indication $\hat{a} \in$ "Combination Therapy with Irinotecan in Colorectal Cancer. Clinical Cancer Research, 2015, 21, 1505-1507.	7.0	2
1600	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nature Reviews Clinical Oncology, 2015, 12, 408-424.	27.6	456
1601	RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data. Current Treatment Options in Oncology, 2015, 16, 33.	3.0	2

#	ARTICLE Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabing alone or in combination with bevacizumab plus or minus mitomycin	IF	CITATIONS
1603	C in advanced colorectal cancer. British Journal of Cancer, 2015, 112, 963-970. Genomic medicine and targeted therapy for solid tumors. Journal of Surgical Oncology, 2015, 111, 38-42.	1.7	13
1605	Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discovery, 2015, 5, 598-609.	9.4	72
1606	Opportunities for Translational Epidemiology: The Important Role of Observational Studies to Advance Precision Oncology. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 484-489.	2.5	13
1607	Personalized Therapy of Cancer. , 2015, , 199-381.		1
1608	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. Medical Oncology, 2015, 32, 182.	2.5	22
1609	Integrating biomarkers in colorectal cancer trials in the West and China. Nature Reviews Clinical Oncology, 2015, 12, 553-560.	27.6	11
1610	Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors. Molecular and Clinical Oncology, 2015, 3, 179-184.	1.0	22
1611	Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies. Clinical Cancer Research, 2015, 21, 3377-3383.	7.0	34
1612	Japanese Society of Medical Oncology Clinical Guidelines: <i><scp>RAS</scp></i> (<i><scp>KRAS</scp>/<scp>NRAS</scp></i>) mutation testing in colorectal cancer patients. Cancer Science, 2015, 106, 324-327.	3.9	37
1613	Therapeutic Antibodies in Cancer Therapy. , 2015, , 95-120.		1
1614	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). Oncolmmunology, 2015, 4, e1049804.	4.6	51
1615	Treatment Individualization in Colorectal Cancer. Current Colorectal Cancer Reports, 2015, 11, 335-344.	0.5	17
1616	Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer. Journal of the National Cancer Institute, 2015, 108, djv394.	6.3	50
1617	Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2015, 22, 2640-2648.	1.5	59
1618	Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells. Molecular Cancer Research, 2015, 13, 659-669.	3.4	22
1619	KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. British Journal of Cancer, 2015, 112, 720-728.	6.4	72
1620	mTOR Signaling in Endometrial Cancer: From a Molecular and Therapeutic Point of View. Current Obstetrics and Gynecology Reports, 2015, 4, 1-10.	0.8	11

~			<u> </u>		
CF	ΓΑΤ	ION	RE	PO	RT

#	Article	IF	CITATIONS
1621	Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 1036-1043.	7.0	31
1622	Emergence of Multiple <i>EGFR</i> Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clinical Cancer Research, 2015, 21, 2157-2166.	7.0	227
1623	Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis. Biochemical and Biophysical Research Communications, 2015, 458, 52-56.	2.1	33
1624	The role of the PI3K pathway in colorectal cancer. Critical Reviews in Oncology/Hematology, 2015, 94, 18-30.	4.4	96
1625	KRAS mutation testing in clinical practice. Expert Review of Molecular Diagnostics, 2015, 15, 375-384.	3.1	20
1626	Sequence Artifacts in DNA from Formalin-Fixed Tissues: Causes and Strategies for Minimization. Clinical Chemistry, 2015, 61, 64-71.	3.2	412
1627	Comparative Effectiveness Research and Demonstrating Clinical Utility for Molecular Diagnostic Tests. Clinical Chemistry, 2015, 61, 142-144.	3.2	5
1628	Nonâ€invasive sensitive detection of <i>KRAS</i> and <i>BRAF</i> mutation in circulating tumor cells of colorectal cancer patients. Molecular Oncology, 2015, 9, 850-860.	4.6	59
1629	A Urokinase Receptor–Bim Signaling Axis Emerges during EGFR Inhibitor Resistance in Mutant EGFR Glioblastoma. Cancer Research, 2015, 75, 394-404.	0.9	48
1630	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, <i>RAS-BRAF</i> wild-type colorectal cancer receiving cetuximab or panitumumab. International Journal of Cancer, 2015, 137, 1467-1474.	5.1	33
1631	Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemotherapy and Pharmacology, 2015, 75, 17-23.	2.3	25
1632	Biomarkers for glioma immunotherapy: the next generation. Journal of Neuro-Oncology, 2015, 123, 359-372.	2.9	23
1633	KRAS mutation screening by chip-based DNA hybridization – a further step towards personalized oncology. Analyst, The, 2015, 140, 2747-2754.	3.5	6
1634	Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer. Molecular Therapy - Nucleic Acids, 2015, 4, e231.	5.1	78
1635	Consensus Statement: The 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5–6, 2014. Current Oncology, 2015, 22, 113-123.	2.2	0
1636	The Potential of panHER Inhibition in Cancer. Frontiers in Oncology, 2015, 5, 2.	2.8	33
1637	Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. European Journal of Cancer, 2015, 51, 1405-1414.	2.8	283
1638	Disruption of thioredoxin metabolism enhances the toxicity of transforming growth factor β-activated kinase 1 (TAK1) inhibition in KRAS-mutated colon cancer cells. Redox Biology, 2015, 5, 319-327.	9.0	14

#	Article	IF	CITATIONS
1639	HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment. Cancer Discovery, 2015, 5, 832-841.	9.4	250
1640	Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13. Genomics, 2015, 106, 71-75.	2.9	12
1641	KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases. Journal of Vascular and Interventional Radiology, 2015, 26, 1102-1111.	0.5	43
1642	Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. Modern Pathology, 2015, 28, 1390-1399.	5.5	53
1643	Matching Kidneys and Urines: Establishing Noninvasive Surrogates of Intrarenal Events in Primary Glomerulonephritis. Seminars in Nephrology, 2015, 35, 256-265.	1.6	1
1644	Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals. Expert Review of Molecular Diagnostics, 2015, 15, 869-880.	3.1	24
1645	Tumour biomarkers: diagnostic, prognostic, and predictive:. BMJ, The, 2015, 351, h3449.	6.0	15
1646	The Cost and Value of Anti–Epidermal Growth Factor Receptor Therapies. JAMA Oncology, 2015, 1, 141.	7.1	4
1647	Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 761-776.	2.2	11
1648	The Key Role of Calmodulin in <i>KRAS</i> -Driven Adenocarcinomas. Molecular Cancer Research, 2015, 13, 1265-1273.	3.4	72
1649	Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. European Journal of Cancer, 2015, 51, 1704-1713.	2.8	127
1650	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer. Expert Review of Molecular Diagnostics, 2015, 15, 1033-1048.	3.1	0
1651	Relationship Between ¹⁸ F-FDG PET/CT Scans and <i>KRAS</i> Mutations in Metastatic Colorectal Cancer. Journal of Nuclear Medicine, 2015, 56, 1322-1327.	5.0	48
1652	Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer. International Journal of Clinical Oncology, 2015, 20, 1147-1155.	2.2	11
1653	Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer. Frontiers in Genetics, 2015, 6, 116.	2.3	28
1654	Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic ColorectalÂCancer. Clinical Colorectal Cancer, 2015, 14, 203-218.	2.3	25
1655	Current and Future Therapies for Advanced Gastric Cancer. Clinical Colorectal Cancer, 2015, 14, 239-250.	2.3	28
1656	Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treatment Reviews, 2015, 41, 653-659.	7.7	49

#	Article	IF	Citations
1657	Systemic Therapy for Patients with Colorectal Cancer: State of the Art. , 2015, , 109-132.		1
1659	Cost Estimates and Economic Implications of Expanded RAS Testing in Metastatic Colorectal Cancer. Oncologist, 2015, 20, 14-18.	3.7	13
1660	Challenges Posed to Pathologists in the Detection of KRAS Mutations in Colorectal Cancers. Archives of Pathology and Laboratory Medicine, 2015, 139, 211-218.	2.5	35
1661	Mechanisms of action of therapeutic antibodies for cancer. Molecular Immunology, 2015, 67, 28-45.	2.2	136
1662	The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 81-100.	1.4	4
1663	Metastatic Colorectal Cancer: Current State and Future Directions. Journal of Clinical Oncology, 2015, 33, 1809-1824.	1.6	418
1666	First-Line Therapy in Metastatic Colorectal Cancer Patients Not Candidates for Curative Surgery. Current Colorectal Cancer Reports, 2015, 11, 54-69.	0.5	0
1667	Immunotherapeutic Strategies for Colon Cancer: Monoclonal Antibody Therapy. Current Colorectal Cancer Reports, 2015, 11, 84-91.	0.5	1
1669	Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation. Cell Death and Disease, 2015, 6, e1718-e1718.	6.3	44
1670	Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer. SpringerPlus, 2015, 4, 7.	1.2	9
1671	A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer, 2015, 15, 258.	2.6	93
1672	IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. Science Translational Medicine, 2015, 7, 272ra12.	12.4	100
1673	PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy. Lung Cancer, 2015, 88, 254-259.	2.0	78
1674	Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type <i>RAS</i> metastatic colorectal cancer. Journal of Medical Economics, 2015, 18, 619-628.	2.1	9
1675	Time Trend Analysis of Primary Tumor Resection for Stage IV Colorectal Cancer. JAMA Surgery, 2015, 150, 245.	4.3	106
1676	BRAF-induced tumorigenesis is IKKα-dependent but NF-κB–independent. Science Signaling, 2015, 8, ra38.	3.6	29
1677	Beyond the Vascular Endothelial Growth Factor Axis: Update on Role of Imaging in Nonantiangiogenic Molecular Targeted Therapies in Oncology. American Journal of Roentgenology, 2015, 204, 919-932.	2.2	10
1678	Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance). Clinical Cancer Research, 2015, 21, 1078-1086.	7.0	67

#	Article	IF	CITATIONS
1679	Textbook of Personalized Medicine. , 2015, , .		27
1680	Prognostic role of <i>KRAS, NRAS, BRAF</i> and <i>PIK3CA</i> mutations in advanced colorectal cancer. Future Oncology, 2015, 11, 629-640.	2.4	49
1681	Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Annals of Oncology, 2015, 26, 1791-1798.	1.2	68
1682	BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. British Journal of Cancer, 2015, 112, 1921-1928.	6.4	146
1683	Scripps Genome ADVISER: Annotation and Distributed Variant Interpretation SERver. PLoS ONE, 2015, 10, e0116815.	2.5	17
1684	Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas. Journal of Thoracic Oncology, 2015, 10, 431-437.	1.1	98
1685	Early Prediction by 18F-FDG PET/CT for Progression-Free Survival and Overall Survival in Patients With Metastatic Colorectal Cancer Receiving Third-Line Cetuximab-Based Therapy. Clinical Nuclear Medicine, 2015, 40, 200-205.	1.3	25
1686	Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. Anti-Cancer Drugs, 2015, 26, 371-378.	1.4	10
1687	Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. International Journal of Clinical Oncology, 2015, 20, 207-239.	2.2	548
1688	Principles of cancer treatment by immunotherapy. Surgery, 2015, 33, 117-121.	0.3	0
1689	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut, 2015, 64, 921-928.	12.1	22
1690	Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies. Biomarkers in Medicine, 2015, 9, 363-375.	1.4	11
1691	Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients. Investigational New Drugs, 2015, 33, 1242-1247.	2.6	26
1692	Terahertz spectroscopy of oligonucleotides in aqueous solutions. Journal of Biomedical Optics, 2015, 20, 095009.	2.6	42
1693	Inhibition of Oncogenic Epidermal Growth Factor Receptor Kinase Triggers Release of Exosome-like Extracellular Vesicles and Impacts Their Phosphoprotein and DNA Content. Journal of Biological Chemistry, 2015, 290, 24534-24546.	3.4	99
1694	Right- and left-sided colorectal cancers respond differently to cetuximab. Chinese Journal of Cancer, 2015, 34, 384-93.	4.9	63
1695	First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405. Current Treatment Options in Oncology, 2015, 16, 52.	3.0	66
1696	Targeted therapies in bladder cancer: an overview of in vivo research. Nature Reviews Urology, 2015, 12, 681-694.	3.8	63

#	Article	IF	CITATIONS
1697	Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer, 2015, 15, 340.	2.6	61
1698	Markers in Colorectal Cancer and Clinical Trials Based Upon Them. Current Colorectal Cancer Reports, 2015, 11, 317-325.	0.5	0
1699	Personalized Medicine: Four Perspectives of Tailored Medicine. Statistics in Biopharmaceutical Research, 2015, 7, 214-229.	0.8	44
1700	βIII-tubulin overexpression is linked to left-sided tumor localization and nuclear β-catenin expression in colorectal cancer. Cancer Treatment Communications, 2015, 4, 96-102.	0.4	0
1701	The Personalization of Therapy: Molecular Profiling Technologies and Their Application. Seminars in Oncology, 2015, 42, 775-787.	2.2	6
1702	Vitamin C selectively kills <i>KRAS</i> and <i>BRAF</i> mutant colorectal cancer cells by targeting GAPDH. Science, 2015, 350, 1391-1396.	12.6	722
1703	Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer. Clinical Cancer Research, 2015, 21, 4569-4575.	7.0	12
1704	High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer. Journal of the National Cancer Institute Monographs, 2015, 2015, 70-75.	2.1	13
1705	Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clinical Cancer Research, 2015, 21, 5294-5304.	7.0	70
1706	How can we identify new biomarkers for patients with for lung metastasectomy in colorectal cancer. Future Oncology, 2015, 11, 2109-2111.	2.4	1
1707	ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development. Cancer Cell, 2015, 28, 183-197.	16.8	67
1708	Personalized medicine: Time for one-person trials. Nature, 2015, 520, 609-611.	27.8	906
1709	The evolution within us. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140235.	4.0	34
1710	Prognostic impact of hyponatraemia in patients with colorectal cancer. Colorectal Disease, 2015, 17, 409-416.	1.4	21
1711	Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. Annals of Oncology, 2015, 26, 2079-2084.	1.2	42
1712	Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer. Cancer Biology and Therapy, 2015, 16, 1289-1295.	3.4	49
1713	Integrated proteo-genomic approach for early diagnosis and prognosis of cancer. Cancer Letters, 2015, 369, 28-36.	7.2	30
1714	Cost Considerations in the Evaluation and Treatment of Colorectal Cancer. Current Treatment Options in Oncology, 2015, 16, 41.	3.0	8

#	Article	IF	CITATIONS
1715	Racial Disparities in Colorectal Cancer Survival: Is Elimination of Variation in Care the Cure?. Journal of the National Cancer Institute, 2015, 107, djv229.	6.3	12
1716	Maintenance Therapy for Colorectal Cancer: Which Regimen and Which Patients?. Drugs, 2015, 75, 1833-1842.	10.9	3
1717	A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, <i>KRAS</i> Wild-Type, Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, djv258.	6.3	72
1718	Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002). Annals of Surgical Oncology, 2015, 22, 1067-1074.	1.5	16
1719	The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment. Journal of the National Cancer Institute, 2015, 107, djv157.	6.3	28
1720	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology, 2015, 26, 1547-1573.	1.2	635
1722	How to Identify the Right Patients for the Right Treatment in Metastatic Colorectal Cancer (mCRC). Current Colorectal Cancer Reports, 2015, 11, 151-159.	0.5	2
1723	Molecular biology of colorectal cancer in clinical practice. Molecular Biology, 2015, 49, 471-479.	1.3	1
1724	Gastrointestinal and Pancreatobiliary Tumors. , 2015, , 375-406.		0
1725	CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR-Targeted Therapy for Colorectal Cancer—From Concept to Practice. Clinical Cancer Research, 2015, 21, 3578-3580.	7.0	17
1726	Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2. Drugs, 2015, 75, 1739-1756.	10.9	6
1727	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Therapy, 2015, 22, 417-430.	4.6	112
1728	Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 516-534.	4.5	67
1729	Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. Cancer Immunology, Immunotherapy, 2015, 64, 977-987.	4.2	44
1730	Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program. Expert Opinion on Drug Safety, 2015, 14, 1171-1179.	2.4	8
1731	Low-frequency <i>KRAS</i> mutations are prevalent in lung adenocarcinomas. Personalized Medicine, 2015, 12, 83-98.	1.5	19
1732	Abordaje terapéutico del carcinoma escamoso cutáneo no operable. Piel, 2015, 30, 594-608.	0.0	0
1733	Challenges in Converting Acute Myeloid Leukemia (AML) Genomics Into AML Clinical Trials. Journal of Clinical Oncology. 2015. 33. 4238-4239.	1.6	0

#	Article	IF	CITATIONS
1734	Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. British Journal of Cancer, 2015, 112, 313-318.	6.4	22
1735	Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients. Clinical Cancer Research, 2015, 21, 357-364.	7.0	127
1736	Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nature Reviews Clinical Oncology, 2015, 12, 197-212.	27.6	162
1737	In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. Advanced Drug Delivery Reviews, 2015, 81, 128-141.	13.7	533
1738	Recent Therapeutic Advances in the Treatment of Colorectal Cancer. Annual Review of Medicine, 2015, 66, 83-95.	12.2	162
1739	lon Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. Journal of Clinical Pathology, 2015, 68, 64-68.	2.0	81
1740	The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?. Critical Reviews in Oncology/Hematology, 2015, 93, 190-202.	4.4	24
1741	Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes and Diseases, 2015, 2, 4-12.	3.4	94
1742	Emerging biomarkers in head and neck cancer in the era of genomics. Nature Reviews Clinical Oncology, 2015, 12, 11-26.	27.6	264
1743	Prognostication Systems as Applied to Primary and Metastatic Hepatic Malignancies. Surgical Oncology Clinics of North America, 2015, 24, 41-56.	1.5	2
1744	Circulating Tumor DNA as a Liquid Biopsy for Cancer. Clinical Chemistry, 2015, 61, 112-123.	3.2	654
1745	<i>KRAS</i> mutation status impacts diagnosis and treatment decision in a patient with two colon tumours: a case report. Journal of Clinical Pathology, 2015, 68, 83-85.	2.0	5
1746	Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies. Targeted Oncology, 2015, 10, 179-188.	3.6	35
1750	KRAS Mutation is Associated with Worse Prognosis in Stage III or High-risk Stage II Colon Cancer Patients Treated with Adjuvant FOLFOX. Annals of Surgical Oncology, 2015, 22, 187-194.	1.5	52
1751	Personalised cancer medicine. International Journal of Cancer, 2015, 137, 262-266.	5.1	277
1752	Estimation of Treatment Effects in All-Comers Randomized Clinical Trials with a Predictive Marker. Biometrics, 2015, 71, 25-32.	1.4	6
1753	Anti-Epidermal Growth Factor Receptor (EGFR) Treatment in Patients with Metastatic Colorectal Cancer. , 0, , .		1
1754	ARMS-PCR based diagnosis of APCB and KRAS genes in colorectal cancer patients in Iraqi Sulaimania province. Journal of Solid Tumors, 2016, 7, 27.	0.1	0

#	Article	IF	CITATIONS
1755	Kras, Braf, PIK3CA and EGFR Gene Mutations are Associated with Lymph Node Metastasis and Right Sided Colon Carcinoma. Journal of Cancer Science & Therapy, 2016, 08, .	1.7	0
1756	Role of targeted therapy in metastatic colorectal cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 642.	2.0	80
1757	Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy. OncoTargets and Therapy, 2016, Volume 9, 4695-4703.	2.0	12
1758	A pilot study employing hepatic intra-arterial irinotecan injection of drug-eluting beads as salvage therapy in liver metastatic colorectal cancer patients without extrahepatic involvement: the first southern Italy experience. OncoTargets and Therapy, 2016, Volume 9, 7527-7535.	2.0	15
1759	Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells. OncoTargets and Therapy, 2016, Volume 9, 7503-7513.	2.0	31
1760	Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. World Journal of Clinical Oncology, 2016, 7, 340.	2.3	7
1761	RAS and BRAF in metastatic colorectal cancer management. Journal of Gastrointestinal Oncology, 2016, 7, 687-704.	1.4	56
1762	Clinical applications of liquid biopsies in gastrointestinal oncology. Journal of Gastrointestinal Oncology, 2016, 7, 675-686.	1.4	10
1763	Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. Oncotarget, 2016, 7, 34811-34823.	1.8	43
1764	Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. BioMed Research International, 2016, 2016, 1-14.	1.9	19
1765	Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. ELife, 2016, 5, .	6.0	191
1766	Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. OncoTargets and Therapy, 2016, 9, 1899.	2.0	44
1768	Personalized medicine and treatment approaches in hypertension: current perspectives. Integrated Blood Pressure Control, 2016, 9, 59.	1.2	18
1769	Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer. International Journal of Environmental Research and Public Health, 2016, 13, 892.	2.6	43
1770	Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in RAS wild-type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trial. Trials, 2016, 17, 459.	1.6	2
1771	Multi-Center Evaluation of the Fully Automated PCR-Based Idyllaâ,,¢ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer. PLoS ONE, 2016, 11, e0163444.	2.5	35
1772	Cancer Markers Selection Using Network-Based Cox Regression: A Methodological and Computational Practice. Frontiers in Physiology, 2016, 7, 208.	2.8	27
1773	Biomarker Development in Targeting Cancer Epigenetic. , 2016, , 123-142.		0

		CITATION REPORT	
#	Article	IF	CITATIONS
1774	3D Pharming: Direct Printing of Personalized Pharmaceutical Tablets. Polymer Science, 2016, 2, .	0.2	12
1775	Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer. OncoTargets and Therapy, 2016, 9, 2329.	2.0	12
1777	Molecular-targeted Therapies in Gastrointestinal Cancer. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1051-1060.	0.0	0
1778	MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers. Medicine (United States), 2016, 95, e3321.	1.0	19
1779	The State of the Art in Colorectal Cancer Molecular Biomarker Testing. Advances in Anatomic Pathology, 2016, 23, 92-103.	4.3	9
1780	Exploratory subgroup analysis in clinical trials by model selection. Biometrical Journal, 2016, 58, 1217-1228.	1.0	20
1781	Nomograms for predicting prognostic value of inflammatory biomarkers in colorectal cancer patients after radical resection. International Journal of Cancer, 2016, 139, 220-231.	5.1	122
1782	miRNAs: mediators of ErbB family targeted therapy resistance. Pharmacogenomics, 2016, 17, 117	5-1187. 1.3	7
1783	Influence of m <scp>RNA</scp> expression of epiregulin and amphiregulin on outcome of patients metastatic colorectal cancer treated with 5â€ <scp>FU/LV</scp> plus irinotecan or irinotecan plus oxaliplatin as firstâ€ine treatment (<scp>FIRE</scp> 1â€trial). International Journal of Cancer, 202 739-746.	with 16, 138, ^{5.1}	32
1784	Ligand-targeted bacterial minicells: Futuristic nano-sized drug delivery system for the efficient and cost effective delivery of shRNA to cancer cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 2485-2498.	3.3	28
1785	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1386-1422.	1.2	2,545
1786	Patient-Derived Xenograft: An Adjuvant Technology for the Treatment of Metastatic Disease. Pathobiology, 2016, 83, 170-176.	3.8	24
1789	The Moment that <i>KRAS</i> Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer. Cancer Research, 2016, 76, 6443-6444.	0.9	7
1790	Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer. BMC Cance 2016, 16, 850.	er, 2.6	22
1791	Early ¹⁸ F-FDG-PET/CT as a predictive marker for treatment response and survival in pawith metastatic colorectal cancer treated with irinotecan and cetuximab. Acta Oncológica, 2016, 1175-1182.	atients 55, 1.8	4
1792	Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer ce by retrievable microRNA-378 expression. Oncology Reports, 2016, 35, 107-116.	ells 2.6	26
1793	Machine Learning for Health Informatics. Lecture Notes in Computer Science, 2016, , .	1.3	27
1794	A Master Pipeline for Discovery and Validation of Biomarkers. Lecture Notes in Computer Science, 2016, , 259-288.	1.3	0

# 1796	ARTICLE Biomarker in Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 156-164.	IF 2.0	Citations 35
1797	Extracellular matrix gene expression profiling using microfluidics for colorectal carcinoma stratification. Biomicrofluidics, 2016, 10, 054124.	2.4	6
1798	SNPing away to individualize induction therapy for acute myelogenous leukemia. Leukemia and Lymphoma, 2016, 57, 742-743.	1.3	0
1799	Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer. Clinical Genitourinary Cancer, 2016, 14, 450-456.e1.	1.9	6
1800	Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. BMC Cancer, 2016, 16, 327.	2.6	42
1801	Therapeutic Antibodies in Cancer Therapy. Advances in Experimental Medicine and Biology, 2016, 917, 95-120.	1.6	36
1802	Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Investigational New Drugs, 2016, 34, 96-103.	2.6	2
1803	Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics. Pathology Research and Practice, 2016, 212, 598-603.	2.3	12
1804	Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. European Urology, 2016, 70, 771-775.	1.9	69
1805	GEP- NETS UPDATE: Genetics of neuroendocrine tumors. European Journal of Endocrinology, 2016, 174, R275-R290.	3.7	55
1806	Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2016, 77, 1209-1215.	2.3	21
1807	Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. Clinical Therapeutics, 2016, 38, 1376-1391.	2.5	11
1808	The Economics of Personalized Therapy in Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2016, 12, 123-129.	0.5	2
1809	QIAGEN TherascreenKRASRGQ Assay, QIAGENKRASPyro Assay, and Dideoxy Sequencing for Clinical Laboratory Analysis ofKRASMutations in Tumor Specimens. Laboratory Medicine, 2016, 47, 30-38.	1.2	4
1810	Novel Approach for Clinical Validation of the cobas KRAS Mutation Test in Advanced Colorectal Cancer. Molecular Diagnosis and Therapy, 2016, 20, 231-240.	3.8	8
1811	A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. Clinical Colorectal Cancer, 2016, 15, 337-344.e2.	2.3	33
1812	Biomarker Tests for Molecularly Targeted Therapies: Laying the Foundation and Fulfilling the Dream. Journal of Clinical Oncology, 2016, 34, 2061-2066.	1.6	17
1813	The Conundrum of Genetic "Drivers―in Benign Conditions. Journal of the National Cancer Institute, 2016, 108, djw036.	6.3	113

#	Article	IF	CITATIONS
1814	<i>KRAS</i> mutation testing in colorectal cancer: the model for molecular pathology testing in the future. Colorectal Cancer, 2016, 5, 73-80.	0.8	0
1815	The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. BMC Cancer, 2016, 16, 120.	2.6	35
1816	Locked nucleic acid probe enhances Sanger sequencing sensitivity and improves diagnostic accuracy of high-resolution melting-based KRAS mutational analysis. Clinica Chimica Acta, 2016, 457, 75-80.	1.1	11
1817	Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer. Expert Opinion on Drug Delivery, 2016, 13, 999-1013.	5.0	6
1818	The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside. Cancer Chemotherapy and Pharmacology, 2016, 78, 233-244.	2.3	29
1819	VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Research, 2016, 44, e108-e108.	14.5	618
1820	The 100 most influential manuscripts in colorectal cancer: A bibliometric analysis. Journal of the Royal College of Surgeons of Edinburgh, 2016, 14, 327-336.	1.8	27
1821	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the <i>KRAS</i> G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. Journal of Clinical Oncology, 2016, 34, 2258-2264.	1.6	52
1822	Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer. Cancer Biology and Therapy, 2016, 17, 751-759.	3.4	14
1823	High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma. European Journal of Cancer, 2016, 60, 125-135.	2.8	91
1824	Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker. Clinical Cancer Research, 2016, 22, 2114-2120.	7.0	6
1825	Oral drugs in the treatment of metastatic colorectal cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 1351-1361.	1.8	21
1826	<i>RAS</i> and <i>RAF</i> mutation status in the selection of patients for anti-EGFR therapy. Colorectal Cancer, 2016, 5, 81-89.	0.8	0
1827	Outcome of Molecular Targeted Agents Plus Chemotherapy for Second-Line Therapy of Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Trials. Clinical Colorectal Cancer, 2016, 15, e149-e156.	2.3	8
1828	Fc-Î ³ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. Clinical Cancer Research, 2016, 22, 2435-2444.	7.0	33
1829	KRAS-related proteins in pancreatic cancer. , 2016, 168, 29-42.		151
1830	Preoperative neutrophil-to-lymphocyte ratio is a more valuable prognostic factor than platelet-to-lymphocyte ratio for nonmetastatic rectal cancer. International Immunopharmacology, 2016, 40, 327-331.	3.8	24
1831	FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer. British Journal of Cancer, 2016, 115, 1223-1233.	6.4	44

#	Article	IF	CITATIONS
1832	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. Oncologist, 2016, 21, 1306-1314.	3.7	36
1833	Final results and outcomes by prior bevacizumab exposure, skin toxicity,Âand hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. European Journal of Cancer, 2016. 68. 51-59.	2.8	56
1834	Phase II Study of Olaparib (AZDâ€2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. Oncologist, 2016, 21, 172-177.	3.7	58
1835	The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers. Seminars in Cell and Developmental Biology, 2016, 58, 108-117.	5.0	10
1836	Bloodâ€based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from <scp>CALGB</scp> 80203 (Alliance). Cancer Medicine, 2016, 5, 2249-2260.	2.8	19
1837	Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study). Cancer Chemotherapy and Pharmacology, 2016, 78, 585-593.	2.3	5
1838	Commentary on "KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer― Cancer Research, 2016, 76, 4309-4310.	0.9	4
1839	Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nature Reviews Drug Discovery, 2016, 15, 771-785.	46.4	457
1840	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti ancer antibodies: IUPHAR Review 18. British Journal of Pharmacology, 2016, 173, 1407-1424.	5.4	56
1842	Non-coding RNAs Enabling Prognostic Stratification and Prediction of Therapeutic Response in Colorectal Cancer Patients. Advances in Experimental Medicine and Biology, 2016, 937, 183-204.	1.6	9
1843	Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen. Clinics in Colon and Rectal Surgery, 2016, 29, 196-204.	1.1	10
1844	Molecular Pathology: A Requirement for Precision Medicine in Cancer. Oncology Research and Treatment, 2016, 39, 804-810.	1.2	24
1845	Targeted Therapy of Head and Neck Cancer. Oncology Research and Treatment, 2016, 39, 780-786.	1.2	17
1847	A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer. Molecular Cancer Therapeutics, 2016, 15, 2244-2250.	4.1	25
1848	Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of <scp> <i>KRAS</i> </scp> status. International Journal of Cancer, 2016, 138, 1516-1527.	5.1	16
1849	High frequency of KRAS mutation in early onset colorectal adenocarcinoma: implications for pathogenesis. Human Pathology, 2016, 56, 163-170.	2.0	33
1850	Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer. Tumor Biology, 2016, 37, 11645-11655.	1.8	21
1851	Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type <i>KRAS</i> Unresectable Metastatic Colorectal Cancer. Journal of Oncology Practice. 2016. 12, e710-e723.	2.5	20

#	Article	IF	CITATIONS
1852	A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. British Journal of Cancer, 2016, 115, 1206-1214.	6.4	47
1853	MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer. Cellular Physiology and Biochemistry, 2016, 40, 62-76.	1.6	80
1854	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open, 2016, 1, e000066.	4.5	17
1855	Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase. Neoplasia, 2016, 18, 654-665.	5.3	100
1856	Impaired coordination between signaling pathways is revealed in human colorectal cancer using single-cell mass cytometry of archival tissue blocks. Science Signaling, 2016, 9, rs11.	3.6	22
1857	Cost-effectiveness of cetuximab for colorectal cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 667-677.	1.4	8
1858	Oncolytic Activity of a Recombinant Measles Virus, Blind to Signaling Lymphocyte Activation Molecule, Against Colorectal Cancer Cells. Scientific Reports, 2016, 6, 24572.	3.3	21
1860	Management of patients with colorectal liver metastasis in eleven questions and answers. Expert Review of Anticancer Therapy, 2016, 16, 1277-1290.	2.4	3
1861	The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. Therapeutic Advances in Gastroenterology, 2016, 9, 861-886.	3.2	44
1862	Systemic Therapy for Metastatic Colorectal Cancer. , 2016, , 275-338.		0
1863	Polymeric nanoparticles for colon cancer therapy: overview and perspectives. Journal of Materials Chemistry B, 2016, 4, 7779-7792.	5.8	93
1864	GATA binding protein 2 overexpression is associated with poor prognosis in KRAS mutant colorectal cancer. Oncology Reports, 2016, 36, 1672-1678.	2.6	11
1865	Low expression of PKC $\hat{l}\pm$ and high expression of KRAS predict poor prognosis in patients with colorectal cancer. Oncology Letters, 2016, 12, 1655-1660.	1.8	18
1866	A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing. BMC Cancer, 2016, 16, 585.	2.6	9
1867	The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer. Medicine (United States), 2016, 95, e5284.	1.0	4
1868	Molecular Triage Trials in Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 218-222.	2.0	Ο
1869	BTH1677 in combination with cetuximab with and without irinotecan in patients with advanced metastatic colorectal cancer. Colorectal Cancer, 2016, 5, 95-108.	0.8	4
1870	Inference on treatment ovariate interaction based on a nonparametric measure of treatment effects and censored survival data. Statistics in Medicine, 2016, 35, 2715-2725.	1.6	2

#	Article	IF	CITATIONS
1871	Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology. Genes Chromosomes and Cancer, 2016, 55, 505-521.	2.8	34
1872	Utilization of Cell-Transfer Technique for Molecular Testing on Hematoxylin-Eosin–Stained Sections: A Viable Option for Small Biopsies That Lack Tumor Tissues in Paraffin Block. Archives of Pathology and Laboratory Medicine, 2016, 140, 1383-1389.	2.5	10
1873	Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. British Journal of Cancer, 2016, 114, 1352-1361.	6.4	81
1874	Molecular Radio-Oncology. Recent Results in Cancer Research, 2016, , .	1.8	1
1875	Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors. Recent Results in Cancer Research, 2016, 198, 107-122.	1.8	12
1876	¹⁸ F-FDG PET/CT imaging in rectal cancer: relationship with the <i>RAS</i> mutational status. British Journal of Radiology, 2016, 89, 20160212.	2.2	54
1877	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC Cancer, 2016, 16, 339.	2.6	15
1878	Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncology, 2016, 5, 175-186.	3.0	11
1880	Mutation spectra of RAS gene family in colorectal cancer. American Journal of Surgery, 2016, 212, 537-544.e3.	1.8	38
1881	Understanding Intratumoral Heterogeneity: Lessons from the Analysis of At-Risk Tissue and Premalignant Lesions in the Colon. Cancer Prevention Research, 2016, 9, 638-641.	1.5	16
1882	Hybridization-Induced Aggregation Technology for Practical Clinical Testing. Journal of Molecular Diagnostics, 2016, 18, 546-553.	2.8	2
1883	A comparison of four methods for detecting KRAS mutations in formalin-fixed specimens from metastatic colorectal cancer patients. Oncology Letters, 2016, 12, 150-156.	1.8	12
1884	Primary tumor location is an important predictive factor for wild-type <i>KRAS</i> metastatic colon cancer treated with cetuximab as front-line bio-therapy. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 207-215.	1.1	18
1885	Colorectal clinical trials: what is on the horizon?. Future Oncology, 2016, 12, 525-531.	2.4	1
1886	Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer. British Journal of Cancer, 2016, 114, 372-380.	6.4	27
1887	⁹⁰ Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study. Journal of Nuclear Medicine, 2016, 57, 665-671.	5.0	79
1888	Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer. Clinica Chimica Acta, 2016, 455, 26-32.	1.1	59
1889	Prognostic Effect of <i>BRAF</i> and <i>KRAS</i> Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab. JAMA Oncology, 2016, 2, 643.	7.1	125

#	Article	IF	CITATIONS
1890	RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, 95-103.	2.3	30
1891	Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer. Journal of Theoretical Biology, 2016, 389, 263-273.	1.7	31
1892	Current and advancing treatments for metastatic colorectal cancer. Expert Opinion on Biological Therapy, 2016, 16, 93-110.	3.1	31
1893	Drug–diagnostic co-development: challenges and issues. Expert Review of Molecular Diagnostics, 2016, 16, 187-204.	3.1	4
1894	Use of auxiliary covariates in estimating a biomarker-adjusted treatment effect model with clinical trial data. Statistical Methods in Medical Research, 2016, 25, 2103-2119.	1.5	10
1895	Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. Journal of the National Cancer Institute, 2016, 108, djv362.	6.3	71
1896	A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, 222-227.	2.3	29
1897	Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance. Cancer Discovery, 2016, 6, 382-399.	9.4	139
1898	Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. Oncologist, 2016, 21, 292-300.	3.7	40
1899	Monitoring Ras Interactions with the Nucleotide Exchange Factor Son of Sevenless (Sos) Using Site-specific NMR Reporter Signals and Intrinsic Fluorescence. Journal of Biological Chemistry, 2016, 291, 1703-1718.	3.4	31
1900	KRAS mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Medicine, 2016, 5, 256-264.	2.8	29
1901	A randomized, placeboâ€controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wildâ€ŧype <i>KRAS</i> who have received firstâ€ŧine systemic therapy. International Journal of Cancer, 2016, 139, 177-186.	5.1	52
1902	The role of exosomes in the pathogenesis of pancreatic ductal adenocarcinoma. International Journal of Biochemistry and Cell Biology, 2016, 75, 131-139.	2.8	15
1903	Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality. Clinical Colorectal Cancer, 2016, 15, 195-203.	2.3	268
1904	K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?. Expert Opinion on Therapeutic Targets, 2016, 20, 831-842.	3.4	29
1905	Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2016, 14, 651-658.	4.4	99
1906	G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumor Biology, 2016, 37, 6823-6830.	1.8	38
1907	Tumor heterogeneity and circulating tumor cells. Cancer Letters, 2016, 374, 216-223.	7.2	63

#	Article	IF	CITATIONS
1908	Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With <i>RAS</i> Wild-Type Advanced Colorectal Cancer. JAMA Oncology, 2016, 2, 633.	7.1	79
1909	New acyclic bis phenylpropanoid and neolignans, from Myristica fragrans Houtt., exhibiting PARP-1 and NF-κB inhibitory effects. Food Chemistry, 2016, 202, 269-275.	8.2	24
1910	Pruning Cancer's Evolutionary Tree with Lesion-Directed Therapy. Cancer Discovery, 2016, 6, 122-124.	9.4	13
1911	Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study. Oncology Letters, 2016, 11, 831-836.	1.8	0
1912	Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy. Cancer Immunology Research, 2016, 4, 366-374.	3.4	61
1913	Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. European Journal of Cancer, 2016, 57, 91-103.	2.8	120
1914	A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer. Japanese Journal of Clinical Oncology, 2016, 46, 228-233.	1.3	13
1915	Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine. Pharmacoeconomics, 2016, 34, 635-644.	3.3	9
1916	BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?. Molecular Diagnosis and Therapy, 2016, 20, 75-82.	3.8	7
1917	A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Investigational New Drugs, 2016, 34, 168-175.	2.6	40
1918	Pharmacologic resistance in colorectal cancer: a review. Therapeutic Advances in Medical Oncology, 2016, 8, 57-84.	3.2	385
1919	Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. Journal of Clinical Pathology, 2016, 69, 35-41.	2.0	23
1920	Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. Cancer Immunology Research, 2016, 4, 204-214.	3.4	175
1921	Immunohistochemical and genetic evaluations of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 2016, 28, 174-181.	0.3	4
1922	MicroRNA-143 replenishment re-sensitizes colorectal cancer cells harboring mutant, but not wild-type, KRAS to paclitaxel treatment. Tumor Biology, 2016, 37, 5829-5835.	1.8	11
1923	Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to <i>KRAS</i> Mutation Status. Journal of the National Cancer Institute, 2016, 108, djv363.	6.3	37
1924	Potent anti-tumor effects of EGFR-targeted hybrid peptide on mice bearing liver metastases. Clinical and Experimental Metastasis, 2016, 33, 87-95.	3.3	2
1925	Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. Annals of Oncology, 2016, 27, 127-133.	1.2	65

#	Article	IF	CITATIONS
1926	Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer. Critical Reviews in Oncology/Hematology, 2016, 97, 85-95.	4.4	19
1927	PLCε signaling in cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 715-722.	2.5	15
1928	Phosphorylated epidermal growth factor receptor expression and KRAS mutation status in salivary gland carcinomas. Clinical Oral Investigations, 2016, 20, 541-551.	3.0	6
1929	Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada. Journal of Medical Economics, 2016, 19, 145-157.	2.1	6
1930	The influence of subclonal resistance mutations on targeted cancer therapy. Nature Reviews Clinical Oncology, 2016, 13, 335-347.	27.6	185
1931	Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry. Clinical Colorectal Cancer, 2016, 15, 32-36.	2.3	37
1932	Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers. Technology in Cancer Research and Treatment, 2016, 15, 573-582.	1.9	7
1933	Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer. Annals of Surgical Oncology, 2016, 23, 197-205.	1.5	39
1934	Biology of Lung Cancer. , 2016, , 912-926.e6.		1
1935	Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer. Medical Care, 2017, 55, e131-e136.	2.4	1
1936	Interim decision-making strategies in adaptive designs for population selection using time-to-event endpoints. Journal of Biopharmaceutical Statistics, 2017, 27, 84-100.	0.8	8
1937	Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 498-506.	1.3	12
1938	The effect of forced expression of mutated <i>Kâ€RAS</i> gene on gastrointestinal cancer cell lines and the IGFâ€1R targeting therapy. Molecular Carcinogenesis, 2017, 56, 515-526.	2.7	6
1939	Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients – a prospective study. BMC Cancer, 2017, 17, 53.	2.6	32
1940	STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics. Molecular and Cellular Endocrinology, 2017, 451, 15-23.	3.2	49
1941	Antibodies for Treatment of Metastatic Colorectal Cancer. , 2017, , 217-244.		0
1942	Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients. Pathology and Oncology Research, 2017, 23, 737-744.	1.9	3
1943	CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. Nature Communications, 2017, 8, 13897.	12.8	54

#	Article	IF	CITATIONS
1944	Racial Differences in Stage IV Colorectal Cancer Survival in Younger and Older Patients. Clinical Colorectal Cancer, 2017, 16, 178-186.	2.3	25
1945	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	7.7	80
1946	Cancer brings forward oviposition in the fly <i>Drosophila melanogaster</i> . Ecology and Evolution, 2017, 7, 272-276.	1.9	29
1947	High expression of ADAMTS5 is a potent marker for lymphatic invasion and lymph node metastasis in colorectal cancer. Molecular and Clinical Oncology, 2017, 6, 130-134.	1.0	12
1948	Serum and tissue markers in colorectal cancer: State of art. Critical Reviews in Oncology/Hematology, 2017, 111, 103-116.	4.4	20
1949	An electrochemiluminescence biosensor for Kras mutations based on locked nucleic acid functionalized DNA walkers and hyperbranched rolling circle amplification. Chemical Communications, 2017, 53, 2910-2913.	4.1	75
1950	A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. British Journal of Cancer, 2017, 116, 575-583.	6.4	73
1951	Personalized medicine: a new option for nuclear medicine and molecular imaging in the third millennium. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 563-566.	6.4	24
1952	Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. Cancer Treatment Reviews, 2017, 54, 43-57.	7.7	28
1953	Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, Canada. International Journal of Cancer, 2017, 140, 2162-2167.	5.1	4
1954	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172.		22
1955	New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets. Autophagy, 2017, 13, 781-819.	9.1	117
1956	Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group Trial (E3205). Journal of Clinical Oncology, 2017, 35, 718-726.	1.6	70
1957	Oncogenic Effects of High MAPK Activity in Colorectal Cancer Mark Progenitor Cells and Persist Irrespective of RAS Mutations. Cancer Research, 2017, 77, 1763-1774.	0.9	58
1958	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. Journal of Clinical Oncology, 2017, 35, 1453-1486.	1.6	255
1959	Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects. Journal of Biopharmaceutical Statistics, 2017, 27, 933-944.	0.8	3
1960	HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy. Clinical Colorectal Cancer, 2017, 16, 247-251.	2.3	32
1961	Novel biotechnology approaches in colorectal cancer diagnosis and therapy. Biotechnology Letters, 2017, 39, 785-803.	2.2	18

#	Article	IF	CITATIONS
1962	Correlation between KRAS mutation and 18F-FDG uptake in stage IV colorectal cancer. Abdominal Radiology, 2017, 42, 1621-1626.	2.1	19
1963	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. Archives of Pathology and Laboratory Medicine, 2017, 141, 625-657.	2.5	75
1964	Molecular Biomarkers for the Evaluation of Colorectal Cancer. Journal of Molecular Diagnostics, 2017, 19, 187-225.	2.8	108
1965	Peripheral Neutrophil to Lymphocyte Ratio Improves Prognostication in Colon Cancer. Clinical Colorectal Cancer, 2017, 16, 115-123.e3.	2.3	38
1966	Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab. JAMA Dermatology, 2017, 153, 291.	4.1	29
1967	Liquid Biopsies, What We Do Not Know (Yet). Cancer Cell, 2017, 31, 172-179.	16.8	395
1968	Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody. Oncology, 2017, 92, 205-212.	1.9	7
1969	Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study. British Journal of Cancer, 2017, 116, 1271-1278.	6.4	55
1970	Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib. Molecular Cancer Therapeutics, 2017, 16, 1717-1726.	4.1	47
1971	Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies. Cancer Treatment Reviews, 2017, 59, 54-60.	7.7	99
1972	Panitumumab interaction with <scp>TAS</scp> â€102 leads to combinational anticancer effects via blocking of <scp>EGFR</scp> â€mediated tumor response to trifluridine. Molecular Oncology, 2017, 11, 1065-1077.	4.6	18
1973	Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis. Molecular and Clinical Oncology, 2017, 6, 403-408.	1.0	8
1974	Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund. Annals of Oncology, 2017, 28, 1738-1750.	1.2	102
1975	Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with <i>BRAF</i> or <i>KRAS</i> Mutations. Clinical Cancer Research, 2017, 23, 5547-5560.	7.0	40
1976	A Novel Combination Treatment Targeting BCL-XL and MCL1 for <i>KRAS/BRAF</i> -mutated and <i>BCL2L1</i> -amplified Colorectal Cancers. Molecular Cancer Therapeutics, 2017, 16, 2178-2190.	4.1	17
1977	Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer. Cancer, 2017, 123, 3513-3523.	4.1	50
1978	Informing materials: drugs as tools for exploring cancer mechanisms and pathways. History and Philosophy of the Life Sciences, 2017, 39, 10.	1.1	11
1979	The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients. Medicine (United States), 2017, 96, e5946.	1.0	12

#	Article	IF	CITATIONS
1980	Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer. Molecular Cancer Therapeutics, 2017, 16, 1999-2007.	4.1	12
1981	Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. Nature Communications, 2017, 8, 15617.	12.8	38
1982	Rapid and sensitive detection of <i>UGT1A1</i> polymorphisms associated with irinotecan toxicity by a novel DNA microarray. Cancer Science, 2017, 108, 1504-1509.	3.9	6
1983	Sensitive detection of cancer gene based on a nicking-mediated RCA of circular DNA nanomachine. Sensors and Actuators B: Chemical, 2017, 251, 692-698.	7.8	23
1984	Systemic Management of Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 699-702.	4.9	29
1985	Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 370-398.	4.9	707
1986	A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and highâ€grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. Pediatric Blood and Cancer, 2017, 64, e26621.	1.5	17
1987	Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status. Anti-Cancer Drugs, 2017, 28, 546-550.	1.4	13
1988	Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. Medicine (United States), 2017, 96, e6931.	1.0	3
1989	Molecular Biomarkers for the Evaluation of Colorectal Cancer. American Journal of Clinical Pathology, 2017, 147, 221-260.	0.7	32
1990	Hepatic metastasis from colorectal cancer. , 2017, , 1339-1354.e4.		1
1991	<scp>DNA</scp> methylation epigenotype and clinical features of <i>NRAS</i> â€mutation(+) colorectal cancer. Cancer Medicine, 2017, 6, 1023-1035.	2.8	22
1992	Combination of Antiangiogenics and Other Targeted Therapies. , 2017, , 1-18.		1
1993	Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale. Contemporary Clinical Trials, 2017, 63, 40-50.	1.8	10
1994	Antibody-Based Cancer Therapy. International Review of Cell and Molecular Biology, 2017, 331, 289-383.	3.2	41
1995	A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer. BMC Cancer, 2017, 17, 188.	2.6	8
1996	Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026617.	6.2	59
1997	The extracellular domain of E cadherin linked to invasiveness in colorectal cancer: a new resistance and relapses monitoring serum-bio marker?. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1177-1190.	2.5	8

#	Article	IF	CITATIONS
1998	Mutation matters in precision medicine: A future to believe in. Cancer Treatment Reviews, 2017, 55, 136-149.	7.7	36
1999	Multidisciplinary management of intrahepatic cholangiocarcinoma: Current approaches. Surgical Oncology, 2017, 26, 146-152.	1.6	40
2000	From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nature Reviews Clinical Oncology, 2017, 14, 235-246.	27.6	466
2001	Current and future biomarkers in the treatment of colorectal cancer. Acta Clinica Belgica, 2017, 72, 103-115.	1.2	30
2002	Bloodâ€based detection of <i><scp>RAS</scp></i> mutations to guide antiâ€ <scp>EGFR</scp> therapy in colorectal cancer patients: concordance of results from circulating tumor <scp>DNA</scp> and tissueâ€based <i><scp>RAS</scp></i> testing. Molecular Oncology, 2017, 11, 208-219.	4.6	125
2003	The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. Personalized Medicine, 2017, 14, 37-50.	1.5	15
2004	High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab. Clinical and Translational Oncology, 2017, 19, 718-726.	2.4	13
2006	Patient-Derived Xenografts in Oncology. Cancer Drug Discovery and Development, 2017, , 13-40.	0.4	0
2007	Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines. Journal of Cancer Research and Clinical Oncology, 2017, 143, 573-600.	2.5	11
2008	Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer. Future Oncology, 2017, 13, 777-786.	2.4	9
2009	Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Science Translational Medicine, 2017, 9, .	12.4	206
2010	Decision making about healthcare-related tests and diagnostic test strategies. Paper 2: a review of methodological and practical challenges. Journal of Clinical Epidemiology, 2017, 92, 18-28.	5.0	27
2011	Molecular testing of gastrointestinal tumours. Diagnostic Histopathology, 2017, 23, 442-449.	0.4	1
2012	Phase III Clinical Trial Designs Incorporating Predictive Biomarkers: An Overview. , 2017, , 85-103.		0
2013	Molecular Testing of Colorectal Cancer in the Modern Era. Surgical Pathology Clinics, 2017, 10, 1009-1020.	1.7	4
2014	Second-Line Therapy for Advanced Colorectal Cancer: EGFR vs. Continuation of VEGF Inhibition. Current Colorectal Cancer Reports, 2017, 13, 411-418.	0.5	0
2015	Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. British Journal of Cancer, 2017, 117, 1819-1827.	6.4	15
2016	Nanotechnology as a Delivery Tool for Precision Cancer Therapies. AAPS Journal, 2017, 19, 1632-1642.	4.4	9

#	Article	IF	CITATIONS
2017	Cancer Precision Medicine: Why More Is More and DNA Is Not Enough. Public Health Genomics, 2017, 20, 70-80.	1.0	30
2018	Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer. Cancer Biomarkers, 2017, 21, 211-220.	1.7	2
2019	Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E8234-E8243.	7.1	236
2020	Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. Cancer Treatment Reviews, 2017, 60, 109-119.	7.7	45
2021	KRAS Alleles: The Devil Is in the Detail. Trends in Cancer, 2017, 3, 686-697.	7.4	257
2022	Overcoming key biological barriers to cancer drug delivery and efficacy. Journal of Controlled Release, 2017, 267, 15-30.	9.9	92
2023	MET Signaling Mediates Intestinal Crypt-Villus Development, Regeneration, and Adenoma Formation and Is Promoted by Stem Cell CD44 Isoforms. Gastroenterology, 2017, 153, 1040-1053.e4.	1.3	48
2024	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. European Journal of Cancer, 2017, 83, 106-115.	2.8	25
2025	BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. Annals of Oncology, 2017, 28, 2648-2657.	1.2	227
2026	Wild-type blocking pcr coupled with internal competitive amplified fragment improved the detection of rare mutation of KRAS. Molecular Medicine Reports, 2017, 16, 2726-2732.	2.4	3
2027	Association of Coloproctology of Great Britain & Ireland (<scp>ACPGBI</scp>): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) – Multidisciplinary Management. Colorectal Disease, 2017, 19, 37-66.	1.4	77
2028	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. Expert Opinion on Biological Therapy, 2017, 17, 1297-1308.	3.1	21
2029	Targeting ornithine decarboxylase (ODC) inhibits esophageal squamous cell carcinoma progression. Npj Precision Oncology, 2017, 1, 13.	5.4	17
2030	Recent developments in the treatment of metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2017, 9, 551-564.	3.2	82
2031	An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma. Surgical Oncology Clinics of North America, 2017, 26, 667-687.	1.5	24
2032	Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis. Seminars in Oncology, 2017, 44, 114-128.	2.2	14
2033	miR-125a-3p/FUT5-FUT6 axis mediates colorectal cancer cell proliferation, migration, invasion and pathological angiogenesis via PI3K-Akt pathway. Cell Death and Disease, 2017, 8, e2968-e2968.	6.3	101
2034	Robust RNA-based in situ mutation detection delineates colorectal cancer subclonal evolution. Nature Communications, 2017, 8, 1998.	12.8	57
#	Article	IF	Citations
------	--	------	-----------
2035	<i>KRAS</i> Testing, Tumor Location, and Survival in Patients With Stage IV Colorectal Cancer: SEER 2010–2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1484-1493.	4.9	39
2036	Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. Cell, 2017, 171, 1678-1691.e13.	28.9	467
2037	Towards a personalized assessment of pancreatic function in diabetes. Expert Review of Precision Medicine and Drug Development, 2017, 2, 275-285.	0.7	0
2038	Patterns and the Occurrence of KRAS Mutations in Metastatic Colorectal Cancers—a Study from Indian Regional Cancer Centre. Indian Journal of Surgical Oncology, 2017, 8, 511-513.	0.7	4
2039	Can <i>ad hoc</i> analyses of clinical trials help personalize treatment decisions?. British Journal of Clinical Pharmacology, 2017, 83, 2337-2338.	2.4	3
2040	The management of colorectal liver metastases. Clinical Radiology, 2017, 72, 617-625.	1.1	26
2041	Targeting metabolic reprogramming in KRAS-driven cancers. International Journal of Clinical Oncology, 2017, 22, 651-659.	2.2	102
2042	Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. The Cochrane Library, 2017, 6, CD007047.	2.8	60
2043	Lessons Learned from Two Decades of Anticancer Drugs. Trends in Pharmacological Sciences, 2017, 38, 852-872.	8.7	74
2044	Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis. Cancer and Metastasis Reviews, 2017, 36, 395-406.	5.9	25
2045	PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models. Molecular Cancer, 2017, 16, 93.	19.2	18
2046	<i>BRAF</i> Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies. Oncologist, 2017, 22, 864-872.	3.7	56
2047	Genomic profiling of colorectal cancers and the future of personalized treatment. Colorectal Cancer, 2017, 6, 11-22.	0.8	1
2048	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2017, 23, 2414-2422.	7.0	148
2049	The Evolution of Oncology Companion Diagnostics from Signal Transduction to Immuno-Oncology. Trends in Pharmacological Sciences, 2017, 38, 41-54.	8.7	21
2050	Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90. Abdominal Radiology, 2017, 42, 451-459.	2.1	16
2051	Mutant KRAS Status Is Associated with Increased KRAS Copy Number Imbalance: a Potential Mechanism of Molecular Heterogeneity. Pathology and Oncology Research, 2017, 23, 417-423.	1.9	3
2052	Targeting Oncoproteins for Molecular Cancer Therapy. , 2017, , 727-756.		0

#	Article	IF	CITATIONS
2053	Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e253-e261.	1.1	4
2054	Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 31-49.	3.3	52
2055	Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102. Clinical Colorectal Cancer, 2017, 16, 51-57.	2.3	42
2056	Utility of serum antiâ€eetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab. British Journal of Clinical Pharmacology, 2017, 83, 623-631.	2.4	16
2057	Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy. Clinical Colorectal Cancer, 2017, 16, e29-e37.	2.3	12
2058	Chasing the personalized medicine dream through biomarker validation in colorectal cancer. Drug Discovery Today, 2017, 22, 111-119.	6.4	22
2059	K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives. European Journal of Medicinal Chemistry, 2017, 125, 299-314.	5.5	39
2060	Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer. Oncology Letters, 2017, 15, 3161-3166.	1.8	16
2062	Cancer resistance to treatment and antiresistance tools offered by multimodal multifunctional nanoparticles. Cancer Nanotechnology, 2017, 8, 7.	3.7	39
2063	Variations in Transrenal DNA and Comparison with Plasma DNA as a Diagnostic Marker for Colorectal Cancer. International Journal of Biological Markers, 2017, 32, 434-440.	1.8	5
2064	Novel Application of Loop-mediated Isothermal Amplification for Rapid Detection of Gene Translocation. Acta Histochemica Et Cytochemica, 2017, 50, 169-176.	1.6	3
2065	Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. Oncotarget, 2017, 8, 42198-42213.	1.8	49
2066	Clinical Equipoise for Trials of Novel Biologic Therapies, Therapeutic Success Rates, and Predictors of Success: A Meta-Analysis. JCO Precision Oncology, 2017, 1, 1-12.	3.0	1
2067	Techniques for maximizing the performance of molecular pathology testing: responsibilities of all pathologists. Turk Patoloji Dergisi, 2017, 34, 113-126.	0.3	1
2068	Mutations in codons 12 and 13 of K-ras exon 2 in colorectal tumors of Saudi Arabian patients: frequency, clincopathological associations, and clinical outcomes. Genetics and Molecular Research, 2017, 16, .	0.2	8
2069	Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer. International Journal of Molecular Sciences, 2017, 18, 1632.	4.1	46
2070	Beyond chemotherapy for advanced disease—the role of EGFR and PD-1 inhibitors. Translational Andrology and Urology, 2017, 6, 848-854.	1.4	12
2071	Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. International Journal of Molecular Sciences, 2017, 18, 2420.	4.1	102

#	Article	IF	CITATIONS
2072	Cancer as a Paradigm for Translational and Clinical Biomedical Research. , 2017, , 587-607.		0
2073	The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in <i>KRAS</i> -wild-type colorectal cancer. Theranostics, 2017, 7, 1114-1132.	10.0	43
2074	Methylglyoxal-Mediated Stress Correlates with High Metabolic Activity and Promotes Tumor Growth in Colorectal Cancer. International Journal of Molecular Sciences, 2017, 18, 213.	4.1	48
2075	Advance, Adapt, Achieve. Neurosurgery, 2017, 64, 45-51.	1.1	1
2076	In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer. Frontiers in Immunology, 2017, 8, 87.	4.8	43
2077	Current Tissue Molecular Markers in Colorectal Cancer: A Literature Review. BioMed Research International, 2017, 2017, 1-8.	1.9	32
2078	Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs. BioMed Research International, 2017, 2017, 1-38.	1.9	40
2079	The Predictive Effect of Primary Tumour Location in the Treatment of Metastatic Colorectal Cancer: A Canadian Consensus Statement. Current Oncology, 2017, 24, 390-400.	2.2	8
2080	Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts. OncoTargets and Therapy, 2017, Volume 10, 3007-3015.	2.0	19
2081	Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC. OncoTargets and Therapy, 2017, Volume 11, 123-129.	2.0	4
2082	In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer. PLoS ONE, 2017, 12, e0174151.	2.5	25
2083	Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer. PLoS ONE, 2017, 12, e0175409.	2.5	13
2084	Comprehensive benchmarking of SNV callers for highly admixed tumor data. PLoS ONE, 2017, 12, e0186175.	2.5	12
2085	eGARD: Extracting associations between genomic anomalies and drug responses from text. PLoS ONE, 2017, 12, e0189663.	2.5	14
2086	Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review. BMC Cancer, 2017, 17, 798.	2.6	6
2087	Recent advances of bispecific antibodies in solid tumors. Journal of Hematology and Oncology, 2017, 10, 155.	17.0	121
2088	Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer. , 2017, 5, 69.		29
2089	Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. Chinese Journal of Cancer,	4.9	28

#	Article	IF	CITATIONS
2090	BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stageÃ ⁻ ¿½IV colorectal cancer. Oncology Letters, 2017, 15, 2195-2201.	1.8	6
2091	The Effect of EGFR Inhibitor Treatment in KRAS G13D Mutated Metastatic Colorectal Cancer Background. Archives of Surgical Oncology, 2017, 03, .	0.1	1
2092	Promising Biomarkers to Predict the Efficacy of Inhibitors of the Epidermal Growth Factor Receptor Tyrosine Kinase in Head and Neck Squamous Cell Carcinoma. Biomarkers Journal, 2017, 03, .	0.2	0
2093	Toll-like receptor 3 as an immunotherapeutic target for <i>KRAS</i> mutated colorectal cancer. Oncotarget, 2017, 8, 35138-35153.	1.8	22
2094	Molecular Testing for Gastrointestinal Cancer. Journal of Pathology and Translational Medicine, 2017, 51, 103-121.	1.1	54
2095	Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. International Journal of Oncology, 2017, 50, 2049-2058.	3.3	15
2096	Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis. OncoTargets and Therapy, 2017, Volume 10, 945-953.	2.0	32
2097	Molecular Testing in Colorectal Cancer. , 2017, , 305-320.		3
2098	State of Art of Cancer Pharmacogenomics in Latin American Populations. International Journal of Molecular Sciences, 2017, 18, 639.	4.1	25
2099	EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics. Oncotarget, 2017, 8, 17810-17818.	1.8	20
2100	Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence <i>in situ</i> hybridization (FISH) to select the optimal patients for matched therapy?. Oncotarget, 2017, 8, 100863-100898.	1.8	16
2101	Induction with Infliximab and a Plant-Based Diet as First-Line (IPF) Therapy for Crohn Disease: A Single-Group Trial. , 2017, 21, 17-009.		34
2102	Genomics of peritoneal surface malignancies. Journal of Peritoneum (and Other Serosal Surfaces), 2017, , .	0.1	1
2103	Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients. Oncotarget, 2017, 8, 77928-77941.	1.8	11
2104	Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Oncotarget, 2017, 8, 35289-35300.	1.8	51
2105	Impact of Variability in Portal Venous Phase Acquisition Timing in Tumor Density Measurement and Treatment Response Assessment: Metastatic Colorectal Cancer as a Paradigm. JCO Clinical Cancer Informatics, 2017, 1, 1-8.	2.1	17
2106	Clinical Pathways: Management of Quality and Cost in Oncology Networks in the Metastatic Colorectal Cancer Setting. Journal of Oncology Practice, 2017, 13, e522-e529.	2.5	17
2107	Adjuvant Chemotherapy for Stage II Colon Cancer: A Clinical Dilemma. Journal of Oncology Practice, 2017, 13, 233-241.	2.5	138

#	Article	IF	Citations
2108	Not All BRAF-Mutant Metastatic Colorectal Cancers Are Identical: Distinct Clinical Consequences of non-V600BRAF Mutations. Journal of Clinical Oncology, 2017, 35, 2598-2599.	1.6	4
2110	Low expression of the GOPC is a poor prognostic marker in colorectal cancer. Oncology Letters, 2017, 14, 4483-4490.	1.8	8
2111	Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer. Oncotarget, 2017, 8, 55632-55645.	1.8	116
2112	Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment. Journal of Gastrointestinal Oncology, 2017, 8, 405-417.	1.4	17
2113	Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. Journal of Gastrointestinal Oncology, 2017, 8, 199-212.	1.4	26
2114	Current biologics for treatment of biliary tract cancers. Journal of Gastrointestinal Oncology, 2017, 8, 430-440.	1.4	33
2115	Next generation sequencing identifies â€~interactome' signatures in relapsed and refractory metastatic colorectal cancer. Journal of Gastrointestinal Oncology, 2017, 8, 20-31.	1.4	14
2116	Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 65-72.	1.3	23
2117	FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer. Medicine (United States), 2018, 97, e0097.	1.0	7
2118	Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. Expert Review of Anticancer Therapy, 2018, 18, 339-349.	2.4	6
2119	Nanomaterials for Cancer Precision Medicine. Advanced Materials, 2018, 30, e1705660.	21.0	136
2120	Early onset sporadic colorectal cancer: Worrisome trends and oncogenic features. Digestive and Liver Disease, 2018, 50, 521-532.	0.9	65
2121	A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine. British Journal of Cancer, 2018, 118, 1302-1312.	6.4	30
2122	Impairment of Kâ€Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miRâ€143. Cancer Science, 2018, 109, 1455-1467.	3.9	36
2123	Emerging Systemic Therapies for Colorectal Cancer. Clinics in Colon and Rectal Surgery, 2018, 31, 179-191.	1.1	26
2124	Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer. Cytokine and Growth Factor Reviews, 2018, 41, 18-27.	7.2	22
2125	Resistance of Colorectal Tumors to Anti-EGFR Antibodies. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 1-27.	0.1	1
2126	Resistance of Lung Cancer to Kinase Inhibitors Specific to EGFR or ALK. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 29-49.	0.1	0

ARTICLE IF CITATIONS Oxaliplatin rechallenge in metastatic colorectal cancer patients after prior oxaliplatin treatment. 2127 2.5 14 Medical Oncology, 2018, 35, 65. Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San 2128 4.5 José, Costa Rica, August 2016. ESMO Open, 2018, 3, e000315. Should Liquid Biopsies Be Considered in Treatment Decisions?., 2018, , 577-580. 0 2129 Epidemiology and Carcinogenesis of Rectal Cancer., 2018, , 19-35. 2130 Estimating dose-specific cell division and apoptosis rates from chemo-sensitivity experiments. 2131 3.3 5 Scientific Reports, 2018, 8, 2705. A novel cell line generated using the <scp>CRISPR</scp>/Cas9 technology as universal quality control material for <i><scp>KRAS</scp></i> G12V mutation testing. Journal of Clinical Laboratory Analysis, 2.1 2018, 32, e22391. The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Review of 2133 2.4 41 Anticancer Therapy, 2018, 18, 251-266. Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling 2134 4.5 on local tumour progression-free survival. European Radiology, 2018, 28, 2727-2734. Understanding the microbiome: Emerging biomarkers for exploiting the microbiota for personalized 2135 9.6 91 medicine against cancer. Seminars in Cancer Biology, 2018, 52, 1-8. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Annals of 1.2 432 Oncology, 2018, 29, 44-70. Interaction of the Wnt/ \hat{l}^2 -catenin and RAS-ERK pathways involving co-stabilization of both \hat{l}^2 -catenin and RAS plays important roles in the colorectal tumorigenesis. Advances in Biological Regulation, 2018, 2138 2.344 68, 46-54. \hat{l}^2 -Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models. 4.1 Molecular Cancer Therapeutics, 2018, 17, 544-553. Understanding preanalytical variables and their effects on clinical biomarkers of oncology and 2140 9.6 49 immunotherapy. Seminars in Cancer Biology, 2018, 52, 26-38. Drug development and clinical trial design in pancreatico-biliary malignancies. Current Problems in 2141 Cancer, 2018, 42, 73-94. Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal 2142 2 3.3 Cancer: A Meta-analysis. Scientific Reports, 2018, 8, 510. Proteome Heterogeneity in Colorectal Cancer. Proteomics, 2018, 18, 1700169. 2143 2.2 Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid 2144 4.1 81 Tumors. Molecular Cancer Therapeutics, 2018, 17, 3-16. Downregulation of dualâ€specificity phosphatase 4 enhances cell proliferation and invasiveness in 2145 colorectal carcinomas. Cancer Science, 2018, 109, 250-258.

#	Article	IF	CITATIONS
2146	The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine. Cancer, 2018, 124, 1650-1659.	4.1	32
2147	miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. Journal of Hematology and Oncology, 2018, 11, 58.	17.0	98
2148	A simulation study on estimating biomarker–treatment interaction effects in randomized trials with prognostic variables. Trials, 2018, 19, 128.	1.6	1
2149	Targeted data-independent acquisition for mass spectrometric detection of RAS mutations in formalin-fixed, paraffin-embedded tumor biopsies. Journal of Proteomics, 2018, 189, 91-96.	2.4	12
2150	Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?. Future Oncology, 2018, 14, 1223-1231.	2.4	8
2152	Technical Validation of a Reverse-Transcription Quantitative Polymerase Chain Reaction In Vitro Diagnostic Test for the Determination of MiR-31-3p Expression Levels in Formalin-Fixed Paraffin-Embedded Metastatic Colorectal Cancer Tumor Specimens. Biomarker Insights, 2018, 13, 117727191876335.	2.5	17
2154	Genomics Reloaded: Rise of the Expression Profiles. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1-3.	0.8	2
2155	Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. Methods in Molecular Biology, 2018, 1765, 281-297.	0.9	12
2156	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	4.9	476
2157	Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, e331-e352.	2.3	13
2158	Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer. Journal of Cellular Physiology, 2018, 233, 2058-2066.	4.1	61
2159	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. International Journal of Clinical Oncology, 2018, 23, 1-34.	2.2	1,187
2160	Response to: "Consideration of KRAS Mutation Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET, in Patients With Colorectal Liver Metastases― Annals of Surgery, 2018, 268, e9-e10.	4.2	0
2161	Biomarker-driven and molecular targeted therapies for colorectal cancers. Seminars in Oncology, 2018, 45, 124-132.	2.2	9
2162	Association between clinicopathological characteristics and RAS mutation in colorectal cancer. Modern Pathology, 2018, 31, 517-526.	5.5	41
2163	Radiomics in Oncological PET/CT: Clinical Applications. Nuclear Medicine and Molecular Imaging, 2018, 52, 170-189.	1.0	81
2164	Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue. Journal of Clinical Pathology, 2018, 71, 336-343.	2.0	19
2165	Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. Clinical Colorectal Cancer, 2018, 17, 73-79.	2.3	17

#	Article	IF	CITATIONS
2166	Case-only Approach to Identifying Markers Predicting Treatment Effects on the Relative Risk Scale. Biometrics, 2018, 74, 753-763.	1.4	9
2167	Pharmacoepigenetics and pharmacoepigenomics of gastrointestinal cancers. Expert Review of Gastroenterology and Hepatology, 2018, 12, 49-62.	3.0	2
2168	New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. Advances in Anatomic Pathology, 2018, 25, 131-142.	4.3	37
2169	Monoclonal Antibodies Directed against Cadherin RGD Exhibit Therapeutic Activity against Melanoma and Colorectal Cancer Metastasis. Clinical Cancer Research, 2018, 24, 433-444.	7.0	20
2170	Molecular Markers and Mutational Analysis. , 2018, , 295-312.		1
2171	Does the Addition of Biologic Agents to Chemotherapy in Patients with Unresectable Colorectal Cancer Metastases Result in a Higher Proportion of Patients Undergoing Resection? A Systematic Review and Meta-analysis. Journal of Gastrointestinal Surgery, 2018, 22, 523-528.	1.7	3
2172	Biomarkers: Delivering on the expectation of molecularly driven, quantitative health. Experimental Biology and Medicine, 2018, 243, 313-322.	2.4	13
2173	Leptomeningeal Carcinomatosis in Colorectal Cancer: The Mayo Clinic Experience. Clinical Colorectal Cancer, 2018, 17, e183-e187.	2.3	11
2174	Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR. Clinical Chemistry, 2018, 64, 317-328.	3.2	42
2175	Clinical Predictors for KRAS Codon 13 Mutations in Patients With Colorectal Cancer. Journal of Clinical Gastroenterology, 2018, 52, 431-436.	2.2	8
2176	From Ras to Rap and Back, a Journey of 35 Years. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031468.	6.2	16
2177	Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models. Anti-Cancer Drugs, 2018, 29, 827-838.	1.4	9
2178	Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. Oncotarget, 2018, 9, 18698-18711.	1.8	127
2179	Biomarkers in colorectal cancer: Current clinical utility and future perspectives. World Journal of Clinical Cases, 2018, 6, 869-881.	0.8	100
2180	Prokineticin 2 expression as a novel prognostic biomarker for human colorectal cancer. Oncotarget, 2018, 9, 30079-30091.	1.8	12
2181	Hypertension as a Predictor of Advanced Colorectal Cancer Outcome and Cetuximab Treatment Response. Current Oncology, 2018, 25, 516-526.	2.2	8
2182	Colorectal cancer vaccines: Tumor-associated antigens <i>vs</i> neoantigens. World Journal of Gastroenterology, 2018, 24, 5418-5432.	3.3	77
2183	Lauren Histology and Lymphatic Permeation are Critical Prognostic Factors in Borrmann Type I Gastric Cancer. International Surgery, 2018, 103, 95-104.	0.1	1

~		<u> </u>	
		IV F D(DDT
\sim	IIAI	IVE F	

#	Article	IF	CITATIONS
2184	Receptor Tyrosine Kinase-Targeted Cancer Therapy. International Journal of Molecular Sciences, 2018, 19, 3491.	4.1	187
2185	Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. British Journal of Cancer, 2018, 119, 1464-1470.	6.4	62
2186	A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab. Experimental and Molecular Medicine, 2018, 50, 1-12.	7.7	20
2187	Targeting KRAS Mutant CMS3 Subtype by Metabolic Inhibitors. Advances in Experimental Medicine and Biology, 2018, 1110, 23-34.	1.6	7
2188	Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All. Advances in Experimental Medicine and Biology, 2018, 1110, 113-131.	1.6	19
2189	miRNAs as Modulators of EGFR Therapy in Colorectal Cancer. Advances in Experimental Medicine and Biology, 2018, 1110, 133-147.	1.6	4
2190	Targeted Therapy of Colorectal Cancer Subtypes. Advances in Experimental Medicine and Biology, 2018,	1.6	0
2191	Wnt Signalling-Targeted Therapy in the CMS2 Tumour Subtype: A New Paradigm in CRC Treatment?. Advances in Experimental Medicine and Biology, 2018, 1110, 75-100.	1.6	7
2192	How the <i>BRAF</i> V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications. Gastroenterology Research and Practice, 2018, 2018, 1-14.	1.5	34
2193	Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-11.	1.9	33
2194	Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1442-1450.	4.9	6
2195	Evaluation of droplet digital PCR and next generation sequencing for characterizing DNA reference material for KRAS mutation detection. Scientific Reports, 2018, 8, 9650.	3.3	75
2196	Apoptosis Induction of Agave lechuguilla Torrey Extract on Human Lung Adenocarcinoma Cells (SK-LU-1). International Journal of Molecular Sciences, 2018, 19, 3765.	4.1	13
2197	The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab. Recent Patents on Biotechnology, 2018, 12, 101-112.	0.8	12
2198	The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line. Journal of Cancer, 2018, 9, 4255-4262.	2.5	2
2199	Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream. Cancer Management and Research, 2018, Volume 10, 5895-5908.	1.9	18
2200	Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer. Journal of Cancer, 2018, 9, 4092-4098.	2.5	2
2201	A competing-risks nomogram for predicting probability of death from CRC in Chinese Han patients with Stage l–III CRC. Japanese Journal of Clinical Oncology, 2018, 48, 1088-1095.	1.3	9

#	Article	IF	CITATIONS
2202	Mutation analysis of the EGFR pathway genes, <i>EGFR, RAS, PIK3CA, BRAF,</i> and <i>AKT1</i> , in salivary gland adenoid cystic carcinoma. Oncotarget, 2018, 9, 17043-17055.	1.8	17
2203	A comprehensive gene mutation analysis of liquid biopsy samples from patients with metastatic colorectal cancer to the ovary: A case report. Oncology Letters, 2018, 16, 6431-6436.	1.8	7
2204	Characteristics, properties, and potential applications of circulating cell-free dna in clinical diagnostics: a focus on transplantation. Journal of Immunological Methods, 2018, 463, 27-38.	1.4	39
2205	Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions. Journal of Visualized Experiments, 2018, , .	0.3	3
2206	DNA Methylation Predicts the Response of Triple-Negative Breast Cancers to All-Trans Retinoic Acid. Cancers, 2018, 10, 397.	3.7	22
2207	Computational Approaches to Prioritize Cancer Driver Missense Mutations. International Journal of Molecular Sciences, 2018, 19, 2113.	4.1	20
2208	Improving Immunotherapy Through Glycodesign. Frontiers in Immunology, 2018, 9, 2485.	4.8	49
2209	Comprehensive Validation of Snapback Primer-Based Melting Curve Analysis to Detect Nucleotide Variation in the Codon 12 and 13 of KRAS Gene. BioMed Research International, 2018, 2018, 1-13.	1.9	3
2210	Fcâ€gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Medicine, 2018, 7, 5478-5487.	2.8	19
2211	What Is the Best Systemic Therapy for Left-sided RAS Wild-type Metastatic Colorectal Cancer?. Current Colorectal Cancer Reports, 2018, 14, 175-183.	0.5	0
2212	Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis. Targeted Oncology, 2018, 13, 735-743.	3.6	6
2213	An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review. Advances in Therapy, 2018, 35, 1497-1509.	2.9	71
2214	Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis. Cancer Management and Research, 2018, Volume 10, 2915-2924.	1.9	9
2215	Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer. Frontiers in Oncology, 2018, 8, 305.	2.8	15
2216	Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis. Reproductive Medicine and Biology, 2018, 17, 369-397.	2.4	35
2217	Novel β-phenylacrylic acid derivatives exert anti-cancer activity by inducing Src-mediated apoptosis in wild-type KRAS colon cancer. Cell Death and Disease, 2018, 9, 877.	6.3	0
2218	Lowering the P Value Threshold. JAMA - Journal of the American Medical Association, 2018, 320, 935.	7.4	1
2219	Overview of Omics Biomarker Discovery and Design Considerations for Biomarker-Informed Clinical Trials. ICSA Book Series in Statistics, 2018, , 23-52.	0.2	0

#	άρτις ι ε	IF	CITATIONS
" 2220	Development and validation of a nomogram for predicting survival in Chinese han patients with resected colorectal cancer. Journal of Surgical Oncology, 2018, 118, 1034-1041.	1.7	12
2221	Lowering the <i>P</i> Value Threshold—Reply. JAMA - Journal of the American Medical Association, 2018, 320, 937.	7.4	4
2222	SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Nature Medicine, 2018, 24, 961-967.	30.7	244
2223	Growth Suppression of Human Colorectal Cancer Cells with Mutated <i>KRAS</i> by 3-Deaza-cytarabine in 3D Floating Culture. Anticancer Research, 2018, 38, 4247-4256.	1.1	3
2224	Surface microstructures are associated with mutational intratumoral heterogeneity in colorectal tumors. Journal of Gastroenterology, 2018, 53, 1241-1252.	5.1	5
2225	Genomics of Peritoneal Malignancies. Surgical Oncology Clinics of North America, 2018, 27, 463-475.	1.5	14
2226	Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy. Medical Oncology, 2018, 35, 114.	2.5	3
2227	A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells. Molecular and Cellular Proteomics, 2018, 17, 1892-1908.	3.8	13
2228	Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer. Journal of Molecular Diagnostics, 2018, 20, 664-676.	2.8	19
2229	The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (Review). Oncology Letters, 2018, 16, 9-18.	1.8	147
2230	Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer. PLoS ONE, 2018, 13, e0201809.	2.5	20
2231	Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Research, 2018, 78, 5398-5407.	0.9	20
2232	Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer. Cancers, 2018, 10, 35.	3.7	19
2233	Screening for long noncoding RNAs associated with oral squamous cell carcinoma reveals the potentially oncogenic actions of DLEU1. Cell Death and Disease, 2018, 9, 826.	6.3	46
2234	Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer. Frontiers in Medicine, 2018, 5, 9.	2.6	96
2235	Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. Gastroenterology Research and Practice, 2018, 2018, 1-21.	1.5	60
2236	Targeted therapy for metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2018, 18, 991-1006.	2.4	44
2237	Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis. Oncotarget, 2018, 9, 20134-20155.	1.8	46

#	Article	IF	CITATIONS
2238	Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clinical Colorectal Cancer, 2018, 17, e699-e709.	2.3	34
2239	SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients. BMC Cancer, 2018, 18, 479.	2.6	34
2240	Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene, 2018, 37, 4599-4610.	5.9	30
2241	Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC. Future Oncology, 2018, 14, 2437-2459.	2.4	7
2242	Molecular Basis of Colorectal Cancer: Tumor Biology. , 2018, , 23-34.		0
2243	Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in <i>KRAS</i> Wild-Type Metastatic Colorectal Cancer. Clinical Cancer Research, 2018, 24, 3838-3844.	7.0	7
2244	Fos-like antigen 2 (FOSL2) promotes metastasis in colon cancer. Experimental Cell Research, 2018, 373, 57-61.	2.6	24
2245	Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations. PLoS ONE, 2018, 13, e0200836.	2.5	8
2246	Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population. Drug Metabolism and Pharmacokinetics, 2018, 33, 141-149.	2.2	2
2247	Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands. Health Economics Review, 2018, 8, 13.	2.0	10
2248	Direct Visualization of Single-Nucleotide Variation in mtDNA Using a CRISPR/Cas9-Mediated Proximity Ligation Assay. Journal of the American Chemical Society, 2018, 140, 11293-11301.	13.7	106
2249	The tyrosine phosphorylated pro-survival form of Fas intensifies the ECF-induced signal in colorectal cancer cells through the nuclear ECFR/STAT3-mediated pathway. Scientific Reports, 2018, 8, 12424.	3.3	23
2250	Assessing the Impact of Circulating Tumor DNA (ctDNA) in Patients With Colorectal Cancer: Separating Fact From Fiction. Frontiers in Oncology, 2018, 8, 297.	2.8	19
2251	A singleâ€index threshold Cox proportional hazard model for identifying a treatmentâ€sensitive subset based on multiple biomarkers. Statistics in Medicine, 2018, 37, 3267-3279.	1.6	11
2252	Previous Bevacizumab and Efficacy of Later Anti–Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry. Clinical Colorectal Cancer, 2018, 17, e593-e599.	2.3	6
2253	Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer. PLoS ONE, 2018, 13, e0189582.	2.5	16
2254	Harnessing Tumor Evolution to Circumvent Resistance. Trends in Genetics, 2018, 34, 639-651.	6.7	49
2255	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. Clinical Colorectal Cancer, 2018, 17, 313-319.	2.3	9

#	Article	IF	CITATIONS
2256	Impact of Emergent Circulating Tumor DNA <i>RAS</i> Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer. Clinical Cancer Research, 2018, 24, 5602-5609.	7.0	45
2257	Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study. PLoS ONE, 2018, 13, e0190497.	2.5	13
2258	Metabolic Imaging Phenotype Using Radiomics of [18F]FDG PET/CT Associated with Genetic Alterations of Colorectal Cancer. Molecular Imaging and Biology, 2019, 21, 183-190.	2.6	35
2259	Relationship between KRAS mutations and dual time point 18F-FDG PET/CT imaging in colorectal liver metastases. Abdominal Radiology, 2019, 44, 2059-2066.	2.1	16
2260	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut, 2019, 68, 1065-1075.	12.1	195
2261	<p>Precision oncology: lessons learned and challenges for the future</p> . Cancer Management and Research, 2019, Volume 11, 7525-7536.	1.9	10
2262	MET Signaling Overcomes Epidermal Growth Factor Receptor Inhibition in Normal and Colorectal Cancer Stem Cells Causing Drug Resistance. Gastroenterology, 2019, 157, 1153-1155.e1.	1.3	14
2263	U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer. Molecular Cancer Therapeutics, 2019, 18, 2043-2050.	4.1	51
2264	Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nature Communications, 2019, 10, 3722.	12.8	131
2265	Predictive Biomarkers for Monoclonal Antibody Therapies Targeting EGFR (Cetuximab, Panitumumab) in the Treatment of Metastatic Colorectal Cancer. , 2019, , .		2
2266	External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS. BMC Cancer, 2019, 19, 681.	2.6	18
2267	Flavopereirine Suppresses the Growth of Colorectal Cancer Cells through P53 Signaling Dependence. Cancers, 2019, 11, 1034.	3.7	12
2268	<i><scp>RAS</scp></i> and <i><scp>BRAF</scp></i> mutations in cellâ€free <scp>DNA</scp> are predictive for outcome of cetuximab monotherapy in patients with tissueâ€tested <i><scp>RAS</scp></i> wildâ€type advanced colorectal cancer. Molecular Oncology, 2019, 13, 2361-2374.	4.6	32
2269	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. Drugs, 2019, 79, 1375-1394.	10.9	48
2270	Clinical and translational advances in esophageal squamous cell carcinoma. Advances in Cancer Research, 2019, 144, 95-135.	5.0	140
2271	A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. British Journal of Cancer, 2019, 121, 378-383.	6.4	2
2272	Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer. Clinical Cancer Research, 2019, 25, 5852-5858.	7.0	116
2273	Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. Clinical Cancer Research, 2019, 25, 6899-6908.	7.0	76

#	Article	IF	CITATIONS
2274	CT texture analysis for the prediction of KRAS mutation status in colorectal cancer via a machine learning approach. European Journal of Radiology, 2019, 118, 38-43.	2.6	35
2275	Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epithelium. Nature Communications, 2019, 10, 2919.	12.8	70
2276	Establishment of an organoid bank of biliary tract and pancreatic cancers and its application for personalized therapy and future treatment. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1906-1910.	2.8	13
2277	Adoptive T-Cell Therapy for Solid Malignancies. Surgical Oncology Clinics of North America, 2019, 28, 465-479.	1.5	10
2278	The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents. Anticancer Research, 2019, 39, 5645-5652.	1.1	9
2279	Effect of KRAS mutational status on disease behavior and treatment outcome in patients with metastatic colorectal cancer: intratumor heterogeneity and mutational status. Journal of Gastrointestinal Oncology, 2019, 10, 886-895.	1.4	7
2280	Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. Frontiers in Oncology, 2019, 9, 849.	2.8	117
2281	The emergence of drug resistance to targeted cancer therapies: Clinical evidence. Drug Resistance Updates, 2019, 47, 100646.	14.4	81
2282	Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. Critical Reviews in Oncology/Hematology, 2019, 143, 153-163.	4.4	49
2283	EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers. International Journal of Pharmaceutics, 2019, 569, 118605.	5.2	28
2284	KRAS Status as a Predictor of Chemotherapy Activity in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2019, 18, e309-e315.	2.3	14
2285	Quality of Life for Patients With Incurable Stage IV Colorectal Cancer: Randomized Controlled Trial Comparing Resection <i>Versus</i> Endoscopic Stenting. In Vivo, 2019, 33, 2065-2070.	1.3	15
2286	Microsatellite Instability in Greek Colorectal Carcinoma Patients: Clinicopathological and Molecular Correlations. Anticancer Research, 2019, 39, 6379-6387.	1.1	3
2287	Cost-Effectiveness Analysis of Selective First-Line Use of Biologics for Unresectable RAS Wild-Type Left-Sided Metastatic Colorectal Cancer. Current Oncology, 2019, 26, 597-609.	2.2	3
2288	Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. Scientific Reports, 2019, 9, 15365.	3.3	54
2289	Precision medicine in colorectal surgery: coming to a hospital near you. ANZ Journal of Surgery, 2019, 89, 995-996.	0.7	0
2290	Efficacy and safety of antiâ€EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wildâ€type metastatic colorectal cancer: A metaâ€analysis. Journal of Evidence-Based Medicine, 2019, 12, 300-312.	1.8	10
2291	Comparative Efficacy of Preoperative, Postoperative, and Perioperative Treatments for Resectable Colorectal Liver Metastases: A Network Meta-Analysis. Frontiers in Pharmacology, 2019, 10, 1052.	3.5	3

	CHAHON	EPUKI	
#	Article	IF	CITATIONS
2293	Precision Oncology—The Quest for Evidence. Journal of Personalized Medicine, 2019, 9, 43.	2.5	13
2294	Sequencing of RAS/RAF pathway genes in primary colorectal cancer and matched liver and lung metastases. Applied Cancer Research, 2019, 39, .	1.0	2
2295	Negative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead. Journal of Clinical Oncology, 2019, 37, 3066-3068.	1.6	9
2296	EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells. International Journal of Molecular Sciences, 2019, 20, 4693.	4.1	25
2297	Immunotherapy for inoperable gliomas. , 2019, , 181-192.		0
2298	A systems mechanism for KRAS mutant allele–specific responses to targeted therapy. Science Signaling, 2019, 12, .	3.6	42
2299	Cost-Effectiveness Analysis of Cytoreductive Surgery and HIPEC Compared With Systemic Chemotherapy in Isolated Peritoneal Carcinomatosis From Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2019, 26, 1110-1117.	1.5	7
2300	Treatment sequencing in metastatic colorectal cancer. European Journal of Cancer, 2019, 109, 70-83.	2.8	215
2301	Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma. American Journal of Clinical Pathology, 2019, 152, 97-108.	0.7	36
2302	An overview on clinical, pathological and molecular features of lung metastases from colorectal cancer. Expert Review of Respiratory Medicine, 2019, 13, 635-644.	2.5	7
2303	Precision Medicine in Cancer Therapy. Cancer Treatment and Research, 2019, , .	0.5	4
2304	Genomics-Enabled Precision Medicine for Cancer. Cancer Treatment and Research, 2019, 178, 137-169.	0.5	9
2305	Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients. International Journal of Molecular Sciences, 2019, 20, 2919.	4.1	36
2306	Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. Scientific Reports, 2019, 9, 8976.	3.3	34
2307	Decoding Metastatic Colorectal Cancer to Improve Clinical Decision Making. Journal of Clinical Oncology, 2019, 37, 1847-1850.	1.6	5
2308	A mutation analysis of the EGFR pathway genes, <i>RAS</i> , <i>EGFR</i> , <i>PIK3CA</i> , <i>AKT1</i> and <i>BRAF</i> , and <i>TP53</i> gene in thymic carcinoma and thymoma type A/B3. Histopathology, 2019, 75, 755-766.	2.9	28
2309	Reduced Frequency and Prognostic Significance of Ring Finger Protein 43 Nucleotide Polymorphisms in a Chinese Colorectal Cancer Cohort. DNA and Cell Biology, 2019, 38, 541-548.	1.9	3
2310	Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial. BMC Cancer, 2019, 19, 552.	2.6	13

#	Article	IF	CITATIONS
2311	Effects of 5-FU and anti-EGFR antibody in combination with ASA on the spherical culture system of HCT116 and HT29 colorectal cancer cell lines. International Journal of Oncology, 2019, 55, 223-242.	3.3	12
2312	Colorectal Cancer Research: A State of theÂArt. Hot Topics in Acute Care Surgery and Trauma, 2019, , 1-13.	0.1	1
2313	RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score. Annals of Surgical Oncology, 2019, 26, 2595-2604.	1.5	25
2314	Statin uses and mortality in colorectal cancer patients: An updated systematic review and metaâ€analysis. Cancer Medicine, 2019, 8, 3305-3313.	2.8	49
2315	Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 207-215.	3.8	17
2316	Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer. Journal of Translational Medicine, 2019, 17, 137.	4.4	13
2317	Systemic Therapy for Advanced and Metastatic Colon Cancer. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2019, 73, 202.	0.4	1
2318	Polymerase Chain Reaction. , 2019, , 111-133.		1
2319	Economic Evaluation of Companion and Complementary Diagnostics. , 2019, , 381-398.		1
2320	[famâ€] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on <i>HER2</i> amplification. International Journal of Cancer, 2019, 145, 3414-3424.	5.1	62
2321	Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma. Cell Reports, 2019, 27, 1265-1276.e4.	6.4	137
2322	Dual Targeting of Y-Box Binding Protein-1 and Akt Inhibits Proliferation and Enhances the Chemosensitivity of Colorectal Cancer Cells. Cancers, 2019, 11, 562.	3.7	15
2323	Acute Respiratory Distress Syndrome Phenotypes. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 019-030.	2.1	83
2324	Challenges and solutions in patient treatment strategies for stage II colon cancer. Gastroenterology Report, 2019, 7, 151-161.	1.3	41
2325	3′-Deoxy-3'-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1713-1722.	6.4	8
2326	Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC) Tj ETQq1 1 0.78	4 3. 54 rgB]	Dverlock
2327	Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. JCO Precision Oncology, 2019, 3, 1-16.	3.0	30
2328	Atlas Drugged. Cell, 2019, 177, 803-805.	28.9	1

#	Article	IF	Citations
2329	Association between oncogenic RAS mutation and radiologic-pathologic findings in patients with primary rectal cancer. Quantitative Imaging in Medicine and Surgery, 2019, 9, 238-246.	2.0	14
2330	Examining the heterogeneity of treatment patterns in attention deficit hyperactivity disorder among children and adolescents in the Texas Medicaid population: modeling suboptimal treatment response. Journal of Medical Economics, 2019, 22, 788-797.	2.1	1
2331	Transcriptome Alterations in Liver Metastases of Colorectal Cancer After Acquired Resistance to Cetuximab. Cancer Genomics and Proteomics, 2019, 16, 207-219.	2.0	13
2332	Sensitive and selective detections of codon 12 and 13 KRAS mutations in a single tube using modified wild-type blocker. Clinica Chimica Acta, 2019, 494, 123-131.	1.1	3
2333	Cancer Treatment in the Genomic Era. Annual Review of Biochemistry, 2019, 88, 247-280.	11.1	24
2334	Relationships among <i>KRAS</i> mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer. World Journal of Gastroenterology, 2019, 25, 808-823.	3.3	28
2335	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. Molecular Cancer Therapeutics, 2019, 18, 845-855.	4.1	58
2336	An ultrasensitive and simple fluorescence biosensor for detection of the <i>Kras</i> wild type by using the three-way DNA junction-driven catalyzed hairpin assembly strategy. Analyst, The, 2019, 144, 3088-3093.	3.5	11
2337	Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies. Current Colorectal Cancer Reports, 2019, 15, 53-60.	0.5	4
2338	ENKUR Is Involved in the Regulation of Cellular Biology in Colorectal Cancer Cells via PI3K/Akt Signaling Pathway. Technology in Cancer Research and Treatment, 2019, 18, 153303381984143.	1.9	8
2339	Rab5C enhances resistance to ionizing radiation in rectal cancer. Journal of Molecular Medicine, 2019, 97, 855-869.	3.9	16
2340	<p>SUVmax and metabolic tumor volume: surrogate image biomarkers of KRAS mutation status in colorectal cancer</p> . OncoTargets and Therapy, 2019, Volume 12, 2115-2121.	2.0	13
2341	Update on systemic therapy for colorectal cancer: biologics take sides. Translational Gastroenterology and Hepatology, 2019, 4, 9-9.	3.0	22
2342	Clinical development of targeted and immune based anti-cancer therapies. Journal of Experimental and Clinical Cancer Research, 2019, 38, 156.	8.6	170
2343	Ramucirumab: the long and winding road toward being an option for mCRC treatment. Expert Opinion on Biological Therapy, 2019, 19, 399-409.	3.1	6
2344	Impact of primary colorectal Cancer location on the KRAS status and its prognostic value. BMC Gastroenterology, 2019, 19, 46.	2.0	36
2345	Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. Journal of Hepatology, 2019, 70, 1262-1277.	3.7	150
2346	RAS Mutation Status Confers Prognostic Relevance in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer. Journal of Surgical Research, 2019, 240, 130-135.	1.6	13

#	Article	IF	CITATIONS
2347	Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety. International Journal of Clinical Oncology, 2019, 24, 836-841.	2.2	3
2348	Combination of KIR2DS4 and FcÎ ³ RIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer. Scientific Reports, 2019, 9, 2589.	3.3	9
2349	Systemic treatment for metastatic colorectal cancer in the era of precision medicine. Journal of Surgical Oncology, 2019, 119, 564-582.	1.7	55
2350	Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells. FEBS Journal, 2019, 286, 1305-1318.	4.7	31
2351	Clinicopathological characterization of SMAD4-mutated intestinal adenocarcinomas: A case-control study. PLoS ONE, 2019, 14, e0212142.	2.5	23
2352	The Developing Story of Predictive Biomarkers in Colorectal Cancer. Journal of Personalized Medicine, 2019, 9, 12.	2.5	111
2353	Bevacizumab Combined With Oxaliplatin/Capecitabine in Patient With Refractory and Recurrent Mucinous Adenocarcinoma of the Appendix: A Case Report. Frontiers in Oncology, 2019, 9, 55.	2.8	7
2354	How we treat metastatic colorectal cancer. ESMO Open, 2019, 4, e000813.	4.5	49
2355	Integrating Osteopathic Philosophy in Cancer Care. Journal of Osteopathic Medicine, 2019, 119, 391-394.	0.8	4
2356	Report from the 20th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28–29 September 2018. Current Oncology, 2019, 26, 773-784.	2.2	1
2357	Anti-epidermal growth factor receptor therapy for glioblastoma in adults. The Cochrane Library, 2019,	2.8	4
2359	Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR. BMC Medical Genomics, 2019, 12, 162.	1.5	17
2360	Comprehensive Analysis of the Expression Profiles of Long Non-Coding RNAs with Associated ceRNA Network Involved in the Colon Cancer Staging and Progression. Scientific Reports, 2019, 9, 16910.	3.3	19
2361	Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer. Growth Factors, 2019, 37, 209-225.	1.7	6
2362	Emergence of KRAS p.G13D mutation and acquired resistance to cetuximab in colorectal cancer with vulvar metastasis. Medicine (United States), 2019, 98, e18423.	1.0	3
2363	Circulating Tumour Cells, Circulating Tumour DNA and Circulating Tumour miRNA in Blood Assays in the Different Steps of Colorectal Cancer Management, a Review of the Evidence in 2019. BioMed Research International, 2019, 2019, 1-11.	1.9	12
2364	GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up. Frontiers in Oncology, 2019, 9, 1102.	2.8	15
2365	A view on drug resistance in cancer. Nature, 2019, 575, 299-309.	27.8	1,391

	CITATION REF	PORT	
Article		IF	Citations
The Evolving Landscape of Cancer Therapeutics. Handbook of Experimental Pharmaco 43-79.	logy, 2019, 260,	1.8	10
Colorectal Cancer Stratification in the Routine Clinical Pathway: A District General Hos Experience. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, e54	spital -e62.	1.2	7
From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Ba Umbrella Clinical Trial Designs in Cancer Drug Development. Cancer Journal (Sudbury, 245-253.	isket and Mass), 2019, 25,	2.0	4
Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic M Metastatic Colorectal Cancer Patients Treated With FOLFIRI. Frontiers in Oncology, 20	1arkers in)19, 9, 1312.	2.8	14
KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jor 2019, 14, e0226473.	dan. PLoS ONE,	2.5	7
The Translational Status of Cancer Liquid Biopsies. Regenerative Engineering and Tran Medicine, 2021, 7, 312-352.	slational	2.9	39
Resection or Stenting in the Treatment of Symptomatic Advanced Metastatic Rectal C Anticancer Research, 2019, 39, 6781-6786.	ancer: A Dilemma.	1.1	5
Optimizing Biologic Sequencing in Metastatic Colorectal Cancer: First Line and Beyon Oncology, 2019, 26, 33-42.	d. Current	2.2	7
Genome Sequencing during a Patient's Journey through Cancer. New England Jour 2019, 381, 2145-2156.	nal of Medicine,	27.0	50
Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision One Phenotypic Data. Cancers, 2019, 11, 1907.	cology with	3.7	12
Current and Emerging Biomarkers in Metastatic Colorectal Cancer. Current Oncology,	2019, 26, 7-15.	2.2	31
Selective Delivery of Doxorubicin to EGFR ⁺ Cancer Cells by Cetuximabâ€ ChemBioChem, 2019, 20, 1014-1018.	"DNA Conjugates.	2.6	19
Synthesis and anti-tumor activity of imidazopyrazines as TAK1 inhibitors. European Jou Medicinal Chemistry, 2019, 163, 660-670.	ırnal of	5.5	10
Diagnostic performance of F-18 FDG PET/CT for prediction of KRAS mutation in colore patients: a systematic review and meta-analysis. Abdominal Radiology, 2019, 44, 1703	ctal cancer 3-1711.	2.1	16
Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metas Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and C Colorectal Cancer, 2019, 18, e140-e149.	tatic O.20. Clinical	2.3	5

2381	Phenotypes in acute respiratory distress syndrome: moving towards precision medicine. Current Opinion in Critical Care, 2019, 25, 12-20.	3.2
2382	Resistance to EGFR Targeting Treatments in Colorectal Cancer. , 2019, , 257-269.	

Regional differences in gallbladder cancer pathogenesis: Insights from a multiâ€institutional comparison of tumor mutations. Cancer, 2019, 125, 575-585. 4.1 34

1

#

2366

2368

2370

2371

2372

2374

2376

2378

2379

2380

ARTICLE IF CITATIONS Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR 2384 1.2 170 re-challenge. Annals of Oncology, 2019, 30, 243-249. Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review 2.1 and meta-analysis. International Journal of Clinical Pharmacy, 2019, 41, 30-41. Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with 2386 RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 1.0 20 41/10. Journal of Geriatric Oncology, 2019, 10, 304-310. A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic 1.1 Colorectal Cancer. Anticancer Research, 2019, 39, 245-252. Genomic landscape of synchronous tubulovillous adenoma and multiple non-familial colon cancers 2388 0.4 1 from a single patient. Cancer Genetics, 2019, 231-232, 54-61. Molecular mechanism of SSFA2 deletion inhibiting cell proliferation and promoting cell apoptosis in 2389 2.3 glioma. Pathology Research and Practice, 2019, 215, 600-606. Development of Isoselenocyanate Compounds' Syntheses and Biological Applications. Journal of 2390 6.4 29 Medicinal Chemistry, 2019, 62, 5261-5275. Multiplex assay for multiomics advances in personalized-precision medicine. Journal of Immunoassay 1.1 and Immunochemistry, 2019, 40, 3-25. Bioinformatics Analysis of Whole Exome Sequencing Data. Methods in Molecular Biology, 2019, 1881, 2393 0.9 29 277-318. Plasma Dynamics of RAS/RAF Mutations in Patients With Metastatic Colorectal Cancer Receiving 2394 2.3 Chemotherapy and Anti-EGFR Treatment. Clinical Colorectal Cancer, 2019, 18, 28-33.e3. Panitumumab Provides Better Survival Outcomes Compared to Cetuximab for Metastatic Colorectal 2395 3 1.9 Cancer Patients Treated with Prior Bevacizumab within 6 Months. Oncology, 2019, 96, 132-139. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment. Investigational 2396 2.6 New Drugs, 2019, 37, 175-183. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse 2397 sequence for previously treated metastatic colorectal cancer patients. Annals of Oncology, 2019, 30, 1.2 56 259-265. New concepts in the diagnosis and management of choroidal metastases. Progress in Retinal and Eye 2398 15.5 Research, 2019, 68, 144-176. Durable complete remission following anti-EGFR antibodies in recurrent metastatic colorectal 2399 0.9 2 cancer. Journal of Oncology Pharmacy Practice, 2019, 25, 239-243. Real-time PCR-based method for the rapid detection of extended RAS mutations using bridged nucleic 2400 1.1 acids in colorectal cancer. Clinica Chimica Acta, 2019, 489, 164-168. Associations Between Molecular Classifications of Colorectal Cancer and Patient Survival: A 2401 4.4 44 Systematic Review. Clinical Gastroenterology and Hepatology, 2019, 17, 402-410.e2. Targeting the RAS-dependent chemoresistance: The Warburg connection. Seminars in Cancer Biology, 2402 2019, 54, 80-90.

ARTICLE IF CITATIONS Small change, big effect: Taking RAS by the tail through suppression of post-prenylation 2403 3 1.6 carboxylmethylation. Small GTPases, 2020, 11, 271-279. Metastatic Profile of Colorectal Cancer: Interplay Between Primary Tumor Location and KRAS Status. 2404 1.6 Journal of Surgical Research, 2020, 246, 325-334. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of 2405 2.2 1.123 colorectal cancer. International Journal of Clinical Oncology, 2020, 25, 1-42. Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A 2406 0.3 Systematic Review. Value in Health, 2020, 23, 114-126. The extended spectrum of RASâ€MAPK pathway mutations in colorectal cancer. Genes Chromosomes and 2407 2.8 11 Cancer, 2020, 59, 152-159. Pathology, Biomarkers, and Molecular Diagnostics., 2020, , 225-253.e8. CD16â€158â€valine chimeric receptor T cells overcome the resistance of KRASâ€mutated colorectal 2409 5.1 15 carcinoma cells to cetuximab. International Journal of Cancer, 2020, 146, 2531-2538. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nature Reviews Clinical 2410 27.6 Oncology, 2020, 17, 11-32. Current Development of Monoclonal Antibodies in Cancer Therapy. Recent Results in Cancer 2411 1.8 16 Research, 2020, 214, 1-70. Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer. 2412 Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 2.8 391-398. Mutated RAS: Targeting the "Untargetable―with T Cells. Clinical Cancer Research, 2020, 26, 537-544. 2413 7.025 Designing clinical studies for biomarker discovery: The Design criteria., 2020, , 441-466. 2414 2415 Gene therapies not related to immunological therapies. , 2020, , 439-451. 0 Utility-Based Interim Decision Rule Planning in Adaptive Population Selection Designs With Survival 2416 0.8 Endpoints. Statistics in Biopharmaceutical Research, 2020, 12, 360-368. Genomics and the History of Precision Oncology. Surgical Oncology Clinics of North America, 2020, 2417 23 1.5 29, 35-49. Impact of KRAS mutation status on outcomes of metastatic colorectal cancer treated with 2418 anti-angiogenic agents: a meta-analysis. Journal of Chemotherapy, 2020, 32, 41-48. Liver Metastases. , 2020, , 846-862.e4. 2419 2 SSIPe: accurately estimating protein–protein binding affinity change upon mutations using evolutionary profiles in combination with an optimized physical energy function. Bioinformatics, 4.1 2020, 36, 2429-2437.

#	Article	IF	CITATIONS
2421	Methods and resources to access mutation-dependent effects on cancer drug treatment. Briefings in Bioinformatics, 2020, 21, 1886-1903.	6.5	5
2423	KRAS mutation status concordance between the primary tumor and the corresponding metastasis in patients with rectal cancer. PLoS ONE, 2020, 15, e0239806.	2.5	7
2424	Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing. , 2020, , .		0
2425	Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges. Oncogenesis, 2020, 9, 66.	4.9	52
2426	Molecular Profiling of Advanced Malignancies: A Community Oncology Network Experience and Review of Literature. Frontiers in Medicine, 2020, 7, 314.	2.6	3
2427	Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Gastroenterology Report, 2020, 8, 179-191.	1.3	60
2428	KRAS: From undruggable to a druggable Cancer Target. Cancer Treatment Reviews, 2020, 89, 102070.	7.7	136
2429	Personalised mapping of tumour development in synchronous colorectal cancer patients. Npj Genomic Medicine, 2020, 5, 27.	3.8	4
2430	The Role of BRAF in Metastatic Colorectal Carcinoma–Past, Present, and Future. International Journal of Molecular Sciences, 2020, 21, 9001.	4.1	8
2432	Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors. Cell Communication and Signaling, 2020, 18, 179.	6.5	9
2433	The role of circulating tumor cells and K-ras mutations in patients with locally advanced rectal cancer: a prospective study. Molecular Biology Reports, 2020, 47, 9645-9657.	2.3	6
2434	In Silico Drug Repositioning Using Omics Data: The Potential and Pitfalls. , 2020, , 929-947.		0
2435	AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer. Cell Communication and Signaling, 2020, 18, 115.	6.5	17
2436	The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells. Frontiers in Oncology, 2020, 10, 1249.	2.8	97
2437	Distant Metastasis in Colorectal Cancer Patients—Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review. International Journal of Molecular Sciences, 2020, 21, 5255.	4.1	38
2438	Biomarkers in Colorectal Cancer: Current Research and Future Prospects. International Journal of Molecular Sciences, 2020, 21, 5311.	4.1	120
2439	Mutant <i>KRAS</i> Promotes NKG2D ⁺ T Cell Infiltration and CD155 Dependent Immune Evasion. Anticancer Research, 2020, 40, 4663-4674.	1.1	6
2440	Improving the Efficacy of Tumor Radiosensitization Through Combined Molecular Targeting. Frontiers in Oncology, 2020, 10, 1260.	2.8	15

#	Article	IF	CITATIONS
2441	Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype. Science Translational Medicine, 2020, 12, .	12.4	40
2442	Subphenotypes in critical care: translation into clinical practice. Lancet Respiratory Medicine,the, 2020, 8, 631-643.	10.7	117
2443	Recent technologies enhancing the clinical utility of circulating tumor DNA. Clinica Chimica Acta, 2020, 510, 498-506.	1.1	3
2444	MK615 Suppresses Hypoxia Tolerance by Up-regulation of E-cadherin in Colorectal Cancer Cells With Mutant KRAS. Anticancer Research, 2020, 40, 4687-4694.	1.1	3
2445	Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on <i>KRAS-</i> mutated human colon cancer cell lines with different microsatellite instability. Journal of Chemotherapy, 2020, 32, 437-444.	1.5	2
2446	The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases. Cancers, 2020, 12, 2434.	3.7	19
2447	Menin-mediated Repression of Glycolysis in Combination with Autophagy Protects Colon Cancer Against Small-molecule EGFR Inhibitors. Molecular Cancer Therapeutics, 2020, 19, 2319-2329.	4.1	3
2448	Organoid in colorectal cancer: progress and challenges. Chinese Medical Journal, 2020, 133, 1971-1977.	2.3	14
2449	Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate. Molecular Cancer Therapeutics, 2020, 19, 2117-2125.	4.1	30
2450	KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples. Translational Lung Cancer Research, 2020, 9, 1759-1769.	2.8	33
2451	Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer. Cancer Genomics and Proteomics, 2020, 17, 605-613.	2.0	6
2452	Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. British Journal of Cancer, 2020, 123, 1502-1512.	6.4	14
2453	Diffusion-Weighted MRI and Diffusion Kurtosis Imaging to Detect RAS Mutation in Colorectal Liver Metastasis. Cancers, 2020, 12, 2420.	3.7	42
2454	Prognosis of Synchronous Colorectal Liver Metastases After Simultaneous Curative-Intent Surgery According to Primary Tumor Location and KRAS Mutational Status. Annals of Surgical Oncology, 2020, 27, 5150-5158.	1.5	8
2455	ASO Author Reflections: Poorest Survival Outcomes in Patients with Right Colon Cancer with KRAS Mutation After Simultaneous Curative-Intent Surgery for Colorectal Cancer Liver Metastases. Annals of Surgical Oncology, 2020, 27, 5159-5160.	1.5	0
2456	Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy. Cancers, 2020, 12, 3736.	3.7	6
2457	Germline and somatic genetic alterations in two firstâ€degree relatives with appendiceal lowâ€grade mucinous carcinoma peritonei. Clinical Case Reports (discontinued), 2020, 8, 3168-3177.	0.5	3
2458	The role of IgE specific for galactose-α-1,3-galactose in predicting cetuximab induced hypersensitivity reaction: a systematic review and a diagnostic meta-analysis. Scientific Reports, 2020, 10, 21355.	3.3	10

ARTICLE IF CITATIONS Sequencing of Dna Isolated From Colorectal Sample Fixed in Liquid Formalin : Obstacles and Required 2459 0.4 0 Modifications. Dhaka University Journal of Biological Sciences, 2020, 29, 165-174. Evolution of <i>RAS</i> testing over time: factors influencing mutation rates in metastatic 2460 0.8 colorectal cancer patients. Colorectal Cancer, 2020, 9, . BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers, 2020, 2461 3.7 23 12, 3236. The relationship between KRAS gene mutation and intestinal flora in tumor tissues of colorectal 2463 cancer patients. Annals of Translational Medicine, 2020, 8, 1085-1085. Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. 2464 2.4 13 Clinical and Translational Oncology, 2020, 22, 1976-1991. The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer. Clinical Cancer Research, 2020, 26, 4313-4325. Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type 2466 3.7 19 Metastatic Colorectal Cancer: The Multicenter "SLAVE―Study. Cancers, 2020, 12, 1259. Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal 2467 Metastases to Direct Personalized Therapy. Clinical Cancer Research, 2020, 26, 3662-3670. Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic 2468 2.9 2 Colorectal Cancer: A Single-Institute Prospective Study. Advances in Therapy, 2020, 37, 2829-2840. The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the 2469 2.2 difference. International Journal of Colorectal Disease, 2020, 35, 1513-1527. Malignant Transformation and Associated Biomarkers of Ovarian Endometriosis: A Narrative Review. 2470 2.9 27 Advances in Therapy, 2020, 37, 2580-2603. Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of 2471 2.6 KRAS or BRAF mutations, irrespective of quantity of mucinous component. BMC Cancer, 2020, 20, 400. A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of 2472 4.1 14 Response to PI3K Inhibition in Pancreatic Cancer. Molecular Cancer Therapeutics, 2020, 19, 1423-1435. Anti-epidermal growth factor receptor therapy for glioblastoma in adults. The Cochrane Library, 2473 2.8 2020, 2020, CD013238. Oncogenic miRNAs and target therapies in colorectal cancer. Clinica Chimica Acta, 2020, 508, 77-91. 32 2474 1.1 The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal 2475 Cancer Patients: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2020, 11, 706. MLH1 Deficiency Induces Cetuximab Resistance in Colon Cancer via Herâ€2/PI3K/AKT Signaling. Advanced 2476 11.2 22 Science, 2020, 7, 2000112. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. Translational 2477 Oncology, 2020, 13, 100795.

		CITATION RE	EPORT	
#	ARTICLE	482.402	IF	Citations
2478	Genomics-guided pre-clinical development of cancer therapies. Nature Cancer, 2020, 1	., 482-492.	13.2	23
2479	Characterization of the Spatial Organization of Raf Isoforms Interacting with K-Ras4B i Membrane. Langmuir, 2020, 36, 5944-5953.	n the Lipid	3.5	6
2480	RAS-targeted therapies: is the undruggable drugged?. Nature Reviews Drug Discovery,	2020, 19, 533-552.	46.4	569
2481	Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-ga Oncogenesis, 2020, 9, 59.	imma.	4.9	6
2482	Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irino with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinote oxaliplatin (WJOG 6510G). European Journal of Cancer, 2020, 135, 11-21.	otecan in patients ecanÂand	2.8	14
2483	Drastic Reduction of Turnaround Time After Implementation of a Fully Automated Assa Mutations in Colorectal Cancer: A Pilot Prospective Study in Real-life Conditions. Patho Oncology Research, 2020, 26, 2469-2473.	ay for RAS-BRAF blogy and	1.9	2
2484	Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colo patients. Cancer Immunology, Immunotherapy, 2020, 69, 2533-2546.	prectal cancer	4.2	31
2485	Changes to aspects of ongoing randomised controlled trials with fixed designs. Trials, 2	2020, 21, 457.	1.6	5
2486	Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Group Expert Opinion. Clinical Colorectal Cancer, 2020, 19, 165-177.	Spanish TTD	2.3	15
2487	Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachm Targeting Ligands to a Universal Immune Receptor. Journal of the American Chemical S 6554-6568.	ent of Society, 2020, 142,	13.7	36
2488	Circulating tumor DNA and liquid biopsy in oncology. Nature Cancer, 2020, 1, 276-290).	13.2	309
2489	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert r congress 2019. Expert Review of Anticancer Therapy, 2020, 20, 251-270.	neeting: ESMO	2.4	4
2490	Decoding the Genomic Report for Radiologists. American Journal of Roentgenology, 20)20, 214, 949-961.	2.2	0
2491	A threshold linear mixed model for identification of treatment-sensitive subsets in a cli based on longitudinal outcomes and a continuous covariate. Statistical Methods in Me 2020, 29, 2919-2931.	nical trial edical Research,	1.5	7
2492	ls There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis. Colorectal Cancer, 2020, 19, 82-90.e9.	Clinical	2.3	6
2493	Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic cancer: results of the phase II North Central Cancer Treatment Group study N054C (Al Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091091.	colorectal liance).	3.2	12
2494	An enzymatic on/off switchâ€mediated assay for KRAS hotspot point mutation detecti tumor DNA. Journal of Clinical Laboratory Analysis, 2020, 34, e23305.	ion of circulating	2.1	3
2495	Immunogenic cell death in colon cancer prevention and therapy. Molecular Carcinoger 783-793.	nesis, 2020, 59,	2.7	65

#	Article	IF	CITATIONS
2496	Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer. Cancers, 2020, 12, 812.	3.7	30
2497	Gene editing particle system as a therapeutic approach for drug-resistant colorectal cancer. Nano Research, 2020, 13, 1576-1585.	10.4	9
2498	Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. Journal of Surgical Oncology, 2020, 121, 1320-1328.	1.7	16
2499	The Function and Prognostic Significance of Cripto-1 in Colorectal Cancer. Cancer Investigation, 2020, 38, 214-227.	1.3	6
2500	Preclinical Evaluation of Cetuximab and Benzoporphyrin Derivativeâ€Mediated Intraperitoneal Photodynamic Therapy in a Canine Model. Photochemistry and Photobiology, 2020, 96, 684-691.	2.5	7
2501	Development and validation of a Super learner-based model for predicting survival in Chinese Han patients with resected colorectal cancer. Japanese Journal of Clinical Oncology, 2020, 50, 1133-1140.	1.3	3
2502	KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location. Pathology and Oncology Research, 2020, 26, 2537-2548.	1.9	7
2503	Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer. Neoplasia, 2020, 22, 365-375.	5.3	7
2504	B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncology, 2020, 16, 1767-1791.	2.4	16
2505	Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G. Cancers, 2020, 12, 1715.	3.7	7
2506	PNA Clamping in Nucleic Acid Amplification Protocols to Detect Single Nucleotide Mutations Related to Cancer. Molecules, 2020, 25, 786.	3.8	19
2507	Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?. International Journal of Colorectal Disease, 2020, 35, 739-746.	2.2	12
2508	RNA expression and risk of venous thromboembolism in lung cancer. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 117-123.	2.3	9
2509	KRAS mutations by digital PCR in circulating tumor cells isolated from the mesenteric vein are associated with residual disease and overall survival in resected colorectal cancer patients. International Journal of Colorectal Disease, 2020, 35, 805-813.	2.2	2
2510	Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling. Frontiers in Oncology, 2020, 9, 1559.	2.8	0
2511	Relationship between KRAS mutation and diffusion weighted imaging in colorectal liver metastases; Preliminary study. European Journal of Radiology, 2020, 125, 108895.	2.6	9
2512	Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants. Trends in Cancer, 2020, 6, 111-129.	7.4	9
2513	mRECIST for HCC: Performance and novel refinements. Journal of Hepatology, 2020, 72, 288-306.	3.7	292

#	Article	IF	CITATIONS
2514	Modeling rectal cancer to advance neoadjuvant precision therapy. International Journal of Cancer, 2020, 147, 1405-1418.	5.1	25
2515	Current Understanding of Urachal Adenocarcinoma and Management Strategy. Current Oncology Reports, 2020, 22, 9.	4.0	23
2516	Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. Lancet, The, 2020, 395, 350-360.	13.7	364
2517	Effects of propofol on colon cancer metastasis through STAT3/HOTAIR axis by activating WIFâ€1 and suppressing Wnt pathway. Cancer Medicine, 2020, 9, 1842-1854.	2.8	48
2518	Latency and interval therapy affect the evolution in metastatic colorectal cancer. Scientific Reports, 2020, 10, 581.	3.3	6
2519	Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting ECFR Pathway. Journal of the National Cancer Institute, 2020, 112, 902-912.	6.3	93
2520	The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. Cancer Cell International, 2020, 20, 30.	4.1	63
2521	Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges. Cancers, 2020, 12, 319.	3.7	141
2522	Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy. Cancer Genomics and Proteomics, 2020, 17, 277-290.	2.0	4
2524	Realizing Cancer Precision Medicine by Integrating Systems Biology and Nanomaterial Engineering. Advanced Materials, 2020, 32, e1906783.	21.0	21
2525	Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1625-1645.	2.5	14
2526	<i>KLF4</i> p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer. Molecular Cancer Therapeutics, 2020, 19, 956-965.	4.1	5
2527	A dose-finding approach for genomic patterns in phase I trials. Journal of Biopharmaceutical Statistics, 2020, 30, 834-853.	0.8	0
2528	Role of FOXO3A in Trastuzumab Combination Chemotherapy in Esophageal Squamous Cell Carcinoma. Anticancer Research, 2020, 40, 1921-1930.	1.1	1
2529	The Use of Genomics to Drive Kidney Disease Drug Discovery and Development. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1342-1351.	4.5	5
2530	Mechanisms of Resistance to NK Cell Immunotherapy. Cancers, 2020, 12, 893.	3.7	34
2531	miR-1285-3p Controls Colorectal Cancer Proliferation and Escape from Apoptosis through DAPK2. International Journal of Molecular Sciences, 2020, 21, 2423.	4.1	12
2532	The unique immune microenvironment of liver metastases: Challenges and opportunities. Seminars in Cancer Biology, 2021, 71, 143-156.	9.6	35

#	Article	IF	CITATIONS
2533	Biomarkers for predicting the outcome of various cancer immunotherapies. Critical Reviews in Oncology/Hematology, 2021, 157, 103161.	4.4	10
2534	Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation. Cancer Immunology, Immunotherapy, 2021, 70, 177-188.	4.2	13
2535	Development of a dual-energy spectral CT based nomogram for the preoperative discrimination of mutated and wild-type KRAS in patients with colorectal cancer. Clinical Imaging, 2021, 69, 205-212.	1.5	12
2536	It's in Our Blood: A Glimpse of Personalized Medicine. Trends in Molecular Medicine, 2021, 27, 20-30.	6.7	26
2537	Expanded Low Allele Frequency <i>RAS</i> and <i>BRAF</i> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. Clinical Cancer Research, 2021, 27, 52-59.	7.0	12
2538	Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway. European Journal of Medicinal Chemistry, 2021, 211, 113006.	5.5	13
2539	Neratinib-Plus-Cetuximab in Quadruple-WT (<i>KRAS, NRAS, BRAF, PIK3CA</i>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. Clinical Cancer Research, 2021, 27, 1612-1622.	7.0	16
2540	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. Cancer Treatment Reviews, 2021, 92, 102135.	7.7	2
2541	Multiâ€omics integration identifies a selective vulnerability of colorectal cancer subtypes to <scp>YM155</scp> . International Journal of Cancer, 2021, 148, 1948-1963.	5.1	11
2542	Multidisciplinary Treatment of Colorectal Cancer. , 2021, , .		2
2543	dPCR application in liquid biopsies: divide and conquer. Expert Review of Molecular Diagnostics, 2021, 21, 3-15.	3.1	15
2544	Prospective practice survey of management of cetuximab-related skin reactions. Supportive Care in Cancer, 2021, 29, 3497-3506.	2.2	1
2545	The multidisciplinary management of oligometastases from colorectal cancer: a narrative review. Annals of Palliative Medicine, 2020, 9, 61-61.	1.2	13
2546	Trends in epidemiology, treatment and molecular testing of metastatic colorectal cancer in a realâ€world multiâ€institution cohort study. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 84-93.	1.1	7
2547	Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110185.	3.2	9
2548	Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer. , 2021, , 221-270.		0
2549	Clinicopathological characteristics and mutational profile of KRAS and NRAS in Tunisian patients with sporadic colorectal cancer. Turkish Journal of Medical Sciences, 2021, 51, 148-158.	0.9	3
2550	CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS?. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery 2021 34 e1574	0.5	1

#	Article	IF	CITATIONS
2551	Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery. Pharmaceutics, 2021, 13, 122.	4.5	112
2552	Case-only Approach in Randomized Clinical Trials -Evaluation of Power to Detect a Treatment Effect Predictive Marker Japanese Journal of Biometrics, 2021, 41, 137-149.	0.0	0
2553	Modeling colorectal cancers using multidimensional organoids. Advances in Cancer Research, 2021, 151, 345-383.	5.0	3
2554	lmaging features associated with survival outcomes among colorectal cancer patients with and without KRAS mutation. Egyptian Journal of Radiology and Nuclear Medicine, 2021, 52, .	0.6	2
2555	Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic <i>KRAS</i> mutant colon cancer. Theranostics, 2021, 11, 3595-3606.	10.0	27
2556	Site of Recurrence and Survival After Surgery for Colorectal Peritoneal Metastasis. Journal of the National Cancer Institute, 2021, 113, 1027-1035.	6.3	25
2557	MicroRNAs for Diagnosis and Treatment of Colorectal Cancer. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, 47-55.	1.2	7
2558	Nanoparticles and colon cancer. , 2021, , 191-223.		1
2559	The Molecular Pathobiology of Malignant Process and Molecular Diagnostic Testing for Cancer. , 2021, , 3-21.		1
2560	Relationship between KRAS mutation and diffusion tensor imaging features in brain metastases due to colorectal cancer; preliminary study. Medicine Science, 2021, 10, 886.	0.1	0
2561	Mathematical Modeling to Study KRAS Mutant-Specific Responses to Pathway Inhibition. Methods in Molecular Biology, 2021, 2262, 311-321.	0.9	2
2562	CLUD1 Promotes Cetuximab Resistance in Metastasis Colorectal Cancer. SSRN Electronic Journal, 0, , .	0.4	0
2563	Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain. Seminars in Oncology, 2021, 48, 34-46.	2.2	7
2564	Pancreatic ductal adenocarcinoma in the era of precision medicine. Seminars in Oncology, 2021, 48, 19-33.	2.2	8
2565	Advances in the Relationship Between Regulator of Ribosome Synthesis 1 (RRS1) and Diseases. Frontiers in Cell and Developmental Biology, 2021, 9, 620925.	3.7	11
2566	Targeting KRAS in Colorectal Cancer. Current Oncology Reports, 2021, 23, 28.	4.0	24
2567	Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer. Oncologist, 2021, 26, 465-e917.	3.7	13
2568	Zinc finger of the cerebellum 5 promotes colorectal cancer cell proliferation and cell cycle progression through enhanced CDK1/CDC25c signaling. Archives of Medical Science, 2021, 17, 449-461.	0.9	9

#	Article		CITATIONS
2569	Liver Transplantation for Colorectal Liver Metastases: Current Management and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 3093.	4.1	7
2571	Group testing can improve the cost-efficiency of prospective-retrospective biomarker studies. BMC Medical Research Methodology, 2021, 21, 55.	3.1	2
2572	Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 433-468.	1.7	7
2573	Prolonged cetuximab treatment promotes p27Kip1-mediated G1 arrest and autophagy in head and neck squamous cell carcinoma. Scientific Reports, 2021, 11, 5259.	3.3	12
2574	KRAS, YWHAE, SP1 and MSRA as biomarkers in endometrial cancer. Translational Cancer Research, 2021, 10, 1295-1312.	1.0	7
2575	Chemotherapy-associated clonal hematopoiesis mutations should be taken seriously in plasma cell-free DNA KRAS/NRAS/BRAF genotyping for metastatic colorectal cancer. Clinical Biochemistry, 2021, 92, 46-53.	1.9	12
2576	MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. Biomedicines, 2021, 9, 318.	3.2	7
2577	Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity. Communications Biology, 2021, 4, 310.	4.4	29
2578	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 329-359.	4.9	758
2579	Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation. Journal of Oncology Pharmacy Practice, 2022, 28, 850-869.	0.9	9
2580	Artificial Intelligence–Assisted Amphiregulin and Epiregulin IHC Predicts Panitumumab Benefit in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 3422-3431.	7.0	10
2581	A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast!. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 123-125.	5.6	9
2582	Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFRâ€ŧargeting agents to treat head and neck squamous cell carcinoma. Medicinal Research Reviews, 2022, 42, 112-155.	10.5	24
2583	Concomitant Mutations G12D and G13D on the Exon 2 of the KRAS Gene: Two Cases of Women with Colon Adenocarcinoma. Diagnostics, 2021, 11, 659.	2.6	4
2584	Personalized and targeted therapies. ChemistrySelect, 2023, 8, 2103-2126.	1.5	0
2585	Early response in phosphorylation of ribosomal protein S6 is associated with sensitivity to trametinib in colorectal cancer cells. Laboratory Investigation, 2021, 101, 1036-1047.	3.7	10
2586	Pharmacoepidemiology: A time for a new multidisciplinary approach to precision medicine. Pharmacoepidemiology and Drug Safety, 2021, 30, 985-992.	1.9	1
2587	EGFR Overexpression and Sequence Analysis of KRAS, BRAF, and EGFR Mutation Hot Spots in Canine Intestinal Adenocarcinoma. Veterinary Pathology, 2021, 58, 674-682.	1.7	0

#	Article		CITATIONS
2588	Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy. Current Oncology Reports, 2021, 23, 67.	4.0	6
2589	Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells. Cellular Oncology (Dordrecht), 2021, 44, 835-850.	4.4	24
2590	Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer. Oncology Letters, 2021, 21, 448.	1.8	5
2591	The Role of Wild-Type RAS in Oncogenic RAS Transformation. Genes, 2021, 12, 662.	2.4	21
2592	Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database. Future Oncology, 2021, 17, 1483-1494.	2.4	7
2593	Prognostic value of KRAS mutation in patients undergoing pulmonary metastasectomy for colorectal cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 160, 103308.	4.4	9
2594	Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. Cancer Discovery, 2021, 11, 874-899.	9.4	107
2595	Pulmonary metastasectomy in colorectal carcinoma. Journal of Thoracic Disease, 2021, 13, 2628-2635.	1.4	11
2596	Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. ESMO Open, 2021, 6, 100093.	4.5	11
2597	Rational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes. Cancer Discovery, 2021, 11, 1644-1660.	9.4	11
2598	Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed. Cells, 2021, 10, 928.	4.1	13
2600	Precision oncology in metastatic colorectal cancer — from biology to medicine. Nature Reviews Clinical Oncology, 2021, 18, 506-525.	27.6	113
2601	Equipping Natural Killer Cells with Cetuximab through Metabolic Glycoengineering and Bioorthogonal Reaction for Targeted Treatment of KRAS Mutant Colorectal Cancer. ACS Chemical Biology, 2021, 16, 724-730.	3.4	12
2602	Primary tumor resection improves prognosis of unresectable carcinomas of the transverse colon including flexures with liver metastasis: a preliminary population-based analysis. BMC Cancer, 2021, 21, 503.	2.6	1
2603	Phenotype-Genotype Correlation in Colorectal Cancer: A Real-Life Study. GE Portuguese Journal of Gastroenterology, 2022, 29, 13-21.	0.8	1
2604	Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer. Nature Ecology and Evolution, 2021, 5, 1024-1032.	7.8	16
2605	Clinical characteristics and prognostic value of the <i>KRAS</i> mutation in Chinese colorectal cancer patients. International Journal of Biological Markers, 2021, 36, 33-39.	1.8	8
2606	Clinicopathological factors associated with tumourâ€specific mutation detection in plasma of patients with <scp><i>RAS</i></scp> â€mutated or <scp><i>BRAF</i></scp> â€mutated metastatic colorectal cancer. International Journal of Cancer, 2021, 149, 1385-1397.	5.1	10

#	Article	IF	Citations
2607	Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients. Patient Education and Counseling, 2022, 105, 452-459.	2.2	5
2608	Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient. Frontiers in Immunology, 2021, 12, 678028.	4.8	5
2609	Preclinical models and technologies to advance nanovaccine development. Advanced Drug Delivery Reviews, 2021, 172, 148-182.	13.7	18
2610	Can Pre-Treatment Inflammatory Parameters Predict the Probability of Sphincter-Preserving Surgery in Patients with Locally Advanced Low-Lying Rectal Cancer?. Diagnostics, 2021, 11, 946.	2.6	0
2611	Irinotecan or Oxaliplatin: Which is the First Move for the Mate?. Current Medicinal Chemistry, 2021, 28, 3158-3172.	2.4	1
2612	Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMGâ€510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCLâ€XL. Molecular and Clinical Oncology, 2021, 15, 148.	1.0	4
2613	Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan. BMC Cancer, 2021, 21, 518.	2.6	16
2614	Identifying Novel Actionable Targets in Colon Cancer. Biomedicines, 2021, 9, 579.	3.2	13
2615	Precision Medicine: Making It Happen for Malaysia. The Malaysian Journal of Medical Sciences, 2021, 28, 1-4.	0.5	2
2616	Clinical and Functional Characterization of Atypical <i>KRAS</i> / <i>NRAS</i> Mutations in Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 4587-4598.	7.0	14
2617	Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. Cancer Research, 2021, 81, 4641-4651.	0.9	67
2618	Treatment sequencing of metastatic colorectal cancer based on primary tumor location. Seminars in Oncology, 2021, 48, 119-129.	2.2	4
2619	Emerging strategies to target RAS signaling in human cancer therapy. Journal of Hematology and Oncology, 2021, 14, 116.	17.0	98
2620	Colorectal Cancer: From Genetic Landscape to Targeted Therapy. Journal of Oncology, 2021, 2021, 1-17.	1.3	28
2621	Precision Medicine for the Treatment of Colorectal Cancer: the Evolution and Status of Molecular Profiling and Biomarkers. Current Colorectal Cancer Reports, 2021, 17, 55-68.	0.5	3
2622	Clinicopathological and Molecular Characteristics of Colorectal Signet Ring Cell Carcinoma: A Review. Pathology and Oncology Research, 2021, 27, 1609859.	1.9	26
2623	Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions. Cancers, 2021, 13, 3739.	3.7	27
2624	Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 7114.	4.1	2

#	Article	IF	CITATIONS
2625	Role of theÂpreoperative circulating tumor DNA <i>KRAS</i> mutation in patients with resectable pancreatic cancer. Pharmacogenomics, 2021, 22, 657-667.	1.3	0
2626	Radiogenomic and Deep Learning Network Approaches to Predict <i>KRAS</i> Mutation from Radiotherapy Plan CT. Anticancer Research, 2021, 41, 3969-3976.	1.1	3
2627	Novel Biomarker-Targeted Therapies for Metastatic Colorectal Cancer. Digestive Disease Interventions, 0, , .	0.2	0
2628	Effect of KRAS and BRAF mutations in metastatic colorectal cancer patients: A systematic review and meta-analysis based on tumor sidedness and KRAS subtypes. Human Antibodies, 2021, 29, 1-10.	1.5	5
2629	Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways. Cancers, 2021, 13, 3805.	3.7	6
2630	Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2137-2144.	2.5	1
2631	Mitogenâ€activated protein kinase activity drives cell trajectories in colorectal cancer. EMBO Molecular Medicine, 2021, 13, e14123.	6.9	47
2632	NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?—Case series and review of the literature. European Journal of Cancer, 2021, 153, 86-95.	2.8	16
2633	Intratumor morphologic and transcriptomic heterogeneity in V600EBRAF-mutated metastatic colorectal adenocarcinomas. ESMO Open, 2021, 6, 100211.	4.5	4
2634	Image-Guided Ablation for Colorectal Liver Metastasis: Principles, Current Evidence, and the Path Forward. Cancers, 2021, 13, 3926.	3.7	25
2635	Complete pathological response in rectal cancer utilising novel treatment strategies for neo-adjuvant therapy: A systematic review. European Journal of Surgical Oncology, 2021, 47, 1862-1874.	1.0	7
2636	Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC. Life, 2021, 11, 843.	2.4	5
2637	The relevance of liquid biopsy in surgical oncology: The application of perioperative circulating nucleic acid dynamics in improving patient outcomes. Journal of the Royal College of Surgeons of Edinburgh, 2021, , .	1.8	1
2638	CD44v6 High Membranous Expression Is a Predictive Marker of Therapy Response in Gastric Cancer Patients. Biomedicines, 2021, 9, 1249.	3.2	3
2639	Analysis of Efficacy, Safety, and Prognostic Factors of mFOLFOX6 Regimen Combined with Cetuximab and Simvastatin in the Treatment of K-RAS Mutant Colorectal Cancer. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-7.	1.2	3
2640	Targeting steroid hormone receptors for antiâ€cancer therapy—A review on small molecules and nanotherapeutic approaches. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1755.	6.1	9
2641	Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. JCI Insight, 2021, 6, .	5.0	10
2642	Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy. Cancers, 2021, 13, 4803.	3.7	6

#	Article	IF	CITATIONS
2643	Infrequent RAS mutation is not associated with specific histological phenotype in gliomas. BMC Cancer, 2021, 21, 1025.	2.6	6
2644	Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?. Molecular Therapy - Oncolytics, 2021, 22, 1-12.	4.4	24
2645	Multisite verification of the accuracy of a multi-gene next generation sequencing panel for detection of mutations and copy number alterations in solid tumours. PLoS ONE, 2021, 16, e0258188.	2.5	8
2646	Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer. Cancer Letters, 2021, 522, 129-141.	7.2	12
2647	Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592098765.	3.2	5
2648	Application and Progress of Targeted Drug Therapy for Colorectal Cancer. World Journal of Cancer Research, 2021, 11, 24-31.	0.1	1
2649	Emerging RAS-directed therapies for cancer. , 2021, 4, 543-558.		8
2650	Mediation of Tumor Cell Death by Naked Antibodies. , 2021, , 57-77.		0
2652	Improved therapeutic antibody delivery to xenograft tumors using cavitation nucleated by gas-entrapping nanoparticles. Nanomedicine, 2021, 16, 37-50.	3.3	10
2653	Prognostic Value of <i>KRAS</i> Exon 3 and Exon 4 Mutations in Colorectal Cancer Patients. Journal of Cancer, 2021, 12, 5331-5337.	2.5	7
2654	Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivo. Clinical and Translational Oncology, 2021, 23, 1549-1560.	2.4	5
2656	Diagnostic and Therapeutic Response Markers. , 2010, , 675-701.		7
2657	Colon and Rectum. , 2010, , 143-164.		43
2658	Colon and Rectum. , 2010, , 173-206.		5
2659	Trial Design: Should Randomized Phase III Trials in Gynecological Cancers Be Abandoned?. , 2014, , 263-284.		1
2660	Genetic Alterations in Colorectal Cancer in Older Patients. , 2013, , 9-20.		3
2661	Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy. , 2010, , 37-83.		2
2662	Targeted Clinical Trials. , 2012, , 157-177.		5

ARTICLE IF CITATIONS Molecular Mechanisms of Colorectal Carcinogenesis., 2013,, 25-65. 2663 7 The PI3K Pathway in Colorectal Cancers., 2013, , 157-199. 2664 Systems Medicine: The Future of Medical Genomics, Healthcare, and Wellness. Methods in Molecular 2665 0.9 29 Biology, 2016, 1386, 43-60. Statistical Design and Evaluation of Biomarker Studies. Methods in Molecular Biology, 2014, 1102, 2666 0.9 667-677. Repeat Hepatectomy for Colorectal Liver Metastases. Cancer Treatment and Research, 2016, 168, 2667 0.5 3 203-220. 2668 Targeted Drug Therapies and Cancer. Recent Results in Cancer Research, 2011, 185, 159-171. 1.8 Molecular Prognostic Markers in Colon Cancer. Cancer Metastasis - Biology and Treatment, 2010, , 2669 0.1 1 321-341. Biomarkers in the Management of Peritoneal Metastases., 2020, , 251-279. 2670 2671 Colon and Rectum., 2012, , 1294-1380. 2 Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial 2.3 (NEXIRI-2/PRODIGE 27). Clinical Colorectal Cancer, 2020, 19, 301-310.e1. Yttrium-90 Radioembolization for Metastatic Colorectal Cancer: Outcomes by Number of Lines of 2677 3 0.8 Therapy. Seminars in Interventional Radiology, 2017, 34, 116-120. Prolonged clinical response with regorafenib administered as second-line therapy in an elderly patient suffering from peritoneal carcinomatosis of colon cancer. Journal of Chemotherapy, 2021, 33, 2678 1.5 187-192. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant 2683 8.2 177 colorectal cancers. Journal of Clinical Investigation, 2011, 121, 4311-4321. Managing Toxicities Associated With Colorectal Cancer Chemotherapy and Targeted Therapy. Clinical 2684 0.6 Journal of Oncology Nursing, 2009, 13, 285-296. Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer. The Journal of 2685 0.1 1 Oncopathology, 2013, 1, 21-29. Use of ChemoFx® for Identification of Effective Treatments in Epithelial Ovarian Cancer. PLOS 2686 1.4 Currents, 2015, 7, . KRAS mutational analysis for colorectal cancerApplication: Pharmacogenomic. PLOS Currents, 2010, 2, 2687 1.4 6 RRN1175. Exome-wide somatic mutation characterization of small bowel adenocarcinoma. PLoS Genetics, 2018, 14, e1007200.

		CITATION R	EPORT	
#	Article		IF	CITATIONS
2689	Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples. PLoS ONE, 2009, 4	, e7887.	2.5	316
2690	KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Poten Prediction of Lung Metastasis. PLoS ONE, 2009, 4, e8199.	tial Role in	2.5	138
2691	1, 9-Pyrazoloanthrones Downregulate HIF-11± and Sensitize Cancer Cells to Cetuximab Anti-EGFR Therapy. PLoS ONE, 2010, 5, e15823.	-Mediated	2.5	16
2692	KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to E Assessment. PLoS ONE, 2011, 6, e29146.	xternal Quality	2.5	30
2693	KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patient: Cancer. PLoS ONE, 2012, 7, e36653.	s with Colorectal	2.5	68
2694	Antitumoral Efficacy of the Protease Inhibitor Gabexate Mesilate in Colon Cancer Cells KRAS, BRAF and PIK3CA Mutations. PLoS ONE, 2012, 7, e41347.	Harbouring	2.5	14
2695	The Clinical Significance of MiR-148a as a Predictive Biomarker in Patients with Advanc Cancer. PLoS ONE, 2012, 7, e46684.	ed Colorectal	2.5	144
2696	Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line C plus Bevacizumab: A TTD Group Cooperative Study. PLoS ONE, 2012, 7, e47345.	hemotherapy	2.5	38
2697	Bio-Imaging of Colorectal Cancer Models Using Near Infrared Labeled Epidermal Growt ONE, 2012, 7, e48803.	h Factor. PLoS	2.5	15
2698	Detection of Low-Abundance KRAS Mutations in Colorectal Cancer Using Microfluidic C Electrophoresis-Based Restriction Fragment Length Polymorphism Method with Optim Conditions. PLoS ONE, 2013, 8, e54510.	Capillary ized Assay	2.5	29
2699	The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer. PLo e59380.	S ONE, 2013, 8,	2.5	12
2700	Colorectal Cancer Patients with Low Abundance of KRAS Mutation May Benefit from E Therapy. PLoS ONE, 2013, 8, e68022.	GFR Antibody	2.5	10
2701	CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Feature 2013, 8, e77945.	s. PLoS ONE,	2.5	104
2702	C-Terminal Tensin-Like Protein Is a Novel Prognostic Marker for Primary Melanoma Patio 2013, 8, e80492.	ents. PLoS ONE,	2.5	21
2703	Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival? A Compara Effectiveness Study in a Population-Based Sample. PLoS ONE, 2014, 9, e94977.	itive	2.5	6
2704	Control of Established Colon Cancer Xenografts Using a Novel Humanized Single Chair Antibody-Streptococcal Superantigen Fusion Protein Targeting the 5T4 Oncofetal Anti- 2014, 9, e95200.	n gen. PLoS ONE,	2.5	10
2705	HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship betwee Amplification and Expression. PLoS ONE, 2014, 9, e98528.	n HER2 Gene	2.5	143
2706	Activated cMET and IGF1R-Driven PI3K Signaling Predicts Poor Survival in Colorectal Ca Independent of KRAS Mutational Status. PLoS ONE, 2014, 9, e103551.	ncers	2.5	21
#	Article	IF	CITATIONS	
------	--	-----	-----------	
2707	Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing. PLoS ONE, 2015, 10, e0121891.	2.5	30	
2708	Upregulated Polo-Like Kinase 1 Expression Correlates with Inferior Survival Outcomes in Rectal Cancer. PLoS ONE, 2015, 10, e0129313.	2.5	40	
2709	Novel Methodology for Rapid Detection of KRAS Mutation Using PNA-LNA Mediated Loop-Mediated Isothermal Amplification. PLoS ONE, 2016, 11, e0151654.	2.5	55	
2710	Heterogeneity of KRAS Mutation Status in Rectal Cancer. PLoS ONE, 2016, 11, e0153278.	2.5	14	
2711	Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. PLoS ONE, 2016, 11, e0155178.	2.5	4	
2712	Feasibility of multiplexed gene mutation detection in plasma samples of colorectal cancer patients by mass spectrometric genotyping. PLoS ONE, 2017, 12, e0176340.	2.5	18	
2713	Characteristics of percutaneous core biopsies adequate for next generation genomic sequencing. PLoS ONE, 2017, 12, e0189651.	2.5	27	
2714	A Systematic Literature Review and Meta-Analysis Describing the Prevalence of <i>KRAS, NRAS</i> , and <i>BRAF</i> Gene Mutations in Metastatic Colorectal Cancer. Gastroenterology Research, 2020, 13, 184-198.	1.3	23	
2715	Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma. Journal of Kidney Cancer and VHL, 2014, 1, 40-45.	1.0	28	
2716	Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada. Oncologist, 2020, 25, e130-e137.	3.7	19	
2717	Dragon (RGMb) induces oxaliplatin resistance in colon cancer cells. Oncotarget, 2016, 7, 48027-48037.	1.8	14	
2718	Myotubularin-related protein 7 inhibits insulin signaling in colorectal cancer. Oncotarget, 2016, 7, 50490-50506.	1.8	21	
2719	Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer. Oncotarget, 2017, 8, 40169-40180.	1.8	20	
2720	Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. Oncotarget, 2017, 8, 108463-108479.	1.8	8	
2721	M2 macrophages induce ovarian cancer cell proliferation via a heparin binding epidermal growth factor/matrix metalloproteinase 9 intercellular feedback loop. Oncotarget, 2016, 7, 86608-86620.	1.8	54	
2722	The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study. Oncotarget, 2017, 8, 17945-17959.	1.8	45	
2723	RHBDD1 upregulates EGFR via the AP-1 pathway in colorectal cancer. Oncotarget, 2017, 8, 25251-25260.	1.8	6	
2724	Anti-helminthic niclosamide inhibits Ras-driven oncogenic transformation via activation of GSK-3. Oncotarget, 2017, 8, 31856-31863.	1.8	22	

#	Article	IF	CITATIONS
2725	Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity. Oncotarget, 2017, 8, 30217-30234.	1.8	12
2726	Molecular dissection of effector mechanisms of <i>RAS</i> -mediated resistance to anti-EGFR antibody therapy. Oncotarget, 2017, 8, 45898-45917.	1.8	12
2727	AKT can modulate the <i>in vitro</i> response of HNSCC cells to irreversible EGFR inhibitors. Oncotarget, 2017, 8, 53288-53301.	1.8	30
2728	Identification of a ternary protein-complex as a therapeutic target for K-Ras-dependent colon cancer. Oncotarget, 2014, 5, 4269-4282.	1.8	21
2729	Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding. Oncotarget, 2014, 5, 4492-4503.	1.8	105
2730	RRS1 silencing suppresses colorectal cancer cell proliferation and tumorigenesis by inhibiting G2/M progression and angiogenesis. Oncotarget, 2017, 8, 82968-82980.	1.8	32
2731	Treatment outcomes regarding the addition of targeted agents in the therapeutic portfolio for stage II-III rectal cancer undergoing neoadjuvant chemoradiation. Oncotarget, 2017, 8, 101832-101846.	1.8	9
2732	Functional profiling of microtumors to identify cancer associated fibroblast-derived drug targets. Oncotarget, 2017, 8, 99913-99930.	1.8	33
2733	Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients. Oncotarget, 2018, 9, 7739-7748.	1.8	9
2734	Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC. Oncotarget, 2014, 5, 9281-9294.	1.8	27
2735	BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications. Oncotarget, 2014, 5, 11752-11777.	1.8	83
2736	$2\hat{a}\in^2$ -deoxy- $2\hat{a}\in^2$ -[18F] fluoro-D-glucose positron emission tomography, diffusion-weighted magnetic resonance imaging, and choline spectroscopy to predict the activity of cetuximab in tumor xenografts derived from patients with squamous cell carcinoma of the head and neck. Oncotarget, 2018, 9, 28572-28585	1.8	6
2737	Spatio-temporal tumor heterogeneity in metastatic CRC tumors: a mutational-based approach. Oncotarget, 2018, 9, 34279-34288.	1.8	17
2738	Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer. Oncotarget, 2018, 9, 35623-35638.	1.8	15
2739	Broad-spectrum receptor tyrosine kinase inhibitors overcome <i>de novo</i> and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer. Oncotarget, 2019, 10, 1320-1333.	1.8	13
2740	CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition. Oncotarget, 2019, 10, 1440-1457.	1.8	19
2741	Constitutive activation of EGFR is associated with tumor progression and plays a prominent role in malignant phenotype of chondrosarcoma. Oncotarget, 2019, 10, 3166-3182.	1.8	3
2742	Advances in targeted therapies and new promising targets in esophageal cancer. Oncotarget, 2015, 6, 1348-1358.	1.8	33

#	Article	IF	CITATIONS
2743	Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget, 2015, 6, 5182-5194.	1.8	72
2744	Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Oncotarget, 2015, 6, 6029-6039.	1.8	29
2745	Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors. Oncotarget, 2015, 6, 8539-8551.	1.8	31
2746	Identification and characterization of <i>RET</i> fusions in advanced colorectal cancer. Oncotarget, 2015, 6, 28929-28937.	1.8	94
2747	89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget, 2015, 6, 30384-30393.	1.8	106
2748	Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy. Oncotarget, 2015, 6, 30287-30294.	1.8	24
2749	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?. Oncotarget, 2015, 6, 24780-24796.	1.8	77
2750	Sur8/Shoc2 promotes cell motility and metastasis through activation of Ras-PI3K signaling. Oncotarget, 2015, 6, 33091-33105.	1.8	28
2751	Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics. Oncotarget, 2015, 6, 30592-30603.	1.8	13
2752	Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors. Oncotarget, 2015, 6, 31272-31283.	1.8	8
2753	Prognostic significance of <i>K-Ras</i> mutation rate in metastatic colorectal cancer patients. Oncotarget, 2015, 6, 31604-31612.	1.8	30
2754	Molecular pathological epidemiology of colorectal cancer in Chinese patients with <i>KRAS</i> and <i>BRAF</i> mutations. Oncotarget, 2015, 6, 39607-39613.	1.8	34
2755	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget, 2015, 6, 39538-39549.	1.8	27
2756	Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation. Oncotarget, 2016, 7, 2159-2174.	1.8	24
2757	Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells. Oncotarget, 2016, 7, 64766-64777.	1.8	22
2758	Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. Oncotarget, 2016, 7, 29492-29506.	1.8	29
2759	Molecular mechanisms and clinical use of targeted anticancer drugs. Australian Prescriber, 2013, 36, 126-131.	1.0	1
2760	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. Journal of Cancer Metastasis and Treatment, 2018, 4, 12.	0.8	5

#	Article	IF	CITATIONS
2761	Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO). Annals of Gastroenterology, 2016, 29, 390-416.	0.6	9
2762	The significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patients. Annals of Translational Medicine, 2016, 4, 271-271.	1.7	6
2763	Colorectal cancer genomics and designing rational trials. Annals of Translational Medicine, 2018, 6, 159-159.	1.7	19
2764	CRISPR-based genetic interaction maps inform therapeutic strategies in cancer. Translational Cancer Research, 2018, 7, S61-S67.	1.0	8
2765	KRAS Gene Mutations and Gender Differences in Colorectal Cancer. International Journal of Biomedicine, 2015, 5, 11-15.	0.2	4
2766	Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients. Current Pharmaceutical Design, 2016, 22, 4717-4728.	1.9	19
2767	Novel Polymethoxylated Chalcones as Potential Compounds Against KRAS-Mutant Colorectal Cancers. Current Pharmaceutical Design, 2020, 26, 1622-1633.	1.9	6
2768	Clinical Next Generation Sequencing for Precision Medicine in Cancer. Current Genomics, 2015, 16, 253-263.	1.6	67
2769	Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer. Current Drug Targets, 2009, 10, 575-576.	2.1	18
2770	Cetuximab/Irinotecan-Chemotherapy in KRAS Wild-type Pretreated Metastatic Colorectal Cancer: A Pooled Analysis and Review of Literature Reviews on Recent Clinical Trials, 2013, 8, 101-109.	0.8	9
2771	Statins and Protein Prenylation in Cancer Cell Biology and Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 303-315.	1.7	49
2772	K-ras in Colorectal Cancer Tumors From Saudi Patients: Frequency, Clinco-pathological Association and Clinical Outcome. Open Colorectal Cancer Journal, 2012, 5, 22-27.	0.5	9
2773	Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients. Anticancer Research, 2016, 36, 4715-4724.	1.1	5
2774	Prediction of KRAS Mutation in Rectal Cancer Using MRI. Anticancer Research, 2016, 36, 4799-7804.	1.1	31
2775	Structure–Activity Relationship of Niclosamide Derivatives. Anticancer Research, 2017, 37, 2839-2843.	1.1	10
2776	Coexistence of and Mutations in Colorectal Cancer: A Case Report Supporting The Concept of Tumoral Heterogeneity. Cell Journal, 2017, 19, 113-117.	0.2	34
2777	KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician. Radiology and Oncology, 2019, 53, 265-274.	1.7	88
2778	Molecular differences in the KRAS gene mutation between a primary tumor and related metastatic sites - case report and a literature review Folia Histochemica Et Cytobiologica, 2011, 48, 597-602.	1.5	6

#	Article	IF	CITATIONS
2779	Insulin-like growth factor receptor type I as a target for cancer therapy. Frontiers in Bioscience - Scholar, 2013, S5, 439-450.	2.1	9
2780	KRAS Codon 12 and 13 Mutations in Gastric Cancer in the Northeast Iran. , 2018, 13, 167-172.		10
2781	¿Existen ventajas clÃnicas al evaluar el estado de los genes KRAS, NRAS, BRAF, PIK3CA, PTEN y HER2 en pacientes con cáncer colorrectal?. Revista Colombiana De Cirugia, 2017, 32, 45-55.	0.2	2
2782	Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. Pathologica, 2020, 112, 248-259.	3.4	35
2783	A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations. Cellular Oncology, 2009, 31, 161-7.	1.9	23
2784	The Treatment of Colorectal Carcinoma With Monoclonal Antibodies - The Importance of KRAS Mutation Analysis and EGFR Status. Deutsches Ärzteblatt International, 2009, 106, 202-6.	0.9	21
2785	The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology) Tj ETQq0 0 0 r	g B⁄I. \$Overl	o cto 10 Tf 50
2786	model. Health Technology Assessment, 2013, 17, 1-237. KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2014, 18, 1-132.	2.8	66
2787	The mutational landscape of hepatocellular carcinoma. Clinical and Molecular Hepatology, 2015, 21, 220.	8.9	108
2788	Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. , 2020, 1, 53-70.		5
2789	Efficacy of the Monoclonal Antibody EGFR Inhibitors for the Treatment of Metastatic Colorectal Cancer. Current Oncology, 2010, 17, 3-17.	2.2	63
2790	Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World Journal of Gastroenterology, 2010, 16, 3133.	3.3	100
2791	Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World Journal of Gastroenterology, 2010, 16, 4823.	3.3	45
2792	Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation. World Journal of Gastroenterology, 2010, 16, 4858.	3.3	21
2793	Impact of <i>KRAS</i> mutation and PTEN expression on cetuximab-treated colorectal cancer. World Journal of Gastroenterology, 2010, 16, 5881.	3.3	19
2794	Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine?. World Journal of Gastroenterology, 2011, 17, 2781-90.	3.3	16
2795	KRAS mutation testing in metastatic colorectal cancer. World Journal of Gastroenterology, 2012, 18, 5171-80.	3.3	166
2796	Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. World Journal of Gastroenterology, 2013, 19, 8474.	3.3	9

#	Article	IF	CITATIONS
2797	Differential gene expression of chemokines in <i>KRAS</i> and <i>BRAF</i> mutated colorectal cell lines: Role of cytokines. World Journal of Gastroenterology, 2014, 20, 2979.	3.3	23
2798	Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World Journal of Gastroenterology, 2014, 20, 3858.	3.3	44
2799	Role of cetuximab in first-line treatment of metastatic colorectal cancer. World Journal of Gastroenterology, 2014, 20, 4208.	3.3	25
2800	Clinical meaning ofBRAFmutation in Korean patients with advanced colorectal cancer. World Journal of Gastroenterology, 2014, 20, 4370.	3.3	11
2801	Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives. World Journal of Gastroenterology, 2014, 20, 6102.	3.3	45
2802	How to select the optimal treatment for first line metastatic colorectal cancer. World Journal of Gastroenterology, 2014, 20, 899.	3.3	31
2803	Recent applications of chemosensitivity tests for colorectal cancer treatment. World Journal of Gastroenterology, 2014, 20, 16398.	3.3	16
2804	Longitudinal molecular characterization of endoscopic specimens from colorectal lesions. World Journal of Gastroenterology, 2016, 22, 4936.	3.3	6
2805	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World Journal of Gastroenterology, 2016, 22, 6345.	3.3	94
2806	Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. World Journal of Gastroenterology, 2016, 22, 6944.	3.3	56
2807	Using gold nanoparticles to detect single-nucleotide polymorphisms: toward liquid biopsy. Beilstein Journal of Nanotechnology, 2020, 11, 263-284.	2.8	9
2809	Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatinâ€ʿbased combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials. Oncology Letters, 2019, 18, 4555-4562.	1.8	4
2810	Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer. Korean Journal of Internal Medicine, 2019, 34, 1188-1196.	1.7	3
2811	Building an innovative model for personalized healthcare. Cleveland Clinic Journal of Medicine, 2012, 79, S1-S9.	1.3	15
2812	EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 59-71.	2.2	13
2813	KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy. Journal of Gastrointestinal Oncology, 2010, 1, 90-6.	1.4	8
2814	Integrating anti-EGFR therapies in metastatic colorectal cancer. Journal of Gastrointestinal Oncology, 2013, 4, 285-98.	1.4	20
2815	Markers of resistance to anti-EGFR therapy in colorectal cancer. Journal of Gastrointestinal Oncology, 2013, 4, 308-18.	1.4	45

#	Article	IF	CITATIONS
2816	Review of systemic therapies for locally advanced and metastatic rectal cancer. Journal of Gastrointestinal Oncology, 2015, 6, 185-200.	1.4	45
2817	Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers. Journal of Gastrointestinal Oncology, 2015, 6, 314-21.	1.4	23
2818	BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. Journal of Gastrointestinal Oncology, 2015, 6, 660-7.	1.4	128
2819	Chemotherapy for advanced cancers. Annals of Palliative Medicine, 2014, 3, 203-28.	1.2	11
2820	Preoperative chemotherapy for locally advanced resectable colon cancer - a new treatment paradigm in colon cancer?. Annals of Translational Medicine, 2013, 1, 11.	1.7	15
2821	Anti-tumor effects of phenolic alkaloids of menispermum dauricum on gastric cancer in vivo and in vitro. Journal of Cancer Research and Therapeutics, 2018, 14, 505.	0.9	6
2822	The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer. Journal of Carcinogenesis, 2014, 13, 13.	2.5	4
2823	Cost-effectiveness analysis of cetuximab in treatment of metastatic colorectal cancer in Iranian pharmaceutical market. International Journal of Preventive Medicine, 2015, 6, 63.	0.4	9
2824	Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib. Asia-Pacific Journal of Oncology Nursing, 2016, 3, 58-65.	1.6	12
2825	Future role of endoscopic ultrasound in personalized management of pancreatic cancer. Endoscopic Ultrasound, 2017, 6, 300.	1.5	5
2826	Rapid and Sensitive Detection of <i>KRAS</i> Mutation by Peptide Nucleic Acid-based Real-time PCR Clamping: A Comparison with Direct Sequencing between Fresh Tissue and Formalin-fixed and Paraffin Embedded Tissue of Colorectal Cancer. Korean Journal of Pathology, 2011, 45, 151.	1.3	9
2827	Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy. Cancer Research and Treatment, 2013, 45, 55-62.	3.0	14
2828	Can Serum be Used for Analyzing the <i>KRAS</i> Mutation Status in Patients with Advanced Colorectal Cancer?. Cancer Research and Treatment, 2015, 47, 796-803.	3.0	6
2829	Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients?. Cancer Research and Treatment, 2014, 46, 48-54.	3.0	10
2830	Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer. Cancer Research and Treatment, 2018, 50, 1351-1361.	3.0	12
2831	Magnetic Resonance-Based Texture Analysis Differentiating KRAS Mutation Status in Rectal Cancer. Cancer Research and Treatment, 2020, 52, 51-59.	3.0	61
2832	The Ethical Implications for Humans in Light of the Poor Predictive Value of Animal Models. International Journal of Clinical Medicine, 2014, 05, 966-1005.	0.2	4
2833	Molecular Markers for the Prediction of Anti-EGFR Monoclonal Antibody Treatment Efficacy in Metastatic Colorectal Cancer. Journal of Cancer Therapy, 2011, 02, 675-682.	0.4	4

#	Article	IF	CITATIONS
2834	Recent Advances in the Management of Stage IV Colon Cancer. Journal of Cancer Therapy, 2012, 03, 1104-1118.	0.4	5
2835	Oncoselectivity in Oncolytic Viruses against Colorectal Cancer. Journal of Cancer Therapy, 2014, 05, 1153-1174.	0.4	5
2836	Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Colorectal Cancer after Failure of Second-Line Therapy—A Potential Strategy for Improved Survival. Journal of Cancer Therapy, 2014, 05, 1270-1288.	0.4	1
2837	High Incidence of Null-Type Mutations of the <i>TP</i> 53 Gene in Japanese Patients with Head and Neck Squamous Cell Carcinoma. Journal of Cancer Therapy, 2014, 05, 664-671.	0.4	2
2838	Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features. World Journal of Gastrointestinal Oncology, 2015, 7, 292.	2.0	15
2839	Inflammation-based factors and prognosis in patients with colorectal cancer. World Journal of Gastrointestinal Oncology, 2015, 7, 111.	2.0	41
2840	Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 1.	2.0	4
2841	Role of circulating free DNA in colorectal cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 810.	2.0	6
2842	Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in <i>KRAS</i> wild-type metastatic colorectal cancer patients. World Journal of Gastrointestinal Oncology, 2016, 8, 222.	2.0	27
2843	Mechanisms underlying ¹⁸ F-fluorodeoxyglucose accumulation in colorectal cancer. World Journal of Radiology, 2016, 8, 880.	1.1	32
2844	Kras in metastatic colorectal cancer. Swiss Medical Weekly, 2010, 140, w13112.	1.6	17
2845	The Molecular Targets for the Diagnosis and Treatment of Pancreatic Cancer. Gut and Liver, 2010, 4, 433-449.	2.9	22
2846	Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a post–EMA-approval descriptive study with a geriatric oncology focus. Turkish Journal of Gastroenterology, 2020, 31, 695-705.	1.1	1
2847	Colorectal liver metastases: Current management and future perspectives. World Journal of Clinical Oncology, 2020, 11, 761-808.	2.3	98
2848	Genomic era diagnosis and management of hereditary and sporadic colon cancer. World Journal of Clinical Oncology, 2014, 5, 1036.	2.3	11
2849	Digital pathology in personalized cancer therapy. Folia Histochemica Et Cytobiologica, 2012, 49, 570-578.	1.5	13
2851	The Role of <i>KRAS</i> Mutation Testing in the Management of Patients With Metastatic Colorectal Cancer. Archives of Pathology and Laboratory Medicine, 2009, 133, 1600-1606.	2.5	98
2852	Molecular Diagnostics of Colorectal Cancer. Archives of Pathology and Laboratory Medicine, 2011, 135, 578-587.	2.5	46

#	Article	IF	CITATIONS
2853	Targeted therapy and its availability in Serbia. Hospital Pharmacology, 2014, 1, 93-101.	0.3	4
2854	Molecular targeted therapy for EGFR and VEGF in head and neck squamous cell carcinomas. Japanese Journal of Head and Neck Cancer, 2010, 36, 436-441.	0.1	3
2855	Inhibitory Effects of Phenolic Alkaloids of Menispermum Dauricum on Gastric Cancer in Vivo. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10825-10830.	1.2	3
2856	Factors Affecting Prognosis in Metastatic Colorectal Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3015-3021.	1.2	23
2857	Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biology and Medicine, 2014, 11, 20-33.	3.0	109
2858	Establishment of a 12-gene expression signature to predict colon cancer prognosis. PeerJ, 2018, 6, e4942.	2.0	30
2859	Child-Turcotte-Pugh Score as a Predictive Factor for Long-Term Survival After Repeat Hepatectomy for Recurrent Liver Metastases of Colorectal Cancer. International Surgery, 2021, 105, 611-618.	0.1	0
2860	Special issue introduction: Statistical Methods in Precision Medicine: Diagnostic, Prognostic, Prognostic, Predictive and Therapeutic. Biostatistics and Epidemiology, 2021, 5, 93-99.	0.4	0
2861	Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges. Molecular Cancer, 2021, 20, 128.	19.2	41
2862	A call to action: molecular pathology in Brazil. Surgical and Experimental Pathology, 2021, 4, .	0.6	5
2863	Profile of esophageal squamous cell carcinoma mutations in Brazilian patients. Scientific Reports, 2021, 11, 20596.	3.3	2
2864	Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clinical Cancer Research, 2021, 27, 6726-6736.	7.0	8
2865	Epidermal Growth Factor Receptor Inhibitor-Induced Hypomagnesaemia: Is There a Best Replacement Strategy?. European Medical Journal (Chelmsford, England), 0, , .	3.0	0
2867	Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. Journal of Experimental and Clinical Cancer Research, 2021, 40, 328.	8.6	62
2868	EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. Clinical Lung Cancer, 2022, 23, 60-71.	2.6	5
2869	Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts. Immunotherapy, 2021, 13, 1355-1367.	2.0	2
2871	Pré-requis avant la mise en route d'une chimiothérapie pour cancer colorectal. , 2009, , 30-46.		2
2872	A therapeutic experience of three cases with salivary duct carcinoma in the parotid gland. Journal of Japan Society for Head and Neck Surgery, 2009, 19, 63-66.	0.0	1

		CITATION RE	PORT	
#	Article		IF	CITATIONS
2873	Personalized Therapy for Cancer. , 2009, , 165-254.			0
2874	Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focu panitumumab. OncoTargets and Therapy, 2009, 2, 161.	ıs on	2.0	3
2875	Inherent Resistance to Epidermal Growth Factor Receptor Antibodies in Refractory Met Colorectal Cancer. Journal of Medical Sciences (Faisalabad, Pakistan), 2009, 9, 165-174	astatic 1.	0.0	1
2876	Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. On Therapy, 2009, 2, 251.	coTargets and	2.0	1
2878	Chemotherapy Trials for Colorectal Cancer in Advanced Disease: Whatâ $\in {}^{\rm TM}{\rm s}$ the Currer 2010, , 27-54.	ıt Hypothesis?. ,		0
2880	Pharmacogenetics in Colorectal Cancer. , 2010, , 61-86.			0
2881	Application of molecular medicine to pancreatic cancer. Suizo, 2010, 25, 35-45.		0.1	0
2882	Biologisch zielgerichtete medikamentöse Therapie. , 2010, , 265-275.			0
2883	Targeting EGFR in HPV-Associated Cancer. , 2010, , 211-234.			0
2884	First-Line Treatment of Metastatic Colorectal Cancer: Focus on Cetuximab in Combinat Chemotherapy. Clinical Medicine Reviews in Oncology, 0, 2, 319-327.	ion with	0.0	0
2885	Development of Novel Pancreatic Tumor Biomarkers. , 2010, , 1173-1201.			0
2886	Lebermetastasen. , 2010, , 639-653.			0
2887	Molekulare Diagnostik und Response-PrÃ ë iktion. , 2010, , 187-197.			0
2888	Basic Principles of Cancer Genetics. , 2010, , 1-22.			1
2889	Chemotherapie und systemische Therapie bei Lebermetastasen. , 2010, , 386-409.			0
2891	KRas and BRaf Mutational Status Analysis From Formalin-Fixed, Paraffin-Embedded Tiss Multiplex Polymerase Chain Reaction–Based Assay. Archives of Pathology and Labora 2010, 134, 620-624.	ues Using atory Medicine,	2.5	9
2892	Safety and Effective Biomakers in Oncology. , 2010, , 275-296.			0
2894	Principles of Systemic Cancer Therapy. , 2010, , 428-437.			0

#	Article	IF	CITATIONS
2895	Practical Gastrointestinal Oncology Correlative Science. , 2011, , 43-66.		0
2896	Unresectable Pancreatic Cancer. , 2011, , 205-224.		0
2897	Monoclonal Antibody Therapy for Cancer. , 2011, , 59-83.		0
2898	Phase III Clinical Trials with Anticancer Agents. , 2011, , 163-188.		0
2899	Proteomic Profiling of Hepatic Metastases: Paving the Way to Individualized Therapy. Cancer Metastasis - Biology and Treatment, 2011, , 401-416.	0.1	0
2900	Neoplastic Diseases of the Colon and Rectum. , 2011, , 889-905.		0
2901	BRAF Mutations and their Implications in Molecular Targeting Therapies for Gastrointestinal Cancers. Journal of Pharmacogenomics & Pharmacoproteomics, 2011, 02, .	0.2	4
2902	To Test or Not To Test: Colon Cancer Pharmacogenetics and Predisposition Genetics. Journal of Pharmacogenomics & Pharmacoproteomics, 2011, 02, .	0.2	2
2903	The Dynamics of the Cell Signaling Network; Implications for Targeted Therapies. , 2011, , 33-53.		0
2904	Health Economics and Cancer Survivorship. , 2011, , 299-327.		0
2905	Conditions of tumor-associated antigens as a proper target for therapeutic antibodies against solid cancers. Journal of Stem Cells and Regenerative Medicine, 2011, 7, 14-28.	2.2	1
2907	Systemic Treatment in Recurrent and Metastatic Unresectable Rectal Cancer. , 0, , .		0
2909	Somatic Alterations and Targeted Therapy. , 2012, , 51-101.		0
2910	A Case of Laparoscopic Surgery That Completely Extirpated Locally-Advanced Rectal Carcinoma with Liver Metastases after Neoadjuvant Therapy. Nihon Daicho Komonbyo Gakkai Zasshi, 2012, 65, 437-441.	0.0	0
2911	Colorectal carcinoma under microscopy: Patohistology or much more?. Acta Chirurgica Iugoslavica, 2012, 59, 31-38.	0.0	0
2912	Metastatic Colorectal Cancer: Optimizing Treatment with Anti-EGFR Monoclonal Antibody. Journal of Cancer Therapy, 2012, 03, 902-911.	0.4	0
2913	Current Research into Head and Neck Cancer Molecular Targeted Therapy and Human Papilloma Virus Infection in Head and Neck Squamous Cell Carcinoma. Practica Otologica, 2012, 105, 183-191.	0.0	0
2915	Survival Outcome in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Followed by	0.2	Ο

** Arrice FF Cristenes 2912 Neodjavant Chemotherapy for Colorectal Liver Metastases, 0, 0 2913 Artie ECFR Treatment in Patients with Colorectal Cancer, 0, 0 2914 Emerging Therapies for Esophageal Cancer, 0, 0 2925 Pedictive Markers in Lung Cancer, 2013, 43-68. 0 2926 Progroup Control Cancer, 2013, 131-162. 0 2927 Taggeted Therapies and Molecular Diagnostics of Castrointestinal Cancers. Molecular Pathology 0.1 2928 Taggeted Therapies and Molecular Diagnostics of Castrointestinal Cancers. Molecular Pathology 0.1 2929 Cancers of the Rectum and Anal Canzel. Malecular Pathology Library, 2013, 213-228. 0.1 0 2929 Cancers of the Rectum and Anal Canzel. Malecular Pathology Library, 2013, 213-228. 0.1 0 2929 Cancers of the Rectum and Anal Canzel. Malecular Pathology Library, 2013, 213-228. 0.1 0 2929 Resistance to the AnthEoren Engevold RAS, In Paters with Metastatic Colorectal Cancer. 0.1 0 2929 Resistance to the AnthEoren Engevold RAS, In Pathets with Metastatic Colorectal Cancer. 0.1 0 2929 Resistance to the AnthEorenet. Heory Canzela Cancer. 2013, 1251-141.<				
2917 Neoadjuant Chemotherapy for Colorectal Liver Metastases, 0, 0 2918 Arti-ECER Treatment in Patients with Colorectal Cancer, ,0, 0 2929 Emerging Therapies for Esophageal Cancer, ,0, 0 2921 Predictive Markers in Lung Cancer, ,2013, ,43-68. 0 2922 Predictive Markers in Color Cancer, ,2013, ,131-162. 0 2923 Eventorian and Christel Outcoane in Metastastic Colorectal Cancer Patients Treated with 0.1 2924 Eventorian and Christel Outcoane in Metastastic Colorectal Cancer Patients Treated with 0.1 2925 Eventorian and Anal Canal Metastastic Colorectal Cancer Patients Treated with 0.1 2926 Uppertension and Christel Outcoane in Metastastic Colorectal Cancer Patients Treated with 0.1 2927 Eventorian and Anal Canal Molecular Pathology Ubrary, 2013, , 213-228. 0.1 0 2928 Molecular Mechanisms of Tumor Metastasts. Molecular Pathology Ubrary, 2013, , 213-228. 0.1 0 2929 Christel Study of the Carolation between Histological Cancer. Milen Daebo Komonhypo 0.0 0 2920 Christel Study of the Carolation between Histological Cancer. 2013, 125-141. 0 0 2921 Resistrance to the Anti-GRR Therappeuk. 2013, 137-35	#	Article	IF	CITATIONS
2927 Neoadjuyant Chemotherapy for Colorectal Luer Metastases, 0, 0 2918 Ami-LCER Instament in Patients with Colorectal Cancer, 0, 0 2929 Emerging Therapies for Esophageal Cancer, 0, 0 2920 Prognostic Markers in Colon Cancer, 2013, 131-162. 0 2921 Hypertransion and Chical Occome in Matastatic Colorectal Cancer, 2012, 29, 324-337. 0.1 1 2922 Hypertransion and Chical Occome in Matastatic Colorectal Cancer, 2013, 131-162. 0 1 2923 Targeted Therapies and Molecular Diagnostics of Gastrointestinal Cancers. Molecular Pathology 0.1 0 2924 Targeted Therapies and Molecular Diagnostics of Gastrointestinal Cancers. Molecular Pathology 0.1 0 2925 Concers of the Rectum and Anal Canal. Molecular Pathology Library, 2013, 141-1271. 0.1 0 2926 Chical Study of the Correlation between Histological Types and the Efficacy of mCDECOK 0.1 0 2927 Chical Study of the Correlation between Histological Types and the Efficacy of mCDECOK 0.1 0 2928 Resistance To Hargeted Anti-cancer Therapy Reyord REAS, in Patients with Metastatic Colorectal Cancer. 0.1 0 2929 Tarastational Activation of KRAS and BRAF in Colorectal Cancer., 2013, 121-156. 0.1 0 2929 Parsanalized Maritione in Cancer., 2013, 137-157.				
2918 Anti-EGFR Treatment in Patients with Colorectal Cancer., 0,,. 0 2919 Emerging Therapies for Esophageal Cancer., 0, 0 2921 Predictive Markers in Lung Cancer., 2013, 131-162. 0 2922 Prognostic Markers in Color Cancer., 2013, 131-162. 0 2923 Hypertension and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with Explanation and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with Explanation and Clinical Outcome in Metastatic Colorectal Cancer Molecular Patients Treated with Explanation and Clinical Outcome in Metastatic Colorectal Cancers. Molecular Pathology 0.1 1 2924 Targeted Therapies and Molecular Diagnostics of Castrointestinal Cancers. Molecular Pathology 0.1 0 2925 Cancers of the Rectum and Anal Canal. Molecular Pathology Library, 2013., 141-171. 0.1 1 2926 Molecular Mechanisms of Tumor Metastasis. Molecular Pathology Library, 2013., 213-228. 0.1 0 2927 Chickal Study of the Correlation between Hierological Types and the Efficacy of mCDCOKe 0.1 0 2928 Resistance To Targeted Antricarear Therapeutics, 2013, 132-141. 0.1 0 2929 Monecional Antribodies in Cancer., 2013, 337-359. 1 0 2929 Resistance To Targeted Antricarear Therapeuti	29	7 Neoadjuvant Chemotherapy for Colorectal Liver Metastases. , 0, , .		0
2918 AnD-LUR Treatment in Patients with Connectal Cancer., 0, 0 2919 Emerging Therapies for Esophageal Cancer., 2013, , 43-68. 0 2922 Prognostic Markers in Colon Cancer., 2013, , 131-162. 0 2924 Hypertension and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with Evacuamab Journal of Korean Society of Health-System Pharmaciets, 2012, 29, 324-337. 0.1 1 2924 Targeted Therapies and Molecular Diagnostics of Castrointestinal Cancers. Molecular Pathology 0.1 0 2925 Cancers of the Rectum and Anal Canal. Molecular Pathology Library, 2013, 141-171. 0.1 1 2926 Molecular Mechanisms of Tumor Metastasis. Molecular Pathology Library, 2013, 213-228. 0.1 0 2927 "Criptian Banceronic Banceron Herological Types and the Efficacy of mECITOXS 0.1 0 2928 Resistance to the Anti-ECRF Therapy. Bayond KRAS, in Patients with Metastatic Colorectal Cancer. Nihon Datche Komonbyo 0.0 0 2929 Monoclonal Antibodies in Cancer., 2013, 137-359. 1 1 2931 Les anti-EGFR personnals A@s selon le statut tumoral KRAS, 2013, 159-175. 0 0 2932 Mutational Activation of KRAS and BRAF in Colorectal Cancer , 2013, 122-156. 1 0 0 <td></td> <td></td> <td></td> <td></td>				
2929 Emerging Theraples for Ecophageal Cancer., Q, ,. 0 2921 Predictive Markers In Lung Cancer., 2013,, 131-162. 0 2922 Prognostic Markers in Colon Cancer., 2013,, 131-162. 0 2923 Bypertension and Clinical Outcome In Metastatite Colorectal Cancer Patients Troated with exact the Color Cancer. Activity of Health-System Pharmaetists, 2012, 29, 324-337. 0.1 1 2924 Egrected Theraples and Molecular Diagnostics of Castrointestinal Cancers. Molecular Pathology 0.1 0 2925 Cancers of the Rectum and Anal Canal. Molecular Pathology Library, 2013, 213-228. 0.1 0 2926 Molecular Mechanisms of Tumor Metastasis. Molecular Pathology Library, 2013, 213-228. 0.1 0 2927 Chickal Socky of the Correlation between Histological Types and the Efficacy of mfOLFOX5 0.1 0 2928 Resistance to the Anti-ECFR Therapy, Bayond KRAS, in Patients with Metastatic Colorectal Cancer. Minor Dialcho Komorehyo 0.0 0 2929 Resistance to the Anti-ECFR Therapy, Bayond KRAS, in Patients with Metastatic Colorectal Cancer. 0.1 0 2929 Monoclonal Antibodies in Cancer., 2013, 137-156. 1 0 0 0 2929 Resistance to Anti-ECFR Therapy, Bayond KRAS, in Patients Wein Metastatic Colorectal C	29:	.8 Anti-EGFR Treatment in Patients with Colorectal Cancer., 0, , .		Ο
2921 Predictive Markers in Lung Cancer., 2013, 43-68. 0 2922 Prognostic Markers in Colon Cancer., 2013, 131-162. 0 2923 bypertension and Chileal Octeome in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Journal of Korean Society of Health System Pharmacists, 2012, 29, 324-337. 0.1 1 2924 Lärgeted Therapies and Molecular Diagnostics of Gastrointestinal Cancers. Molecular Pathology 0.1 0 2925 Cancers of the Rectum and Anal Canal. Molecular Pathology Library, 2013, 141-171. 0.1 1 2926 Molecular Mechanisms of Tumor Metastasis. Molecular Pathology Library, 2013, 121-1228. 0.1 0 2927 Christal Study of the Contralation between Histological Types and the Efficacy of mfOLFOX6 0.0 0 2928 Resistance to the Anti-EGR Iberapy. Beyond KRAS, in Patients with Metastatic Colorectal Cancer. 0.1 0 2929 Monoclonal Antibodes in Cancer., 2013, 337-359. 1 0 2931 Les anti-EGR personnalisA@s selon le statut tumoral KRAS, 2013, 125-175. 0 0 2932 Mutational Medicine in Oncology and Companion Diagnostics:Development and Challenges. 0.4 0 2933 Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. 0.4	29	9 Emerging Therapies for Esophageal Cancer. , 0, , .		0
2921 Predictive Markers in Lung Cancer., 2013,, 131-162. 0 2922 Prognostic Markers in Colon Cancer., 2013,, 131-162. 0 2923 bypertension and Chineal Outcome in Metastatic Colorectal Cancer. Patients Treated with Devaceumab. Journal of Korean Society of Heath'system Pharmacists, 2012, 29, 324-337. 0.1 1 2924 Targeted Therapies and Molecular Diagnostics of Gastrolintestinal Cancers. Molecular Pathology 0.1 0 2925 Cancers of the Rectum and Anal Canal. Molecular Pathology Library, 2013, 141-171. 0.1 1 2926 Molecular Mechanisms of Tumor Metastasis. Molecular Pathology Library, 2013, 213-228. 0.1 0 2927 Chineal Study of the Correlation between Histological Dypes and the Efficacy of mEOLFOX6 0.0 0 2928 Resistance to the Anti-EGR Iherapy. Beyond KRAS, in Patients with Metastatic Colorectal Cancer. 0.1 0 2929 Monoclonal Antibodes in Cancer., 2013, 337-359. 1 1 2929 Mutational Activation of KRAS and BRAF in Colorectal Cancer., 2013, 125-141. 0 0 2929 Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. 0.4 0 2929 Personalized Medicine (Sunnyvale, Call*), 103, 0.3 0 0 0 <td></td> <td></td> <td></td> <td></td>				
2922 Prognostic Markers in Colon Cancer., 2013,, 131-162. 0 2923 Hypertension and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with Evacerunds, Journal of Korean Society of Health System Pharmacists, 2012, 29, 324-537. 0.1 1 2924 Largeted Therapies and Molecular Diagnostics of Gastrointestinal Cancers. Molecular Pathology 0.1 0 2925 Cancers of the Rectum and Anal Canal. Molecular Pathology Library, 2013,, 141-171. 0.1 1 2926 Molecular Mechanisms of Tumor Metastasis. Molecular Pathology Library, 2013,, 213-228. 0.1 0 2927 Clinical Study of the Correlation between Histological Types and the Efficacy of mFOLFOX6 0.0 0 2928 Resistance to the Antri-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer. Nihon Daicho Komonbyo 0.0 0 2929 Monoclonal Antibodies in Cancer., 2013, 337-359. 1 0 2931 Les anti-EGFR personnalis& 9 selon le statut tumoral KRAS., 2013, 159-175. 0 0 2932 Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. 0.4 0 2933 Resistance to Antricancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted 0 0 2934 TYPES OF DNA DAMAGE, 2013	292	Predictive Markers in Lung Cancer. , 2013, , 43-68.		Ο
2922 Prognostic Markers in Colon Cancer., 2013,, 131-162. 0 2923 Hypertension and Clinical Outcome in Metaatatic Colonectal Cancer Patients, Treated with Bevacizumab, Journal of Korean Society of Health System Pharmacists, 2012, 29, 324-337. 0.1 1 2924 Largeted Therapies and Molecular Diagnostics of Gastrointestinal Cancers. Molecular Pathology 0.1 0 2925 Cancers of the Rectum and Anal Canal. Molecular Pathology Library, 2013,, 141-171. 0.1 1 2926 Molecular Mechanisms of Tumor Metastasis. Molecular Pathology Library, 2013,, 213-228. 0.1 0 2927 Clinical Study of the Correlation between Histological Types and the Efficacy of mFOLFOX6 0.0 0 2928 Resistance to the Anti-EGFR Therapy, Beyond KRAS, In Patients with Metastatic Colorectal Cancer. Nihon Daicho Komonbyo 0.0 0 2929 Monoclonal Antibodies in Cancer., 2013, 337-359. 1 0 2931 Les anti-EGFR personnalis&@s selon le statut tumoral KRAS, 2013, 159-175. 0 2932 Mutational Activation of KRAS and BRAF in Colorectal Cancer., 2013, 121-156. 1 2933 Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. 0.4 0 2934 TYPES OF DNA DAMACE, 2013, 115-118. 0 0				
2923Hypertension and Clinical Outcome in Metaetatic Colorectal Cancer Patients Treated with Bevacizumab. Journal of Korean Society of Health System Pharmacists, 2012, 29, 324-337.0.112924Targeted Therapies and Molecular Diagnostics of Gastrointestinal Cancers. Molecular Pathology Ubray, 2013, 33-41.0.112925Cancers of the Rectum and Anal Canal. Molecular Pathology Ubrary, 2013, 141-171.0.112926Molecular Mechanisms of Tumor Metastasis. Molecular Pathology Ubrary, 2013, 213-228.0.102927Clinical Study of the Correlation between Histological Types and the Efficacy of mFOLFOX6 ("Pubrann; Bevacizumab in Patients with Metastatic Colorectal Cancer. Nilnon Datcho Komonbyo 	292	Prognostic Markers in Colon Cancer. , 2013, , 131-162.		0
2923 behacizumab. Journal of Korean Society of Health-System Pharmacists, 2012, 29, 324-337. 0.1 1 2924 Targeted Therapies and Molecular Diagnostics of Gastrointestinal Cancers. Molecular Pathology 0.1 0 2925 Cancers of the Rectum and Anal Canal. Molecular Pathology Library, 2013, , 141-171. 0.1 1 2926 Molecular Mechanisms of Tumor Metastasis. Molecular Pathology Library, 2013, , 213-228. 0.1 0 2927 Clinical Study of the Correlation between Histological Types and the Efficacy of nFOLFOX6 0.0 0 2928 Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer. Nihon Dalcho Komonbyo 0.1 0 2930 Monoclonal Antibodies in Cancer. , 2013, , 337-359. 1 0 2931 Les anti-EGFR personnalisÃ@s selon le statut tumoral KRAS., 2013, , 129-175. 0 2932 Mutational Activation of KRAS and BRAF in Colorectal Cancer. , 2013, , 129-175. 0 2933 Personalized Medicine in Oncology and Companion Diagnostics.Development and Challenges. Translational Medicine (Sumnyale, Calif'), 2013, 03. 0 2934 TYPES OF DNA DAMACE., 2013, , 115-118. 0 2935 Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Oil 0.1 0 </td <td></td> <td>Hypertension and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with</td> <td></td> <td></td>		Hypertension and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with		
2924Targeted Therapies and Molecular Diagnostics of Gastrointestinal Cancers. Molecular Pathology0.102925Cancers of the Rectum and Anal Canal. Molecular Pathology Library, 2013, , 141-171.0.112926Molecular Mechanisms of Tumor Metastasis. Molecular Pathology Library, 2013, , 213-228.0.102927Clinical Study of the Correlation between Histological Types and the Efficacy of mFOLFOX6 ("Pulusma; Bevacizumab in Patients with Metastatic Colorectal Cancer. Nihon Dalcho Komonbyo0.002928Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer.0.102929Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer.0.102929Monoclonal Antibodies in Cancer., 2013, 337-359.12931Les anti-EGFR personnalisÃos selon le statut tumoral KRAS., 2013, 159-175.02932Mutational Activation of KRAS and BRAF in Colorectal Cancer., 2013, 121-156.12933Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. Translational Medicine (Sunnyvale, Calif), 2013, 03,.02944TYPES OF DNA DAMACE, 2013, 115-118.02945Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013, 1,247-265.0.1	29:	²³ Bevacizumab. Journal of Korean Society of Health-System Pharmacists, 2012, 29, 324-337.	0.1	1
2224 LbFary, 2013, 3341. 0.1 0.1 2925 Cancers of the Rectum and Anal Canal. Molecular Pathology Library, 2013, , 141-171. 0.1 1 2926 Molecular Mechanisms of Tumor Metastasis. Molecular Pathology Library, 2013, , 213-228. 0.1 0 2927 Clinical Study of the Correlation between Histological Types and the Efficacy of mFOLFOX6 (1) Tolusmi, Bevacizumab in Patients with Metastatic Colorectal Cancer. Nihon Daicho Komonbyo 0.0 0 2928 Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer. 0.1 0 2930 Monoclonal Antibodies in Cancer., 2013, , 125-141. 0.1 0 2931 Les anti-EGFR personnalisà ©s selon le statut tumoral KRAS., 2013, , 159-175. 0 2932 Mutational Activation of KRAS and BRAF in Colorectal Cancer. , 2013, , 121-156. 1 2933 Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. 0.4 0 2934 TYPES OF DNA DAMACE., 2013, , 115-118. 0 0 2935 Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Theraputics, 2013, , 1-24. 0.1 0 2936 Colorectal Cancer Cenome and Its Implications., 2013, , 247-265. 0.1 0	204	Targeted Therapies and Molecular Diagnostics of Gastrointestinal Cancers. Molecular Pathology	0.1	0
2925Cancers of the Rectum and Anal Canal. Molecular Pathology Library, 2013,, 141-171.0.112926Molecular Mechanisms of Tumor Metastasis. Molecular Pathology Library, 2013,, 213-228.0.102927Clinical Study of the Correlation between Histological Types and the Efficacy of mFOLFOX6 (]^plusmn; Bevacizumab in Patients with Metastatic Colorectal Cancer. Nihon Daicho Komonbyo0.002928Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2013, 125-141.0.102930Monoclonal Antibodies in Cancer., 2013, 337-359.112931Les anti-EGFR personnalisÃ@s selon le statut tumoral KRAS., 2013, 159-175.02932Mutational Activation of KRAS and BRAF in Colorectal Cancer., 2013, 121-156.12933Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. Translational Medicine (Sunnyvale, Calif), 2013, 03, .02934TYPES OF DNA DAMACE., 2013, 115-118.02935Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted 	292	Library, 2013, , 33-41.	0.1	0
2926Molecular Mechanisms of Tumor Metastasis. Molecular Pathology Library, 2013, , 213-228.0.102927Clinical Study of the Correlation between Histological Types and the Efficacy of mFOLFOX6 () plusming Bevacizumab in Patients with Metastatic Colorectal Cancer. Nihon Daicho Komonbyo (a) plusming Bevacizumab in Patients with Metastatic Colorectal Cancer.0.002928Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer.0.102930Monoclonal Antibodies in Cancer., 2013, , 337-359.12931Les anti-EGFR personnalisÅ@s selon le statut tumoral KRAS., 2013, , 159-175.02932Mutational Activation of KRAS and BRAF in Colorectal Cancer., 2013, , 121-156.12933Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. Translational Medicine (Sunnyvale, Calif.), 2013, 03,.02934TYPES OF DNA DAMACE., 2013, , 115-118.02935Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Arti-cancer Therapeutics, 2013, , 124-265.0.1	292	25 Cancers of the Rectum and Anal Canal. Molecular Pathology Library, 2013, , 141-171.	0.1	1
2926Molecular Mechanisms of Tumor Metastasis. Molecular Pathology Library, 2013, 213-228.0.102927Clinical Study of the Correlation between Histological Types and the Efficacy of mFOLFOX6 Cakkai Zasshi, 2013, 66, 80-85.0.002928Resistance to the Anti-ECFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer. Nihon Dalcho Komonbyo Cakkai Zasshi, 2013, 66, 80-85.0.102929Monoclonal Antibodies in Cancer., 2013, 337-359.12931Les anti-ECFR personnalisés selon le statut tumoral KRAS., 2013, 159-175.02932Mutational Activation of KRAS and BRAF in Colorectal Cancer., 2013, 121-156.12933Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. Translational Medicine (Sunnyvale, Calif), 2013, 03, .02934TYPES OF DNA DAMAGE., 2013, 115-118.02935Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013, 124.0.1				
2927Clinical Study of the Correlation between Histological Types and the Efficacy of mFOLFOX6 Clarkal Zasshi, 2013, 66, 80-85.0.002928Resistance to the Anti-ECFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2013, 125-141.0.102930Monoclonal Antibodies in Cancer. , 2013, 337-359.12931Les anti-EGFR personnalisés selon le statut tumoral KRAS. , 2013, 159-175.02932Mutational Activation of KRAS and BRAF in Colorectal Cancer. , 2013, 121-156.12933Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. Translational Medicine (Sunnyvale, Calif), 2013, 03,.02934TYPES OF DNA DAMAGE. , 2013, 115-118.02935Resistance to Anticancer Antibiodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013, 1-24.0.1	292	Molecular Mechanisms of Tumor Metastasis. Molecular Pathology Library, 2013, , 213-228.	0.1	0
2927 Cakkal Zasshi, 2013, 66, 80-85.0.00.002928 Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 125-141.0.102930Monoclonal Antibodies in Cancer. , 2013, , 337-359.12931Les anti-EGFR personnalisÃ@s selon le statut tumoral KRAS. , 2013, , 159-175.02932Mutational Activation of KRAS and BRAF in Colorectal Cancer. , 2013, , 121-156.12933Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. Translational Medicine (Sunnyvale, Calif), 2013, 03, .0.42934TYPES OF DNA DAMAGE., 2013, , 115-118.02935Resistance to Anticancer Antibodies: from Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 1-24.0.1		Clinical Study of the Correlation between Histological Types and the Efficacy of mEOLEOX6		
2928Resistance to the Anti-ECFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2013, 125-141.0.102930Monoclonal Antibodies in Cancer. , 2013, 337-359.12931Les anti-EGFR personnalis˩s selon le statut tumoral KRAS. , 2013, 159-175.02932Mutational Activation of KRAS and BRAF in Colorectal Cancer. , 2013, 121-156.12933Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. Translational Medicine (Sunnyvale, Calif.), 2013, 03,.0.42934TYPES OF DNA DAMACE. , 2013, , 115-118.02935Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013, 1-24.0.1	292	27 ^ ^plusmn; Bevacizumab in Patients with Metastatic Colorectal Cancer. Nihon Daicho Komonbyo Gakkai Zasshi, 2013, 66, 80-85.	0.0	Ο
2928Resistance To Targeted Anti-cancer Therapeutics, 2013, 125-141.0.102930Monoclonal Antibodies in Cancer., 2013, 337-359.12931Les anti-EGFR personnalisÃ@s selon le statut tumoral KRAS., 2013, 159-175.02932Mutational Activation of KRAS and BRAF in Colorectal Cancer., 2013, 121-156.12933Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. Translational Medicine (Sunnyvale, Calif), 2013, 03, .0.402934TYPES OF DNA DAMAGE., 2013, 115-118.02935Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013, 1-24.0.10		Resistance to the Anti-EGER Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer.		
2930Monoclonal Antibodies in Cancer., 2013,, 337-359.12931Les anti-ECFR personnalisÃ@s selon le statut tumoral KRAS., 2013,, 159-175.02932Mutational Activation of KRAS and BRAF in Colorectal Cancer., 2013,, 121-156.12933Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. Translational Medicine (Sunnyvale, Calif.), 2013, 03.0.42934TYPES OF DNA DAMACE., 2013,, 115-118.02935Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013,, 1-24.0.1	292	Resistance To Targeted Anti-cancer Therapeutics, 2013, , 125-141.	0.1	0
2931 Les anti-ECFR personnalisÃ@s selon le statut tumoral KRAS., 2013,, 159-175. 0 2932 Mutational Activation of KRAS and BRAF in Colorectal Cancer., 2013,, 121-156. 1 2933 Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. Translational Medicine (Sunnyvale, Calif), 2013, 03,. 0.4 0 2934 TYPES OF DNA DAMAGE., 2013,, 115-118. 0 2935 Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013,, 1-24. 0 2936 Colorectal Cancer Genome and Its Implications., 2013,, 247-265. 0	205	an Monoclonal Antibodies in Cancer 2013 337-359		1
2931Les anti-EGFR personnalisÃ@s selon le statut tumoral KRAS., 2013,, 159-175.02932Mutational Activation of KRAS and BRAF in Colorectal Cancer., 2013,, 121-156.12933Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. rranslational Medicine (Sunnyvale, Calif), 2013, 03,.0.402934TYPES OF DNA DAMAGE., 2013,, 115-118.02935Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013,, 1-24.0.102936Colorectal Cancer Genome and Its Implications., 2013,, 247-265.00	290			*
2932Mutational Activation of KRAS and BRAF in Colorectal Cancer., 2013,, 121-156.12933Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. Translational Medicine (Sunnyvale, Calif), 2013, 03, .0.402934TYPES OF DNA DAMACE., 2013,, 115-118.02935Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013,, 1-24.0.102936Colorectal Cancer Genome and Its Implications., 2013,, 247-265.00	293	Les anti-EGFR personnalisés selon le statut tumoral KRAS. , 2013, , 159-175.		0
2932Mutational Activation of KRAS and BRAF in Colorectal Cancer., 2013,, 121-156.12933Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. Translational Medicine (Sunnyvale, Calif), 2013, 03, .0.402934TYPES OF DNA DAMACE., 2013,, 115-118.02935Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013,, 1-24.0.102936Colorectal Cancer Genome and Its Implications., 2013,, 247-265.00				
2933Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges.0.402934TYPES OF DNA DAMAGE., 2013, , 115-118.02935Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 1-24.0.102936Colorectal Cancer Genome and Its Implications., 2013, , 247-265.00	293	Mutational Activation of KRAS and BRAF in Colorectal Cancer. , 2013, , 121-156.		1
2933Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges.0.402934TYPES OF DNA DAMACE., 2013, , 115-118.02935Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted0.102936Colorectal Cancer Genome and Its Implications., 2013, , 247-265.0				
2934TYPES OF DNA DAMAGE., 2013,, 115-118.02935Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013,, 1-24.0.102936Colorectal Cancer Genome and Its Implications., 2013,, 247-265.0	293	Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. Translational Medicine (Sunnyvale, Calif), 2013, 03, .	0.4	0
2934TYPES OF DNA DAMAGE., 2013, , 115-118.02935Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 1-24.0.102936Colorectal Cancer Genome and Its Implications., 2013, , 247-265.0				
2935Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 1-24.0.102936Colorectal Cancer Genome and Its Implications. , 2013, , 247-265.0	293	34 TYPES OF DNA DAMAGE. , 2013, , 115-118.		Ο
2930 Anti-cancer Therapeutics, 2013, , 1-24. 0.1 0 2936 Colorectal Cancer Genome and Its Implications. , 2013, , 247-265. 0	0.01	Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted	0.1	0
2936 Colorectal Cancer Genome and Its Implications. , 2013, , 247-265. 0	293	Anti-cancer Therapeutics, 2013, , 1-24.	0.1	U
	293	Colorectal Cancer Genome and Its Implications. , 2013, , 247-265.		0

#	Article	IF	CITATIONS
2937	The Clinical Significance of Mutations in Colorectal Cancer. , 2013, , 231-245.		0
2938	Adenocarcinoma of the Colon and Rectum. , 2013, , 2051-2074.		0
2941	Biologic Agents in the Treatment of Colorectal Cancer: The Last Decade; the Lost Decade?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e121-e125.	3.8	1
2943	Signal Transduction Inhibitors of the HER Family. , 2013, , 17-50.		0
2944	Pathology, Biomarkers, and Molecular Diagnostics. , 2014, , 226-252.e6.		1
2945	Availability of the Drugs for Malignant Diseases Treatment: Comparison between Developing and Developed Countries. British Journal of Pharmaceutical Research, 2014, 4, 1500-1520.	0.4	0
2946	Medical Oncology. , 2014, , 71-82.		0
2947	Biomarker-Based Designs of Phase III Clinical Trials for Personalized Medicine. , 2014, , 247-263.		0
2948	Case Report: Long-Term Survival in Patient with Cirrhosis of the Liver and Colon Cancer K-ras Wild-Type. Case Reports in Clinical Medicine, 2014, 03, 373-377.	0.2	0
2949	EGFR-Targeted Therapies in Non-small Cell Lung Cancer. , 2014, , 31-66.		0
2950	Research Methods for Clinical Trials in Personalized Medicine: A Systematic Review. , 2014, , 659-684.		1
2951	EGF/EGFR signaling axis is a significant regulator of the proteasome expression and activity in colon cancer cells. ScienceOpen Research, 2014, .	0.6	2
2952	Scientific Challenges and Implementation Barriers to Translation of Pharmacogenomics in Clinical Practice. , 2014, , 95-133.		1
2953	Rare Cancers. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 109-130.	0.6	0
2954	Treatment Strategies for KRAS Mutated Non-small Cell Lung Cancer. , 2015, , 157-185.		0
2956	Epidermal growth factor/epidermal growth factor receptor signaling axis is a significant regulator of the proteasome expression and activity in colon cancer cells. ScienceOpen Research, 2014, .	0.6	0
2957	Metastatic Rectal Cancer. , 2015, , 287-310.		0
2958	Genetics, Screening, and Chemoprevention. , 2015, , 57-80.		0

#	Article	IF	CITATIONS
2959	Analysis of the role of RAS Family Mutations in Metastatic Colorectal Cancer (mCRC): Current Treatment Practice. Forum of Clinical Oncology, 2014, 5, 12-15.	0.2	0
2960	Biomarkers in Metastatic Colorectal Cancer. Biomarkers in Disease, 2015, , 601-629.	0.1	1
2961	Assessment of Biomarkers' Predictive Value of Efficacy. , 2015, , 101-112.		0
2962	Targeted Therapies For Intestinal Tumorigenesis. , 2015, , 391-440.		0
2963	A Single Nucleotide Polymorphism in the MGMT Gene is a Novel Prognostic Biomarker in Patients with Metastatic Colorectal Cancer. British Journal of Medicine and Medical Research, 2015, 5, 604-611.	0.2	0
2965	Le traitement multidisciplinaire. Bulletin De L'Academie Nationale De Medecine, 2015, 199, 213-222.	0.0	0
2966	Multimodality Management of Colorectal Malignancies Beyond Endoscopy. , 2015, , 291-309.		0
2969	Future Directions and Clinical Trials in Penile Cancer. , 2016, , 311-324.		0
2970	METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY. Farmakoekonomika, 2016, 9, 38-44.	1.2	1
2971	A Comprehensive Evaluation of Solid Tumor Analysis in the Clinical Space. Journal of Next Generation Sequencing & Applications, 2016, 3, .	0.3	1
2974	Gastrointestinal Malignancy: Genetic Implications to Clinical Applications. Cancer Treatment and Research, 2016, 168, 393-479.	0.5	0
2975	Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 27-107.	0.1	0
2976	Mutations by Next Generation Sequencing in Stool DNA from Colorectal Carcinoma Patients – A Literature Review and our Experience with this Methodology. Journal of Analytical Oncology, 2016, 5, 24-32.	0.1	1
2977	Frequency and Clinical Impact of KRAS Mutations in Patients with Colorectal Cancer from the Middle East. Journal of Analytical Oncology, 2016, 5, .	0.1	1
2979	Personalized Medicine for the Treatment of Human Cancer. , 2017, , 843-855.		0
2980	Early drop in serum lactate dehydrogenase concentrations as a predictor of tumor response to ongoing anti-epidermal growth factor receptorÂantibody treatment. Annals of Cancer Research and Therapy, 2017, 25, 95-99.	0.3	0
2981	Systemic chemotherapy for hepatic colorectal cancer. , 2017, , 1488-1501.e5.		0
2982	Clinical Predictors of Cetuximab for First-Line Therapy of Metastatic Colorectal Cancer: A Single Institutional Retrospective Study. Journal of Cancer Therapy, 2017, 08, 827-837.	0.4	0

		CITATION RE	PORT	
#	Article		IF	CITATIONS
2983	Anti-EGFR therapy in colorectal carcinoma. Onkologie (Czech Republic), 2017, 11, 66-7	1.	0.1	0
2987	Neutral evolution of drug resistant colorectal cancer cell populations is independent of status. PLoS ONE, 2017, 12, e0175484.	their KRAS	2.5	1
2988	Salvage Line Chemotherapies in Metastatic Colorectal Cancer Patients. Nihon Daicho Ko Zasshi, 2018, 71, 387-392.	omonbyo Gakkai	0.0	1
2989	The Role of Systemic Chemotherapy in Colorectal Cancer. , 2018, , 329-343.			0
2990	A system-wide approach to monitor responses to synergistic BRAF and EGFR inhibition i cancer cells. SSRN Electronic Journal, 0, , .	n colorectal	0.4	0
2991	Early Serum Carcinoembryonic Antigen Reduction Predicts Tumor Shrinkage and Overal Colorectal Cancer Patients with Distant Metastasis, after Primary Surgery Followed by N Bevacizumab Treatment. Open Journal of Gastroenterology, 2018, 08, 147-153.	l Survival in Afolfox6 Plus	0.1	0
2992	Pathologic Assessment and Specimen Quality After Total Mesorectal Excision of Rectal 99-106.	Cancer. , 2018, ,		0
2995	Increased Expression of the YPEL3 Gene in Human Colonic Adenocarcinoma Tissue and Proliferation, Migration, and Invasion of Colonic Adenocarcinoma Cells In Vitro via the Wnt/b-Catenin Signaling Pathway. Medical Science Monitor, 2018, 24, 4767-4775.	the Effects on	1.1	7
2996	New therapeutic agents for metastatic colorectal cancer: literature review. OnkologiÄes Koloproktologiâ, 2018, 8, 34-46.	skaâ	0.1	0
2998	Principles of Adjuvant and Neoadjuvant Therapy for Locally Advanced Rectal Cancer. , 2	019, , 445-463.		0
2999	Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Can the registry of the Gastro-intestinal Cancer Study Group (GIC-SG). Forum of Clinical One 31-36.	cer (mCRC) on cology, 2019, 9,	0.2	2
3000	Combination of Anti-angiogenics and Other Targeted Therapies. , 2019, , 359-376.			0
3001	Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases. Indian Jo Cancer, 2019, 56, 176.	ournal of	0.2	2
3002	KRAS as Potential Target in Colorectal Cancer Therapy. , 2019, , 389-424.			1
3003	Cancer Clinical Trials Based on Master Protocol. Japanese Journal of Biometrics, 2019, 3	9, 85-101.	0.0	1
3004	In silico Drug Repositioning Using Omics Data: The Potential and Pitfalls. , 2019, , 1-19.			0
3005	Metastatic Colorectal Cancer. , 2019, , 135-160.			0
3006	消化器ãŒã,". Journal of Otolaryngology of Japan, 2019, 122, 717-723.		0.1	0

#	Article	IF	CITATIONS
3007	Safety and Effective Biomakers in Oncology — A Regulatory Drug and Device Perspective. , 2019, , 275-296.		0
3008	KRAS Mutation as Predictor Factor in Locally Advanced Rectal Cancer. Annals of Clinical Oncology, 2019, , 1-4.	0.0	0
3009	GEFT protein expression in digestive tract malignant tumors and its clinical significance. Oncology Letters, 2019, 18, 5577-5590.	1.8	4
3010	Temporary loss of consciousness during cetuximab treatment of a patient with metastatic colon cancer: a case report. Surgical Case Reports, 2019, 5, 145.	0.6	1
3011	Adenocarcinoma of the Colon and Rectum. , 0, , .		0
3012	Prognosis and Management of Recurrent Metastatic Colorectal Cancer. , 2020, , 571-587.		0
3013	Defining Resectability of Colorectal Cancer Liver Metastases: Technical and Oncologic Perspectives. , 2020, , 129-144.		0
3014	Precision medicine in medical oncology: hope, disappointment and reality. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1427-1431.	2.3	4
3016	Genetic biomarkers: Potential roles in cancer diagnosis. Cellular and Molecular Biology, 2020, 66, 1.	0.9	7
3017	Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer. Growth Factors, 2020, 38, 127-136.	1.7	0
3018	Clinico-Pathological Study of K-ras Mutations in Colorectal Tumors: A Single-Center Retrospective Study of 51 Patients in Madinah, Saudi Arabia. Cureus, 2020, 12, e9978.	0.5	5
3019	Mismatch Repair Status in Patient-Derived Colorectal Cancer Organoids Does Not Affect Intrinsic Tumor Cell Sensitivity to Systemic Therapy. Cancers, 2021, 13, 5434.	3.7	5
3020	Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer. Gastroenterology Report, 2020, 8, 411-424.	1.3	4
3021	Applications of Antibodies in Therapy, Diagnosis, and Science. Learning Materials in Biosciences, 2021, , 129-159.	0.4	0
3022	The Effect of Tumor Sideness and Mutational Status on First Line Treatment Response and Survival in The Patients with Metastatic Colorectal Cancer. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2020, 30, 197-206.	0.1	0
3023	Prognostic Inflammatory Index Based on Preoperative Peripheral Blood for Predicting the Prognosis of Colorectal Cancer Patients. Cancers, 2021, 13, 3.	3.7	12
3024	Clinical pharmacogenetics. , 2022, , 189-212.		0
3025	Colorectal Cancer Genetics: An Overview of the Actionable Building Blocks. , 2020, , 29-71.		1

		CITATION REPORT	
#	Article	IF	CITATIONS
3026	Biomarkers in colon cancer and its clinical implications. Journal of Current Oncology, 2020, 3, 66.	0.2	1
3027	Labordiagnostik/Tumormarker: Was ist sinnvoll/effektiv, was wird kommen?. , 2020, , 191-207.		0

 $_{3028}$ Clinical biomarkers directing the management of patients with colon and lung cancer (beyond) Tj ETQq0 0 0 rgBT $\binom{0.2}{0.2}$ Tf 50 66

3029	Significance of Radiofrequency Ablation for Unresectable Colorectal Cancer With Liver Metastases. Anticancer Research, 2021, 41, 5539-5547.	1.1	7
3030	Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Molecular Cancer, 2021, 20, 143.	19.2	117
3031	Context Matters—Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 760705.	3.7	3
3032	Bone Marrow Biopsy: RNA Isolation with Expression Profiling in Men with Metastatic Castration-resistant Prostate Cancer—Factors Affecting Diagnostic Success. Radiology, 0, , 121782.	7.3	0
3033	INFLUENCE OF SOMATIC MUTATIONS OF KRAS, NRAS, BRAF AND MICROSATELLITE INSTABILITY STATUS ON SURVIVAL OF COLORECTAL CANCER PATIENTS WITH PERITONAL CARCINO. Siberian Journal of Oncology, 2020, 19, 61-67.	0.3	0
3035	Automated synthesis of 18F radiolabelled indole containing Oncrasin-like molecules; a comparison of iodonium salts and boronic ester chemistry. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 23.	3.9	0
3036	Chemotherapy and Targeted Drugs for Patients with Metastatic Colorectal Cancer. , 2021, , 187-202.		0
3037	MiRNAs: A New Approach to Predict and Overcome Resistance to Anticancer Drugs. Clinical Cancer Drugs, 2020, 7, 65-77.	0.3	0
3038	The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospecive economic assessment from a single-center experience. Tumori, 2012, 98, 408-12.	1.1	2
3039	Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia. Tumori, 2014, 100, 75-9.	1.1	14
3040	The evolution of colorectal cancer genetics-Part 2: clinical implications and applications. Journal of Gastrointestinal Oncology, 2014, 5, 336-44.	1.4	6
3041	Cetuximab for patients with colon cancer and hepatic metastasis complicated by liver dysfunction and icterus. Gastrointestinal Cancer Research: GCR, 2009, 3, 171-2.	0.7	2
3042	Accomplishments in 2008 in biologic markers for gastrointestinal cancers-focus on colorectal cancer. Gastrointestinal Cancer Research: GCR, 2009, 3, S73-8.	0.7	2
3043	Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer. Gastrointestinal Cancer Research: GCR, 2009, 3, S23-7.	0.7	2
3044	Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. P and T, 2009, 34, 554-64.	0.9	17

		CITATION REF	PORT	
#	Article		IF	CITATIONS
3045	KRAS Testing: Optimizing Cancer Therapy. Biotechnology Healthcare, 2009, 6, 7-9.		0.2	2
3046	Current status of treatment of metastatic colorectal cancer with special reference to c elderly patients. OncoTargets and Therapy, 2009, 2, 17-27.	etuximab and	2.0	3
3047	Evolving role of cetuximab in the treatment of colorectal cancer. Cancer Management 2009, 1, 79-88.	and Research,	1.9	5
3048	The role of oncogenes in gastrointestinal cancer. Gastrointestinal Cancer Research: GC S2-S15.	IR, 2010, ,	0.7	3
3050	Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-bas second-line chemotherapy. Gastrointestinal Cancer Research: GCR, 2011, 4, 168-72.	ed	0.7	13
3051	KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Basec Analysis. Ontario Health Technology Assessment Series, 2010, 10, 1-49.	and Economic	1.8	17
3052	Monoclonal antibodies in cancer therapy. Cancer Immunity, 2012, 12, 14.		3.2	206
3053	Evaluating the treatment of metastatic colorectal cancer with monoclonal antibodies. Medicine and Life, 2012, 5, 168-72.	Journal of	1.3	0
3054	A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenoc Wisconsin Oncology Network study. Journal of Gastrointestinal Oncology, 2012, 3, 90	arcinoma: A I-6.	1.4	17
3056	KRAS gene mutations are more common in colorectal villous adenomas and in situ car carcinomas. International Journal of Molecular Epidemiology and Genetics, 2013, 4, 1-2	cinomas than in 10.	0.4	12
3057	Alternate dosing of cetuximab for patients with metastatic colorectal cancer. Gastroin Cancer Research: GCR, 2013, 6, 47-55.	testinal	0.7	8
3060	Targeted therapies in colorectal cancer: the dos, don'ts, and future directions. Journal Gastrointestinal Oncology, 2013, 4, 239-44.	of	1.4	0
3061	Molecular targeted therapy for biliary tract malignancy: defining the target. Hepatobiliand Nutrition, 2012, 1, 53-4.	ary Surgery	1.5	5
3062	KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Ca Model. Gastrointestinal Cancer Research: GCR, 2014, 7, 23-6.	ncer Cell Line	0.7	28
3063	Drug designs fulfilling the requirements of clinical trials aiming at personalizing medici Clinical Oncology, 2014, 3, 14.	ne. Chinese	1.2	9
3064	The efficacy and safety of adding bevacizumab to cetuximab- or panitumumab-based t treatment of patients with metastatic colorectal cancer (mCRC): a meta-analysis from control trials. International Journal of Clinical and Experimental Medicine, 2015, 8, 334	herapy in the randomized -45.	1.3	8
3065	Saudi Oncology Society clinical management guideline series. Colorectal cancer 2014. Abdulaziz University, Islamic Economics, 2014, 35, 1538-44.	Journal of King	1.1	5
3066	KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancrea colorectal cancer are reflective of patient tumors and stable across passages. American 2014, 80, 873-7.	atic and h Surgeon,	0.8	12

#	Article	IF	CITATIONS
3068	A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer. Avicenna Journal of Medical Biotechnology, 2015, 7, 134-44.	0.3	33
3069	A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer. Chinese Journal of Cancer Research: Ófficial Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 12-8.	2.2	1
3070	Novel Therapies in Development for Metastatic Colorectal Cancer. Gastrointestinal Cancer Research: GCR, 2014, 7, S2-7.	0.7	2
3071	Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience. Cancer Biology and Medicine, 2016, 13, 136-41.	3.0	2
3072	Circulating miR-21 as an independent predictive biomarker for chemoresistance in esophageal squamous cell carcinoma. American Journal of Cancer Research, 2016, 6, 1511-23.	1.4	26
3073	A novel E1B55kDa-deleted oncolytic adenovirus carrying microRNA-143 exerts specific antitumor efficacy on colorectal cancer cells. American Journal of Translational Research (discontinued), 2016, 8, 3822-3830.	0.0	7
3074	Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment. American Journal of Cancer Research, 2017, 7, 2587-2599.	1.4	2
3076	KRAS Codon 12 and 13 Mutations in Gastric Cancer in the Northeast Iran. Iranian Journal of Pathology, 2018, 13, 167-172.	0.5	3
3078	Targeting snoRNAs as an emerging method of therapeutic development for cancer. American Journal of Cancer Research, 2019, 9, 1504-1516.	1.4	5
3079	Clinical proteomics: a driving force for cancer therapeutic target discovery and precision medicine. Cancer Biology and Medicine, 2019, 16, 623-629.	3.0	0
3080	Not all mutations of predict poor prognosis in patients with colorectal cancer. International Journal of Clinical and Experimental Pathology, 2019, 12, 957-967.	0.5	11
3081	The emerging role of long non-coding RNAs in the drug resistance of colorectal cancer. International Journal of Clinical and Experimental Pathology, 2018, 11, 4735-4743.	0.5	4
3082	Prognostic impact of and mutations in patients who underwent simultaneous resection for initially resectable colorectal liver metastases. International Journal of Clinical and Experimental Pathology, 2018, 11, 5981-5991.	0.5	1
3083	Prognostic significance of preoperative platelet-lymphocyte ratio in a Chinese cohort patient with colorectal cancer. International Journal of Clinical and Experimental Pathology, 2017, 10, 8686-8694.	0.5	0
3084	Photothermal therapy technology of metastatic colorectal cancer. American Journal of Translational Research (discontinued), 2020, 12, 3089-3115.	0.0	7
3085	High frequency of microsatellite instability and its substantial co-existence with and mutations in Vietnamese patients with colorectal cancer. Oncology Letters, 2021, 21, 41.	1.8	2
3086	SOD2 Enhancement by Long-Term Inhibition of the PI3K Pathway Confers Multi-Drug Resistance and Enhanced Tumor-Initiating Features in Head and Neck Cancer. International Journal of Molecular Sciences, 2021, 22, .	4.1	0
3087	SOD2 Enhancement by Long-Term Inhibition of the PI3K Pathway Confers Multi-Drug Resistance and Enhanced Tumor-Initiating Features in Head and Neck Cancer. International Journal of Molecular Sciences, 2021, 22, 11260.	4.1	4

#	Article	IF	CITATIONS
3088	A Novel Mutation of the KLK6 Gene in a Family With Knee Osteoarthritis. Frontiers in Genetics, 2021, 12, 784176.	2.3	3
3089	CRISPR/Cas9 in Gastrointestinal Malignancies. Frontiers in Cell and Developmental Biology, 2021, 9, 727217.	3.7	4
3090	Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment. Frontiers in Oncology, 2021, 11, 764912.	2.8	10
3091	Circular RNA UBR1 promotes the proliferation, migration, and invasion but represses apoptosis of lung cancer cells via modulating microRNA-545-5p/SSFA2 axis. Bioengineered, 2021, 12, 12135-12147.	3.2	9
3092	Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer Cells. Cancers, 2021, 13, 5779.	3.7	5
3093	Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers. Cancers, 2021, 13, 5750.	3.7	4
3094	Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences. Frontiers in Pharmacology, 2021, 12, 745701.	3.5	1
3095	The Epithelial–Mesenchymal Transition Influences the Resistance of Oral Squamous Cell Carcinoma to Monoclonal Antibodies via Its Effect on Energy Homeostasis and the Tumor Microenvironment. Cancers, 2021, 13, 5905.	3.7	9
3096	Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review. Molecular Diagnosis and Therapy, 2021, 25, 715-734.	3.8	6
3097	Age-dependent prognostic value of <i>KRAS</i> mutation in metastatic colorectal cancer. Future Oncology, 2021, 17, 4883-4893.	2.4	5
3098	High frequency of microsatellite instability and its substantial co‑existence with <i>KRAS</i> and <i>BRAF</i> mutations in Vietnamese patients with colorectal cancer. Oncology Letters, 2020, 21, 41.	1.8	7
3099	Nephrotic syndrome induced by cetuximab in a patient with metastatic colorectal cancer. Journal of Oncology Pharmacy Practice, 2022, , 107815522110737.	0.9	1
3100	Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition. International Journal of Molecular Sciences, 2022, 23, 679.	4.1	0
3101	Predictive and Therapeutic Implications of a Novel PLCÎ ³ 1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer. Clinical Cancer Research, 2022, 28, 1203-1216.	7.0	7
3102	<i>KRAS</i> mutationâ€independent downregulation of MAPK/PI3K signaling in colorectal cancer. Molecular Oncology, 2022, 16, 1171-1183.	4.6	6
3103	Strategies to minimize heterogeneity and optimize clinical trials in Acute Respiratory Distress Syndrome (ARDS): Insights from mathematical modelling. EBioMedicine, 2022, 75, 103809.	6.1	9
3104	The path to the clinic: a comprehensive review on direct KRASG12C inhibitors. Journal of Experimental and Clinical Cancer Research, 2022, 41, 27.	8.6	73
3105	Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines. Npj Systems Biology and Applications, 2022, 8, 2.	3.0	0

#	Article	IF	CITATIONS
3106	Performance of prognostic models incorporating KRAS mutation status to predict survival after resection of colorectal liver metastases. Hpb, 2022, , .	0.3	2
3107	Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 2022, , .	1.1	0
3108	Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncology, The, 2022, 23, 115-124.	10.7	147
3109	A comprehensive framework for early-onset colorectal cancer research. Lancet Oncology, The, 2022, 23, e116-e128.	10.7	49
3110	A KRAS-Associated Signature for Prognostic Prediction in Colon Cancer. SSRN Electronic Journal, 0, , .	0.4	0
3111	Treatment decision based on molecular profiling in metastatic colorectal cancer with aÂfocus on RAS pathway mutations. Memo - Magazine of European Medical Oncology, 2022, 15, 39.	0.5	1
3112	Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Scientific Reports, 2022, 12, 1248.	3.3	3
3113	Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going. Clinical Colorectal Cancer, 2022, 21, 71-79.	2.3	4
3114	Genetic and molecular biology of gastric cancer among Iranian patients: an update. Egyptian Journal of Medical Human Genetics, 2022, 23, .	1.0	4
3115	Development and validation of a prognostic and predictive 32-gene signature for gastric cancer. Nature Communications, 2022, 13, 774.	12.8	52
3116	Correlation between 18F-FDG PET/CT intra-tumor metabolic heterogeneity parameters and KRAS mutation in colorectal cancer. Abdominal Radiology, 2022, 47, 1255-1264.	2.1	6
3117	Preclinical Identification of Sulfasalazine's Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling. Biomedicines, 2022, 10, 377.	3.2	5
3118	Genomic profiling of gallbladder carcinoma: Targetable mutations and pathways involved. Pathology Research and Practice, 2022, 232, 153806.	2.3	4
3119	Anticancer drug resistance: An update and perspective. Drug Resistance Updates, 2021, 59, 100796.	14.4	122
3120	Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. Clinical and Translational Oncology, 2009, 11, 737-47.	2.4	3
3121	Chirurgische Onkologie. , 2022, , 369-381.		0
3122	Chemotherapy in resectable or potentially resectable colon cancer with liver metastases. Expert Opinion on Pharmacotherapy, 2022, 23, 663-672.	1.8	3
3123	Growth factor receptor and β1 integrin signaling differentially regulate basal clonogenicity and radiation survival of fibroblasts via a modulation of cell cycling. In Vitro Cellular and Developmental Biology - Animal, 2022, 58, 169-178.	1.5	3

#	Article	IF	CITATIONS
3124	Frequency and Clinicopathological Characteristics of Patients With KRAS/BRAF Double-Mutant Colorectal Cancer: An In Silico Study. Pathology and Oncology Research, 2022, 28, 1610206.	1.9	3
3125	Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers. Cancer Chemotherapy and Pharmacology, 2022, 89, 413-422.	2.3	2
3126	Utilization of genetic biomarkers testing and its associated factors in advanced colorectal cancer patients in China: a nationwide multicenter clinical epidemiological study. Annals of Translational Medicine, 2022, 10, 324-324.	1.7	1
3127	Senescence-associated reprogramming induced by interleukin-1 impairs response to EGFR neutralization. Cellular and Molecular Biology Letters, 2022, 27, 20.	7.0	7
3128	Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use. International Journal of Molecular Medicine, 2022, 49, .	4.0	2
3129	The impact of KRAS mutation, microsatellite instability, and tumor laterality on the prognosis of nonmetastatic colon cancer. Surgery, 2022, 171, 657-665.	1.9	6
3130	Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer. Cureus, 2022, 14, e23543.	0.5	0
3131	Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer. Annals of Surgical Oncology, 2022, , 1.	1.5	1
3132	KRAS: A Druggable Target in Colon Cancer Patients. International Journal of Molecular Sciences, 2022, 23, 4120.	4.1	13
3133	Precision medicineâ€based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience. Molecular Oncology, 2022, 16, 2575-2584.	4.6	8
3134	Comparison of Next-Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment-Related Genomic Status in Patients with Metastatic Colorectal Cancer. Current Issues in Molecular Biology, 2022, 44, 1552-1563.	2.4	3
3135	Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF-mutant metastatic and/or unresectable colorectal cancer. Critical Reviews in Oncology/Hematology, 2022, 173, 103646.	4.4	3
3136	Optimal solutions in the third line therapy for refractory metastatic colorectal cancer. CORRECTness and CONCURency. Meditsinskiy Sovet, 2021, , 47-52.	0.5	0
3137	9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells. Frontiers in Pharmacology, 2021, 12, 777114.	3.5	3
3138	Identification and functional analysis of IncRNAs and mRNAs between tumorigenesis and metastasis in CRC. Aging, 2021, 13, 25859-25885.	3.1	5
3139	Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach. Cell Reports, 2021, 37, 110096.	6.4	7
3140	Prevalence of KRAS, PIK3CA, BRAF and AXIN2 gene mutations in colorectal cancer and its relationship with dental agenesis: a systematic review. Revista Facultad De Medicina, 2021, 71, e95595.	0.2	0
3141	Comparative Effectiveness of Biologic Agents Among Black and White Medicare Patients in the US With Metastatic Colorectal Cancer. JAMA Network Open, 2021, 4, e2136378.	5.9	5

#	Article	IF	CITATIONS
3142	Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). Clinical Cancer Research, 2022, 28, 2779-2788.	7.0	11
3143	Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients. BMC Cancer, 2021, 21, 1332.	2.6	2
3144	Targeting KRAS G12C with Covalent Inhibitors. Annual Review of Cancer Biology, 2022, 6, 49-64.	4.5	16
3146	Advances in tests for colorectal cancer screening and diagnosis. Expert Review of Molecular Diagnostics, 2022, 22, 449-460.	3.1	28
3147	KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1273-1283.	2.5	6
3148	Biologic Agents in the Treatment of Colorectal Cancer: The Last Decade; the Lost Decade?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e121-e125.	3.8	2
3149	Use of ChemoFxÂ $^{\otimes}$ for Identification of Effective Treatments in Epithelial Ovarian Cancer. PLOS Currents, 0, , .	1.4	0
3162	Tumours of the Small and Large Bowel. , 0, , 270-282.		0
3165	The HER family as therapeutic targets in colorectal cancer. Critical Reviews in Oncology/Hematology, 2022, 174, 103681.	4.4	9
3166	Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. Nature Cancer, 2022, 3, 418-436.	13.2	46
3167	Bispecific antibodies seek out colon cancer stem cells. Nature Cancer, 2022, 3, 379-380.	13.2	3
3170	Aggressive multimodality treatment for advanced rectal cancer. Acta Medica Okayama, 2015, 69, 113-8.	0.2	0
3171	Clinical proteomics: a driving force for cancer therapeutic target discovery and precision medicine. Cancer Biology and Medicine, 2019, 16, 623-629.	3.0	1
3179	Translating basic research in cancer patient care. Annali Dell'Istituto Superiore Di Sanita, 2011, 47, 64-71.	0.4	4
3180	Multimodal immune activation abilities and characteristics of reovirus American Journal of Translational Research (discontinued), 2021, 13, 14176-14185.	0.0	0
3181	Antibody-drug conjugates: beyond current approvals and potential future strategies. Exploration of Targeted Anti-tumor Therapy, 0, , 252-277.	0.8	11
3182	Clinical management of metastatic colorectal cancer in the era of precision medicine. Ca-A Cancer Journal for Clinicians, 2022, 72, 372-401.	329.8	167
3184	Statin Treatment as a Targeted Therapy for APC-Mutated Colorectal Cancer. Frontiers in Oncology, 0, 12, .	2.8	9

щ	Apticie	IF	CITATIONS
#	AKTICLE	IF	CHATIONS
3185	recurrent gastric cancers after chemotherapy. Genes and Genomics, 2022, 44, 1425-1435.	1.4	1
3186	A robust threshold t linear mixed model for subgroup identification using multivariate T distributions. Computational Statistics, 0, , .	1.5	0
3187	KRAS Gene Copy Number as a Negative Predictive Biomarker for the Treatment of Metastatic Rectal Cancer With Cetuximab: A Case Report. Frontiers in Oncology, 0, 12, .	2.8	0
3188	Multivariate Risk Analysis of RAS, BRAF and EGFR Mutations Allelic Frequency and Coexistence as Colorectal Cancer Predictive Biomarkers. Cancers, 2022, 14, 2792.	3.7	2
3189	Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	8.6	9
3190	Clinical Updates for Colon Cancer Care in 2022. Clinical Colorectal Cancer, 2022, 21, 198-203.	2.3	32
3191	Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer. Journal of Cancer Policy, 2022, , 100342.	1.4	1
3192	A KRAS-Associated Signature for Prognostic, Immune and Chemical Anti-Cancer Drug-Response Prediction in Colon Cancer. Frontiers in Pharmacology, 0, 13, .	3.5	2
3193	Potential for cure and predictors of long-term survival after radiofrequency ablation for colorectal liver metastases: A 20-years single-center experience. European Journal of Surgical Oncology, 2022, 48, 2487-2494.	1.0	2
3194	Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma. Pancreatology, 2022, 22, 741-748.	1.1	8
3195	Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer. Cancer Treatment Reviews, 2022, 109, 102433.	7.7	15
3196	Prognostic Models Incorporating RAS Mutation to Predict Survival in Patients with Colorectal Liver Metastases: A Narrative Review. Cancers, 2022, 14, 3223.	3.7	2
3197	The emerging era of personalized medicine in advanced colorectal cancer. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1411-1425.	2.8	6
3198	Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments. OncoTargets and Therapy, 0, Volume 15, 747-756.	2.0	14
3199	The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer. Future Oncology, 2022, 18, 2733-2744.	2.4	1
3200	Use of molecular markers and other personalized factors in treatment decisions for metastatic colorectal cancer. , 2023, , 65-80.		0
3201	Immunotherapy and targeted therapies for colorectal liver metastasis. , 2023, , 231-246.		0
3202	Heteronemin and Tetrac Induce Anti-Proliferation by Blocking EGFR-Mediated Signaling in Colorectal Cancer Cells. Marine Drugs, 2022, 20, 482.	4.6	2

#	Article	IF	CITATIONS
3203	Molecular Docking studies of THC-HCA on Cancer Receptors. Research Journal of Pharmacy and Technology, 2022, , 3195-3199.	0.8	3
3204	Hot-Spot-Specific Probe (HSSP) for Rapid and Accurate Detection of KRAS Mutations in Colorectal Cancer. Biosensors, 2022, 12, 597.	4.7	1
3205	Clinical applications of mass spectrometryâ€based proteomics in cancer: Where are we?. Proteomics, 2023, 23, .	2.2	20
3207	Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement. , 2022, 33, 627-663.		0
3208	Healthy and unhealthy plantâ€based diets in relation to the incidence of colorectal cancer overall and by molecular subtypes. Clinical and Translational Medicine, 2022, 12, .	4.0	12
3209	Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart. Pharmaceutics, 2022, 14, 1612.	4.5	0
3211	Ki-67, topoisomerase IIα and miR-221 have a limited prostate cancer risk stratification ability on a medium-term follow-up: results of a high-risk radical prostatectomy cohort. Translational Andrology and Urology, 2022, 11, 1271-1281.	1.4	0
3212	Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells. Molecular Therapy - Nucleic Acids, 2022, 30, 49-61.	5.1	6
3213	The role of chemotherapy in the treatment of advanced appendiceal cancers: summary of the literature and future directions. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211124.	3.2	5
3214	Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211117.	3.2	8
3215	Genetic alterations shaping tumor response to anti-EGFR therapies. Drug Resistance Updates, 2022, 64, 100863.	14.4	4
3216	Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol. BMJ Open, 2022, 12, e063071.	1.9	6
3218	ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. Nature Communications, 2022, 13, .	12.8	9
3219	PD-1 Blockade in Mismatch Repair–Deficient Rectal Cancer. New England Journal of Medicine, 2022, 387, 854-856.	27.0	2
3220	Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. Frontiers in Oncology, 0, 12, .	2.8	3
3221	Evolution of precision oncologyâ \in guided treatment paradigms. WIREs Mechanisms of Disease, 2023, 15, .	3.3	5
3222	Incidence and clinical profile of brain metastasis treated with whole brain radiotherapy in a tertiary hospital in eastern India: A retrospective audit. Indian Journal of Cancer, 2022, .	0.2	0
3223	Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with <i>KRAS/NRAS/BRAF</i> Wild-Type Colorectal Cancer. Oncologist, 2022, 27, 1006-e930.	3.7	2

#	Article	IF	CITATIONS
3224	Clinical strategy of conversion therapy and surgical treatment for liver metastases from colorectal cancer. World Chinese Journal of Digestology, 2022, 30, 897-913.	0.1	0
3226	Targeting Asparagine Synthetase in Tumorgenicity Using Patient-Derived Tumor-Initiating Cells. Cells, 2022, 11, 3273.	4.1	4
3227	Targeting RAS mutants in malignancies: successes, failures, and reasons for hope. Cancer Communications, 2023, 43, 42-74.	9.2	9
3228	Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2023, 34, 10-32.	1.2	316
3229	Correlations among KRAS Mutation, Microsatellite Instability, and 18F-FDG Uptake in Colon Cancer. Asian Pacific Journal of Cancer Prevention, 2022, 23, 3501-3506.	1.2	2
3230	Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study. BMC Cancer, 2022, 22, .	2.6	2
3232	Chemotherapy plus panitumumab/cetuximab versus chemotherapy plus bevacizumab in wild-type KRAS/RAS metastatic colorectal cancer: a meta-analysis. Expert Review of Anticancer Therapy, 2022, 22, 1333-1347.	2.4	2
3233	Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. EBioMedicine, 2022, 86, 104352.	6.1	13
3234	Targeted Therapy with Anti-EGFR and Anti-VEGF Therapy and Beyond. , 2022, , 293-299.		0
3235	Treatment Refractory Metastatic Colorectal Cancer. , 2022, , 287-292.		0
3235 3236	Treatment Refractory Metastatic Colorectal Cancer. , 2022, , 287-292. Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer. Frontiers in Oncology, 0, 12, .	2.8	0
3235 3236 3237	Treatment Refractory Metastatic Colorectal Cancer. , 2022, , 287-292. Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer. Frontiers in Oncology, 0, 12, . A Comparison of Patients' and Physicians' Knowledge and Expectations Regarding Precision Oncology Tests. Current Oncology, 2022, 29, 9916-9927.	2.8	0 8 1
3235 3236 3237 3238	Treatment Refractory Metastatic Colorectal Cancer., 2022, , 287-292. Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer. Frontiers in Oncology, 0, 12, . A Comparison of Patients' and Physicians' Knowledge and Expectations Regarding Precision Oncology Tests. Current Oncology, 2022, 29, 9916-9927. Rational combinations of targeted cancer therapies: background, advances and challenges. Nature Reviews Drug Discovery, 2023, 22, 213-234.	2.8 2.2 46.4	0 8 1 69
3235 3236 3237 3238 3239	Treatment Refractory Metastatic Colorectal Cancer. , 2022, , 287-292. Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer. Frontiers in Oncology, 0, 12, . A Comparison of Patients' and Physicians' Knowledge and Expectations Regarding Precision Oncology Tests. Current Oncology, 2022, 29, 9916-9927. Rational combinations of targeted cancer therapies: background, advances and challenges. Nature Reviews Drug Discovery, 2023, 22, 213-234. Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. Journal of Clinical Medicine, 2022, 11, 7523.	2.8 2.2 46.4 2.4	0 8 1 69
3235 3236 3237 3238 3239 3240	Treatment Refractory Metastatic Colorectal Cancer. , 2022, , 287-292. Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer. Frontiers in Oncology, 0, 12, . A Comparison of Patients' and Physicians' Knowledge and Expectations Regarding Precision Oncology Tests. Current Oncology, 2022, 29, 9916-9927. Rational combinations of targeted cancer therapies: background, advances and challenges. Nature Reviews Drug Discovery, 2023, 22, 213-234. Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. Journal of Clinical Medicine, 2022, 11, 7523. Are chemical compounds in medical mushrooms potent against colorectal cancer carcinogenesis and antimicrobial growth?. Cancer Cell International, 2022, 22, .	2.8 2.2 46.4 2.4 4.1	0 8 1 69 1
3235 3236 3237 3238 3239 3240	Treatment Refractory Metastatic Colorectal Cancer. , 2022, , 287-292. Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer. Frontiers in Oncology, 0, 12, . A Comparison of Patientsâ∈™ and Physiciansâ∈™ Knowledge and Expectations Regarding Precision Oncology Tests. Current Oncology, 2022, 29, 9916-9927. Rational combinations of targeted cancer therapies: background, advances and challenges. Nature Reviews Drug Discovery, 2023, 22, 213-234. Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. Journal of Clinical Medicine, 2022, 11, 7523. Are chemical compounds in medical mushrooms potent against colorectal cancer carcinogenesis and antimicrobial growth?. Cancer Cell International, 2022, 22, . Current Targeted Therapy for Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2023, 24, 1702.	2.8 2.2 46.4 2.4 4.1	0 8 1 69 1 6
 3235 3236 3237 3238 3239 3240 3241 3242 	Treatment Refractory Metastatic Colorectal Cancer., 2022, , 287-292. Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer. Frontiers in Oncology, 0, 12, . A Comparison of Patients' and Physicians' Knowledge and Expectations Regarding Precision Oncology Tests. Current Oncology, 2022, 29, 9916-9927. Rational combinations of targeted cancer therapies: background, advances and challenges. Nature Reviews Drug Discovery, 2023, 22, 213-234. Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. Journal of Clinical Medicine, 2022, 11, 7523. Are chemical compounds in medical mushrooms potent against colorectal cancer carcinogenesis and antimicrobial growth?. Cancer Cell International, 2022, 22, 22, 22, 22, 22, 22, 22, 22,	2.8 2.2 46.4 2.4 4.1 4.1	0 8 1 69 1 6 22 14

#	Article	IF	CITATIONS
3244	Covariate-adjusted response-adaptive designs for censored survival responses. Journal of Statistical Planning and Inference, 2023, 225, 219-242.	0.6	1
3245	Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 755-767.	3.3	3
3246	The Cytokine Network in Colorectal Cancer: Implications for New Treatment Strategies. Cells, 2023, 12, 138.	4.1	15
3247	Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors. Life, 2023, 13, 395.	2.4	0
3248	Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. , 2023, , 13-27.		0
3249	MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS-mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. , 2023, , 145-150.		0
3250	A phase Ia dose-escalation trial of Ametumumab (a fully human monoclonal antibody against epidermal) Tj ETQqQ Medical Oncology, 2023, 15, 175883592311659.) 0 0 rgBT 3.2	/Overlock 10 0
3251	Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. World Journal of Gastroenterology, 0, 29, 926-948.	3.3	4
3252	Targeting Rat Sarcoma Viral Oncogene Homolog for Treatment of Gastrointestinal Cancers. Advances in Oncology, 2023, 3, 161-177.	0.2	0
3253	Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials. European Journal of Cancer, 2023, 184, 106-116.	2.8	7
3254	KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics. Critical Reviews in Oncology/Hematology, 2023, 186, 103987.	4.4	3
3255	The impact of RAS mutation on the treatment strategy of colorectal cancer. Medicine and Pharmacy Reports, 2023, 96, 5-15.	0.4	0
3256	Exploiting Liver CT scans in Colorectal Carcinoma genomics mutation classification. , 2022, , .		0
3257	Construction and Validation of a Novel Prognosis Model in Colon Cancer Based on Cuproptosis-Related Long Non-Coding RNAs. Journal of Clinical Medicine, 2023, 12, 1528.	2.4	1
3258	Germline variation in <scp> <i>RASAL2</i> </scp> may predict survival in patients with <scp> <i>RAS</i> </scp> â€activated colorectal cancer. Genes Chromosomes and Cancer, 2023, 62, 332-341.	2.8	0
3259	Urachal carcinoma: The journey so far and the road ahead. Pathology Research and Practice, 2023, 243, 154379.	2.3	2
3260	Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends in Pharmacological Sciences, 2023, 44, 222-236.	8.7	30
3261	A Review of Translational Research for Targeted Therapy for Metastatic Colorectal Cancer. Cancers, 2023, 15, 1395.	3.7	4

#	Article		CITATIONS
3262	Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer. Nature Medicine, 2023, 29, 605-614.	30.7	27
3263	KRAS, NRAS, BRAF signatures, and MMR status in colorectal cancer patients in North China. Medicine (United States), 2023, 102, e33115.	1.0	0
3264	Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial. JCO Oncology Practice, 2023, 19, e859-e866.	2.9	11
3265	Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. World Journal of Gastroenterology, 0, 29, 1395-1426.	3.3	8
3266	Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies. Advances in Cancer Research, 2023, , 145-184.	5.0	5
3267	Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies. Cancers, 2023, 15, 1679.	3.7	6
3268	Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation. Current Issues in Molecular Biology, 2023, 45, 2505-2520.	2.4	2
3269	The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1 st line treatment of metastatic colorectal (mCRC) patients with <i>RAS</i> wild-type tumour (wt <i>RAS</i>) – a real- life data report 2013–2018. Radiology and Oncology, 2023, 57, 103-110	1.7	1
3270	A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer. Journal of Gastrointestinal Oncology, 2023, 14, 663-675.	1.4	1
3271	The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers. Cancers, 2023, 15, 2375.	3.7	5
3272	A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial. Targeted Oncology, 2023, 18, 369-381.	3.6	1
3273	A review on emerging targeted therapies for the management of metastatic colorectal cancers. , 2023, 40, .		6
3274	Less demand on stem cell marker-positive cancer cells may characterize metastasis of colon cancer. PLoS ONE, 2023, 18, e0277395.	2.5	1
3275	SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022). Clinical and Translational Oncology, 0, , .	2.4	1
3276	KRAS Mutation Reduces Thymoquinone Anticancer Effects on Viability of Cells and Apoptosis. Anti-Cancer Agents in Medicinal Chemistry, 2023, 23, .	1.7	0
3277	FBXW7β loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	5
3278	Advances in KRAS mutation inhibition in metastatic colorectal cancer. , 2023, 2, .		0
3279	Global application of National Comprehensive Cancer Network resource-stratified guidelines for systemic treatment of colon cancer: a population-based, customisable model for cost, demand, and procurement. Lancet Oncology, The, 2023, 24, 682-690.	10.7	2

#	Article	IF	CITATIONS
3280	Efficacy and safety of third-line or later-line targeted treatment for patients with metastatic colorectal cancer: a meta-analysis. Frontiers in Oncology, 0, 13, .	2.8	0
3282	Pharmacogenetics of Anticancer Drugs: Clinical Response and Toxicity. Cancer Treatment and Research, 2023, , 141-175.	0.5	0
3283	Construction of prediction model for KRAS mutation status of colorectal cancer based on CT radiomics. Japanese Journal of Radiology, 2023, 41, 1236-1246.	2.4	2
3284	The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists' perspective. Pathologica, 0, , 1-11.	3.4	1
3285	Osthole inhibits malignant phenotypes and induces ferroptosis in KRAS-mutant colorectal cancer cells via suppressing AMPK/Akt signaling. Cancer Chemotherapy and Pharmacology, 0, , .	2.3	2
3286	MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells. Cancer Letters, 2023, 567, 216264.	7.2	2
3287	Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements. Frontiers in Oncology, 0, 13, .	2.8	1
3288	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. ESMO Open, 2023, 8, 101558.	4.5	9
3289	Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?. International Journal of Molecular Sciences, 2023, 24, 9165.	4.1	3
3290	Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (V.) Tj ETQq1	1 0.784314	rgBT /Overlo
3291	Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment. Biomolecules, 2023, 13, 1042.	4.0	2
3292	Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes. Oncologist, 2023, 28, 885-893.	3.7	3
3293	Recent Research Progress in Targeted Ther-apy of Metastatic Colorectal Cancer. Advances in Clinical Medicine, 2023, 13, 10321-10328.	0.0	0
3294	Exploration of novel clusters and prognostic value of immune‑related signatures and identify HAMP as hub gene in colorectal cancer. Oncology Letters, 2023, 26, .	1.8	1
3295	Advances in personalized gastroenterology and hepatology 2016. Russian Journal of Gastroenterology Hepatology Coloproctology, 2016, 26, 4-10.	1.1	0
3296	Early Onset Metastatic Colorectal Cancer: Current Insights and Clinical Management of a Rising Condition. Cancers, 2023, 15, 3509.	3.7	2
3297	Zukunftspotenziale der Labormedizin. , 2023, , 181-231.		0
3299	Prevalence of <i>KRAS</i> G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review. Oncologist, 2023, 28, e981-e994.	3.7	3

#	Article	IF	CITATIONS
3300	The New Big Is Small: Leveraging Knowledge from Small Trials for Rare Disease Drug Development ― Blarcamesine for Rett Syndrome. British Journal of Clinical Pharmacology, 0, , .	2.4	0
3302	Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer. Clinical Cancer Research, 2023, 29, 4530-4539.	7.0	2
3303	Prognostic scoring system based on eosinophil- and basophil-related markers for predicting the prognosis of patients with stage II and stage III colorectal cancer: a retrospective cohort study. Frontiers in Oncology, 0, 13, .	2.8	0
3304	The role of genetic testing in the prognosis and management of solid tumors. A literature review. Romanian Journal of Laboratory Medicine, 2023, 31, 163-174.	0.2	0
3305	Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review. International Journal of Molecular Sciences, 2023, 24, 12030.	4.1	3
3306	Dysregulated Signalling Pathways Driving Anticancer Drug Resistance. International Journal of Molecular Sciences, 2023, 24, 12222.	4.1	5
3307	The Importance of Feasibility Assessment in the Design of ctDNA Guided Trials – Results From the OPTIPAL II Study. Clinical Colorectal Cancer, 2023, 22, 421-430.e1.	2.3	1
3308	Sex Difference of Colon Adenoma Pathway and Colorectal Carcinogenesis. World Journal of Men?s Health, 0, 41, .	3.3	1
3309	IGF2BP3 promotes the progression of colorectal cancer and mediates cetuximab resistance by stabilizing EGFR mRNA in an m6A-dependent manner. Cell Death and Disease, 2023, 14, .	6.3	4
3310	Ceramide synthase CERS4 gene downregulation is associated with KRAS mutation in colorectal cancer. Scientific Reports, 2023, 13, .	3.3	1
3311	Molecular testing in colorectal cancer. , 2024, , 339-358.		0
3312	Vitamin C intake and colorectal cancer survival according to KRAS and BRAF mutation: a prospective study in two US cohorts. British Journal of Cancer, 0, , .	6.4	0
3313	Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer. Clinical Colorectal Cancer, 2023, 22, 457-463.	2.3	0
3315	Imaging prediction of <i>KRAS</i> mutation in patients with rectal cancer through deep metric learning using pretreatment [¹⁸ F]Fluorodeoxyglucose positron emission tomography/computed tomography. British Journal of Radiology, 2023, 96, .	2.2	0
3316	Effectiveness of Biologic Agents Among Hispanic Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2024, 23, 14-21.e1.	2.3	0
3317	Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada. PharmacoEconomics - Open, 0, , .	1.8	0
3318	Conditional Overall Survival After Diagnosis of Non-Metastatic Colon Cancer: Impact of Laterality, MSI, and KRAS Status. Annals of Surgical Oncology, 2024, 31, 142-151.	1.5	1
3319	Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches. Frontiers in Pharmacology, 0, 14, .	3.5	3

#	Article	IF	CITATIONS
3320	Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12C. New England Journal of Medicine, 2023, 389, 2125-2139.	27.0	21
3321	ITGAM-macrophage modulation as a potential strategy for treating neutrophilic Asthma: insights from bioinformatics analysis and in vivo experiments. Apoptosis: an International Journal on Programmed Cell Death, 2024, 29, 393-411.	4.9	0
3322	Personalizing adjuvant therapy for patients with colorectal cancer. Nature Reviews Clinical Oncology, 2024, 21, 67-79.	27.6	1
3323	CRISPR/Cas9: a powerful tool in colorectal cancer research. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	8.6	0
3324	Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1. International Journal of Clinical Oncology, 0, , .	2.2	1
3325	<i>RAS</i> mutation status in combination with the <scp>JSHBPS</scp> nomogram may be useful for preoperative identification of colorectal liver metastases with high risk of recurrence and mortality after hepatectomy. Journal of Hepato-Biliary-Pancreatic Sciences, 2024, 31, 69-79.	2.6	0
3326	Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer. Current Treatment Options in Oncology, 0, , .	3.0	0
3327	The Importance of Optimal Thermal Ablation Margins in Colorectal Liver Metastases: A Systematic Review and Meta-Analysis of 21 Studies. Cancers, 2023, 15, 5806.	3.7	1
3328	Radiogenomics: Contemporary Applications in the Management of Rectal Cancer. Cancers, 2023, 15, 5816.	3.7	0
3329	KRAS and BRAF Mutation Rates and Survival Outcomes in Colorectal Cancer in an Ethnically Diverse Patient Cohort. International Journal of Molecular Sciences, 2023, 24, 17509.	4.1	0
3331	Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications. Cells, 2024, 13, 47.	4.1	1
3332	A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study. BMC Medical Research Methodology, 2024, 24, .	3.1	0
3333	Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials. Clinical Cancer Research, 2024, 30, 1121-1130.	7.0	0
3334	Somatic mutation: Pharmacogenomics in oncology care. , 2024, , 329-356.		0
3335	Precision medicine: Dose for anticancer therapy. , 2024, , 357-367.		0
3336	How does time speak about cancer, its diagnosis, treatments, and challenges?. , 2024, , 55-81.		0
3338	Development of tumor-evolution-targeted anticancer therapeutic nanomedicineEVT. CheM, 2024, 10, 1337-1356.	11.7	0
3339	The Prognostic Utility of KRAS Mutations in Tissue and Circulating Tumour DNA in Colorectal Cancer Patients. Gastroenterology Insights, 2024, 15, 107-121.	1.2	0

		CITATION REPORT	
#	Article	IF	Citations
3340	Longitudinal plasma proteome profiling reveals the diversity of biomarkers for diagnosis and cetuximab therapy response of colorectal cancer. Nature Communications, 2024, 15, .	12.8	1
3341	Impacts of systemic treatments on health-related quality of life for patients with metastatic colorectal cancer: a systematic review and network meta-analysis. BMC Cancer, 2024, 24, .	2.6	1
3342	Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2024, , .	2.3	0
3343	Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of bener patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database. British Journal of Cance 2024, 130, 1269-1278.	fit in r, 6.4	0
3344	Delphi consensus for the third-line treatment of metastatic colorectal cancer. Clinical and Translational Oncology, 0, , .	2.4	0
3345	Focus on RAS Codon 61 Mutations in Metastatic Colorectal Cancer: A Retrospective Analysis. Cance 2024, 16, 988.	ers, 3.7	0
3346	Pancreatic Adenocarcinoma with Co-Occurrence of <i>KRAS</i> and <i>EGFRMutations: Case Report and Literature Review. Case Reports in Oncology, 2024, 17, 399-406.</i>	gt; 0.7	0
3347	Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer. Anti-Cancer Drugs, 2024, 35, 459-461.	1.4	0
3348	Epigenetic Alteration in Colorectal Cancer: Potential Diagnostic and Prognostic Implications. International Journal of Molecular Sciences, 2024, 25, 3358.	4.1	0
3349	Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2. International Journal of Clinical Oncology, 2024, 29, 512-534.	2.2	0
3350	Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment. International Immunopharmacology, 2024, 131, 111887.	3.8	0
3351	Detection of KRAS Mutations in Triple-negative Breast Cancers by Polymerase Chain Reaction. Journ of Datta Meghe Institute of Medical Sciences University, 2024, 19, 71-76.	al 0.1	0
3352	Myotubularin-related-protein-7 inhibits mutant (G12V) K-RAS by direct interaction. Cancer Letters, 2024, 588, 216783.	7.2	0
3353	Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: postÂhoc analysis of the phase III SUNLIGHT trial. ESMO Op 2024, 9, 102945.	n en, 4.5 	0